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Preface 
 
 
 
There has been a number of research work carried out by number of researchers in 
various areas. These researches have made a significant contribution in the existing 
knowledge base and opened various newer fields for learning and have significantly 
contributed to the overall well being of society at large. The contribution by several 
researchers aids in the overall economic progress which leads to growth of any 
country or many countries and finally tries to make things simpler and more 
convenient. 
 
The present research work is a very modest effort from the side of researcher to add to 
the current knowledge base in the area of Pharmaceutical Industry and its financial 
performance. There are several research conducted by several researchers in and 
outside country for the Indian Pharmaceutical Industry as the industry is on the 
threshold of a paradigm shift from process patents to product patents and several such 
legal international issues.  
 
The Indian Pharmaceutical sector is highly fragmented with more than 20,000 
registered units. The pharmaceutical industry in India meets around 70% of the 
country's demand for bulk drugs, pharmaceutical formulations, chemicals, tablets, 
capsules, orals and injectibles. There are about 250 large units and about 8000 Small 
Scale Units, which form the core of the pharmaceutical industry in India (including 5 
Central Public Sector Units). These units produce the complete range of 
pharmaceutical formulations, i.e., medicines ready for consumption by patients and 
about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production 
of pharmaceutical formulations. The Indian Pharmaceuticals sector has come a long 
way, being almost non-existing during 1970, to a prominent provider of health care 
products, meeting almost 95% of country’s pharmaceutical needs. The domestic 
pharmaceutical output has increased at a compound growth rate (CAGR) of 13.7% per 
annum. Currently the Indian pharma industry is valued at approximately $ 8.0 billion. 
Globally, the Indian industry ranks 4th in terms of volume and 13th in terms of value. 
Indian pharmaceuticals industry has over 20,000 units. Around 260 constitute the 
organized sector, while others exist in the small-scale sector.2 According to the 
analysts at RNCOS, “India accounts for 23% of the global generics market and is 
rapidly emerging as a regional hub of global R&D activities in the healthcare space.3  
 
In this scenario there are two major things coming out, firstly, Indian Pharmaceutical 
Industry is growing in output, value, volume, number of units - steadily and showing 
resemblance to the entire growth story of Indian Economy. Secondly, there is a major 
change occurring to the very basic system of pharmaceutical business in India. By 
issuing the patent ordinance, India met a WTO commitment to recognize foreign 
product patents from 1st January 2005, the culmination of 10 year process. In this new 
scenario, the Indian Pharmaceutical manufacturers would not be able to manufacture 
patented drugs which they have been doing since long although by another process.  
This situation brought a very interesting and exciting research scope into the financial 
abilities of the industry. As such the crux of any growth or decline depends largely on 
the financial health it was imperative for the researcher to carry out a detailed 
profitability analysis of the leading pharma companies of India. 
 
Thus, a study of some selected units of Indian Pharmaceutical Industry for a period of 
8 years is carried out to study their financial performance before the patent regime and 
make a financial situational analysis of the industry to judge their economic standing 
to meet the technological and economic challenges. This has been carried out with the 
help of several parameters and a humble effort has been made to draw inferences out 
of the research work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/ 
2. A FICCI report for National Manufacturing Competitiveness Council: “Competitiveness of 
the Indian Pharmaceutical Industry in the new Product Patent Regime”, March 2005 
3. http://www.newswiretoday.com/news/7486/ 
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1. Introduction 
 
Every act in this world is done with an intention; similarly every business activity is 
carried out with some aim, objective or goal. And when this aim is to make oneself 
financial wealthier, that aim is referred to as Profit Objective, or in other words, to 
have reasonable surplus for the survival and growth of the organization.  There are so 
many types of people on this earth carrying out variety of financial activities. Hence 
there are innumerable views for this concept of profit. Prof. Knight has observed that 
“Perhaps no term or concept in economic discussion is used with a more bewildering 
variety of established meaning than profit.” 
 
 But here an effort is made to make the meaning of the term “Profit” clear. Let us  start 
with examining the meaning of profit given by various dictionaries: 
 
a) OXFORD DICTIONARY: 
 Profit is , “money gained in business, especially the difference between 
the amount earned and the amount spent” 1 
 Profit is, “advantage or benefit gained from something.” 1 
 
b) WEBSTER DICTIONARY 
 Profit is, “money left in a business or for distribution to shareholders 
after all costs and charges have been deducted from sales.” 
 
 
After looking to all definitions, one can say that profit is the positive difference of 
revenue account of a particular period, in other words it represents the excess of credit 
side of Trading Account and Profit and Loss Account over the debit side of the 
account.  It is considered as the oxygen of the organization. This word shows the 
importance of profit for any economic organization, survival of any organization in 
long run is only depends on profit or surplus.  The market reputation or goodwill, 
credibility of management and organization is measured through their profit.  It is 
considered as the efficiency of the management as well as efficiency of resources used 
by the business unit. 
 
In general parlance we refer profit as the financial gain from any transaction. Say for 
example if Mr. A purchases goods at Rs. 100 per kg. and then sells at Rs. 125 per kg.; 
it is said that he has earned a profit of Rs.25 per kg. But going into the details of the 
transaction, we will realize that there are so many expenses incurred which made this 
transaction possible.  Even Mr. A has given his time in this transaction, so looking to 
the opportunity cost of time, it would add to the total expenses. Hence we need to 
restate the profit after giving the expenses, the due consideration. 
 
 
 
 
 
 
 
2. Various concepts of Profit: 
1.  Accounting Profit 
 There are several concepts of profit in Accounting like Gross Profit, Net Profit, etc. 
  Gross Profit:  The excess of the proceeds of goods sold and services      
rendered during a period over their cost, before taking into account administration, 
selling, distribution and financial expenses, is called Gross Profit. When the result of 
this computation is negative it is referred to as gross loss. 
Gross margin shows the profitability of the trade, i.e., buying and selling. It partly 
reflects on the efficiency of the firm’s buying and selling activities and any 
unsatisfactory state of the gross profit is traced into some defect in any of these two 
activities comprising trade. 2 
 
 Net Profit:      The excess of revenue during a particular accounting                                             
period is called net profit.  When the result of this computation is negative, it is 
referred to as net loss.  Net profit is the earning of the business unit and so brings out 
the profitability of the trade unit.  In other words it throws light on the efficiency of 
spending and capabilities of earning extra incomes.  Hence, accounting profit is the 
residual after charging all cost and expenses, paid or payable. 
 
 
 
 
 
 
2.  Economic Profit 
 
In Economics, profit is taken to be the reward for risk taking as a factor of production 
in the same way as wages are regarded to be the reward for labor and interest for 
capital. Economists generally define profit, i.e. the reward for the entrepreneur as 
residual of production after all other factors of production get their rewards.  This 
definition is justified because the ultimate risk is borne by the entrepreneur and it is 
only for that reason that he is given a share in the production.3 According to Taussig, 
“only that amount which is over and above interest on the owner’s capital, rent for 
owner’s premises and monopoly gains should be regarded as business profits” 4    Here 
it is implied that rent, wages and interest payable to parties other than the owner have 
already been paid.  
 
One important point here need attention is that entrepreneur is getting his share after 
paying to other factors of production, therefore he would do his best to procure land, 
labor and capital at the lowest possible price. If he succeeds in that he would earn that 
much more, now this addition in his income is due his ability other than risk taking. 
This addition is nothing but the difference between the market price of land, labor, 
capital and the price paid by him. This theory is based on the basic assumption that 
even if he has selected cheaper factors of production, it will in no case adversely affect 
the production quantity and quality. Or we can say that he is paying less prices to 
quality factors of production. Hence this benefit as addition in his income is due to his 
bargaining ability. 
 
 
Accounting Profit Vs. Economic Profit 
 
Economics is the basic theory from which all the financial concepts have evolved and 
Accounting is practical art and science of recording the financial transaction to arrive 
at some conclusion regarding the financial affairs and efficiency of the business. 
 
Concept of profit as per economics is based on the return to the factors of production. 
That is to say, owner of the business gets his share of profit is nothing but his payment 
as one of the factors of production. After paying for land, labor and capital whatever is 
left, belongs to the owner of the business – the entrepreneur. This return to the 
entrepreneur is residual amount and he receives it on account of his ability to take risk.   
 
Entrepreneur is taking the risk of arranging for capital, land, laborers, organization, etc 
and making an agreement with them to pay them after some definite period of time. 
This means that he is legally obliged to pay all of them. This is absolutely risky.  As 
such he is assuming that proper production as per market requirement will be carried 
out and will be sold out in time, and revenues will be generated which will be used in 
payment to other factors of production. Hence an entrepreneur is taking a big liability 
on his head on a mere assumption. 
 
While accounting profit is nothing but the difference between total revenue income of 
the year and the revenue expenses of the year. Accountants follow the accounting 
concepts  
 
and conventions to prepare the accounts for a particular accounting period. Total 
business income is calculated which is from the normal course of the business and all 
the expenses which are made to earn the income are deducted from the total income, 
the difference between the income and expense is referred to as profit by the 
Accountants. This amount shows the exact financial benefit to the business during the 
year as the accounts are maintained by following the scientific rules and principles of 
preparing the accounts. 
 
 
3. Concept of Profitability 
Profitability refers to the capacity or capability of earning profit. In financial language 
it may be referred as “Earning Capacity”, which means what is the capability of a 
company to earn profit in current year and future. In this sense, profitability is usually 
defined as the ability of a given investment to earn a return from its use.  As such 
market in which a company operates gives equal opportunity to all. Finance can also 
be acquired by all, at a common rate of interest, let us assume that even work-force is 
also available, and trained as per requirement. In this situation, a company has to earn 
profit in a competitive situation. This is the earning power or to say the ability of the 
company to earn profit. We will discuss later in the chapter that which factors affect 
profit and to which extent. Concept of profitability is a relative rather than an absolute 
one. As such if we check the figures of profit of a company we cannot come to any 
conclusion that whether the profit is good enough or not. Hence profitability is a 
relative concept rather than absolute one. Profitability can be calculated with the help 
of profitability ratios, which we will see later  
 in this chapter. There are two profitability ratios they are: Gross Profit Ratio and Net 
Profit Ratio. The gross profit margin ratio tells us the profit a business makes on its 
cost of sales, or cost of goods sold. It is a very simple idea and it tells us how much 
gross profit per Re. 1 of turnover our business is earning. 
Gross profit is the profit we earn before we take off any administration costs, selling 
costs and so on. So we should have a much higher gross profit margin than net profit 
margin. For example ABC Co. has a Gross Profit ratio of 25.26%. 
The net profit margin ratio tells us the amount of net profit per Re.1 of turnover a 
business has earned. That is, after taking account of the cost of sales, the 
administration costs, the selling and distributions costs and all other costs, the net 
profit is the profit that is left, out of which they will pay interest, tax, dividends and so 
on. For example ABC Co. has a Gross Profit ratio of 4.05%. 
 
We still can't say, though, whether a gross profit margin of about 25% is good or bad 
and we can't say whether a net profit margin of around 4% is good or bad: we still 
need even more information. 
There are two ways to tell whether ratio result is good:  
 find ratio values for the business we are looking at for three, four or more year, 
preferably more: this is known as trend analysis;  
 find ratio values for other businesses in the same industry: this is known as inter 
firm comparison  
 
In the interpretation of financial statements of various business houses that are made 
today considerable importance and weightage is given to the measurement and 
evaluation of their current and prospective earning capacities.  In this sense, 
profitability is usually defined as the ability of a given investment to earn a return 
from its use. 
 
4. Factors Affecting Profit 
We have already discussed various aspects of profit and profitability. Now let us 
discuss that what are the elements or which factors affects profit. Or to say which 
factors would make an impact over profit or profitability. These factors may be 
discussed in two broad parts: 
{a} Internal Factors 
1) Goal or objective of the organization 
2) Management 
3) Finance 
4) Labour Force 
5) Relationship between Management and Labour Force 
{b} External Factors 
1) Market Condition 
2) Response of Consumers 
3) Government Policy 
4) Natural Factors 
 
Now let us discuss each point in detail: 
{a} Internal Factors 
1. Goal or objective of the organization 
Most of the organizations have profit maximization as their prime  goal, but there are 
various types of entities coming into existence  which do not have this objective. 
Hence apart from the ability and  possibility of earning profit it is the willingness, 
which is also very  important factor which affect profit. 
2. Management 
It is a well know truth that unless you have efficient management, profit is not 
possible. In order to achieve the set objectives and for earning reasonable profit also 
the management must be strong enough. Management can utilize the scarce resources 
efficiently, can handle the man-power, and take such decisions, which will be proved 
decisive at the end. Hence top management is one of the most important factor 
affecting profit. 
3. Finance 
Finance lies in the center of all the business activities. It is not just the adequacy of the 
capital but also the timely availability of capital and in proper form is also very 
important. Profit basically is the indicator of sound business operations. Or to say that 
if the business is operated smoothly than only the business will be in profitable 
situation. But for smooth operation of the business, there should be adequate finance 
available in the hands of business as and when required. 
 
 
4. Labour Force 
In a capital intensive unit also there is a significant contribution from the expert 
operators, supervisors and the technical staff. But take labour intensive unit and you 
need a separate independent department which can take care of labour force. Workers 
or employees are as important for a business undertaking as the blood for a human 
body. As such employees carry out the majority of work, there are various types of 
workers like – experts workers, technically knowledgeable workers, unskilled labour, 
etc. 
 
5. Relationship between Management and Labour Force 
There is a famous saying regarding labour force that is if you can manage you men, 
they will manage everything. Modern managers have realized the importance of 
labour force, and they have realized that in order to take work from labour force, it is 
essential to motivate them. Hence if labour force is properly motivated they will work 
efficiently which will result in profit situation for the company. 
{b} External Factors 
1. Market Condition 
External factors are largely uncontrollable. Market is the place where the business can 
buy and sell goods and services. Hence from the beginning to end market plays an 
important role in a business unit. Profit is affected by the cost of production and 
realized amount of output, both these are highly affected by market conditions. 
Starting from procuring raw materials, other goods, services, etc to selling the finished 
product, if market conditions are favourable then only a business can earn profit. 
Another important  
 
factor in market is of the business units in the similar business providing similar goods 
or services. Hence if a business unit has enough plans and strengths to fight 
competition in the market, then it can earn consistent profit.  
2. Response of Consumers 
Consumer is considered the king of market. All the products, marketing and sales 
promotion is consumer oriented. As such if consumer likes the goods or services than 
only he will buy the product which will lead to sales and thus the profit. Hence profit 
of a business unit is to a great extent dependent on the behavior of consumers. In other 
words profit is much affected by how a consumer reacts to a new product (or service) 
launched by the business, or how he (consumer) reacts to the modification made in the 
product or service. 
3. Government Policy 
Every industry is affected by the regulation and restriction laid by government. 
Especially in country like India every industry has to do business while following the 
strict line of rules lay down by the state and central government. But the other side of 
the coin is for government also provides man incentives to the business unit engaged 
in the business of certain kind, and also to those businesses that are carrying out their 
activities in certain notified areas. Hence as per the government policy a business will 
stand  benefited and may lose also. But as it is an external factor businessmen can do 
very little about it.  
4. Natural Factors 
Nature is still the dominating factor even in this hi-tech age. It is more than 100% true 
especially for those business concerns who are partly or totally dependent on the 
natural  
 
factors. Adverse environment not only directly harms the business but it also 
indirectly harms by causing distress to the manpower of the business unit. 
 
5. Concept of Value Added 
Value Added Concept is the emerging accounting concept which has been discussed 
since long, but applied in practice in the recent past. Very few Indian companies are 
showing the value addition compared to some foreign companies. Value addition is 
show by way of preparing a Value Added Statement. 
 
Value Added Concept is as the name suggests, regarding what value has been added 
to the goods which are purchased and sold. Value added is the wealth an entity has 
been able to create through the utilization of land, labour, capital and management. In 
the words of Ravi M. Kishore, “The ‘Value Added’ is a basic and broad standard of 
judging the performance of an enterprise.”5 
First the goods and services are purchased from the market, than some changes are 
made to these purchases, that is to say their form is changed and they are sold at some 
other place, which is nothing but changing the availability location of the goods. 
Hence these alterations made to the goods and services purchased are known as value 
addition or value generation, which is nothing but the extra price realized by selling 
these (altered) goods and services in the market. 
 
 
6. Financial Statements 
Financial statements include the Trading and Profit & Loss Account, Profit & Loss 
Appropriation Account and Balance Sheet. These statements are prepared to show the 
result of operations during a period. The basic objective of financial statements is to 
communicate financial position and performance of the business entities to the users 
of accounts. Financial position of a business entity is indicated through Balance Sheet 
and performance is indicated through Profit & Loss Account.  
Trading account gives the overall result of trading i.e. purchasing and selling of goods. 
In other words, it explains whether purchasing of goods and selling them has proved 
to be profitable for the business or not.  It takes into account on the one hand the cost 
of goods sold and on the other the value for which they have been sold away. In case 
the sales value is higher than the cost of goods sold, there will be gross profit, while in 
reverse, there will be a loss. 
The Trading account simply tells about the gross profit or loss made by a businessman 
on purchasing and selling of goods. It does not take into account the other operating 
expenses incurred by him during the course of running the business. Besides this, a 
businessman may have other sources of income.  In order to ascertain the true profit or 
loss which the business has made during a particular period, it is necessary that all 
such expenses and incomes should be considered. Profit and Loss Account considers 
all such expenses and incomes and gives the net profit made or loss suffered by a 
business during a particular period. Balance Sheet is prepared to know the financial 
position of the business. Balance  Sheet is the statement of assets and liabilities on a 
particular date.  
 
Balance sheet has two sides. On the left hand side, the liabilities of the business are 
shown while on the right hand side the assets of the business appear. According to 
Palmer, “The Balance Sheet is a statement at a given date showing on one side the 
trader’s property and possessions and on the other side his liabilities.” According to 
American Institute of Certified Public Accountants, Balance Sheet is “a list of 
balances of the asset and liability account. This list depicts the position of assets and 
liabilities of a specific business at a specific point of time.”  
 
Now let us examine some definitions of financial statements given by various authors: 
 
Hampton John J has defined financial statements in his work “Financial Decision 
Making “, 8(Ed 1977 page 62) “A Financial Statement is an organised collection of 
data according to logical and consistent accounting procedures. Its purpose is to 
convey an understanding of some financial aspects of a business firm. It may show a 
position at a moment of time as in the case of a balance sheet, or may reveal a series 
of activities over a given period of time, as in the case of an Income Statement.” 
S.N. Maheshwari has defined financial statements 9: A financial statement is an 
organized collection of data according to logical and consistent accounting 
procedures. Its purpose is to convey an understanding of some financial aspects of a 
business firm. It may show a position at a moment of time as in the case of a balance 
sheet, or may reveal a series of activities over a given period of time, as in  he case of 
an Income Statement.   
 
 
Thus, the term financial statements generally refer to two basic statements: 
(i)  The Income Statement. 
(ii) The Balance Sheet. 
Additional of statements are as under 
(iii)  A statement of Retained Earnings. 
(iv) A statement of changes in financial position. 
 7. Analysis and Interpretation of Financial Statements 
Financial Statements reveals the financial position of the business and also reveals in 
detail the reasons for the profit or loss and the financial position. Financial statements 
are of immense importance to various parties.  
Financial Statements are prepared by Accountants, but there are various other 
parties who are very much interested in the statements like: 
 the executives, who require the information for running the business,  
 the bankers and financial institutions, who require the information to justify the 
making of the loans,  
 the investors, who require the information to warrant their purchase of securities of 
the business, 
 the creditors and suppliers, who require the information to check the security of 
their lending, 
 the labour leaders, who require the information to check how the   
       
 company stands in relation to labour and its welfare. 
 the debenture holders, who require the information to check that whether the 
company’s income generates a sufficient margin to pay the interest, whether the 
cost is adequate, and whether the company will have enough funds to retire 
debentures at maturity.  
 the tax authorities, who require the information to check the authenticity of the 
income shown by the business,  
 the government departments, who require the information to check the figures of 
sales, sources of finance, type of activity, export-import composition, growth, prices 
charged, etc, 
 the employees, who require the information to know the profits earned by the 
business and its use and the extent of profits kept reserved, 
 the research institutions, who require the information for their research work 
 the stock exchanges, who require the information for various purposes 
 the news agencies, who require the information for publishing the  information 
of the company’s affairs, etc 
 the general public, etc who require the information of social cost and benefit. 
The above list shows the importance of financial statements, but it is not only the 
statements which are of such immense importance, but it is its interpretation which is 
also equally, and sometimes more important than the statements themselves. Unless 
and until they are properly interpreted it will not have that much utility. 
 
 
Now let us examine the meaning of interpretation and analysis. 
 
According to F. Wood, “Interpret means to put the meaning of a statement into simple 
terms for the benefit of a person.” 
 
According to S.N.Maheshwari, “The term ‘Interpretation’ means explaining the 
meaning & significance of the data simplified by analysis.”10 
 
Interpretation of financial statement refers to converting the statements into such a 
form that can be understood by various interested parties. It should speak the language 
which is understood by the interested parties and the picture which is hidden behind 
the various figures should be clear and easy to understand.  
 
According to Myers, “Financial Statement analysis is largely a study of relationship 
among the various financial factors in a business as disclosed by a single set of 
statements and study of the trends of these factors as shown in a series of statements.”   
 
According to S.N.Maheshwari, the term “Analysis” means methodical classification 
of the data given in the financial statements.11 
 
Analysis of financial statements also means breaking into parts the material presented 
in the form of financial statements. 
 
Therefore while analysis comprises resolving the statements by breaking them into 
simpler statements by a process of rearranging, regrouping and the calculation of 
ratios, interpretation is the mental process of understanding the terms of such 
statements and forming opinions or inferences about the financial health, profitability, 
efficiency and such other aspects of the undertaking.  
 
 
 
 
Now let us examine the relationship between Analysis of financial statements and 
Interpretation of financial statements. 
 
Interpretation of financial statements is the final and main objective for which 
Analysis is done, hence interpretation includes analysis. Analysis helps in arranging 
the data so that data can be interpreted. Thus we can say that data is simplified by 
Analysis and its (data) meaning and significance is explained by Interpretation. 
 
Analysis & interpretation of financial statements, therefore, refers to such a treatment 
of the information contained in the income statement and the Balance sheet so as to 
afford full diagnosis of the profitability and financial soundness of the business. 
 
However both “Analysis” and “Interpretation” are complementary to each other. 
Interpretation requires analysis, while analysis is useless without interpretation. 
 
 
 
Reasons or Need or Utility of Analysis of Financial Statements: 
 Managers would be interested in checking the financial position of the business 
 Potential Investors would be interested in the earning capacity of the business and 
the dividend policy, etc 
 Institutional investors are interested in the growth potential of the company and  
sound financial base. According to Harry G. Guthmann, “investors as a class need 
to know, first, that the whole financial structure is strong-not merely that the 
concern will be able to meet the obligations; and second, that there is sufficient 
evidence in the history of its earnings to warrant a belief in future growth, or at least 
reasonable stability.” 
 Debenture holders, Shareholders, Potential Investors, etc would be interested to 
know whether the company would be able to pay its long term debt. 
 Trade Creditors would be interested in the liquidity position of the company. 
 
Tools used for Analysis of Financial Statements: 
 [1] Ratio Analysis  
 
 [2] Dynamic or Horizontal or Trend Analysis 
 
 [3] Static or Vertical or Structural Analysis 
 
 [4]  Fund Flow Analysis 
 
  
 
Now let us examine each of the above tools in detail: 
[1] Ratio Analysis  
A ratio is a relation between two amounts, which shows how many times one contains 
the other. Ratio is a unit of measurement to measure the relationship between two 
amounts. In other words a ratio is a statistical yardstick that provides a measure of 
relationship between two accounting figures. Thus if we want to observe the 
relationship of two variables we could find out their ratio which would give the 
information of their inter-relationship. In the words of S.N.Maheshwari, “Ratios are 
mathematical relationship expressed between inter-connected accounting figures.”12 
 
The individual amounts are non-expressive or to say they cannot convey any message 
or meaning, but if they are compared with some other figure or other relevant amount, 
then this comparison can convey a significant or important conclusion. This 
comparison of different amounts with each other is known as Ratio. And using this 
comparison to find out the hidden meaning of the figures is known as Ratio Analysis. 
In other words, when we try to find out the relationship between two relevant figures, 
which would lead to some conclusion, we are referring to Ratio Analysis.  
 
This is one of the most important and key tool of analysis of financial statements. 
Ratio analysis helps the management to quickly understand the working of the 
enterprise and plan for the future. A single ratio is not likely to tell the whole story. It 
is therefore, necessary in order to arrive at correct conclusions to study a number of 
related ratios. 
 
Financial ratios are calculated from one or more pieces of information from a 
company's financial statements. For example, the "gross margin" is the gross profit 
from operations divided by the total sales or revenues of a company, expressed in 
percentage terms. In isolation, a financial ratio is a useless piece of information. In 
context, however, a financial ratio can give a financial analyst an excellent picture of a 
company's situation and the trends that are developing.13 
 
A ratio gains utility by comparison to other data and standards. For example, a gross 
profit margin for a company of 25% is meaningless by itself. If we know that this 
company's competitors have profit margins of 10%, we know that it is more profitable 
than its industry peers which are quite favourable. If we also know that the historical 
trend is upwards, for example has been increasing steadily for the last few years, this 
would also be a favourable sign that management is implementing effective business 
policies and strategies. 
 
 There are basically three main ways in which ratio can be calculated: 
 Depending upon the type of amount and accounting figure, any of the above 
listed  ratio may be used: 
(a) Plain Ratio:   This is the simplest ratio which can be derived by simply 
dividing one number by another. For  example if we want to know what is the gross 
profit ratio , i.e. what is the proportion of gross profit to sales , we can find out by 
dividing sales by gross profit. For example, if Sales if Rs. 1, 00,000 and gross profit is 
Rs. 50,000- then the ratio would be 2:1. Which means gross profit is half of sales. 
 
(b)   Percentage Ratio:  This ratio shows the interrelation in percentage. If  we 
continue the earlier example, then we can say that gross profit ratio will be 50%,  
     which means gross profit is 50 %( half) of sales. 
 
(c) Rate Ratio:   This ratio shows how many times one amount contains 
another amount. If we continue the earlier example, then we can say that gross profit 
will be half of sales or sales are two times (twice) the gross profit. 
 
Types of Ratios: 
There are various types of ratios, and they are to be calculated as per the requirement, 
they are classified as per below three classifications: 
 
(A) Traditional Classification 
 
 1. Balance Sheet Ratios or Financial Ratios 
 Current Ratio 
 Liquid Ratio 
 Proprietary Ratio 
 Stock – Working Capital Ratio 
 Capital Gearing Ratio 
2. Profit and Loss Account Ratios 
 Gross Profit Ratio 
 Operating Ratio 
 
 Expenses Ratio 
 Net Profit Ratio 
 Stock Turnover Ratio 
 
3. Composite or Combined Ratios (Balance Sheet and Profit and Loss 
Account    
    Ratios) 
 Return on Capital Employed 
 Return on Shareholders’ funds 
 Earnings Per Share 
 Debtors’ Turnover Ratio 
 Creditors’ Turnover Ratio  
 Turnover of Fixed Assets 
 
 
 
 
 
(B) Functional Classification 
 1. Liquidity Ratios 
 2. Leverage Ratios 
 3. Activity Ratios 
 4. Profitability Ratios 
 
Ratios 
Balance Sheet Ratios P&L Statement Ratios Composite Ratios 
1. Current Ratio 
2. Liquid Ratio 
3. Proprietary Ratio 
4. Stock – Working 
Capital Ratio 
5. Capital Gearing 
Ratio 
 
1. Gross Profit Ratio 
2. Operating Ratio 
3. Expenses Ratio 
4. Net Profit Ratio 
5. Stock Turnover 
Ratio 
 
1. Return on Capital 
Employed 
2. Return on 
Shareholders’ 
funds 
3. Earnings Per Share 
4. Debtors’ Turnover 
Ratio 
5. Creditors’ 
Turnover Ratio  
6. Turnover of Fixed 
Assets 
(C) Classification from the view point of users. 
1. From Shareholders’ Point of View  
 Earnings Per Share 
 
 
 
2. From Long term Creditors Point of View 
 Debt-Equity Ratio 
 Long term funds to Fixed Assets Ratio 
 
3. From Short term Creditors Point of View 
 Liquidity Ratio 
i. Current Ratio 
ii. Quick Ratio 
 Stock Turnover Ratio 
 Debtors’ Turnover Ratio 
Now let us discuss each ratio in detail 
1. Current Ratio 
Current Ratio: = Current Assets / Current Liabilities 
Current Ratio is calculated by dividing Current Assets by Current Liabilities. This 
ratio shows the availability of current assets with the firm to meet its current 
liabilities.  
1:1 current ratio means; the company has Re. 1 in current assets to cover each Re.1 in 
current liabilities. Look for a current ratio above 1:1 and as close to 2:1 as possible. 
One problem with the current ratio is that it ignores timing of cash received and paid 
out.14 For example, if all the bills are due this week, and inventory is the only current 
asset, but won't be sold until the end of the month, the current ratio tells very little 
about the company's ability to survive. 
  
 
2. Liquid Ratio 
Liquid Ratio: = Current Assets-Inventories / Current Liabilities 
This ratio is also referred as Quick Ratio or Acid Test Ratio. It is calculated by 
dividing liquid assets by current liabilities. Liquid assets mean those assets which can 
be immediately converted into cash. This ratio shows the short term solvency position 
of the firm. 
 
Indicates the extent to which you could pay current liabilities without relying on the 
sale of inventory -- how quickly you can pay your bills. Generally, a ratio of 1:1 is 
good and indicates you don't have to rely on the sale of inventory to pay the bills.15 
Although a little better than the Current ratio, the Quick ratio still ignores timing of 
receipts and payments. 
 
3. Stock-Working Capital Ratio 
Stock-Working Capital Ratio: = stock / Working Capital 
This ratio is also referred as ‘Inventory-Working Capital Ratio’ or ‘Inventory net 
current assets ratio’. This ratio shows the relationship between stock and working 
capital. 
This ratio tells how much of a company's funds are tied up in inventory. It preferable 
to run your business with as little inventory as possible on hand, while not affecting 
potential sales opportunities. Keeping track of inventory levels is crucial to 
determining  
 
 
the financial health of your business. If this number is high compared to the average 
for your industry, it could mean your business is carrying too much inventory. 16 
 
4. Capital Gearing Ratio 
 
Funds bearing fixed interest or fixed 
dividend 
Capital gearing ratio: = 
                                                   Total Capital Employed 
 
 
This is a capital structure ratio, which shows the proportion of debt and equity in the 
total capital employed.  
 
This ratio can be calculated by dividing “Funds bearing fixed interest or fixed 
dividend” by “Total Capital Employed”. High ratio is known as highly geared, while 
low ratio is known as low geared ratio. This ratio is very important when company 
wishes to give the benefit of its earning to the equity shareholders. As such fixed 
interest or fixed dividends are to be given to debenture holders or preference share 
holders, and hence any surplus earned on their funds can be given to the equity share 
holders. This is also referred as “Trading on Equity”. 
 
 
 
 
5. Gross Profit Ratio 
 
Gross Profit Ratio: = Gross Profit / Net Sales 
This ratio shows the rate at which gross profit is earned on sales. The gross profit 
margin ratio tells us the profit a business makes on its cost of sales, or cost of goods 
sold. It is a very simple idea and it tells us how much gross profit per Re.1 of turnover 
our business is earning. Gross profit is the profit we earn before we take off any 
administration costs, selling costs and so on. So we should have a much higher gross 
profit margin than net profit margin.17 
The gross profit margin is a measurement of a company’s manufacturing and 
distribution efficiency during the production process. The gross profit tells an investor 
the percentage of revenue / sales left after subtracting the cost of goods sold.  A 
company that boasts a higher gross profit margin than its competitors and industry is 
more efficient. Investors tend to pay more for businesses that have higher efficiency 
ratings than their competitors, as these businesses should be able to make a decent 
profit as long as overhead costs are controlled [overhead refers to rent, utilities, etc.]  
6. Operating Ratio 
Operating ratio: = Operating Costs / Net Sales This ratio is calculated by 
dividing operating costs by net sales. This is very important ratio for the management 
to check its operating expenses. 
 
7. Net Profit Ratio 
Net Profit Ratio: = Net Profit / Net Sales 
This ratio shows the rate at which net profit is earned on sales. The net profit margin 
ratio tells us the amount of net profit per £1 of turnover a business has earned. That is, 
after taking account of the cost of sales, the administration costs, the selling and 
distributions costs and all other costs, the net profit is the profit that is left, out of 
which they will pay interest, tax, dividends and so on.18 
 
8. Stock Turnover Ratio 
Stock Turnover Ratio: = Cost of Goods Sold / Average Stock 
This ratio is also referred as ‘Inventory ratio’ or ‘Inventory Turnover ratio’ or ‘Stock 
turn ratio’ or ‘Merchandise Turnover ratio’ or ‘Stock Velocity ratio’ or ‘Velocity of 
stock’.  
This ratio measures the number of times stock turns or flows or rotates in an 
accounting period compared to the sales effected during that period. In other words, 
the ratio indicates the frequency of inventory replacement i.e., the number of times the 
inventory has been sold and replaced during a given period of time. 
 
9. Return on Capital Employed 
 
                Net profit before tax, interest and preference 
dividend  
Return on Capital Employed = 
Capital employed 
 
 
This ratio is also referred as “Return on Investment” or “Overall Profitability Ratio” 
This ratio shows the percentage of total profits earned with relation to the total capital 
employed or total assets utilized. If one wants to assess the efficiency of any company, 
one of the obvious indicators is of course sales figure. If the company  has 
operated efficiently, it would have higher sales and hence it would be rewarded with 
higher profits. Lack of efficiency will result in lesser sales and thus less profit. One 
more angle to look over less profit is the cost aspect. Lower profitability is also the 
result of uncontrolled cost. This ratio is a very good indicator of how good the assets 
are utilized and how much optimum the resources are utilized. If this ratio is 
compared with the same ratio of different years or with the ratio of other companies, it 
can give very important conclusions on which the strategy for the future course of 
action can be prepared. 
 
 
10. Return on Shareholders’ Funds 
                                Net profit after tax and interest   
Return on Shareholders’ Funds= 
Shareholders’ Funds 
 
 
This ratio shows the profit available for shareholders of the company. Here we are 
using profit which is after interest and tax, which means the profit which is available 
to the shareholders of the company. As such after paying for tax and interest on long 
term loans and debentures, whatever profit remains that belongs to the shareholders. 
 
 
11. Return on Equity Shareholders’ Funds 
 
                                  Net profit after tax, interest and           
                             Preference Dividend   
Return on Equity Shareholders’ Funds= 
                                                                                                            Equity Shareholders’ Funds 
 
The above ratio is same as previous, but this ratio shows the profits which are 
available to only Equity Shareholders. After paying tax and interest from the profit, 
whatever profit is left that is available for Preference and Equity Shareholders.  
 
But as Preference Shareholders are entitled to a fix rate of dividend on their 
investment before Equity shareholders, they will be paid first and then whatever profit 
remains that entirely is available for the Equity Shareholders. This profit compared to 
Equity shareholders’ funds (i.e. Equity Share Capital + Reserves + Retained Earnings 
+ Surplus) gives the Return on Equity Shareholders’ Funds. This is considered one of 
the most important indicators of the efficiency of the management. Higher the ratio 
higher will be the level of expertise of the management.  
 
    
12. Debtors’ Turnover Ratio 
                                   
                                       Debtors’ Turnover Ratio   =                         Credit Sales   
                                                                                                   
Average Accounts Receivables 
  
 
This ratio is also referred as ‘Debtors’ Velocity’ or ‘Turnover of debtors’ ratio’ or 
‘Accounts receivable turnover ratio’ or ‘Debtors Turnover period’ or ‘Average 
collection period’. This ratio shows the rate at which the trade debts are collected. 
This number indicates how quickly customers are paying to the business. The greater 
the number of times receivables turn over during the year, the shorter the time 
between sales and cash collection.  
 
 
13. Creditors’ Turnover Ratio 
                                   
                                       Creditors’ Turnover Ratio   =                         Credit Purchases  
                                                                                                       
Average Accounts Payables 
 
 
This ratio shows the rate at which creditors are paid. This number reveals how quickly 
your company pays its bills. The payables turnover ratio reveals how often payables 
turn over during the year. A high ratio means there is a relatively short time between 
purchase of goods and services and payment for them. A low ratio may be a sign that 
the company has chronic cash shortages.  It is a very important ratio with regard to the 
cash management of the firm as such creditors should not be paid too early, but 
looking to the reputation aspect of the firm the payments should not be too delayed as 
it creates negative impression of the firm in the eyes of the creditors who are major 
source of credit purchases. 
  
14. Debt-Equity Ratio 
                                   
                                       Debt-Equity Ratio   =       Total Liabilities/Debts 
                                                                                           
Total Equity                          
 
This ratio shows the ratio between capital invested by the owners and the funds 
provided by lenders and does the comparison of how much of the business was 
financed through debt and how much was financed through equity. 
 
The higher the ratio, the greater the risk to a present or future creditor. Too much debt 
can put your business at risk, but too little debt may mean you are not realizing the full 
potential of your business, and may actually hurt your overall profitability. This is 
particularly true for larger companies where shareholders want a higher reward 
(dividend rate) than lenders (interest rate).  
 
 
This ratio shows the proportion of borrowed capital and ownership capital. It can be of 
two types: 
  (a)  Debt-Equity Ratio   =        Long Term Debts 
                       Shareholders’ Funds                 
 
 (b) Debt-Equity Ratio   =        Long Term Debts 
         Shareholders’ Funds + Long Term Debts 
                             
The ratio shares favourable or unfavourable financial position of  
the concern. It shows long term capital structure. The low ratio is  
 
viewed as favourable from long term creditors point of view. It reveals high margin of 
safety to the creditors. Higher ratio is unfavourable. Higher the ratio greater will be 
the risk involved in respect of creditors. It indicates too much dependence on long 
term debts.  
 
 
[2] Dynamic or Horizontal or Trend Analysis 
 
When financial statements of different years are compared with regard to  individual 
items, it is referred to as Dynamic Analysis or Horizontal Analysis or  Trend 
Analysis. For example, sales figures, cost figures, etc are compared over  the years. 
 
In case of this type of analysis, financial statements for a number of years are 
reviewed and analyzed .The current year’s figures are compared with the standard or 
base year. The analysis statement usually contains figures for two or more  years and 
the changes are shown regarding each item from the base year usually in the form of 
percentage. Such an analysis gives the management considerable insight into levels 
and areas of strength and weakness. Since this type of analysis is based on the data 
from year to year rather than on one date, it is also termed  dynamic analysis. 
 
 
 
 
 
 
[3] Static or Vertical or Structural Analysis 
 
When different accounting variables of the same year’s financial statement are 
compared with each other, the analysis is known as Static or Vertical or Structural 
Analysis. 
 
In case of this type of analysis a study is made of the quantitative relationship of  the 
various items in the financial statements on a particular date. For example, the ratios 
of different items of costs for a particular period may be calculated with the sales for 
that period. Such an analysis is useful in comparing the performance of  several 
companies in the same group, or division or departments in the same company. Since 
this analysis depends on the data for one period, this is not very conductive to a proper 
analysis of the company’s position. It is also called ‘Static  Analysis’ as it is 
frequently used for referring to ratios developed on one date or  for one accounting 
period. It is to be noted that both analysis-vertical & horizontal  can be done 
simultaneously also. For example- the income statement of a  company for 
several  years may be given horizontally it may show the change in  different 
elements of cost and sales over a number of years. On  the other hand, vertically 
it may show the percentage of each element of cost to sales. 
 
 
 
 
 
[4] Fund Flow Analysis 
 
The balance sheet shows the financial position of the company on a particular  day. 
Income statement or Profit & Loss Account shows the operational profit of  the 
company. But if we want to know the working capital transaction of the year,  we 
need to prepare Fund Flow Statement. 
 
A Fund Flow Statement is prepared for recording inflows and outflows of funds.  
During the year there are numerous transactions resulting in increase and decrease of 
working capital. If a payment is made working capital would be reduced and if there is 
a receipt working capital would be increased. Thus in fund flow analysis,  we prepare 
a fund flow statement which records the flow of funds which means change in funds 
or change in working capital. 
 
A Fund Flow Statement records all the inflows and outflows of funds irrespective  of 
its revenue or capital nature.  It is different from Income Statement in that  regard and 
also income statement records the income and expenditure pertaining  to current 
year only. For example, if debentures are issued for cash, it becomes a  source of 
funds while preparing Fund Flow Statement, but it is not an item of  income for 
an Income Statement. During a year there are numerous transactions,  but only 
fund transactions would be recorded in the Fund Flow Statement.  Any  non fund 
transaction would not find any place in Fund Flow Statement. Thus, any  fund 
transaction or the transaction which affects working capital  
 
would be  recorded in Fund Flow Statement. Comparing Fund flow statement 
with Balance  Sheet some authors have observed that, “The purpose of Fund flow 
statement is  not to match the asset and liabilities as on a particular date but to show 
as to what  have happened to the funds available from different sources. Thus the 
fund flow  statement emphasis on change and not on status as it is in the case of 
balance  sheet.”19 
 
FUND FLOW ANALYSIS AS TOOL OF FINANCIAL  STATEMENT 
ANALYSIS 
We have seen the meaning and use of fund flow analysis; here we are discussing fund 
flow analysis as a tool of financial statement analysis. Now let us examine Fund Flow 
Analysis as a tool of financial statement analysis. In the words of Dr. 
S.N.Maheshwari, “Fund Flow Statement helps the financial analyst in having a more 
detailed analysis and understanding of changes in the distribution of resources 
between two balance sheet dates. In case such study is required regarding the future 
working capital position of the company, a projected  funds flow statement can 
be prepared.” 
Although a company prepares various financial statements but fund flow  statement 
has its own usefulness.  It is one of the very important tool of analysis  of financial 
statement. 
 It throws light on the liquidity position of the company 
 It throws light on the use of profit 
 It helps in allocating scare resources of the company 
 It checks the effective use of working capital. 
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1. Introduction & International Pharmaceutical Industry 
 
The multinational pharmaceutical industry is unique in that it is largely organized and 
operated by privately owned companies, created to realize profits for its stockholders. 
The industry deals in life-and-death issues, and its products not only relieve illness, 
but can often improve the quality of life. In addition to the life-giving aspect, the 
composition of products usually consists of highly toxic chemicals, which, when 
mixed discriminately, can cause serious health problems and even death. Since public 
health is of concern to all governments, the pharmaceutical industry is heavily 
regulated on the national level worldwide. This regulation takes the form of prior 
approval in order to market a new product and in some countries the establishment of 
a price for the product. 
 
At the global level, the pharmaceutical industry is divided into two kinds of firms, the 
innovative firm and the generic firm (producer of generic drugs).1 
 
The first, the innovative or patent-protected firms, rely heavily on patent protection. 
These firms believe that in order to carry out the intensive research required to 
produce new products, patent protection is essential. As a result of the extensive 
research and cost to produce a patent-protected drug, patent-protected firms tend to be 
located in highly developed and industrialized countries. Not all research efforts are 
successful. It is only a small fraction that reaches the market. It is through the period 
of exclusivity provided under the patent, generally twenty years from the date of 
filing, that the firm can recoup its research and development (R&D) costs to continue 
new and innovative research. Actually, the effective term of the patents is more like 
14-15 years due to delays in the patent approval process and in obtaining rights to 
market the new drug. These firms are dependent on patent protection and are reluctant 
to introduce new products in countries that deny such protection. Because the patent 
grant provides a period of exclusivity, the patent owning firm can establish a higher 
price for the product since no competition is allowed. This is true when patent 
protection exists, even in countries where the government regulates the price of the 
product.  
 
The second, the generic pharmaceutical firm, manufactures and markets 
pharmaceutical products that are not subject to patent protection. In countries with 
patent protection, generic firms come into their own at the expiration of the patent. At 
such time, the technology is in the public domain (as referred in US) and anyone is 
free to manufacture the product. Generic products are subject to some government 
regulation before any sales can be made, (in the United States the manufacturer must 
demonstrate to the satisfaction of the Food & Drug Administration (FDA) that the 
generic version is the bio-chemical equivalent of the patented product).  
 
Generally speaking, once the generic drug appears on the market, it will be available 
at a lower cost than the original patented version. Often, several generic products will 
appear on the market within the same timeframe, thus causing even larger price 
reductions. In countries lacking pharmaceutical patent protection, the entire industry 
could be said to be generic. In such countries, the profile of the industry will include 
firms that may manufacture, internationally used drugs, which are in the public 
domain in the country of origin. In such a case, the industry is similar to the generic 
firm in the United States. However, many firms in countries that do not recognize 
pharmaceutical product patents manufacture products that are still under patent 
protection in the country of origin, thus diluting the value of the patent. This practice 
is viewed negatively by the country providing patent protection and is often 
characterized as piracy or counterfeiting by the firm whose patent is not being 
recognized. Yet it is perfectly legitimate and legal in the country where the drug is 
being manufactured and sold.  
 
Both the patent-protected and generic industries are patent-driven. The former rely on 
strong, effective patent laws and extending patent protection as long as possible both 
at home and abroad. The generic industry (as in the United States) is eager to begin 
manufacturing the generic equivalent as quickly as possibly so as to gain market 
access at the earliest time, and is obviously opposed to any form of patent term 
extension. Each, however, is convinced that it is providing unique service to the 
public: the patent-protected firm by introducing the newest, breakthrough product and 
the generic firm by offering quality products at lower costs.  
 
The Pharmaceutical Research Manufacturers Association (PhRMA) located in 
Washington, DC, is a trade association representing the interests of the innovative or 
patent-protected manufacturers of pharmaceuticals. Its mission: 
…is to help the research-based pharmaceutical industry successfully meet its 
goal of discovering, developing, and bringing to market medicines to improve 
human health, patient satisfaction, and the quality of life around the world, as 
well as to reduce the overall cost of health care. 2 
Currently, “PhRMA” membership consists of substantially all of the patent-protected 
pharmaceutical firms. A partial list of names and addresses of PhRMA member firms 
is provided in Exhibit 1. High on PhRMA’s agenda is obtaining strong and effective 
patent protection in all countries where its members are active. In addition, PhRMA 
addresses such concerns as price control and generic competition, issues that could 
adversely affect the interests of its members domestically and abroad. On a global 
level, PhRMA keeps careful track of the availability and effectiveness of intellectual 
property protection throughout the world. Annually, it notifies the United States Trade 
Representative (USTR) of the outcome of its review and makes recommendations as 
to what action the United States government should take against countries believed to 
be deficient in meeting international standards.  
 
For years, India had been a problem country and high on PhRMA’s list because of 
failure to grant pharmaceutical product patents. As a result of the intellectual property 
environment in India, PhRMA members tended to be low profile, and principally 
marketed drugs no longer protected by patent, as opposed to their premier, innovative 
products.  
 
Global pharmaceutical firms watched developments in India closely after 1991. The 
situation in India may be changing. In 1995 India became a signatory of the Uruguay 
Round Agreement, Trade Related Aspects of Intellectual Property (TRIPS), and 
thereby showing willingness to accept one of its requirements, the issuance of 
pharmaceutical product patents. India’s adherence to TRIPS would become effective 
in 2005 as a result of a provision of the Agreement granting developing countries an 
additional period if it is required “to extend patent protection to areas of technology 
not so protectable in its territory.” In an important first step towards full compliance, 
India acceded to the Paris Convention for Protection of Industrial Property (Paris 
Convention) and the Patent Co-operation Treaty (PCT).3 Adherence to the Paris 
Convention is required under the TRIPS, and membership in the PCT provided instant 
benefits to Indian firms seeking multiple country patent protection. As the year 2005 
approached, the global pharmaceutical industry watched India with new interest and 
the Indian pharmaceutical 
industry positioned itself, for the first time, to face international competition.4 
 
 
Before moving ahead let us clarify the basic production of pharmaceutical industry. 
Be it anywhere in the world, a pharmaceutical company, producing pharmaceutical 
products will be engaged in basically two types of products:  
 
(a) Bulk Drugs, which is the therapeutic molecule(molecules are the bulk drugs 
that are the active component in any pharmaceutical product) in powder form in the 
drugs, in other words chemicals having therapeutic value and used for production of 
pharmaceutical formulations, and 
 
(b) Formulations, which is the final compound. Formulations can be tablets, 
injections and syrups or in the form of plasters where the therapeutic drug is absorbed 
through the skin. In other words formulations are medicines ready for consumption by 
patients. 
 
 
 
2. Indian Pharmaceutical Industry 
 
 
The Indian Pharmaceutical Industry is no less than a success story as it has provided 
employment for millions and made the drugs available to the vast population of the 
country at very affordable prices. The Indian pharmaceutical industry with a domestic 
market turnover of Rs 18,000 Crores and growing at five per cent as per the MAT - 
ORG September 2003 is poised for a paradigm shift. The Indian pharmaceutical 
industry has moved through several phases of ups and downs. 
 
The evolution and growth of the Indian pharmaceutical industry has been largely 
driven by regulatory forces — the DPCO (Drug Price Control Order), which regulated 
the prices of bulk drugs and formulations, and the Indian Patent Act, which granted 
process patents but not product patents. 
 
Pharmaceutical Business came into existence in India in the year 1901 when Bengal 
Chemicals and Pharmaceutical Company started its production in Calcutta. Since then 
there is no looking back and today India has become one of the leading 
pharmaceutical products manufacturing nation. This fact would become evident by the 
current scenario of the industry, wherein it is not just meeting the increasing demand 
of the huge population of the country, but also exporting the products to other 
developing and developed countries of the world including the USA. Starting from the 
humble beginning of repacking imported raw materials; the Indian pharmaceutical 
industry has graduated to become a net foreign exchange earner, making its presence 
felt in the global pharmaceutical arena. India is the fourth largest producer of bulk 
drugs and formulations in terms of volumes though not in terms of value. Indian drugs 
have the distinction of being the most competitive in terms of price causing much 
heartburn to the MNCs. In spite of the impressive statistics of the Indian 
pharmaceutical industry, our per capita consumption of drugs is one of the lowest in 
the world and only 30 per cent of the population mostly in the urban areas has access 
to modern drugs. The shortcomings of the Indian pharmaceutical industry are in the 
fields of R&D and new drug discovery. 
 
 
  
3. Features of Indian Pharmaceutical Industry 
 
1. Self Sufficient to meet the domestic demand 
Looking to the features of Indian Population, like, huge size, majority of lower income 
group, less personal budget for medical treatment, adverse climatic conditions, etc, it 
is very important that they get quality medical treatment and medical products , not 
only that but at affordable prices. Indian Pharmaceutical Industry is called a Success 
Story, because it has served the population of the country in spite of the above limiting 
features.  
 
The pharmaceutical industry in India meets around 70% of the country's demand for 
bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, 
capsules, orals and injectibles.5 More than 85% of the formulations produced in the 
country are sold in the domestic market. India is largely self-sufficient in case of 
formulations. Some life saving, new generation under-patent formulations continue to 
be imported, especially by MNCs, which then market them in India. Overall, the size 
of the domestic formulations market is around Rs160bn and it is growing at 10% p.a.6 
 
The pharmaceutical industry today is in the front rank of India’s science-based 
industries, with wide ranging capabilities in the complex field of drug manufacturing 
and technology. It is a front-runner in the third world in terms of technology, quality 
and range of medicines manufactured. Almost all types of medicines – ranging from 
simple pain relieving pills to sophisticated antibiotics and complex cardiac compounds 
– are now made in the country. These have made India fairly self-sufficient in this 
field. 
 
2. Gigantic Size 
Over 20,000 registered pharmaceutical manufacturers exist in the country.5 The 
leading 250 pharmaceutical companies control 70% of the market with market leader 
holding nearly 7% of the market share. Over the four decades between 1969-70 and 
1998-99 the number of business units engaged in the production of drugs and 
pharmaceuticals grew nearly ten times from 2257 to 20053 (OPPI, 1998-99). Indian 
Pharmaceutical Industry is one of the largest and most advanced among the 
developing countries. 
 
 
 
 
The data shown in the following table, will give an idea of how the size of the industry 
has increase over the period of 30 to 35 years: 
Table 2.1 5 Growth of Pharmaceutical Industry in India   
     
(Rs. In Crores) 
     Particulars          1965-66          1999-00 
     Capital Investment            140.00           2,500 
     Production of Bulk Drugs             18.00           3,777 
     Production of Formulations          150.00         15,960 
     Import                 8.20               3,441 
     Export      3.05           6,631 
     R&D Expenditure                3.00              320 
          (Source:www.pharmaceutical-drug-manufacturers.com/pharmaceutical-
industry) 
 
 
3. High volume of production 
 
Between 1965-66 and 1998-99 the production of formulations rose from a value of 
Rs.1.5 million to almost Rs. 139 billion, and that of bulk drugs from Rs.180 million to 
more than Rs. 31 billion. 
 
 
Table 2.2: Production of Bulk Drugs and Formulations in India 7 
(Rs.Million 
Year   Value 
   Bulk Drugs          Formulations      Total 
1980-81        2400    12000     14400 
1990-91        7300    38400     45700 
1994-95      15180    79350     94530 
1998-99      31480    138780    170260 
          
         (Source: Indian Pharmaceutical Guide, 1998; Annual Report (1999-2000),  
 Department of Chemicals and Fertilizers.) 
 
4.Low Prices 
Another significant factor characterizing India’s pharmaceutical market is its 
extremely low drug prices, among the lowest in the world. In a country of almost one 
billion people, price controls served as a means of ensuring that even the poorest had 
access to drugs. A price comparison of certain drugs is illustrated in the following 
table of U.S. prices and Indian prices. 
 
 
 
 
 
 
 
 
Table 2.3 4  Price Comparison of Certain Drugs in U.S. & India 
 
 
     U.S. Price          Indian Price 
   Brand Name /Generic Name  Dosage    per Tablet ($)   per Tablet ($) 
 
             Prilosec/Astra Merck Omeprazole      20 mg          $3.76    $0.09 
 
             Prozac/Eli Lilly Fluoxetine                10 mg          $2.28    $0.63 
 
             Zocor/Merck Simvastatin                10 mg          $2.07   $0.21 
 
             Zantac/Glaxo-Wellcome Ranitidine  150 mg          $1.72   $0.02 
 
            
 (Source: Investing in the Indian Pharmaceutical Industry: The American 
 Graduate School of International Management, Professor Robert Tancer  and 
 student Srinivas Josyula, 1999 Thunderbird) 
 
The Indian Patents Act (IPA) of 1970 only recognized process patents. 
Thus, the market became highly competitive with extremely low drug prices. Drug 
prices in India were sometimes 1/10th of U.S. prices.4 
 
5. Growth in Exports 
Over 60% of India’s bulk drug production is exported. The balance is sold locally to 
other formulators. India’s pharmaceutical exports are to the tune of Rs87bn, of which 
formulations contribute nearly 55% and the rest 45% comes from bulk drugs. In 
financial year 2000, exports grew by 21%. India’s pharmaceuticals imports were to 
the tune of Rs20.3bn in financial year 2001. Imports have registered a CAGR of only 
2% in the past 5 years. Import of bulk drugs have slowed down in the recent years. 
The exports of Pharmaceuticals during the year 1998-97 were Rs 49780 million. From 
a meager Rs 46 crores worth of Pharmaceuticals, Drugs and Fine Chemicals exports in 
1980-81, pharmaceutical exports has risen to approximately Rs 6152 Crores 
(Prov.1998-99), a rise of 11.91% against the last year exports. Amongst the total 
exports of India, the percentage share of Drugs, Pharmaceuticals and Fine Chemicals 
during April-October (2000-2001) was 4.1%, an increase of 7%. 
Exports have been rising at around 30% CAGR over last five years. There is a shift in export 
profile towards value added formulations from low value bulk drugs.8 
Table 2.4 
9  
 
Export of Bulk Drugs and Formulation     [Rs. Million] 
 
 Year          Exports of Bulk Drugs       Exports of Formulations       Total 
   
  1980-81              113             351            464 
  1984-85   293             995          1288 
  1989-90                   3505           3142          6647 
  1990-91            4134            3714          7848 
  1991-92            7226           5586        12812 
  1992-93  4095           9655        13750 
  1993-94  5308         13108        18416 
  1994-95             7601         15055        22656 
  1995-96           11329         20448        31777 
  1996-97           15811         25092        40903 
  1997-98           17379         33432        50811 
  1998-99           23277         30385        53662
  
 
(Source: Indian Pharmaceutical Guide, 1998; Annual Report (1999-2000), 
Department of  Chemicals and Fertilizers, OPPI, 33rd Annual Report 1998-99) 
 
 
 
India exported drugs and pharmaceuticals to more than 200 countries in 1998-99. The 
share of Indian exports to the USA remained eleven per cent over the years 1994-95 to 
1998-99. Exports to Germany and Hong Kong increased by nearly two percentage 
points, whereas that to Russia came down by seven percentage points. In 1998-99, 
drugs and pharmaceuticals constituted 28 per cent of India’s exports to Vietnam, 21 
per cent to Nepal and 20 per cent to Nigeria. As far as the major trade blocs are 
concerned, in 1998-99 Latin American Integration Association had the largest 
combined share (14.7 per cent), followed by ASEAN (8.1 percent), CIS (7.6 per cent) 
and SAARC (6.1 per cent) countries in that order. 
 
The process of economic reforms introduced in India in 1991 had a clear accent on 
trade and industry liberalisation, economic reform and macroeconomic stabilisation. 
Internationally, the midnineties proved to be a watershed, with the approval at the 
1994 GATT summit of the Dunkel proposals, which envisaged drastic changes in the 
intellectual property laws and investment policies of India, which were known to have 
lenient rules and weak enforcement mechanisms. The developed countries were 
insistent that many aspects of IPRs were ‘trade related’ and thus had to be negotiable 
at the multilateral level. India’s domestic programme of liberalisation, coupled with 
the global pressure for stricter regulatory norms, have redefined the contours of the 
business environment facing many industries, including pharmaceuticals. 
 
 
 
6. Drug Price Control Order 
Manufacturers are free to produce any drug duly approved by the Drug Control Authority.  The 
Drug Pricing Control Order (DPCO) has been the millstone around the neck of Indian industry as 
it has severely restricted profitability and hence innovation. However, the government has been 
relaxing controls in a slow but progressive manner. The span of control of DPCO has come down 
from 90% in 1980s to 50% in 1995 and is likely to be further reduced as per the latest proposed 
changes. 
The central government remained a key influence and a controlling factor in the 
direction of India’s pharmaceutical industry. The inward-looking policies adopted by 
politicians since independence had slowed foreign direct investment into Industries of 
India, and pharmaceuticals were no exception. The Drug Price Control Order (DPCO) 
was established in 1985, enabling the government to dictate drug prices for 143 basic 
drugs, with the purpose of ensuring the availability of medicines at low prices. Price 
controls disrupted free-market forces further because there was no control over the 
price of any raw materials needed for manufacturing drugs. In 1999, there were 76 
bulk drugs under the DPCO and approximately 260 formulations that use these bulk 
ingredients. 10 
 
In a country of almost one billion people, price controls served as a means of ensuring 
that even the poorest had access to drugs. A drug would be controlled if its overall 
annual turnover exceeded $1.05 million or if there were less than five bulk drug 
manufacturers or ten formulation manufacturers of that specific drug. However, with 
the liberalization of the industry, the government felt strongly encouraged to dissolve 
the price controls in favor of natural market economic pricing.  
The main argument against the DPCO was that it did not leave any scope for 
sufficient returns to be reinvested in research and development. Domestic firms 
argued that unless the permissible profit margins increased, they would be unable to 
be competitive in 2005 when product patent legislation took effect and they could no 
longer produce copies of existing drugs.10 
7. Patents and the Patent Act(which granted process patents but not product 
patents) 
Patent refers to an official document giving the holder the sole right to make, use or 
sell an invention and preventing others from copying it.11 The basic obligation in the 
area of patents is that, inventions in all fields of technology whether products or 
processes shall be patentable if they meet the three tests of being novel, involving an 
inventive step and being capable of industrial application. In addition to the general 
security exception, which applies to the entire TRIPS Agreement, specific exclusions 
are permissible from the scope of patentability. These are available in the areas of 
inventions whose commercial exploitation is to be prevented to protect public order or 
morality, human, animal plant life or health or to avoid serious prejudice to the 
environment. In addition, we can exclude from patentability diagnostic, therapeutic 
and surgical methods for the treatment of human and animals, plants and animals 
other than microorganisms, and essentially biological process for the production of 
plants and animals other than non-biological and micro biological processes. To meet 
our TRIPS obligations as on 1.1.2000, the Patents (Second Amendment) Bill, 1999 
has been introduced in the Parliament in December 1999 and is before the Joint 
Committee of the Houses. 
 
Patents are granted after considerable time and money have been invested in a 
particular invention. At one extreme, the patent represents a basic property right 
granted to the inventor in recognition of an achievement. Under such a system, the 
inventor is granted the exclusive right to exploit the patent for a designated period of 
time. Under the TRIPS, the term is twenty years from the date of filing for the patent. 
The public interest is minimized and is recognized only by publication of the patent to 
promote further knowledge in the field of the invention. This is typically the view of 
the developed, industrialized countries of the world. At the other extreme are those 
countries that do not protect any kind of intellectual property. Thus, in the case of 
patents, the inventor does not receive any form of protection and a work may be 
copied with impunity. Generally, the least developed and poorest countries fall into 
this category.10 
 
The growth of the Indian pharmaceutical industry over the last three decades or so is 
to a great extent due to the 1970 Act, which allowed the domestic marketing of 
patented products without a license. By following a process patent system, India’s 
pharmaceutical industry has sharpened its competence in applied research for 
developing production-process technology.  
 
The Indian Patents Act (IPA) of 1970 only recognized process patents. 
Thus, the market became highly competitive with extremely low drug prices. Drug 
prices in India were sometimes 1/10th of U.S. prices.10 
 
Patents play an important role in encouraging Research and Development. The new 
WTO rules imply that India will have to switch to a product patent regime post 2005 
from its current process patent regime. This would alter the scenario in the Indian 
market over the next 10-15 years.12 
 
The production of pharmaceutical products increased several times between the early 
1970s and early 1990s, and the country could attain near self-sufficiency in bulk drug 
production. Also, the time lag between new product introduction in the world market 
by the inventor and in the Indian market by domestic producers was found to be only 
about 4.5 years on average (Keayla, 1994). For most Indian companies, more than 20 
per cent of sales came from products that were less than two years old.13 
 
Patent applications filed declined from 5100 in 1970-71 to an annual average of about 
3500 between 1985 and 1992, during the post-1995 period patent applications 
increased two-fold as compared to the previous years. Two notable aspects of this 
substantial rise in patent applications after 1995 are: 
 
i. This indicates the clear advantage the new IPR regime would offer to foreign 
   firms, who are already endowed with R&D capabilities; and 
 
ii. The number of Indian patent applications has certainly increased, a large    
     number having come from public sector organizations, notably, the CSIR and  
     IITs.13 
 
8. Research and Development 
 
Research and Development is the key to the future of pharmaceutical industry. The 
pharmaceutical advances for considerable improvement in life expectancy and health 
all over the world are the result of a steadily increasing investment in research. The 
Pharmaceutical Industry is such an industry which is very much dependent on 
Research and Development and this industry is a typical case where the Research and 
Development and Profit are closely interrelated. Ironically, the shortcomings of the 
Indian pharmaceutical industry are in the fields of Research and Development and 
new drug discovery. Research and development has always taken the back seat 
amongst Indian pharmaceutical companies.  
 
Despite the large base of scientific manpower, India’s pharmaceutical industry did not 
invest heavily in Research and Development. One of the major reasons for this was 
that there were no product patent laws in place for pharmaceutical products in India. 
Without product patents, domestic Indian firms have grown their indigenous market 
through the creation of different processes. The Research and Development 
expenditure by the Indian pharmaceutical industry is around 1.9% of the industry’s 
turnover. This obviously, is very low when compared to the investment on Research 
and Development by foreign research-based Pharma companies. They spend 10 - 16% 
of the turnover on Research and Development. However, now that India is entering 
into the Patent protection area, many companies are spending relatively more on 
Research and Development. 14 
Major players such as Ranbaxy, Dr. Reddy’s, and Torrent, are recognizing that to 
remain viable once product patent laws took effect, they must begin developing their 
own molecules to compete effectively in India and abroad. 15 
There is considerable scope for collaborative Research and Development in India. 
India can offer several strengths to the international Research and Development 
community. These strengths relate to availability of excellent scientific talents who 
can develop combinatorial chemistry, new synthetic molecules and plant derived 
candidate drugs.  
 
Research and Development in the pharmaceutical industry in India is critical to find 
answers for some of the diseases peculiar to a tropical country like India and also for 
finding solutions for unmet medical needs. Industrial Research and Development 
groups can carry out limited primary screening to identify lead molecules or even 
candidate drugs for further in vivo screening, pre-clinical pharmacology, toxicology, 
animal and human pharmacokinetics and metabolic studies before taking them up for 
human trials. In such collaborations, harmonized standards of screening can be 
assured following established good laboratory practices.  
 
When it comes to clinical evaluation at the time of multi-center trials, India would 
provide a strong base considering the real availability of clinical materials in diverse 
therapeutic areas. Such active collaboration will be mutually beneficial to both 
partners. According to a survey by the Pharmaceutical Outsourcing Management 
Association and Bio/Pharmaceutical Outsourcing Report, pharmaceutical companies 
are utilizing substantially the services of Contract Research Organizations (CROs).  
Indian Pharmaceutical Industry, with its rich scientific talents, provides cost-effective 
clinical trial research. It has an excellent record of development of improved, cost-
beneficial chemical syntheses for various drug molecules. Some MNCs are already 
sourcing these services from their Indian affiliates.  
 
The Pharmaceutical and Biotechnology Industry is eligible for weight deduction for 
Research and Development expense up to 150%. These Research and Development 
companies will also enjoy tax holiday for 10 years. A promotional research and 
development fund of Rs.150 crores is set up by the Government to promote research 
and development in the pharmaceuticals sector.14 
 
Although the domestic R&D intensity has improved during the later part of the 1990s, 
the level of investment has remained very low (Pradhan, 2002: 650). Moreover, much 
of this investment has been made by a few dominant pharmaceutical firms, such as 
Ranbaxy, Lupin, Dr. Reddy’s Labs and Nicholas Piramal. That majority of Indian 
pharmaceutical units, mostly small, have no resources to invest in R&D remains the 
hard fact. 
 
9. TRIPS  (Trade Related Aspects of Intellectual Property Rights) 
Proposed and formalised by a select group of industrialised countries way back in 
1883 (and subsequently revised in 1967), in what is called the Paris Convention for 
Protection of Industrial Property, international legal protection for intellectual 
property rights (IPRs) became prominent on the global economic agenda only in 1986, 
during opening summit for the Uruguay Round of the General Agreement on Tariffs 
and Trade (GATT). The IPR regime, as it is often referred to in the literature, is a 
mega proposition on comprehensively enforcing and regulating, on a global scale, 
protections for patents, copyrights, designs and the entire system of intellectual 
property.  The stakeholders who would if affected include manufacturing sector, 
government, etc. This is especially the case when the activities involve the so-called 
knowledge-based sectors, e.g., biotechnology, pharmaceuticals and microelectronics. 
The coming into being of the World Trade Organisation (WTO) in 1995, through the 
Final Act of the Uruguay Round of GATT negotiations, has posed formidable 
challenges to member-states, especially those classified as developing countries or 
least developed countries (LDCs). Among these challenges is the need to 
accommodate the provisions of the much debated Trade-Related Aspects of 
Intellectual Property Rights (TRIPs) Agreement.  
 
The Agreement sets out minimum standards to be adopted by the parties, though they 
are free to provide higher standards of protection. A transition period of five years is 
available to all developing countries to give effect to the provisions of the TRIPS 
Agreement. This period ended on 1.1.2000. No transitional period is available, 
however, for grant of national treatment and most-favoured-nation treatment. 
Countries that did not provide product patents in certain areas of technology as on 
1.1.1995, can delay the grant of product patents in those areas for another five years 
i.e. up to 1.1.2005.14 
 
The shift away from the patents and Design Act of 1911, that was both ‘exploitative’ 
and framed to serve the western capitalist/imperialist interests, was fraught with 
intense debates in the public sphere as also both the Houses of the Parliament. The 
pressure to come up with a new patent law in 1970 stemmed from the fact that ‘A 
number of cases highlighted that foreign patent owners were neither using their 
patents for domestic manufacture nor allowing them to be used by local firms’ 
(Kumar 2003:217). As S. Velaraman, the director of the Indian Patent Office and a 
key driver behind the enactment of the Patents Act of 1970, observed, ‘We are not 
against patent. And we are prepared to pay decent license fees. But we in India cannot 
afford monopolies’(quoted inGester n.d: 4). 
 
The operationalisation of the new patent regime in 2005 is likely to bring about 
fundamental changes in the composition of the pharmaceutical industry. The 
reintroduction of product patent would mean that companies would not be able to 
copy drugs patented after 1995. In other words, most Indian companies may face an 
acute decline in market opportunities after 2005. It is also pointed out that a shift to a 
product patent regime would demand that basic capabilities of indigenous research be 
developed. Big companies have started preparing themselves for improving their 
R&D standard as well as R&D budget and also making tie-ups with the leaders for the 
R&D, but the real test is for the small units because they not only lack financial 
resources but also lack trained manpower and accessible testing facilities.  
 
It has also been argued that in the changed patent scenario, the compulsory licensing 
provisions are diluted considerably to ensure ‘working’ of patents. As importation is 
considered as working of a patent, the failure to meet the obligation of import alone 
would be seen as the legitimate condition to issue a compulsory license. This means 
that the government will not be able to use the compulsory licensing provision to 
facilitate technology transfer. These have grave implications for the reform measures 
underway in the country with respect to technology transfer (DRPSCC, 1993). 
 
The passage of the Patents (Amendment) Act, in 1999 was the first important step in 
facilitating product patents in the country by accepting product patents applications 
since 1995 and providing for the grant of exclusive marketing rights (EMR) in India.13 
 
After decades of denial, in 1999 India became party to the Paris Convention and the 
Patent Cooperation Treaty. It has been argued that the IPR regime can significantly 
constrain access to technology by developing countries and increase dependence on 
imports. The local firms would, under such circumstances, be left with no option other 
than collaborating with the foreign firms or simply giving up business. Similarly, a 
stronger patent system can dissuade innovative activity by local firms whose R&D 
function, dependent on the spill over effects of other firms and important in itself, 
would be affected adversely by the restricted access to these spillovers (Kumar, 2003: 
221). 
 
Due to the process patent system domestic manufacturers could produce inexpensive, 
generic versions of on-patent regimes . The product patent regime would disallow 
such production and trade. It is apprehended that the prices of newly patented drugs 
would increase substantially, thereby imposing tremendous social and economic costs 
on the poor on these countries. The argument that higher prices would induce greater 
innovative activity by the patent protected developed nations is highly flawed. Even if 
a large part of the expenditure by multinational firms on R&D is geared towards the 
many so-called ‘poor’ country diseases (viz., tuberculosis, malaria, cholera, 
HIV/AIDS, etc), the developing country consumers would still find the cost of 
medicines prohibitive; consequently, through low sales, R&D investment would be 
reduced. In any case, prices of medicines for the ‘global’ ailments (viz., cancer, 
cardiac diseases, etc.) would also be high for new drugs in developing countries, 
irrespective of the patent regimes. The R&D activity shall, evidently, continue to 
derive strength from consumers in the developed nations. In fact, a recent UNDP 
report estimates that once TRIPs comes into force, it could induce a price hike ranging 
between 12 per cent and 68 per cent. It concludes: ‘To expect developing countries to 
accept such price spirals without adequately addressing their concerns of access to 
cheaper medicines to fight  life threatening diseases, particularly in a public health 
emergency, seems unfair’ (Polycarp, 2003: 37). 
 
Changes in India’s policy regime did not come about automatically with the signing of 
the WTO-TRIPs Agreement. However, the Indian pharmaceutical majors were both 
aware of and prepared for the implications of the new regime. But the shift in policy 
away from the established and much-favoured process patent system involved a 
gradual reorientation of political and business mindsets. An important contributing 
factor was the initiation of India’s general programme of economic reforms in mid 
1991. This process increased general understanding of market mechanisms, global 
business trends, the role of international organisations, new perspectives on trade, the 
evolution of patent systems and other issues that have a bearing on public debates 
about economic policymaking.13 
 
 
One unintended consequence of the dissent emanating from both the political and 
business circles had been that a lot of information on such issues as patents and world 
trade became available in the popular media; this enhanced awareness in the public 
mind.  
 
By the late 1990s, sections of the Congress and BJP were gradually beginning to grasp 
the implications of the proposed global IPR regime. Moreover, as argued by Pederson 
(2000), even while the reform process per se was described as ‘half-hearted’ – and 
opposed by business groups that stood to gain from deregulation, the loss of subsidies, 
high tariff barriers and other forms of protectionism – a certain section of Indian 
industry, which adopted advanced technological and management practices, in fact 
had a ‘global’ outlook and came out in support of the reforms process. In keeping with 
the growing needs of such industries, by the early 1990s, the major industry bodies, 
such as the Confederation of Indian Industry (CII), the Associated Chambers of 
Commerce and Industry (ASSOCHAM) and the Federation of Indian Chambers of 
Commerce and Industry (FICCI), had been building a strong case for upholding global 
norms that favoured a strict form of IPR protection. The Council of Scientific and 
Industrial Research (CSIR) also played a crucial role in creating awareness, 
encouraging domestic patent protection and making its presence felt in international 
fora, especially in a number of cases concerning agricultural produce. Hence, by the 
late 1990s the implications and challenges of the IPR regime were fairly known. The 
active political debates in India – manifested in terms of both partisan conflict and a 
wider public discussion – a had generated widespread concern amongst various 
stakeholders, including the NGOs. 
 
10. Dichotomous Structure of Industry 14 
As a result of the manner in which the pharmaceutical industry has grown in India, it 
has resulted in a clearly dichotomous industry structure. A small number of large 
enterprises and MNC subsidiaries have come to coexist with a very large number of 
small units. These two broad groups have distinct styles of functioning as they not 
only operate at substantially different levels technological and managerial 
sophistication, but also access very different market segments. These factors largely 
determine their stances with reference to TRIPs-related issues. 
 
11. Growing Industry (include information on investment) 
With a humble beginning more than a century ago(in1901), and with a total sales 
volume of only Rs.10 million in 1948, the industry is currently capable of meeting 
about 70 per cent of the domestic requirement of bulk drugs and almost the entire 
demand for formulations.  The growth in the production of bulk drugs and 
formulations in the country has been quiet impressive. 15 
 
The Indian pharmaceutical industry is highly fragmented, but has grown rapidly due 
to the friendly patent regime and low cost manufacturing structure. Intense 
competition, high volumes and low prices characterize the Indian domestic market. 
Starting from the repacking imported raw materials; the Indian pharmaceutical 
industry has graduated to become a net foreign exchange earner, making its presence 
felt in the global pharmaceutical arena. India is the fourth largest producer of bulk 
drugs and formulations in terms of volumes though not in terms of value. 16 
 
The number of pharmaceutical firms in India multiplied dramatically from 3,000 in 
1977 to over 24,000 in 1997.17 By 1999, India’s pharmaceutical market was growing 
at 15% per year in terms of sales revenues, which was among one of the highest 
growth rates in the world.18 According to Dr. Parvinder Singh, Chairman of Ranbaxy, 
one of India’s largest pharmaceutical companies, India’s pharmaceutical sales were 
expected to grow to $8 to $10 billion by the year 2005.19 
 
 
 
 Table 2.5  Indian Pharmaceutical Industry Growth Indicators 
           Particulars                     1965-66(in $000)   1996-97(in $000) 
      Capital Investment              36,842    4,21,053 
   Production: 
   Formulations             39,474         24,01,316 
   Bulk Drugs               4,737   4,79,474 
   Import                2,158   4,84,211 
   Export                   803         10,76,316 
   R&D Expenditure                 789     48,684
  
 
(Source: OPPI Directory 1997, p. 56.) 
 
Table 2.6 Investment in Pharmaceutical Industry: Selected Years [Rs. Million] 
Year      Investment 
1965     1600 
1973     2250 
1979     5000 
1985     6500 
1988     10600 
1994     12000 
1996     16500 
1998     21500 
  
(Source: Indian Pharmaceutical Guide, 1998; Annual Report (1999-2000), 
Department of  Chemicals and Fertilizers, OPPI, 33rd Annual Report 1998-99) 
 
India is one of the largest pharmaceutical markets in the world by volume, and ranks 
amongst the top 15 by value. The size of the Indian drugs and pharmaceutical 
products market, in terms of its value, is estimated at Rs. 142 billion (US$ 3.2 billion) 
in 1998-99. The Indian pharmaceutical industry is essentially volume driven rather 
than value driven. Even a slight variation in the volume of sales has a direct bearing 
on the overall growth of the market. For instance, when unit sales of pharmaceutical 
packs rose by 10 per cent in 1998 from their 1997level, the corresponding increase in 
sales value was 14.1 per cent. In the first six months of 1999, unit sales decreased by 
4.2 per cent compared to 1998, and the corresponding growth in rupee terms dropped 
to 5.4 per cent. Hence, despite its large size, India’s share in the global market is 
insignificant due to low product prices. The prices are low because of the limited 
ability of India’s consumers to pay higher prices. Price rises are also controlled by 
both severe price competition (with small units entering into what would be highly 
regulated markets in many other countries), and government-controlled prices for 
many products.  
 
The Indian pharmaceutical market is also very fragmented. The top 400 produce 80 
per cent of the drug requirements of the country, and the remaining 20 per cent is met 
by the rest, with a good share accounted for by small- scale manufacturers. Twenty 
per cent of the drugs produced by the small -scale manufacturers are supplied to 70 
per cent of the population, as these manufacturers largely depend upon the supplies to 
the government agencies. This is mainly due to the regulatory provision requiring the 
government to purchase on a ‘rate contract’ basis. The market is dominated by low-
end pharmaceutical products.  
 
Antibiotics constitute 24 per cent of the drugs sold in the country as compared to 13 
per cent in the developed world. Cardiovascular treatments, the largest selling 
therapeutic category in the developed market (16 per cent of annual drug sales), 
constitutes only six per cent of the Indian market.  
 
Over the years the drugs and pharmaceuticals sector has emerged as a net foreign 
exchange earner, a status it has maintained since 1988-89. The average annual growth 
rate of exports between 1980-81 and 1998-99 was about 33 per cent as against 22 per 
cent in the case of Imports.20 
 
4. Strengths of Indian Pharmaceutical Industry21 
It needs to be emphasized at the outset that the pharmaceutical industry in India, 
almost 
uniquely, has not only performed exceedingly well in terms of production, domestic R 
& D, value addition, regional spread and diversification but also in contributing to 
better health for millions of people by being largely cost-effective and, hence, 
providing medicines at affordable prices. Moreover, the Indian pharmaceutical 
industry has been able to export its products to a number of countries where Indian 
medicines have been popular a due both to their low cost and effectiveness. 
 
The pharmaceutical industry today is in the front rank of India’s science-based 
industries, 
with wide ranging capabilities in the complex field of drug manufacturing and  
technology. It is a front-runner in the third world in terms of technology, quality and 
range of medicines manufactured. Almost all types of medicines – ranging from 
simple pain relieving pills to sophisticated antibiotics and complex cardiac compounds 
– are now made in the country. These have made India fairly self-sufficient in this 
field. A large domestic market and relatively inexpensive trained manpower have also 
enabled the country to emerge as a low-cost production centre. The Indian 
pharmaceutical industry has registered significant increases in capital investment over 
the years. It has also been a net export earner and a major source of employment.22 
 
 
 
 
 
 
 
 
1. Competent workforce:  
India has a pool of personnel with high managerial and technical competence as also 
skilled workforce. It has an educated work force and English is commonly used. 
Professional services are easily available.  One of the reasons of the progress of Indian 
Pharmaceutical Industry is its relatively large resource of well educated and trained 
scientist and engineers, compared to other developing countries, which enabled 
domestic companies to develop new methods to produce even complicated 
pharmaceutical products. 
 
2. Cost-effective chemical synthesis:  
Its track record of development, particularly in the area of improved cost-beneficial 
chemical synthesis for various drug molecules is excellent. It provides a wide variety 
of bulk drugs and exports sophisticated bulk drugs.  
 3. Legal & Financial Framework:  
India has a 53 year old democracy and hence has a solid legal framework and strong 
financial markets. There is already an established international industry and business 
community.  
 
4. Consolidation:  
For the first time in many years, the international pharmaceutical industry is finding 
great opportunities in India. The process of consolidation, which has become a 
generalized phenomenon in the world pharmaceutical industry, has started taking 
place in India. 
5. Technologically Strong 
Despite of severe criticism of Indian pharmaceutical industry by the foreign 
companies and the foreign media the fact remains clear that Indian Pharmaceutical 
industry has made noteworthy progress in the technological side of the industry. 
Looking to the limited resources available to the Indian firms and the low profit 
margin business, they have not spent enough money on R&D as they would have 
liked but some of the fine discoveries in the field of medicine has been made by the 
Indian scientists. This would be evident by the fact that the number of Indian patent 
applications has certainly increased, a large number 
having come from public sector organizations, notably, the CSIR and IITs. And  
a notable move was by the Council of Scientific Industrial Research, the apex national 
organisation, when its scientists were particularly encouraged to apply for patents and 
not just to publish scientific papers. This transformation of approach, it was argued by 
the CSIR director-general, has give Indian scientists an edge over their competing 
counterparts elsewhere (Jolly, 2001). As the debate on the proposed new patent 
legislation came to a hear, it was possible for those advocating the product-patent 
system to point to the definite rise in patent applications observed during the post-
1995 era – and this despite the significant presence of foreign firms in India. 
 
6. Low cost of Production 
One of the highlighting features of Indian pharmaceutical market is its low price.  This 
low price situation is achieved by the extremely low cost of production. Plenty 
availability of labour at cheap rates and there is no shortage of highly skilled talented 
scientists in India, this has made the production significantly cheaper. India is a 
developing nation and majority of its population is middle-class and lower-middle-
class income group, hence it was a challenge to provide medicines to this major 
population of the country, as such they cannot afford costly medicines and highly 
sophisticated medical treatment. Pharmaceutical industry of India has definitely 
contributed to the better health of millions of people of India by providing medicines 
at affordable prices. 
 
 Moreover, the Indian pharmaceutical industry has been able to export its products to a 
number of countries where Indian medicines have been popular due both to their low 
cost and effectiveness. 
 
A large domestic market and relatively inexpensive trained manpower have also 
enabled the country to emerge as a low-cost production centre. 
 
5. Achievements of Indian Pharmaceutical Industry23 
 
Pharmaceutical industry in India, almost uniquely, has not only performed 
exceedingly well in terms of production, domestic R & D, value addition, regional 
spread and diversification but also in contributing to better health for millions of 
people by being largely cost-effective and, hence, providing medicines at affordable 
prices. Moreover, the Indian pharmaceutical industry has been able to export its 
products to a number of countries where Indian medicines have been popular due both 
to their low cost and effectiveness. 
The phenomenal progress, technological capabilities, and cost and production 
efficiencies achieved by the Indian drug industry are demonstrated by the facts: - 
1. Indian researchers have developed more than a dozen new drugs in the past four 
 decades and released in the market; 
a. One of them is Guggulipid (a blood cholesterol reducing drug) extracted and 
 purified from the plant Guggul (Commiphora Mukul).  
b. Another such new drug developed by Indian Scientists from CDRI is Drug 
 Memory  Plus, this memory reinforcing drug contains Baculosides (a chemical 
 extracted from family of the Brahmi plant). 
c. NCL scientists have developed indigenous technology for extracting a cancer 
 curing drug Vincristine from Sadabahar (Vinca Rosea) plants.  
 
2. One of the very important medicines, Vitamin B6, which is required for many 
medicinal formulations as well as by food industries, was not earlier produced in 
sufficient quantity in India and it was imported till the 1980 at a price of US$1000 per 
kilogram. This was produced by only two producers, who were not ready to share the 
know-how of this product with India, but scientists at IICT took the challenge and in 
just two years of time they set up a factory for producing Vitamin B6. The result is, 
today the price of this chemical is US $ 80 per kilogram, and India has not just 
became self-reliant but she is also exporting this chemical. Same case is with the anti-
AIDS drug AZT (also called zidovudine), once it was imported at a whopping price 
and today India is self reliant in that very same drug, due to the development of the 
process by the scientists of IICT. 
3. A very useful painkiller Paracetamol was once imported, but in 1960s the 
scientists of CDRI found out the new process of developing the drug. 
 
4. Today world is looking to India as a major supplier of important drugs like 
Ethambutol, Metronidazole (used for diarrhea and other gastrointestinal infections), 
Tinidazole and Paracetamol. 
 
5. After independence , India has acquired a strong hold over the biomedical 
research, following are the examples of its feat: 
a. Jaipur foot, an entirely indigenous artificial limb-prosthesis that can be flexed 
just  like a natural foot. This foot has lent support to thousands of handicapped to 
lead a  normal life by freeing them from using rigid prosthesis. 
b. The Chitra Heart Valve developed by the Sri Chitra Tirunal Institute of 
Medical Technology, Trivandrum is not only of world standard but is quite affordable 
and  offers better chances of survival for patients of rheumatic heart disease. 
c. Sri Chitra Tirunal Institute of Medical Technology has also developed 
disposable polymeric bags for storage and transport of blood. This bag has, besides 
reducing the risks of contamination, also helped easy transportation and storage. 
d. DRDO scientists have developed biomedical stent which is used as a shunt 
during  heart surgeries. 
e. DRDO scientists have also developed a heat pace maker device. 
f. Central Glass and Ceramics Research Institute, Kolkata has developed a 
hybrid  hip-prosthesis using titanium metal and ceramic materials, is used in patients 
of  arthritis who need hip replacement. 
 
6. One of the major problems for India after independence is the Population 
Explosion, and thus the top most priority of the government was to slow down the 
population growth rate. CDRI scientists have proved their mite in this regard by 
developing a once-a-week contraceptive pill, now marketed as Saheli, which has the 
distinction of being the ONLY NON-STEROIDAL CONTRACEPTIVE PILL IN THE 
WORLD. Besides, being user-friendly (it is needed to taken only once in a week 
instead of everyday as is the case with other pills), Saheli also protects women from 
developing breast cancer. 
 
7. National Institute of Immunology, New Delhi, have come up with a vaccine 
developed from much revered Neem Tree which acts like a contraceptive. NII also has 
the distinction of producing the second immunological contraceptive, a vaccine based 
on HCG (a human hormone), which is now being tested on humans. A group of 
researchers at the Indian Institute of Science, Bangalore have developed a male 
injectable vaccine which has been found quite effective on monkeys. 
 
8. In February 2001, CIPLA offered to supply one year course of the triple 
combination drug required for treatment of AIDS/HIV to countries in Africa, @ US $ 
350, as against the patent holder's price of US $ 10,000 to 12,000 for the same 
quantity of the same drug. 
9. Even under the continuing process patent regime of Patent Act 1970, many of 
the national sector units like Ranbaxy, Dr. Reddy's Laboratories, CIPLA, Sun Pharma, 
Wokhardt, Zydus Cadila, J. B. Chem., and others have come out with original 
research on development of new drugs, delivery systems and even new molecules, 
acquiring patents in countries like USA and others; 
 
10. Some of the multinational corporations have entered into arrangements with 
some of these Indian Companies for research or co-marketing such new products for 
other countries, confirming the value of such research;  
 
11. The products of Indian manufacturers are accepted on WHO lists of essential 
drugs and also approved by regulatory authorities in USA, and EU countries;  
 
12. Some of the Indian companies have set up their own associate companies or 
entered into collaboration for production, marketing or research in other countries; and 
that the exports of drugs have gone Rs.1490crores in 1992-93, to Rs.8730crores in 
2000-2001 i.e. more than six times in 8 years. 
 
13. Some of the other significant achievements include availability of most 
sophisticated medical facilities in every major city of India, like every other city of 
India has an Ophthalmologist using laser knives to mend defective sight. 
Transplantation of organs such as kidneys and hearts has also become common. 
Diagnostic techniques like Ultrasonography, Magnetic Imaging (MRI), CT scan and 
so on are available in major cities.  
 
6. International Pharmaceutical Industry, CHINA and 
 INDIA 
 
 
 
China has got the largest population in the world, ranking second among the producers 
of pharmaceutical ingredients and first in the production of Penicillin, Cephalosporin, 
Doxycycline HC1, Terramycin, and Vitamin C in the world.  
 
The Chinese pharmaceutical market is currently the 7th largest in the world (worth 
$14 bn), and by the year 2010, it is estimated to be the 5th largest. Considering the 
Chinese economic boom and the pace with which the country is growing, it is surely a 
market which cannot be ignored. The high incidence of diseases in china on account 
of the consistently changing lifestyles and consumption patterns, and ultimately, the 
demands for drugs are also rising consistently.  
 
The economical manufacturing and operational costs add to the attractiveness of the 
Chinese market. Globalization being the primary motive of Indian firms, china offers 
huge opportunities to tap other markets world over. The increasingly congenial trade 
ties between India and china have also fueled investments by Indian companies in 
china. The pharmaceutical industries play an important role in the economic 
development of both the countries. Thus the Indian pharmaceutical players are making 
the most of these opportunities and are entering china. However, the Chinese 
pharmaceutical market is unique in many ways and the Indian players have to play 
their cards with utmost care to sustain their business in the long term.  
 
 
7. Understanding the Chinese Pharmaceutical Market 
A variety of factors make the Chinese pharmaceutical market an enticing option. The 
pharmaceutical industry in china is one of the fastest growing industries with an 
average annual growth of 17.7%. According to a survey by the Boston Consultancy 
Group (BCG), the Chinese pharmaceutical market is likely to emerge as the fifth 
largest market globally, with revenues over of over $24. Approximately, 70% of the 
Chinese market (6800 firms) is controlled by the domestic firms (in terms of value). 
There are about 1700 sino-foreign joint ventures, with an investment of around $2 bn, 
according to IMS Health, a global source for pharmaceutical market intelligence. 
These foreign companies include some of the world’s leading players. The 
subsidiaries set up by top players like GlaxoSmithKline, Novartis, Pfizer, and Roche, 
are among the top 10 marketing companies in china, in terms of sales. 
 
Some of the important factors that make the Chinese market attractive are low labour 
costs and better infrastructure for manufacturing when compared to India. According 
to DFID Health Systems Resources Center, with the acceleration of patent expiries, 
about $60 bn worth of blockbusters will open up to legitimate generic competition in 
the regulated markets. It will lead to a gradual global migration of manufacturing 
companies to china, which has the expertise and infrastructure for low-cost generic 
manufacturing. As Chenthir K, CEO, Plutus Pharma Network Pvt. Ltd. Opinies, “ 
Indian pharma companies are searching for a destination where cost of manufacturing  
base in china would help Indian companies to compete in generics business in 
regulated markets and fulfil their dreams in export of Active Pharmaceutical 
Ingredients (APIs) with non-infringing processes.” 
 
Though India is becoming an R&D hub in itself, China also provides excellent 
opportunities for research activities. And with both the countries becoming TRIPS 
compliant, R&D is the key to develop new formulations for drugs. Neeraj Bharadwaj, 
CEO, RocSearch Ltd., a global research support service company, says, “Beyond 
pharma sales, China is also an attractive for clinical research services and contract 
manufacturing. As a low cost R&D base, with a huge pool of PhDs and scientists, and 
dedicated infrastructure, Indian pharma companies may also explore China for 
outsourcing research and development.”  
 
The demographic and socio-economic factors of china make its pharmaceutical 
market a unique proposition in itself. China is the world’s most populous country with 
around 1.33 billion population, which is ageing at an estimated rate of 3% per annum. 
The country has more than 88.1 million people aged 65 or over, more than in any 
other country in the world. It ranks second among the largest producers of 
pharmaceutical ingredients in the world and ranks first in the world in the production 
of important medicines like penicillin, cephalosporin, vitamin c, etc. These factors are 
adding attractiveness of doing business in china’s pharmaceutical market. 
 
One of the factors typical in Chinese Pharmaceuticals is that hitherto, there have been 
no private clinics; doctors were available only at hospitals. Therefore, companies have 
to sell their products primarily through hospitals. In India, drugs are sold mainly 
through doctors’ recommendation and 4,00,000 medical stores. While as in China, 
interestingly, 85% of the drugs are sold through hospitals and for this to happen, the 
firms have to first register their products with concerned medical authorities in each 
province. This is lengthy and tiring processes for the firms. Therefore, it requires great 
levels of patience and commitment on part of the venturing companies. However, this 
scenario is also gradually changing with the onset of economic reforms. Some private 
clinics and hospitals have been established in the last 3-4 years, though they are very 
costly for the consumers.  
 
China is becoming a major competitor to India, especially in exports of Active 
Pharmaceutical Ingredients (APIs). China’s Pharmaceutical Industry ranks 7th in the 
world and is expected to become world’s 5th largest by 2010. China’s domestic drug 
sales have been estimated at about US $ 8 billion in 2003 and the exports are growing 
at 20% per annum.24 
The reasons for Chinese competitive advantage are: 
 The electricity costs are lower in China as compared to India. The power costs 
range from Rs.1.50 to 2.50 per KWH as against Indian cost of Rs.4.5 to 6.0 per 
KWH. Labour charges are 40% lower in China than India. 
 More favourable labour policies like policy of hire and fire in China 
 On the whole China is more cost competitive in manufacturing sector. 
 China has already implemented clear intellectual property laws and data exclusivity 
rules that take it one step ahead of India in attracting foreign players. In 1992, a pact 
was signed with US, which heralded the Product patent regime coming in force in 
China. 
 China has established a large number of profit oriented research and development 
institutions, which are today independent of government funding in contrast to 
institutions in India, which are mostly dependant on government funding. 
 The Chinese government provides an income tax holiday of 100 per cent for the 
first two winning years (profit making years) and 50 per cent for the next three 
years.  
 The companies are also allowed duty free import of capital equipment. 
 Lower turnaround time for ships at Chinese ports make it conducive as a base for 
exports. 
 
 
8. Indian Ventures in China 
A lot of Indian pharmaceutical companies have ventures into China and most of them 
exist as joint ventures with Chinese Pharmaceutical companies. The joint ventures are 
necessary considering the complex and fast changing nature of the market. Indian 
companies are leveraging china as an effective platform to make their exports 
activities more efficient. Initially companies enter china and gain market share, then 
companies make it as home base and finally, as manufacturing base to export globally. 
 
Dr. Reddy’s Laboratories entered the Chinese market in the year 2000 as a joint 
venture between Dr. Reddy’s (51%), Canada Rotam Enterprise (47.41%), and 
Kunshan Double Crane Pharma Co. (1.59%). The partnership venture is known as 
Kunshan Rotam Reddy Pharmaceutical Co. Ltd. (KRRP), is involved in producing 
and repackaging bulk formulations, tablets, ointments, gels, etc. KRRP currently 
supplies its products to more than 100 distributors across 18 provinces. The firm 
registered a turnover of $9 mn during 2004-05, and now it is targeting a turnover of 
$12 mn and gradually $15 mn, which would then create profits for the firm. 
Globalization is the primary motive of Dr. Reddy’s as C V Narayan Rao, Chief 
Representative, KRRP said, “ We want to be a global company and we can’t claim  to 
be one without being in China.” Dr. Reddy’s has its manufacturing facilities only in 
India and China, though it has its subsidiaries in other countries as well. 
 
Ranbaxy entered china in the year 1993; in fact, it is one of the earliest Indian 
Companies to enter China. It formed a joint venture with Guangzhou Qiaoguang 
Pharmaceutical co. and HK New Chemic, with an initial investment of $17 mn. It 
currently holds an 83% stake in the subsidiary (Ranbaxy Guanghou China Ltd. 
RGCL) and manufactures and unlimited number of capsules, tablets, infusion bottles, 
etc. Today Ranbaxy has become a brand to reckon  with in china, with its drug 
cepodem (Cefpodoxine Proxetil) becoming the market leader in the first year of its 
launch. Cifran (ciprofloxacin) has also emerged as the market leader in the country 
with a market share of 40% (app. In the year 2003). RGCL improved its ranking from 
31 to 27 amongst the leading joint venture companies operating in china and achieved 
sales of $12.3 mn, showing a growth of 87% in the year 2003. the firm reaches out to 
500 hospitals and more than 20,000 doctors in the country. RGCL has been 
consistently trying to expand its market reach by venturing into varied therapeutic 
segments and introducing new drugs.  
 
Orchid Chemical and Pharmaceuticals is another Indian Pharma player that has 
ventured into the Chinese market. It started its operations in 2002 as a $25 mn 
manufacturing and marketing joint venture (50:50) with the leading Chinese Pharma 
Company North China Pharmaceutical Group Corporation  (NCPC).  The firm has a 
30 million ton manufacturing capacity and offers a product range of six cephalosporin 
bulk actives. The business strategy followed by Orchid is to target more regulated 
markets like the US and Europe, having high value generics that are out of patent. The 
JV was able to add $20 mn to the top line in just one year and it is expected to 
increase to $30 mn by 2006. 
 
It is not easy going for in fact every Indian Pharmaceutical Company. Aurobindo 
Pharma has invested a huge sum of $75 mn, one of the largest investments by an 
Indian company. It was already buying huge quantities of Penicillin G from china and 
thus, thought it was wiser to set up a branch in China itself. The company entered 
china in the year 2000 as a $10 mn 50:50 venture with the Chinese pharma company 
Shanxi Tongling Pharmaceutical to form Aurobindo Tongling Pharmaceutical. 
However in, 2002, Aurobindo acquired its partner’s stake and thus, formed a 100% 
owned subsidiary. Aurobindo Pharma has another entity in China, Aurobindo Bio-
Pharma. The combined turnover of both entities is Rs. 270 cr, which is one of the 
highest. Aurobindo also employs one of the highest numbers of people. Though all 
this seems to give a rosy picture, the unfortunate part is that the subsidiary is not 
making profits. Aurobindo Bio-Pharma ran into a loss of Rs. 4.2 cr. on a turnover of 
Rs.123 cr. and Aurobindo Tongling made a loss of Rs. 8.4 cr on a turnover of Rs. 
147.9 cr. Though the subsidiaries were making money a few years back, this sudden 
turn of events is due to the fact that Chinese drug market is very price sensitive. A 
well defined market segmentation can be used to market different drugs (and prices) 
to different segments of the population. Price of Penicillin G, which can be called the 
flagship drug of Aurobindo’s china operations, has taken a dip and, therefore the 
losses. The company has invested a huge sum of $75 mn. hence it can never think of 
packing its bags from china. Even the objective of every Indian company to venture in 
Dragon Land is to expand their operations globally and make their presence felt world 
over. 
 
 
9. Reasons for Indian Pharmaceutical Companies 
 Venturing into the Chinese Market. 
The Chinese pharmaceutical market is quickly evolving into a large market due to the 
rising incomes of a significant portion of the Chinese population. Even if one assumes 
that only 5% of the Chinese population has the purchasing power to acquire certain 
pharmaceuticals, this is still a huge market of 65 million consumers. This is a larger 
market than most European countries, and it is certainly growing a lot faster. One of 
the key reasons for Indian Pharmaceutical companies foraying into China is the huge 
Chinese domestic market, and the low operational costs. In addition, china is 
providing an excellent infrastructure and speedy implementation of new projects.  
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Exhibit 1: Partial list of PhRMA Member Firms 
AMERICAN HOME PRODUCTS CORPORATION 
Five Giralda Farms 
Madison NJ 07940 
(973) 660-5000 
 
BAYER CORPORATION 
One Mellon Center 
500 Grant Street 
Pittsburgh, PA 15219-2502 
(421) 394-5500 
 
BOEHRINGER INGELHEIM CORPORATION 
900 Ridge bury Road 
P.O. Box 368 
Ridgefield, CT 06877 
(203) 798-9988 
 
BRISTOL-MYERS SQUIBB COMPANY 
345 Park Avenue 
New York, NY 10154 
(212) 546-4000 
 
GLAXO WELLCOME, INC. 
Five Moore Drive 
Box 13408 
Research Triangle Park, NC 27709 
(919) 248-2100 
 
HOECHST MARION ROUSSEL, INC 
9300 Ward Parkway 
P.O. Box 8480 
Kansas City, MO 64114-0480 
(816) 966-4000 
 
HOFFMANN-LA ROCHE, INC. 
340 Kingsland Street 
Nutley, NJ 07110 
(973) 235-5000 
Exhibit 2: Abbreviations used in the chapter 
 
1. IPR = Intellectual Property Rights 
2. GATT = General Agreement on Tariffs and 
Trade 
3. Paris Convention for Protection of Industrial 
Property, 
4. CII = Confederation of Indian Industry 
5. ASSOCHAM = the Associated Chambers of  
                            Commerce and Industry 
   6. FICCI = the Federation of Indian Chambers 
                   of Commerce and Industry  
   7. CSIR = the Council of Scientific and Industrial 
                   Research  
   8. CoS = Committee of Secretaries (Drawing upon senior 
 secretaries from the Industries of Commerce, Finance, External Affairs, 
 Economic Affairs and Industries.) 
9. CCEA = Cabinet Committee on Economic Affairs  
10. IDMA = Indian Drug Manufacturers’ Association 
11. OPPI = Organisation of Pharmaceutical 
Producers    
                of India 
12. IPA = Indian Pharmaceuticals Association 
13. IPA = Indian Pharmaceutical Alliance  
(IPA is a group of research-based national pharmaceutical Companies, It 
consists of the following members: Alembic Limited, Nicholas Piramal India 
Limited, Cipla Limited, Ranbaxy Laboratories Limited, Dr. Reddy’s 
Laboratories Ltd., Sun Pharmaceutical Industries Limited, Lupin Laboratories 
Limited, Wockhardt Limited. These companies’ annual R & D spend, at Rs. 
250 crore, accounts for 90 per cent of total private sector spending in 
pharmaceutical R and D. These companies contribute one-fourth of the 
country’s exports of drugs and pharmaceuticals and share over 23 per cent of 
the domestic market.) 
 
14. FIEO = Federation of Indian Export Organisation 
15. IFPMA = International Federation of  
                      Pharmaceutical Manufacturers 
 16. IGPA = International Generic Pharmaceutical                                   
                Association [located at Brussels] 
17. AIOCD = All India Organisation of Chemists and  
                  Druggists  
18. MDMA = Medical Disposables Manufacturers  
                   Association  
   19.CSIR = Council of Scientific Industrial Research, 
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1. Introduction 
 
It is very well said that in order to speak with confidence you need to have evidences 
and concrete reasons to support your say. In any serious work you need to take help of 
some expert and in the same way in order to provide some new knowledge to the 
world which is the basic objective of any Ph.D. degree we need to use some strong 
technical way to come to some conclusion. 
 
To know the details and to come to some conclusions and provide some suggestion to 
the businesses this research work is a humble effort. This work which is basically 
done for the Ph.D. Degree is dealing with the Pharmaceutical Industry of India. The 
main parameter or measurement of any business activity is Profit and hence in order to 
assess the performance of this industry in the past decade we have made an analysis of 
profitability of the companies of the Pharmaceutical Industry of India. 
 
In this study a comparison has been done in between different Pharmaceutical 
companies, selected for the study. Financial details for the period from 1997-98 to 
2004-05 have been taken into consideration. 
 
 
 
 
 
 
 
2. Period of the Study 
The following research work is carried out on the 8 (Eight) selected units of 
Pharmaceutical Industry of India for the period of 8 (Eight) years from 1997-98 to 
2004-05. The duration of the period is good enough to cover the short term 
fluctuations and is enough to provide insights into the performance of the different 
selected companies. 
 
The new Patent Protection would be operational from the year 2005, and hence the 
entire scenario of Indian Pharmaceutical Industry would change from then. In the light 
of this change how Indian Pharmaceutical Industry is poised to face the challenge; the 
study period is taken close to a decade just before the new patent protection comes 
into force in India. 
 
The reintroduction of product patent would mean that companies would not be able to 
copy drugs patented after 1995. In other words, most Indian companies may face an 
acute decline in market opportunities after 2005. It is also pointed out that a shift to a 
product patent regime would demand that basic capabilities of indigenous research be 
developed. Big companies have started preparing themselves for improving their 
R&D standard as well as R&D budget and also making tie-ups with the leaders for the 
R&D, but the real test is for the small units because they not only lack financial 
resources but also lack trained manpower and accessible testing facilities.  
 
The passage of the Patents (Amendment) Act, in 1999 was the first important step in 
facilitating product patents in the country by accepting product patents applications 
since 1995 and providing for the grant of exclusive marketing rights (EMR) in India.1 
After decades of denial, in 1999 India became party to the Paris Convention and the 
Patent Cooperation Treaty. It has been argued that the IPR(Intellectual Property 
Rights) regime can significantly constrain access to technology by developing 
countries and increase dependence on imports. The local firms would, under such 
circumstances, be left with no option other than collaborating with the foreign firms or 
simply giving up business. Similarly, a stronger patent system can dissuade innovative 
activity by local firms whose R&D function, dependent on the spill over effects of 
other firms and important in itself, would be affected adversely by the restricted 
access to these spillovers. 1 
 
Due to the process patent system domestic manufacturers could produce inexpensive, 
generic versions of on-patent regimes. The product patent regime would disallow such 
production and trade. It is apprehended that the prices of newly patented drugs would 
increase substantially, thereby imposing tremendous social and economic costs on the 
poor on these countries. The argument that higher prices would induce greater 
innovative activity by the patent protected developed nations is highly flawed. Even if 
a large part of the expenditure by multinational firms on R&D is geared towards the 
many so-called ‘poor’ country diseases (viz., tuberculosis, malaria, cholera, 
HIV/AIDS, etc), the developing country consumers would still find the cost of 
medicines prohibitive; consequently, through low sales, R&D investment would be 
reduced. In any case, prices of medicines for the ‘global’ ailments (viz., cancer, 
cardiac diseases, etc.) would also be high for new drugs in developing countries, 
irrespective of the patent regimes. The R&D activity shall, evidently, continue to 
derive strength from consumers in the developed nations. In fact, a recent UNDP 
report estimates that once TRIPs comes into force, it could induce a price hike ranging 
between 12 per cent and 68 per cent. It concludes: ‘To expect developing countries to 
accept such price spirals without adequately addressing their concerns of access to 
cheaper medicines to fight  life threatening diseases, particularly in a public health 
emergency, seems unfair’ (Polycarp, 2003: 37). 
 
Changes in India’s policy regime did not come about automatically with the signing of 
the WTO-TRIPs Agreement. However, the Indian pharmaceutical majors were both 
aware of and prepared for the implications of the new regime. But the shift in policy 
away from the established and much-favoured process patent system involved a 
gradual reorientation of political and business mindsets. An important contributing 
factor was the initiation of India’s general programme of economic reforms in mid 
1991. This process increased general understanding of market mechanisms, global 
business trends, and the role of international organisations, new perspectives on trade, 
the evolution of patent systems and other issues that have a bearing on public debates 
about economic policymaking.2 
 
3. Scope of the Study 
As the current study is for the pharmaceutical industry of India all the companies of 
pharmaceutical industry of India can be included in the study. But the companies with 
meager investments or very less market are excluded from the scope. Hence the 
selection was to be done from the public limited companies from the entire 
pharmaceutical industry. 
 
There are further classifications in the public limited companies as those who are into 
business of: 
 
1. Bulk Drugs 
2. Formulations 
3. Bulk Drugs & Formulations. 
 
Hence the selection of the companies has been done from the last type of companies 
in the pharmaceutical industry of India. In order to understand the pulse of Indian 
Pharmaceutical Industry it was essential to select the major players of the Industry and 
as still the industry was driven by volumes it was imperative on the part of the 
researcher to select those companies which are having the highest market share in 
terms of volumes. 
 
 
The annual sales figures for the year ended on 2003-04 were ranging from  
Rs. 12 crores (Wintac) to Rs. 3474 Crores, hence the selection was done for the Top 
10 companies. But the biggest player in terms of sales (Ranbaxy) was not fulfilling the 
requirements of accounts getting closed on 31st March and hence unfortunately could 
not be included in the selection. All the selected companies have annual sale figures of 
more than Rs. 500 Crores. 
 
 
 
 
The selected 8 (Eight) companies are as under: 
 
1. Aurobindo Pharmaceuticals Ltd. 
2. Cadila Healthcare Ltd. 
3. Cipla Ltd. 
4. Dr. Reddy’s Laboratories Ltd. 
5. IPCA Laboratories Ltd. 
6. Matrix Laboratories Ltd. 
7. Nicholas Piramal India Ltd. 
8. Sun Pharmaceuticals Industries Ltd. 
 
 
4. Objectives of the Study 
 
 To understand the basic nature and composition of Pharmaceutical Industry. 
 
 To understand the various ways to measure the profitability and thereby the 
financial performance. 
 
 To calculate different measures of profit for different companies under study 
for the study period [From 01-04-1997 to 31-03-2005]. 
 
 To identify any relationship in-between companies in the various measures of 
profit. 
 
 To identify any relationship in-between different years for the trend of various 
measures of profit. In other words to identify any trend in the profit in the 
study period. 
 
 To derive conclusions about the performance of the companies with regard to 
several criteria. 
 
 To provide some suggestion to the companies under study. 
 
 
5. Data Collection 
 
All data which are necessary for the research have been collected from the annual 
reports of different companies under study. Additional information required was 
collected by Personal interviews with the executives of the companies and other 
dignitaries and also from various Journals, Magazines and other publications. This 
research is based on secondary data.  
 
Companies selected for the research are on the basis of sales figures of the year  
2003-04 year from the various financial magazine like “Capital Market” and “Fortune 
India”.  
 
 
 
6. Research Methodology for the Interpretation of the 
 Data 
The research work is based on data taken from the annual reports of the selected 
companies for the period of study. Various other publications for the Pharmaceutical 
Industry have also been taken into consideration. The data obtained have been duly 
classified, edited and tabulated under various groups and sub-groups, as per 
requirement of the study.  
 
Statistical measures like Arithmetic Mean, Index Numbers, F-test and various ratios 
are used as per requirement. Following is the chapter plan for the study: 
 
 
7. Hypothesis 
 
Hypothesis for different Companies for the Study Period 
 
In order to observe some concrete conclusions by comparing the annual results 
between the selected Pharmaceutical companies under study following hypothesis are 
made. 
1. “The individual cost to total cost ratio is same among different companies 
 during the period of study.” 
2. “The profit margin ratio is same among different companies during the period 
 of study.” 
3. “The assets turnover ratio is same among different companies during the 
 period  of study.” 
4. “The return on investment ratio is same among different companies during the 
 period of study.” 
 
Hypothesis for each (individual) Pharmaceutical Company among different 
years. 
By comparing annual financial results of each (individual) Pharmaceutical company 
for all consecutive years of the study period, following hypothesis are made in order 
to derive conclusions. 
1. “The individual cost to total cost ratio of each individual company is same 
 during all the years of the study period.” 
2. “The profit margin ratio of each individual company is same during all the 
 years of the study period.” 
3. “The asset turnover ratio of each individual company is same during all the 
 years of the study period.” 
4. “The return on investment ratio of each individual company is same during all 
 the years of the study period.” 
 
 
9. Tools for Analysis 
a) Ratio Analysis 
When we use ratio analysis we can work out how profitable a business is, it can also 
help us to check whether a business is doing  better this year than it was last year; and 
it can tell us if our business is doing better or worse than other businesses doing and 
selling the same things. Financial ratios are useful indicators of a firm's performance 
and financial situation.3 Most ratios can be calculated from information provided by 
the financial statements. Financial ratios can be used to analyze trends  and to 
compare the firm's financials to those of other firms. In some cases, ratio analysis can 
predict future bankruptcy. 4 
Financial ratios can be classified according to the information they  provide. The following types 
of ratios frequently are used: 
• Liquidity ratios  
• Asset turnover ratios  
• Financial leverage ratios  
• Profitability ratios  
• Dividend policy ratios  
 
b) Arithmetic Mean 
The arithmetic mean of a set of values is the quantity commonly called "the" mean or the 
average. In mathematics and statistics, the arithmetic mean (or simply the mean) of a list of 
numbers is the sum of all the members of the list divided by the number of items in the list. If 
one particular number occurs more times than others in the list, it is called a mode. The 
arithmetic mean is what students are taught very early to call the "average". If the list is a 
statistical population, then the mean of that population is called a population mean.5 If the list is 
a statistical sample, we call the resulting statistic a sample mean. 
c) Index Numbers 
Index number, in econometrics, is a figure reflecting a change in value or qauntity as compared 
with a standard or base. The base usually equals 100 and the index number is usually expressed 
as a percentage. For example, if a commodity cost twice as much in 1970 as it did in 1960,its 
index number would be 200 relative to 1960. Index numbers are used especially to compare 
business activity, the cost of lving, and employment. They enable economists to reduce 
unwieldly business data into easily understood terms. 
 
d) F-Test 
Analysis of variance (ANOVA) is used to uncover the main and interaction effects of 
categorical independent variables (called "factors") on an interval dependent variable. 
The new general linear model (GLM) implementation of ANOVA also supports 
categorical dependents. A "main effect" is the direct effect of an independent variable 
on the dependent variable. An "interaction effect" is the joint effect of two or more 
independent variables on the dependent variable. Whereas regression models cannot 
handle interaction unless explicit crossproduct interaction terms are added, ANOVA 
uncovers interaction effects on a built-in basis. For the case of multiple dependents, 
discussed separately, multivariate GLM implements multiple analysis of variance 
(MANOVA), including a variant which supports control variables as covariates 
(MANCOVA).6 
The key statistic in ANOVA is the F-test of difference of group means,  testing if 
the means of the groups formed by values of the independent variable (or 
combinations of values for multiple independent variables)  are different enough not to 
have occurred by chance. If the group means do not differ significantly then it is 
inferred that the independent  variable(s) did not have an effect on the dependent 
variable. If the F test shows that overall the independent variable(s) is (are) related to 
the dependent variable, then multiple comparison tests of significance are  used to 
explore just which values of the independent(s) have the most to do with the 
relationship.  
If the data involve repeated measures of the same variable, as in before-after or 
matched pairs tests, the F-test is computed differently from the usual between-groups 
design, but the inference logic is the  same. There are also a large variety of other 
ANOVA designs for special purposes, all with the same general logic.  
Note that analysis of variance tests the null hypotheses that group means do not differ. 
It is not a test of differences in variances, but rather assumes relative homogeneity of 
variances. Thus some key ANOVA assumptions are that the groups formed by the 
independent variable(s) are relatively equal in size and have similar variances on  the 
dependent variable ("homogeneity of variances"). Like regression, ANOVA is a 
parametric procedure which assumes multivariate normality (the dependent has a 
normal distribution for each value category of the independent(s)). 7 
F-test, also called the F-ratio. The F-test is an overall test of the null hypothesis that 
group means on the dependent variable do not differ. It is used to test the significance 
of each main and interaction effect (the residual effect is not tested directly). A "Sig." 
or "p" probability value of .05 or less on the F test conventionally leads the researcher 
to conclude the effect is real and not due to chance of sampling. For most ANOVA 
designs, F is between-groups mean square variance divided by within-groups mean 
square variance. (Between-groups variance is the variance of the set of group means 
from the overall mean of all observations. Within-groups variance is a function of the 
variances of the observations in each group weighted for group size.) If the computed 
F score is greater than 1, then there is more variation between groups than within 
groups, from which we infer that the grouping variable does make a difference. If the 
F score is enough above 1, it will be found to be significant in a table of F values, 
using df=k-1 and df=N-k-1, where N is sample size and k is the number of groups 
formed by the factor(s). That is, the logic of the F-test is that the larger the ratio of 
between-groups variance (a measure of effect) to within-groups variance (a measure 
of noise), the less likely that the null hypothesis is true.  
If the computed F value is around 1.0, differences in group means are only random 
variations. If the computed F score is significantly greater than 1, then there is more 
variation between groups than within groups, from which we infer that the grouping 
variable does make a difference. Note that the significant difference may be very 
small for large samples. The researcher should report not only significance, but also 
strength of association, discussed below.  
 
10. Survey of the existing literature 
 
The analysis of Profitability of Pharmaceutical Industry of India is a particular area of 
work hence not a very popular matter to write on. There are number of articles and 
research papers published for Profitability and for Pharmaceutical Industry of India 
but nothing is specifically of relevance for the present study.  
 
The present study is a unique work of research which is for selected companies under 
study and for a specified period. There are some technical points included apart from 
the financial research. These are TRIPS, WTO, Patent Regime, various national and 
international pharmaceutical manufactures’ association. 
 
The work of Keshab Das on TRIPS and its political implication has been referred by 
the researcher to get the insights into the matter. 8Professor Robert Tancer has worked 
on Indian Pharmaceutical Industry as an investment destination. Robert Warren has 
worked for the pharmaceutical industry. 9 
 
Similar sort of work has been carried out in the same university before a long time 
period of 16 years. The study was emphasized on the working capital management, 
entitled “Working Capital Management of Pharmaceutical Industry in India” by  
Dr. Shashi A. Jain in the year 1990.10The study tried to make an in-depth analysis of 
the working capital management of the selected pharmaceutical companies for a 
period of time.  
 
Another major research work has been carried out in the year 1992 by  
Dr. Akhileshwar Sharma on the topic “Profitability Analysis of Drugs and 
Pharmaceutical Companies in India” in May 1992. 11This study tried to find out the 
profitability position of various selected units during that period of time using several 
criteria. 
 
But the above work were carried out in the scenario when economy was in a closed 
state. The steps for liberalization by privatisation and globalisation were initiated by 
then Prime Minister of India Lt. Shri Narsimha Rao, and afterwards a gradual shift 
was found in the entire economy of India. 
 
With the WTO agreement and de-regulation of prices and the implementation of 
Patent Act there is a dramatic change observed in the pharmaceutical industry of India 
which makes the background for the study. 
 
There are lot of information available about the industry at national and international 
level from the Internet and it can be accessed through various search engines. 
 
 
11. Limitations of the Study 
 The present study is based on data taken from the annual reports of the company and 
all the conclusions and suggestions are given from the statistical analysis of the 
several ratios calculated. 
 
The basic inherent limitations of figures, calculations, statistical analysis and human 
error are the limitations of the study. Much care and diligence have been exercised in 
making all the calculations, calculating various ratios for various companies for 
various years, statistical analysis and deriving conclusions from it but then also there 
can be some human error, which will make the study weaker to that extent. 
 
The study is carried out for limited number of companies only. But it is difficult to 
draw conclusions from sample. Hence although much care has been taken to have a 
nice representation of population in the sample but then also a sample survey is not as 
good as a population survey. Hence the limitations of sample survey apply to this 
research also. 
 
The study is carried out for a period of 8 (Eight) years to derive conclusions about the 
performance of the companies and industry as a whole. But this number of years is not 
enough for a thorough understanding of business movements and their reactions to the 
changes of the economy.  
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1. Introduction to Financial Statements 
 
At the end of the accounting period, every business unit prepares certain statements 
which narrate the entire story of financial activities carried out by that business unit, 
during the year. In other words they narrate the entire financial effect of all the 
activities. As these statements narrate the financial story, they are known as “Financial 
Statements”, and they are prepared by the experts, as per the norms applicable for that 
business unit. Financial Statements refer to at least two statements which the 
accountant prepares at the end of the financial period: 
a. Profit and Loss Account 
b. Balance Sheet 
 
The basic objective for preparing these statements is to see the effect of operations and 
management decisions made by the managers on financial health of the unit.  
Financial statements are prepared for the purpose of presenting a periodical review or 
report on the progress by the management and deal with the: 
a. Status of the investment in the business, and  
b.
 Results achieved during the period under review.1 
Financial statements once prepared do not serve the purpose of the management, as 
such figures have no value unless and until they are made understandable. Hence in 
order to draw some meaningful conclusion from financial statements, it is important to 
analyse the financial statements. 
 
 
 
2. Analysis and Interpretation of Financial Statements 
 
As financial statements are prepared by following certain format as well as certain 
norms applicable to entity, it may not directly speak the story! In other words we need 
to decode the information already there in the financial statements. And hence we 
need a system of mechanism which decodes the information already present in the 
statements into some form which is understandable and which can be useful in coming 
to some conclusions and make decisions. Analysis and interpretation of financial 
statements refers to such a treatment of the information contained in the income 
statement and the balance sheet so as to afford full diagnosis of the profitability and 
financial soundness of the business.2 
 
Hence to know the real message conveyed by financial statements, it is essential to 
analyze and interpret them. Among various tools of financial statement analysis, trend 
analysis is one of the most important tools to analyze the financial statements. 
 
 
3. Trend Analysis 
Trend analysis is the tool which analyses the financial statements by comparing the 
figures of several years and examining their trend. As per the dictionary meaning of 
the word “Trend”, it means, “a general tendency or direction”3 
 
As such no conclusion can be reliable if they are drawn from the figures of a particular 
year or two. But if figures of same items for a number of years are methodically 
arranged and if some analysis is made, then that analysis would definitely give some 
very authentic and reliable conclusive piece of information. 
 
Trend analysis can be carried out with the help of several methods:4  
1. Year to Year Comparison 
2. Index Number 
3. Trend Series 
4. Trend Ratio 
 
4. Advantages of Trend Analysis 
1. Huge figures can be converted into percentages; hence brevity and readability 
are achieved. 
2. Figures of individual year’s financial statements have much less significance, 
but if figures of several years are put together, give meaningful information. 
3. Trend analysis can be done of any financial statements. 
4. Any year which is stable can be taken as base year. This may be in the 
beginning, mid or end of period of study. 
5. Trend Analysis can be carried out with the number of tools, like : 
a. Year to Year Comparison 
b. Index Number 
c. Trend Series 
d. Trend Ratios 
e. Etc. 
6. Conclusion regarding favourable or unfavourable tendencies can be easily 
made with the help of trend analysis.  
5. Limitations of Trend Analysis 
1. Trend Analysis can be logical only if the accounting principles and practices 
followed are constant throughout the period for which analysis is made. In the 
absence of such consistency, the comparability will be adversely affected.5 
 
2. Base year is to be selected very carefully; it should be a normal year without 
any internal or external major fluctuation. 
 
3. Although financial analysis gives some useful information regarding the 
performance, but still it is not the final thing. After analysis, proper 
interpretation is required for coming to any final conclusion. 
 
4. Trend Analysis is carried out on the figures of financial statements which are 
prepared on historical cost basis. Hence the price level changes are not given 
effect, thus whatever results are obtained are not up-to-date. 
 
6. Cost Structure of Pharmaceutical Companies under 
study 
1. Raw Materials Consumed 
2. Employee Cost 
3. Excise Duty 
4. Factory Overheads 
5. Administrative Cost 
6. Selling & Distribution Cost 
7. Method to carry out Trend Analysis 
In order to study the movement of total costs of all the companies under study, total 
cost of each year has been taken as 100, and each element of cost is taken as 
percentage of total cost. This would enable us to identify the importance or 
contribution of each item of cost in the total cost of each company over the entire 
period of study. 
 
 
 
8. Analysis of Individual Cost to Total Cost of sample 
 units. 
1. Raw Material Consumed 
Every production unit normally converts the raw material into finished goods and then 
sells it into the market. This raw material either may be purchased from the market or 
it can even be manufactured by the unit itself, depending upon particular situation. 
The term “Material” refers to the commodities supplied to an undertaking for the 
purpose of consumption in the process of manufacture or of rendering service or for 
transformation into products.6 There are two types of materials: Direct Materials and 
Indirect Materials.  All the materials which becomes an internal part of the finished 
product and which can be conveniently assigned to specific physical units is termed as 
“Direct Material”7 While all material which is used for purpose ancillary to the 
business and which cannot be conveniently assigned to specific physical units is 
termed as “Indirect Material”8 For example: Consumable Stores, Oil and waste, etc 
 
The calculation of raw material cost is done as under: 
 The opening stock of raw material is taken as the base for the current year’s total 
expenses on raw materials consumed. Additional purchases of raw materials are added 
to this opening stock of raw materials. Purchase of trading goods is also added to the 
total expenses for the raw materials. Further direct expenses on the purchases of this 
raw material like the expenses paid on freight or such incidental expenses made for 
the purchase of raw material is added to the raw material expenses. Finally the closing 
stock of raw materials is adjusted in order to arrive at the final figure of raw material 
consumption of the year. 
 
 
Table:  4.1                
Table Showing Proportion of Raw Materials Cost to Total Cost of Pharmaceutical 
Companies under Study [in percentage] 
Period: 1997-98 to 2004-05 
Co.Name 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
Aurobindo 73.66 76.86 75.25 76.85 74.55 72.88 68.78 63.05 
Cadila 55.98 58.1 56.98 48.43 48.5 45.17 40.02 45.48 
Cipla 63.07 58.12 59.59 59.72 58.32 58.86 59.27 58.5 
Dr. Reddy 40.42 43.99 37.22 40.92 39.18 35.85 36.41 32.73 
IPCA 61.45 56.92 54.04 52.64 52.95 52.23 53.35 50.36 
Matrix 84.57 70.96 71.42 69.39 67.03 58.59 63.21 62.68 
N.Piramal 47.94 51.02 53.55 51.93 50.94 50.54 48.99 47.24 
Sun 52.01 58.39 56.03 55.08 54.01 52.73 55.19 59.55 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
From the above Table no. 4.1 it is evident that proportion of raw material cost to total 
cost for Aurobindo Pharma for the year 1997-98 was73.66% it increased to 76.86% in 
the year 1998-99 to 76.86 and showed a stead trend until in the year 2001-02 declining 
trend started which continued till the end. The ratio is between 76.86% (1998-99) to 
63.05%(2004-05) with an average of 72.74% which is very high as compared to the 
overall average of 56.09% for the study period. For six years the ratio was higher than 
the average and it remained lower than the average for two years of the study period. 
 
The proportion of raw material cost to total cost for Cadila Healthcare for the year 
1997-98 was 55.98% and it increased to 58.1% which was the highest throughout the 
study period. The lowest ratio was observed in the year 2003-04 as 40.02% with an 
average of 49.83. There are three instances where the ratio was higher than the 
average otherwise in the remaining five years the ratio was lower as compared to the 
average.  
 
The proportion of raw material cost to total cost for Cipla Ltd. was 63.07% in the year 
1997-98 which was highest for the entire study period, the lowest value observed was 
58.12 which was in the year 1998-99. The average for the entire study period was 
59.43% which is slightly higher than the overall average 56.09% for the study period. 
There are three instances in which the ratio is higher than the average otherwise for 
the five years the ratio has remained lower than the average. 
 
The proportion of raw material cost to total cost for Dr. Reddy’s Laboratories was 
40.42% in the year 1997-98 which increased to 43.99% in the next year i.e. 1998-99 
which was the highest value for the entire study period. The lowest value was 32.73% 
which occurred in the year 2004-05. The average value is 38.34 and there are four 
instances in which the ratio was higher than the average otherwise remaining four 
times the ratios were lower than the average. The average is lower than the overall 
average of 56.09% for the same study period. 
 
The proportion of raw material cost to total cost for IPCA Labs was 61.45% for the 
year 1997-98 which remained the highest value for the entire study period, while the 
value 50.36% in the year 2004-05 was the lowest observed during the study period. 
The average ratio for the company is 54.24% and there are two instances when the 
ratio was higher than the average otherwise in the remaining six instances the ratio 
remained lower than the average. 
The proportion of raw material cost to total cost for Matrix Laboratories was 84.57% 
in the year 1997-98 which was highest in the entire study period. The lowest ratio 
58.59% was observed in the year 2002-03. The average is 68.48 which is higher than 
the overall average of 56.09. 
 
The proportion of raw material cost to total cost for Nicholas Piramal was 47.94 in the 
first year of the study period. It was highest 53.55 in the year 1999-2000 while it was 
lowest 47.24 in the year 2004-05. The average is 50.27 which is lower than overall 
average 56.09 for the same study period. 
 
The proportion of raw material cost to total cost for Sun Pharmaceuticals lies in 
between 59.55(2004-05) and 52.01(1997-98) with an average of 55.37 which is lower 
than the overall average of 56.09 for the same study period. For three years the ratio 
was higher as compared to average and for rest four year the ratio remained lower 
than the average.  
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of raw material cost to total cost among 
different Pharmaceutical companies under study during the study period and for 
establishing relationship in the ratio of raw material cost to total cost among different 
years for each (individual) company, F-Test ANOVA is used. The statements of 
hypothesis for the comparison among different companies and for comparison among 
different years for individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of raw material cost to total cost between 
different companies under study during the study period 
is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of raw material cost to total cost between 
different companies under study during the study period 
is not same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of raw material cost to total cost between 
different years during the study period in each company 
under study is same.” 
Alternate Hypothesis (H1):-  “The ratio of raw material cost to total cost between 
different years during the study period in each company 
under study is not same.” 
 
In the following Table 4.1(a) the calculation of F Test (ANOVA) is shown of raw 
material cost to total cost ratio for the pharmaceutical companies under study, during 
the study period. 
 
 
 
 
Table:  4.1(a)                
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 6670.360425 952.9086321 68.18768486 
Between 
Years 7 468.1026 66.8718 4.785173594 
Error 49 684.76475 13.97479082  
Total 63 7823.227775   
 
 
The above Table 4.1(a) shows the F value of 68.19 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of raw 
material cost to total cost. F value of 4.79 at 5% level of significance and at (7,49) 
degree of freedom is also greater than the Table value of 2.16 hence null hypothesis is 
rejected and alternate hypothesis is accepted, which means that there is a significant 
difference between different years’ ratios for all the individual companies. 
 
Hence it can be concluded that the raw material to total cost ratio among different 
companies under study is not same and the raw material to total cost ratio between 
different years of each company is also not same. 
 
 
2. Employees Cost 
Once raw materials are arranged, it is required to convert them into finished product; 
this conversion can be done only by human labour or in some cases partly by human 
labour and partly by machines. Even fully automatic machines require human beings 
to operate them and monitor it. 
Labourers may be of different category, depending upon their expertise and skill. And 
for the services they render, they are paid. This payment may be of two types :  
a. Monetary Payment 
b. Non-Monetary Payment 
Any amount paid as wages or salary or other allowance or bonus is referred as 
monetary payment.  Amount paid at the time of retirement, i.e. Gratuity or after 
retirement is also one of the forms of monetary payment. While any facility like 
housing, medicines, free education and other benefits given by the employer to 
employee refers to non-monetary payment. It also includes staff welfare expenses, 
VRS compensation and other employee cost.  
 
 
 
 
 
Table :    4.2              
Table Showing Proportion of Employees Cost to Total Cost of Pharmaceutical 
Companies under Study [in percentage] 
Period: 1997-98 to 2004-05 
Co.Name 97-98 98-99 99-00 00-01 2001-02 2002-03 2003-04 2004-05 
Aurobindo 2.19 1.77 2.09 2.28 2.69 3.12 4.3 6.08 
Cadila 9.34 9.32 8.25 8.9 8.85 10.57 10.7 12.49 
Cipla 5.05 5.74 5.17 5.72 4.63 4.72 5.11 5.06 
Dr. Reddy 9.1 8.58 9.37 9.78 9.79 10.64 10.63 11.51 
IPCA 9.37 10.61 10.04 10.66 10.62 10.82 10.57 12.84 
Matrix 1.53 2.52 1.92 2.65 4.94 4.95 4.62 7.07 
N.Piramal 15.7 13.64 13.1 11.25 10.15 9.74 11.75 10.86 
Sun 9.87 9.19 7.53 7.15 7.59 7.86 9.34 8.72 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
From the above Table No. 4.2 it is evident that proportion of employees cost to total 
cost for Aurobindo Pharma is in between 6.08(2004-05) and 1.77(98-99) with an 
average of 3.07 which is lower than the overall average of 7.86. For five years the 
ratio has remained lower than the average while for three years the ratio was higher 
than the average. 
 
The proportion of employees cost to total cost for Cadila Healthcare lies in between 
12.49(2004-05) and 8.25(1999-2000) with an average of 9.80 which is higher than the 
overall average of 7.86 for the same study period.  
 
The proportion of employees cost to total cost for Cipla Ltd. is in between 5.74(98-99) 
and 4.63(2001-02) with an average of 5.15 which is lower than the overall average of  
7.86 for the same study period. 
The proportion of employees cost to total cost for Dr. Reddy’s Laboratories lies in 
between 11.51(2004-05) and 8.58(98-99) with an average of 9.93 which is lower than 
overall average 7.86 for the same study period. 
 
The proportion of employees cost to total cost for IPCA Labs lies in between 
12.84(2004-05) and 9.37(97-98) with an average of 10.69 which is higher than overall 
average of 7.86. 
 
The proportion of employees cost to total cost for Matrix Labs lies in between 
7.07(2004-05) and 1.53(1997-98) with an average of 3.78 which is lower than overall 
average of 7.86 for the same study period. 
 
The proportion of employees cost to total cost for Nicholas Piramal lies in between 
15.7(97-98) and 9.74(2002-03) with an average of 12.02 which is higher as compared 
to the overall average of 7.86. 
 
The proportion of employees cost to total cost for Sun Pharmaceuticals lies in between 
9.87(97-98) and 7.15(2000-01) with an average of 8.41 which is higher than overall 
average of 7.86 for the same period. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of employee cost to total Cost among 
different Pharmaceutical companies under study during the study period and for 
establishing relationship in the ratio of Employee cost to total cost among different 
years for each (individual) company, F-Test ANOVA is used. The statements of 
hypothesis for the comparison among different companies and for comparison among 
different years for individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of employee cost to total cost between 
different companies under study during the study period 
is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of employee cost to total cost between 
different companies under study during the study period 
is not same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of employee cost to total cost between 
different years during the study period in each company 
under study is same.” 
Alternate Hypothesis (H1):-  “The ratio of employee cost to total cost between 
different years during the study period in each company 
under study is not same.” 
In the following Table 4.2(a) the calculation of F Test (ANOVA) is shown of 
employee cost to total cost ratio for the pharmaceutical companies under study, during 
the study period. 
 
 
 
Table :  4.2(a)                
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 645.6947859 92.24211228 59.93226134 
Between 
Years 7 27.59321094 3.941887277 2.561153606 
Error 49 75.41620156 1.539106154   
Total 63 748.7041984     
 
The above Table 4.2(a) shows the F value of 59.93 at 5% level of significance and at 
(7,49) degree of freedom for different pharmaceutical companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of 
employee cost to total cost. F value of 2.56 at 5% level of significance and at (7,49) 
degree of freedom is also greater than the Table value of 2.16 hence null hypothesis is 
rejected and alternate hypothesis is accepted, which means that there is a significant 
difference between different years’ ratios for all the individual companies. 
 
Hence it can be concluded that the employee cost to total cost ratio among different 
companies under study is not same and the employee cost to total cost ratio between 
different years of each company is also not same. 
 
3. Excise Duty 
The Central Board of Excise & Customs (CBEC) (Department of Revenue, Ministry 
of Finance - Government of India) is responsible for formulation of policy relating to 
levy and collection of Indirect Taxes namely Customs, Central Excise and Service 
Tax.  The CBEC also exercises overall supervision over Customs, Central Excise and 
Service Tax field formations located all over the country.  The Board discharges 
various tasks assigned to it, with the help of various Directorates headed by officers of 
the rank of Director General (Addl. Sec. Rank) and Director (Jt. Sec. Rank) 
  
Generally, excise is a duty on excisable goods manufactured or produced in India. 
Central Excise Act is the basic act providing for charging of duty, valuation, powers 
of officers, provisions of arrests, penalty, etc. In the following events excise duty is 
applicable: 
 
1. Article must be goods i.e. the article must be movable and marketable. 
2. Article must be ‘excisable goods’ i.e. it must be included in central excise 
Tariff Act, 1985. 
3. Must be produced. 
4. Manufacture or production must be in India. 
Table : 4.3 
Table Showing Proportion of Excise Duty to Total Cost of Pharmaceutical Companies 
under Study [in percentage] 
Period: 1997-98 to 2004-05 
Co.  97-98 98-99 99-00 00-01 2001-02 2002-03 2003-04 2004-05 
Aurobindo 11.12 9.54 7.61 5.89 7.05 7.61 7.41 6.98 
Cadila 6.59 5.91 6.81 11.76 10.83 9.49 7.44 6.11 
Cipla 7.58 9.89 10.51 9.26 9.4 8.35 8.12 7.37 
Dr. Reddy 13.16 13.46 14.12 9.13 7.68 7.12 5.46 4.99 
IPCA 6.62 9.24 6.44 6.94 6.65 6.05 4.42 4.08 
Matrix 0 11.47 11.31 10.99 10.68 6.23 5.2 5.36 
N.Piramal 13.61 13.52 12.7 12.67 10.4 9.29 5.49 5.04 
Sun 10.45 7.6 9.7 10.45 10.48 11.55 7.44 5.22 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
From the above Table no. 4.3 it is evident that proportion of Excise Duty to Total cost 
for Aurobindo Pharma lies in between 11.12(97-98) and 5.89(2000-01) with an 
average of 7.9 which is higher than overall average of 8.45 for the same period. 
 
The proportion of Excise Duty to Total cost for Cadila Healthcare lies in between 
11.76(2000-01) and 5.91(98-99) with an average of 8.12 which is lower than overall 
average of 8.45 for the same period.  
 
The proportion of Excise Duty to Total cost for Cipla Ltd. lies in between 10.51(1999-
2000) and 7.37(2004-05) with an average of 8.81 which is higher than overall average 
of 8.45 for the same study period. 
 
The proportion of Excise Duty to Total cost for Dr. Reddy’s Laboratories lies in 
between 14.12(1999-2000) and 4.99(2004-05) with an average of 9.39 which is higher 
than overall average of 8.45 for the same period. 
 
The proportion of Excise Duty to Total cost for IPCA Labs lies in between 9.24(98-
99) and 4.08(2004-05) with an average of 6.31 which is lower than the overall average 
of 8.45 for the same period.  
 
The proportion of Excise Duty to Total cost for Matrix Labs lies in between 11.47(98-
99) and 5.2(2003-04) with an average of 7.66 which is lower than overall average of 
8.45 for the same period. 
 
The proportion of Excise Duty to Total cost for Nicholas Piramal lies in between 
13.61(97-98) and 5.04(2004-05) with an average of 10.34 which is very high as 
compared to 8.45 for the same period. 
 
The proportion of Excise Duty to Total cost for Sun Pharmaceuticals lies in between 
11.55% (2002-03) and 5.22% (2004-05) with an average of 9.11% which is higher 
than overall average of 8.45 for the study period. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Excise Duty to Total Cost among 
different Pharmaceutical companies under study during the study period and for 
establishing relationship in the ratio of Excise Duty to total cost among different years 
for each (individual) company, F-Test ANOVA is used. The statements of hypothesis 
for the comparison among different companies and for comparison among different 
years for individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of excise duty to total cost between different 
companies under study during the study period is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of excise duty to total cost between different 
companies under study during the study period is not 
same.” 
 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of excise duty to total cost between different 
years during the study period in each company under 
study is same.” 
Alternate Hypothesis (H1):-  “The ratio of excise duty to total cost between different 
years during the study period in each company under 
study is not same.” 
 
 
In the following Table 4.3(a) the calculation of F Test (ANOVA) is shown of excise 
duty to total cost ratio for the pharmaceutical companies under study, during the study 
period. 
 
Table :  4.3(a)                
Table Showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 85.337375 12.19105357 2.271834535 
Between 
Years 7 151.454325 21.63633214 4.031986758 
Error 49 262.9424 5.366171429   
Total 63 499.7341     
 
The above Table 4.3(a) shows the F value of 2.27 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of excise 
duty to total cost. F value of 4.03 at 5% level of significance and at (7,49) degree of 
freedom is also greater than the Table value of 2.16 hence null hypothesis is rejected 
and alternate hypothesis is accepted, which means that there is a significant difference 
between different years’ ratios for all the individual companies. 
 
Hence it can be concluded that the excise duty to total cost ratio among different 
companies under study is not same and the excise duty to total cost ratio between 
different years of each company is also not same. 
 
 
4. Factory Overheads 
There are three elements of cost; materials, lobour and other expenses. Any of these or 
all, if attributable or which can be identified with cost unit refers to direct cost. While 
Indirect cost constitutes the overhead cost, which is the aggregate of indirect material 
cost, indirect wages and indirect expenses.9 Hence the cost which cannot be allocated 
to a particular cost unit, but only can be apportioned is referred as “Overheads”. 
 
Now this indirect cost or overheads pertaining factory or manufacturing process are 
known as factory overheads. Hence, factory overhead is the indirect cost of factory or 
manufacturing process, which includes indirect factory wages, indirect factory 
materials as well as indirect factory expenses.  Following are some examples of 
factory overheads in the pharmaceutical companies under study: 
Power, oil, fuel, electricity, water, freight, transport, packing material, repairing 
expenses, technical expenses, drilling, etc 
 
Table : 4.4 
Table Showing Proportion of Factory Overheads to Total Cost of Pharmaceutical 
Companies under Study [in percentage] 
Period: 1997-98 to 2004-05 
Co. Name 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
Aurobindo 7.41 6.81 8.46 9.32 9.81 10.11 11.35 14 
Cadila 3.42 3.74 4.36 5.7 4.29 4.39 4.27 4.82 
Cipla 10.37 11.46 10.36 10.74 11.95 12.65 12.16 12.46 
Dr. Reddy 13.59 11.03 12.45 12.27 11.28 12.05 11.86 12.04 
IPCA 7.32 7.62 9.1 8.92 9.61 10.4 9.38 8.5 
Matrix 8.4 9.65 10.7 9.66 8.8 10.38 10.9 9.78 
N. Piramal 7.3 5.18 4.36 4.9 4.18 3.82 4.3 6.64 
Sun 4.68 3.55 6.28 6.63 6.1 6.5 5.75 5.74 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
From the above Table No. 4.4 it is evident that proportion of factory overheads to total 
cost for aurobindo pharma lies in between 14% (2004-05) and 6.81% (98-99) with an 
average of 9.66 which is higher than overall average of 8.38 for the same period. 
 
It is evident that proportion of factory overheads to total cost for cadila healthcare lies 
in between 5.7(2000-01) and 3.42(97-98) with an average of 4.37 which is lower than 
overall average of 8.38 for the same period. 
 
It is evident that proportion of factory overheads to total cost in cipla ltd. lies in 
between 12.65(2002-03) and 10.36(1999-2000) with an average of 11.52 which is 
higher than overall average of 8.38 for the same period. 
 
It is evident that proportion of factory overheads to total cost of Dr. Reddy’s 
Laboratories lies between 13.59(97-98) and 11.03(98-99) with an average of 12.07 
which is higher than overall average of 8.38 for the same period. 
 
It is evident that proportion of factory overheads to total cost in IPCA Labs lies 
between 10.4 (2002-03) and 7.32(97-98) with an average of 8.86 which is almost 
equal to the overall average of 8.38 for the same period. 
 
It is evident that proportion of factory overheads to total cost of Matrix Labs lies in 
between 10.9(2003-04) and 8.4(97-98) with an average of 9.78 which is higher than 
overall average of 8.38 for the same period. 
 
It is evident that proportion of factory overheads to total cost of Nicholas Piramal lies 
in between 10.9(2003-04) and 8.4(97-98) with an average of 5.09 which is lower than 
the overall average of 8.38 for the same period. 
 
It is evident that proportion of factory overheads to total cost of Sun Pharmaceuticals 
lies in between 6.63(2000-01) and 3.55(98-99) with an average of 5.65 which is lower 
than overall average of 8.38 for the same study period. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of factory overheads to total cost among 
different pharmaceutical companies under study during the study period and for 
establishing relationship in the ratio of factory overheads to total cost among different 
years for each (individual) company, F-Test ANOVA is used. The statements of 
hypothesis for the comparison among different companies and for comparison among 
different years for individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of factory overheads to total cost between 
different companies under study during the study period 
is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of factory overheads to total cost between 
different companies under study during the study period 
is not same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of factory overheads to total cost between 
different years during the study period in each company 
under study is same.” 
Alternate Hypothesis (H1):-  “The ratio of factory overheads to total cost between 
different years during the study period in each company 
under study is not same.” 
 
In the following Table 4.4(a) the calculation of F Test (ANOVA) is shown of factory 
overheads to total cost ratio for the pharmaceutical companies under study, during the 
study period. 
 
 
Table :  4.4(a)                
Table Showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 493.1913859 70.45591228 55.6294434 
Between 
Years 7 19.40723594 2.772462277 2.18903607 
Error 49 62.05957656 1.266521971   
Total 63 574.6581984     
 
The above Table 4.4(a) shows the F value of 55.63 at 5% level of significance and at 
(7,49) degree of freedom for different pharmaceutical companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of 
factory overheads to total cost. F value of 2.19 at 5% level of significance and at 
(7,49) degree of freedom is also greater than the Table value of 2.16 hence null 
hypothesis is rejected and alternate hypothesis is accepted, which means that there is a 
significant difference between different years’ ratios for all the individual companies. 
 
Hence it can be concluded that there is a significant difference in the factory 
overheads to total cost ratio among different companies under study and there is a 
significant difference in the factory overheads to total cost ratio between different 
years of each company. 
 
 
 
 
5. Administrative Overheads 
Normally cost accounting is focused on production or manufacturing cost. But 
administration and the expenses incurred on that is equally important. Without 
administration whatever produced cannot be sold in the market. All planning and 
controlling of any organization is dependent upon the administration. And this 
administration expenses are normally in the nature of indirect cost. 
Administrative overheads, termed administration costs by some accountants, are 
mainly in the nature of indirect costs and refer to all expenditure incurred in 
formulating the policy, directing the organization and controlling the operation of an 
undertaking which is not directly related to research and development, production, 
distribution and selling activity functions.10 
Some examples of administrative overheads are as follows:  
Accounts office expenses, audit fees, bank charges, depreciation of office building and 
equipment, legal expenses, stationery, telegram and telephone, internet expenses, etc. 
Table : 4.5 
Table Showing Proportion of Administrative Overheads to Total Cost of 
Pharmaceutical Companies under Study [in percentage] 
Period: 1997-98 to 2004-05 
Co. 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
Aurobindo 2.04 2.42 3.27 2.71 2.84 3.47 4.68 6.05 
Cadila 13.54 12.37 11.92 13.97 14.33 18.64 25.27 16.24 
Cipla 5.57 6.72 5.32 4.21 5.09 5.83 6 7.15 
Dr. Reddy 8.86 9.22 10.52 14.53 18.79 20.68 22.61 25.74 
IPCA 6.94 6.96 7.36 7.74 8.65 8.34 9.63 9.78 
Matrix 2.3 2.65 2.61 3.34 4.32 7.66 8.86 9.84 
N. Piramal 11.38 10.71 11.93 13.13 6.94 7.67 11.06 12.58 
Sun 6.33 5.94 6.74 7.3 6.35 6.81 8.12 9.53 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
From the above Table no. 4.5 it is evident that proportion of administration overheads 
to Total cost for Aurobindo Pharma lies in between 6.05(2004-05) and 2.04(97-98) 
with an average of 3.44 is lower than overall average of 9.06 for the same period. 
 
From the above Table no. 4.5 it is evident that proportion of administration overheads 
to total cost for Cadila Healthcare lies in between 25.27(2003-04) and 11.92(1999-
2000) with an average of 15.79 which is higher than overall average of 9.06 for the 
same period. 
 
From the above Table no. 4.5 it is evident that proportion of administration overheads 
to total cost for Cipla Ltd. lies in between 7.15 (2004-05) and 4.21(2000-01) with an 
average of 5.74 which lower than overall average of 9.06 for the same period. 
From the above Table no. 4.5 it is evident that proportion of administration overheads 
to total cost for Dr. Reddy’s Laboratories lies between 25.74(2004-05) and 8.86(97-
98) with an average of 16.37 which is very high as compared to the overall average of 
9.06 for the same study period. 
 
From the above Table no. 4.5 it is evident that proportion of administration overheads 
to total cost for IPCA lies between 9.78(2004-05) and 6.94(97-98) with an average of 
8.18 which is low as compared to the overall average of 9.06 for the same study 
period. 
 
From the above Table no. 4.5 it is evident that proportion of administration overheads 
to total cost for Matrix Laboratories lies between 9.84(2004-05) and 2.3(97-98) with 
an average of 5.20 which is low as compared to the overall average of 9.06 for the 
same study period. 
 
From the above Table no. 4.5 it is evident that proportion of administration overheads 
to total cost for Nicholas Piramal lies between 13.13(2000-01) and 6.94(2001-02) with 
an average of 10.68 which is high as compared to the overall average of 9.06 for the 
same study period. 
 
From the above Table no. 4.5 it is evident that proportion of administration overheads 
to total cost for Sun Pharmaceuticals lies between 9.53(2004-05) and 5.94(98-99) with 
an average of 7.14 which is low as compared to the overall average of 9.06 for the 
same study period. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of administrative overheads to total cost 
among different pharmaceutical companies under study during the study period and 
for establishing relationship in the ratio of administrative overheads to total cost 
among different years for each (individual) company, F-Test ANOVA is used. The 
statements of hypothesis for the comparison among different companies and for 
comparison among different years for individual companies during the study period 
are as under: 
 
 
 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of administrative overheads to total cost 
between different companies under study during the 
study period is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of administrative overheads to total cost 
between different companies under study during the 
study period is not same.” 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of administrative overheads to total cost 
between different years during the study period in each 
company under study is same.” 
Alternate Hypothesis (H1):-  “The ratio of administrative overheads to total cost 
between different years during the study period in each 
company under study is not same.” 
In the following Table 4.5(a) the calculation of F Test (ANOVA) is shown of 
Administrative Overheads to Total Cost ratio for the Pharmaceutical Companies under 
study, during the study period. 
Table :  4.5(a)                
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 1306.624119 186.6605884 27.5723452 
Between 
Years 7 238.3926688 34.05609554 5.030555354 
Error 49 331.7225563 6.769848087   
Total 63 1876.739344     
 
The above Table 4.5(a) shows the F value of 27.57 at 5% level of significance and at 
(7,49) degree of freedom for different pharmaceutical companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of 
administrative overheads to total cost. F value of 5.03 at 5% level of significance and 
at (7,49) degree of freedom is also greater than the Table value of 2.16 hence null 
hypothesis is rejected and alternate hypothesis is accepted, which means that there is a 
significant difference between different years’ ratios for all the individual companies. 
Hence it can be concluded that there is a significant difference in the administrative 
overheads to total cost ratio among different companies under study and there is a 
significant difference in the administrative overheads to total cost ratio between 
different years of each company. 
6. Selling and Distribution Overheads 
 
Selling and Distribution overheads are also one of the important indirect costs.  As 
such every business unit has to incur this cost, be it a manufacturing concern of a 
trading concern, and be it a retail shop or wholesale business. 
 
The nature of selling and distribution overheads is different from any manufacturing 
overheads. Even sometimes selling and distribution overheads are given more 
importance than any other manufacturing overheads, because whatever is produced 
cannot be sold unless the promotional efforts are made.  Selling and Distribution 
overheads includes market research expenses, advertisement expenses, salaries and 
commission of salesmen, sales office expense, packing and shipping expenses, 
warehouse expenses etc. 
 
Even before production a business unit which is relatively new has to incur expenses 
on market research and after production proper advertisement and sales promotion 
expenses are to be made in order to sell the produce.  As every business unit has a 
objective of profit maximization, it can be achieved only by increasing sales, which 
can be achieved by making selling and distribution expenses very tactfully.  With 
increased efforts for promoting sales and also due to increase in competition, 
considerable expenditure is incurred on selling and distribution and this sometimes 
exceeds even the cost of manufacture.11 
 
 
 
Table : 4.6 
 
Table Showing Proportion of Selling & Distribution Overheads to Total Cost of 
Pharmaceutical Companies under Study [in percentage] 
Period: 1997-98 to 2004-05 
Co. 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
Aurobindo 3.58 2.6 3.31 2.95 3.05 2.8 3.48 3.83 
Cadila 11.13 10.56 11.68 11.23 13.21 11.73 12.3 14.87 
Cipla 8.37 8.06 9.04 10.35 10.6 9.58 9.34 9.46 
Dr .Reddy 14.87 13.72 16.32 13.37 13.29 13.66 13.03 12.98 
IPCA 8.3 8.65 13.02 13.1 11.52 12.15 12.65 14.42 
Matrix 3.18 2.75 2.04 3.97 4.24 12.2 7.21 5.27 
N. Piramal 4.07 5.92 4.36 6.12 17.39 18.94 18.41 17.65 
Sun 16.67 15.33 13.73 13.38 15.47 14.55 14.17 11.25 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
From the above Table no. 4.6 it is evident that proportion of Selling and Distribution 
Overheads to Total cost for Aurobindo Pharma lies between 3.83(2004-05) and 
2.6(98-99) with an average of 3.20 which is low as compared to the overall average of 
10.16 for the same study period. 
 
It is evident that proportion of Selling and Distribution Overheads to Total cost for 
Cadila Healthcare lies between 14.87(2004-05) and 10.56(98-99) with an average of 
12.09 which is high as compared to the overall average of 10.16 for the same study 
period. 
 
It is evident that proportion of Selling and Distribution Overheads to Total cost for 
Cipla Ltd. lies between 10.35(2000-01) and 8.06(98-99) with an average of 9.35 
which is low as compared to the overall average of 10.16 for the same study period. 
 
It is evident that proportion of Selling and Distribution Overheads to Total cost for Dr. 
Reddy’s Laboratories lies between 16.32(1999-2000) and 12.98(2004-05) with an 
average of 13.91 which is high as compared to the overall average of 10.16 for the 
same study period. 
 
It is evident that proportion of Selling and Distribution Overheads to Total cost for 
IPCA lies between 14.42(2004-05) and 8.3(97-98) with an average of 11.73 which is 
high as compared to the overall average of 10.16 for the same study period. 
 
It is evident that proportion of Selling and Distribution Overheads to Total cost for 
Matrix Laboratories lies between 12.2(2002-03) and 2.04(99-00) with an average of 
5.11 which is very low as compared to the overall average of 10.16 for the same study 
period. 
 
It is evident that proportion of Selling and Distribution Overheads to Total cost for 
Nicholas Piramal lies between 18.94(2002-03) and 4.07(97-98) with an average of 
11.61 which is high as compared to the overall average of 10.16 for the same study 
period. 
It is evident that proportion of Selling and Distribution Overheads to Total cost for 
Sun Pharmaceuticals lies between 16.67(97-98) and 11.25(2004-05) with an average 
of 14.32 which is high as compared to the overall average of 10.16 for the same study 
period. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Selling and Distribution Overheads to 
Total Cost among different Pharmaceutical companies under study during the study 
period and for establishing relationship in the ratio of Selling and Distribution 
Overheads to total cost among different years for each (individual) company, F-Test 
ANOVA is used. The statements of hypothesis for the comparison among different 
companies and for comparison among different years for individual companies during 
the study period are as under: 
Hypothesis for comparison between different companies:- 
 
Null Hypothesis (H0):-  “The ratio of selling and distribution overheads to total 
cost between different companies under study during the 
study period is same.” 
Alternate Hypothesis (H1):-  “The ratio of selling and distribution overheads to total 
cost between different companies under study during the 
study period is not same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of selling and distribution overheads to total 
cost between different years during the study period in 
each company under study is same.” 
Alternate Hypothesis (H1):-  “The ratio of selling and distribution overheads to total 
cost between different years during the study period in 
each company under study is not same.” 
 
In the following Table 4.6(a) the calculation of F Test (ANOVA) is shown of Selling 
and Distribution Overheads to Total Cost ratio for the Pharmaceutical Companies 
under study, during the study period. 
 
Table :  4.6(a)                
Table Showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 913.7126734 130.5303819 16.26002689 
Between 
Years 7 104.6594734 14.95135335 1.862473731 
Error 49 393.3565891 8.027685491   
Total 63 1411.728736     
 
 
The above Table 4.6(a) shows the F value of 16.26 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of 
Selling and Distribution Overheads to total cost. F value of 1.86 at 5% level of 
significance and at (7,49) degree of freedom is lower than the Table value of 2.16 
hence null hypothesis is accepted and alternate hypothesis is rejected, which means 
that there is a no significant difference between different years’ ratios for all the 
individual companies. 
 
Hence it can be concluded that he selling and distribution overheads to total cost ratio 
among different companies under study are not same and the selling and distribution 
overheads to total cost ratio between different years of each company are same. 
 
 
9. Sales trend of sample units 
 
After making an in-depth analysis of cost structure of pharmaceutical companies 
under study and its trend analysis for the period of 8 years, we have got very clear 
indication regarding the importance of each cost element in the total cost and their 
movements over the years. Now we will study sales in detail. 
 
Sales are the major source of revenue for majority of businesses. Hence it occupies an 
important position in any business performance analysis. The present study is a study 
on profitability of selected pharmaceutical companies of Indian pharmaceutical 
industry, and therefore sales and its trend of the selected companies during the period 
of study is of immense importance for this study. 
A sole contributor to the financial growth of the company needs to be tracked on 
regular interval to monitor the progress. Profit margins and their effects on overall 
profitability is also dependent on sales. Profits have got dual relationship with sales, 
one with regard to the margins which means with the increase in sales profit will 
increase in the ratio of profit margin and the other relationship is that of volumes, with 
the increase in sales the income would increase due to volumes. During times when 
profit margins are shrinking most businesses play the game of margins. 
 
For the purpose of studying the trend of sales we have used the index analysis. In 
index analysis, the figures of sales are expressed as an index relative to the base year 
sales. All items in the base year are assumed a value of 100.  Here year 1997-98 has 
been taken as the base year and sales of all other consequent years are compared with 
that of base year and their index numbers have been calculated on that basis. 
 
 
 
 
 
 
 
 
 
Table : 4.7:  
Table Showing Indices of Sales in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05 
[Base Year= 1997-98 = 100]                                                     [Sales = Rs. in Crores] 
 
SampleCo. 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
                  
Aurobindo 295.31 550.03 739.9 972.52 1007.96 1180.33 1334.83 1153.43 
Indicies 100.00 186.26 250.55 329.32 341.32 399.69 452.01 390.58 
  
                
Cadila 303.58 358.4 475.7 502.3 581.7 1005.2 1116 1125.3 
Indicies 100 118.06 156.70 165.46 191.61 331.12 367.61 370.68 
  
                
Cipla 514.43 617.16 759.75 1047.51 1385.84 1549.79 1974.63 2327.63 
Indicies 100.00 119.97 147.69 203.63 269.39 301.26 383.85 452.47 
  
                
Dr. Reddy 331.62 425.86 493.02 984.11 1557.78 1598.32 1740.2 1625.08 
Indicies 100.00 128.42 148.67 296.76 469.75 481.97 524.76 490.04 
  
                
IPCA 282.74 335.66 363.31 385.38 444.18 506.51 649.32 721.74 
Indicies 100.00 118.72 128.50 136.30 157.10 179.14 229.65 255.27 
  
                
Matrix 27.51 40.73 45.19 60.78 102.18 416.93 556.86 671.69 
Indicies 100.00 148.06 164.27 220.94 371.43 1515.56 2024.21 2441.62 
  
                
N.Piramal 534.64 429.99 486.48 566.76 946.48 1136.13 1434.66 1384.68 
Indicies 100.00 80.43 90.99 106.01 177.03 212.50 268.34 258.99 
  
                
Sun 279.77 358.11 478.35 613.78 753.1 864.65 998.16 1263.86 
Indicies 100.00 128.00 170.98 219.39 269.19 309.06 356.78 451.75 
 
From the above Table no. 4.7 it is evident that trend for the sales in Aurobindo 
Pharma is increasing in majority of cases. Taking 100 as index for the base year the 
sales have shown positive growth in all the years of the study period. There is minor 
decrease observed in the last year but apart from that overall increasing trend in 
evident from the table. 
The trend for the sales in Cadila Healthcare is increasing in majority of cases. Taking 
100 as index for the base year the sales have shown positive growth in all the years of 
the study period.  
 
The trend for the sales in Cipla Ltd. is increasing in majority of cases. Taking 100 as 
index for the base year the sales have shown positive growth in all the years of the 
study period. There is tremendous increase observed in the sales of last year of the 
study period which is more than 450. 
 
The trend for the sales in Dr. Reddy’s Laboratories is increasing in majority of cases. 
Taking 100 as index for the base year the sales have shown positive growth in all the 
years of the study period. There is minor decrease observed in the last year but apart 
from that overall increasing trend in evident from the table. 
 
The trend for the sales in IPCA Labs is increasing in majority of cases. Taking 100 as 
index for the base year the sales have shown positive growth in all the years of the 
study period.  
The trend for the sales in Matrix Laboratories is increasing in majority of cases. 
Taking 100 as index for the base year the sales have shown positive growth in all the 
years of the study period. There is more than significant increase observed in the sales 
figures of the company for the last three years of the study period, making it a very big 
company as far as sales volumes are concerned. 
 
The trend for the sales in Nicholas Piramal is showing a decline in the second year but 
after that there is a steady increasing trend observed in the sales of the company for 
the study period. Taking 100 as index for the base year the sales have shown positive 
growth in all the years of the study period.  
 
The trend for the sales in Sun Pharmaceuticals is increasing in majority of cases. 
Taking 100 as index for the base year the sales have shown positive growth in all the 
years of the study period. 
 
 
 
10. Conclusion  
From the above calculation of individual cost to total cost ratio there can be some 
general conclusions drawn from the statistical analysis. From the study of six 
individual cost to total cost ratio and their comparison among companies for the study 
period and individual companies comparison for different years, following 
conclusions can be drawn: 
 The ratio of raw material cost to total cost among companies is not same and the 
 ratio of raw material cost to total cost between different years of each individual 
 company under study for the study period is also not same. 
 
 The ratio of Employee cost to total cost among companies is not same and the  
  ratio of Employee cost to total cost between different years of each individual 
   company under study for the study period is also not same. 
 
 The ratio of excise to total cost among companies is not same and the ratio of 
 Excise to total cost between different years of each individual company under 
 study for the study period is also not same. 
 
 The ratio of factory overheads to total cost among companies is not same and the 
 ratio of factory overheads to total cost between different years of each individual 
 company under study for the study period is also not same. 
 
 The ratio of administrative overheads to total cost among companies is not same 
 and there is ratio of administrative overheads to total cost between different years 
 of each individual company under study for the study period is also not same. 
 
 The ratio of selling & distribution cost to total cost among companies is not same 
 but the percentage of selling & distribution cost to total cost between different 
 years of each individual company under study for the study period is same. 
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1. Concept 
 
Profit is the guiding light for so many managerial decisions. Almost all the major 
business decisions are directly or indirectly dependent on profit and profitability. For 
example, dividend payments, bonus to employees, expansion of business, raising of 
additional finance, etc. Apart from manager there are other parties also who are 
interested in profit and profitability like the shareholders, general public, government, 
creditors, bankers, financial institutions, etc. The shareholder has to make decision 
regarding holding or selling the shares, creditors have to decide regarding the credit 
policy and further credit to the firm, etc. Hence profit can be considered as an 
important criterion for various business decisions making by the internal and external 
parties. But profit when seen and observed individually fails to convey any significant 
message, and can be meaningful when compared with other figures. These other 
figures may be profits of other companies in the same industry, average industry 
profits figures, or the profit compared with the average investment made in the firm. 
 
Fulfilling the social responsibility towards various classes of society would also be not 
possible without the surplus funds which can be collected only if the company is 
earning profit. Social responsibilities can be fulfilled by offering the goods or services 
at lower rates in times of natural calamities or provide the assistance to government 
and other non-government organizations (NGOs) in their relief work, constructing and 
maintaining public schools, public hospitals, public libraries, etc. 
Profit earning can also be viewed as a cushion for the future unexpected situation of 
market. A negative change in demand or negative change in the prices of inputs or the 
resources may be balanced by the sufficient profit earned in the earlier years. Sudden 
decision with regard to the above situation can be taken if the company is earning 
profit regularly.   
Profitability is the ability to earn profit but any firm can be termed profitable only 
when compared with someone. Hence profitability is definitely a relative term. A 
simple example will explain the difference between profit and profitability: two 
similar amounts of profits for two different firms may be referred to as two firms 
having similar amounts of profits but in no case can be stated to have similar 
profitability; profitability can only be known when the operating profit margins are 
compared with the investment.  
Return on Investment (ROI) is one of the key profitability ratio.1 ROI is the 
percentage of profit to capital employed and is the product of two ratios: (i) 
Percentage of profit to sales and (ii)sales to capital employed, i.e. the rate of asset 
turnover. Thus 
 
ROI = 
 
 
Return on Investment can be considered as the ultimate measure of profitability; as 
such it uses profit margin as well as the productivity to measure the real profitability 
of any business enterprise. Hence for the present study this measure will be the most 
important to measure the profitability situation of the companies of pharmaceutical 
industry of India.  
         Profit  
Capital Employed = 
Profit 
Sales X 
         Sales 
Capital Employed 
Hence we can conclude that Return on Investment is the factor of Profit Margin as 
well as Asset Turnover. Hence if there is any change in Return on Investment it may 
be either due to the change in the proportion of profit to sales or the proportion of 
sales to capital employed. 
 
2. Calculation of Gross Profit Margin of sample units 
The gross profit margin is a measurement of a company’s manufacturing and 
distribution efficiency during the production process. Gross profit is the profit in sales 
after deducting all the trading expenses like the cost of raw materials, the direct 
expenses on purchases, excise duty, etc. The effect of stock adjustment is also given 
along with deducting factory overheads at this stage, and the result is Gross Profit.  In 
other words when manufacturing cost of goods sold is deducted form the sales the 
resultant profit are referred to as Gross Profit. The gross profit margin informs an 
investor about the percentage of revenue / sales left after subtracting the 
manufacturing cost of goods sold.  A company that boasts a higher gross profit margin 
than its competitors and industry is more efficient.  
Gross Profit Margin Ratio =   
Gross Profit margin is an indicator of the percentage of sales revenue which is above 
the cost. For making a pricing decision this margin can be utilized for decreasing the 
price. Theoretically it can be said that the price of a product can be decreased 
maximum up to the extent of gross profit margin, decrease in price up to this margin 
would give the firm enough revenue to continue the operations.  
Gross Profit 
     Sales X 100 
Profit is more of a motivator or a driving force rather than bread and butter. To make 
the total profitability analysis we have chosen to analyze the profitability (of the 
selected companies of pharmaceutical industry of India) step by step i.e. to start with 
the calculation and analysis of Gross Profit margin will be done and then net profit 
margin and operating profit margin will be calculated and analyzed.  
Table: 5.1:  
Gross Profit to Sales Ratio in Pharmaceutical Companies under Study [in percentage]  
Period: 1997-98 to 2004-05  
Co. 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
Aurobindo 20.21 19.88 21.39 17.73 15.97 22.07 26.16 22.77 
  
                
Cadila 37.03 38.16 37.78 39.88 42.07 44.08 48.81 51.85 
  
                
Cipla 38.65 38.33 36.77 37.14 38.05 35.57 33.28 36.05 
  
                
Dr. Reddy 47.64 46.55 49.46 53.4 62.54 60.5 55.89 54.72 
  
                
IPCA 32.19 33.68 38.31 38.34 40.49 41.81 44.27 47.25 
  
                
Matrix 13.16 14.61 -2.85 9.56 22.6 47.67 46.23 41.17 
  
                
N.Piramal 42.77 43.74 41.31 42.58 43.74 47.26 50.71 49.33 
  
                
Sun 46.36 45.12 44.09 46.76 46.81 50.24 52.38 47.88 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
There is no particular trend observed in the Gross Profit Margin of Aurobindp 
Pharma. It lies in between 26.16(03-04) and 15.97(01-02) with an average of 20.77 
which is lower compared to the overall average 38.75 of the selected companies for 
the same study period. Apart from the year 2001-02 where the margin showed a 
tremendous down trend all the years have shown pretty consistent rate of gross profit 
margin. 
 
Cadila Healthcare has shown a constant increasing trend in the Gross Profit Margin 
for the study period. It lies between 37.03 (1997-98) and 51.85 (2004-05) with an 
average of 42.46 which is a very fine average by all standards especially the overall 
average is 38.75 for all the selected companies for the study period. The company can 
be said to be reliable and consistent as far as Gross Profit Margin is concerned as it 
has shown a steady increasing trend for the study period. 
 
Cipla Ltd. has shown the consistent gross profit margin ratio for the entire study 
period. There is neither any increasing trend visible nor any decreasing trend in the 
ratio. The ratio lies between 38.65(1997-98) and 33.28(2003-04) with an average of 
36.73 which is close to the overall average 38.75 of all the selected companies for the 
study period. The gap between the highest and lowest value shows the absence of any 
major fluctuation in the gross profit margin of the company. 
 
Dr. Reddy’s Laboratories is showing a mixed trend for the study period. As there is a 
constant increasing trend observed till the year 2001-02, but after that year there was a 
downfall in the gross profit margin which continued till the end of the study period. 
The eight year high for the company is 62.54(2001-02) while the lowest value is 
47.64(1997-98). And the average is 53.84 which shows that its performance is far 
higher than the overall average of 38.75 but the downtrend observed in the latter part 
of period is concerning. 
IPCA Laboratories is showing a continuous increasing trend for the gross profit 
margin for the study period. This is the first company which is showing a clear and 
continuous increasing trend of gross profit margin for the study period. This can be 
nothing but the reason for the continuous improvement in the financial management of 
the business. The highest value is at the end of the study period 47.25 (2004-05) and 
lowest is at the beginning of the study period 32.19 (1997-98) with an average of 
39.54 which is higher than the overall average of 38.75 for the selected companies for 
the same study period. Although the average is little bit higher than the overall 
average but there is much more potential in the company than what is visible if it 
continues to operate like in the past. 
 
Matrix Laboratories has made a successful attempt to stabilize after few very weak 
period especially 1999-2000 when it made a gross loss but ever since then it has tried 
to recover and it has successfully done with an increasing trend. But overall there is an 
amount of fluctuation observed in the gross profit margin of the company as after loss 
period there were very high profits and then a slight declining trend has been observed 
in the last two years of the study period. This un-stability can cause a serious concern 
to the stakeholders of the company. It lies between 47.67(2002-03) and -2.85(1999-
2000) with an average of 24.03 which is quite lower than the overall average 38.75 for 
the same study period. But more than the average the fluctuation can cause some 
serious problems for the company.  
 
Nicholas Piramal Pharmaceuticals is neither showing any clear positive or negative 
trend of gross profit margin for the study period but is showing a semi consistent trend 
which is a good sign for the financial stability of any company. The ratio lies between 
50.71(2003-04) and 41.31(1999-2000) with an average of 45.18 which is far better 
than the overall average 38.75 for all the selected companies for the same study 
period. 
 
Sun Pharmaceuticals is showing a very fine consistent trend for the study period with 
no major fluctuations. There is only one big downfall in the ratio in the last year apart 
from that there is good amount of consistence observed. The ratio is highest at 52.38 
(2003-04) and lowest at 44.09 (1999-2000) with an average of 47.46 which is a very 
impressive and much better than the overall average of 38.75 for the same study 
period. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Gross Profit to Sales Ratio among 
different Pharmaceutical companies under study during the study period and for 
establishing relationship in the ratio of Gross Profit to Sales Ratio among different 
years for each (individual) company, F-Test ANOVA is used. The statements of 
hypothesis for the comparison among different companies and for comparison among 
different years for individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Gross Profit to Sales between different 
companies under study during the study period is same.” 
Alternate Hypothesis (H1):-  “The ratio of Gross Profit to Sales between different 
companies under study during the study period is not 
same.” 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Gross Profit to Sales between different 
years during the study period in each company under 
study is same.” 
Alternate Hypothesis (H1):-  “The ratio of Gross Profit to Sales between different 
years during the study period in each company under 
study is not same.” 
 
 
In the following Table 5.1(a) the calculation of F Test (ANOVA) is shown of Gross 
Profit to Sales ratio for the Pharmaceutical Companies under study, during the study 
period. 
 
Table :  5.1(a)                
Table showing calculation of F-Test (ANOVA) 
 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 7225.7978 1032.256829 24.20289293 
Between 
Years 7 1242.027425 177.4324893 4.160185161 
Error 49 2089.856975 42.65014235   
Total 63 10557.6822     
 
The above Table 5.1(a) shows the F value of 24.20 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of Gross 
Profit to Sales. F value of 4.16 at 5% level of significance and at (7,49) degree of 
freedom is also greater than the Table value of 2.16 hence null hypothesis is rejected 
and alternate hypothesis is accepted, which means that there is a significant difference 
between different years’ ratios for all the individual companies. 
 
Hence it can be concluded that there is a significant difference in the Gross Profit to 
Sales Ratio among different companies under study and there is a significant 
difference in the Gross Profit to Sales ratio between different years of each company. 
 
3. Calculation of Operating Profit Margin for sample 
units 
Among the various measures of profitability, this ratio has got its own importance. 
Operating profit margin is calculated in order to find the operating efficiency of the 
company. When total operating costs are deducted from total operating or business 
income the result is Operating Profit or Operating Loss. The name itself suggests that 
the result which is obtained from the operations of the business is the Operating Profit 
Margin. In this study we have tried to calculate the Operating Profit Margin by 
adjusting all the operating expenses against operating income.  
 
The expenses that are adjusted to gross profit margin are Employees Cost, which 
includes Salaries, Wages, Bonus, Contribution to funds, Staff welfare expenses, VRS 
compensation, Gratuity and other employee costs. Second expense head that has been 
adjusted to find out operating profit is Selling and Administrative Expenses, which 
includes Insurance Expenses, Advertisement Expenses, Marketing Expenses, 
Distribution Expenses, Legal Expenses, Selling Expenses, Communication Expenses, 
Travel Expenses, Audit Expenses, Printing and stationery, Technical fees and other 
administrative expenses. 
Operating Profit Margin Ratio =   
Table : 5.2:  
Operating Profit to Sales Ratio in Pharmaceutical Companies under Study [in 
percentage]  
Period: 1997-98 to 2004-05  
 
Co. 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
  
                
Aurobindo 13.41 13.77 14 10.21 8.25 13.7 15.28 7.95 
  
                
Cadila 14.32 16.13 16.3 15.91 15.58 14.85 12.1 12.64 
  
                
Cipla 23.29 22.51 20.32 20.24 20.68 18.08 16.4 17.56 
  
                
Dr. Reddy 22.74 21 20.79 23.49 35.05 26.99 17.42 7.18 
  
                
IPCA 8.51 9.32 9.91 7.78 12.73 14.65 14.61 14.32 
  
                
Matrix 6.51 7.05 -8.65 0.53 9.39 30.58 30.04 23.91 
  
                
N.Piramal 17.18 19 15.87 16.94 15.61 16.22 15.58 10.74 
  
                
Sun 21.1 20.58 22.08 23.79 25.66 29.37 29.57 26.1 
Source: Annual Reports of Companies from the year 1997-98 to 2004-05 
Aurobindo Pharma is showing a fluctuating trend of Operating Profit Margin Ratio for 
the study period. It lies between 15.28(2003-04) and 7.95(2004-05) with an average of 
12.07 which is very low compared to overall average of 16.64 for the same study 
Sales 
Operating profit 
period. The company could never get stability as far as its operating profit margin is 
concerned and this should be of serious concerns to all the stakeholders. 
 
Cadila Healthcare is showing a mixed trend for the operating profit margin in the 
study period. As there is a positive trend observed in the initial years for three years 
and then there is a continuously downtrend observed for the rest of the years. The 
highest is 16.30 (1999-2000) and lowest is 12.1 (2003-04) with an average of 14.73 
which is lower than overall average of 16.64.  
 
Cipla Ltd. is very consistent for the initial five years but the last three years were not 
equally good for the company as the operating profit margin started to decline in the 
last three years. Although the decrease is not too sharp but it can damage the average 
of the company. The ratio lies between 23.29 (1997-98) and 16.4 (2003-04) with an 
average of 19.89 which is better than the overall average of 16.64 but company need 
to rectify its declining trend and then it can continue its success story. 
 
Dr. Reddy’s Laboratories has shown a mixed trend but the latter years proved to be 
worst for the company. The margins were best in the year 2001-02 35.05 but after that 
a serious fall has been observed which was as low as 7.18(2004-05) and hence the 
average works out to be 21.83 which is although better than overall average of 16.64 
but the figures are not that reliable. Company needs to improve a lot on its operating 
margins. 
IPCA Labs. is showing a mixed increasing trend in the study period. The best part is 
the stability of its operating margins in the latter part of the period. The margins lie 
between 14.65 (2002-03) and 7.78(2000-01) with an average of 11.48 which is lower 
than overall average of 16.64 but if IPCA continues its success story than it can do 
wonders for all the stakeholders. 
 
Matrix Laboratories Ltd. has again a sad story to narrate especially with a loss in the 
study period but after that it has tried to recover a lot in the last five years and 
improved its operating margins to a great extent. Its eight year low is -8.65(1999-
2000) and high is 30.58(2002-03) with an average of 12.42 which is lower than the 
overall average of 16.64 for the same study period. Rather than the average the 
fluctuations in the initial period can be of serious concerns. But there is a ray of hope 
if company continues with its positive trend in the coming years. 
 
Nicholas Piramal is showing a fluctuating trend for the operating margins in the study 
period. It lies between 17.18(97-98) and 10.74(2004-05) with an average of 15.89 
which is not much lower than overall average of 16.64 but the fluctuations can make it 
an unstable company as far as operating margins are concerned. 
 
Sun Pharmaceuticals a very fine consistent and positive trend for the study period. 
Except a decline in the last year it has shown either positive or constant trend. It lies 
between 29.57(2003-04) and 20.58(1998-99) with an average of 24.78 which is far 
better than the overall average of 16.64 by any means. The company can do wonders 
if it continues its increasing trend of its operating profit margin ratio. 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of operating profit to sales ratio among 
different pharmaceutical companies under study during the study period and for 
establishing relationship in the ratio of operating profit to sales ratio among different 
years for each (individual) company, F-Test ANOVA is used. The statements of 
hypothesis for the comparison among different companies and for comparison among 
different years for individual companies during the study period are as under: 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of operating profit to sales between different 
companies under study during the study period is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of operating profit to sales between different 
companies under study during the study period is not 
same.” 
 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of operating profit to sales between different 
years during the study period in each company under 
study is same” 
Alternate Hypothesis (H1):-  “The ratio of operating profit to sales between different 
years during the study period in each company under 
study is not same.” 
In the following Table 5.2(a) the calculation of F Test (ANOVA) is shown of 
Operating Profit to Sales ratio for the Pharmaceutical Companies under study, during 
the study period. 
 
 
 
Table :  5.2(a)                
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 1386.43145 198.0616357 5.160853458 
Between 
Years 7 289.832625 41.40466071 1.078873178 
Error 49 1880.506825 38.37769031   
Total 63 3556.7709     
 
 
The above Table 5.2(a) shows the F value of 5.16 at 5% level of significance and at 
(7,49) degree of freedom for different pharmaceutical companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that among the 
different companies under study the ratio of operating profit to sales are not same. F 
value of 1.07 at 5% level of significance and at (7,49) degree of freedom is smaller 
than the Table value of 2.16 hence null hypothesis is accepted and alternate hypothesis 
is rejected, which means that different years’ ratios for all the individual companies 
are same. 
 
Hence it can be concluded that the operating profit to sales ratio among different 
companies under study are not same but the operating profit to sales ratio between 
different years of each company is same. 
 
 
 
 
4. Calculation of Net Profit Margin of sample units 
The final step of profit is the calculation of net profit margin. gross profit was the 
profit in sales after deducting manufacturing cost of goods sold, whereas the operating 
profit is the profit after deducting the employees cost, administrative overheads and  
selling overheads from the gross profit. Finally the Net Profit margin is arrived after 
the gross profit margin and operating profit margin.  Net Profit is arrived at after 
making adjustments on both the sides, i.e. income as well as expenses side. All other 
income except the operating income and all other expenses other than operating 
expenses including depreciation are adjusted to arrive at the final profit which we 
refer to as Net Profit. 
The profit margin tells how much profit a company makes for every Re. 1 it generates 
in revenue. Profit margins vary by industry, but all else being equal, the higher a 
company’s profit margin compared to its competitors, the better.  
Net profit is one of the most important indicators of a company’s efficiency and 
ability. A high net profit margin will lead to higher payments to the shareholders and 
thus increasing the shareholders’ wealth. High net profits also mean the company and 
its products are accepted by the society at large and it could continue its endeavour in 
serving the society.  
 
Profit is the reward for the efficiency of the management in doing the financial 
activity. A profit earning business enterprise has the resources and funds to make 
efforts in the direction of improving the products and services and provide better 
products and services to the society.  
 Net Profit Margin Ratio =  
 
 
Just like the gross profit margins, the net profit margins also vary from business to 
business and from industry to industry.  
 
Table : 5.3 :  
Net Profit to Sales Ratio in Pharmaceutical Companies under Study [in percentage] 
Period: 1997-98 to 2004-05 
Co. 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
Aurobindo 8.09 9.12 10.07 7.08 6.04 7.93 9.53 3.05 
  
                
Cadila 5.55 8.76 7.95 12.91 11.64 8.31 13.51 12.54 
  
                
Cipla 19.78 18.53 17.35 16.65 16.53 15.45 15.72 15.44 
  
                
Dr. Reddy 16.63 12.21 12.27 14.76 29.53 24.53 16.61 3.9 
  
                
IPCA 6.87 7.36 7.23 5.33 7.82 12.22 12.27 10.79 
  
                
Matrix 0.55 1.03 -19.01 6.91 4.38 18.21 22.6 19.42 
  
                
N.Piramal 8.54 9.86 10.74 12.02 8.03 14.62 14.55 7.22 
  
                
Sun 19.91 16.5 17.48 22.05 23.15 26.43 23.44 23.73 
Source: Annual Reports of Companies from the year 1997-98 to 2004-05 
The most important profit margin ratio of net profit margin can be considered as the 
most important indicator of the profitability of any company. Hence this ratio holds 
much more importance in this study as it focuses basically on the profitability analysis 
of the selected pharmaceutical companies for the study period. 
Net Profit 
     Sales X  100 
Aurobindo Pharma is showing a fluctuating trend in the net profit margin ratio for the 
study period. It lies between 10.07(1999-2000) and 3.05(2004-05) with an average of 
7.61 which is lower than the overall average 12.35 for all the selected companies for 
the same study period. For the initial three years the company has showed an 
increasing trend but then there was a fluctuating trend ending at the eight year low of 
3.05 in the last year of the study period. 
Cadila Healthcare is showing a mixed trend of increasing and little fluctuating in 
between years. It lies between 13.51(2003-04) and 5.55(97-98) with an average of 
10.15 which is lower than the overall average of 12.35 for the same study period. But 
the positive about the story of Cadila Healthcare is the positive trend in the last three 
years observed.  
Cipla Ltd. is showing a clear declining trend in this net profit margin. Although a very 
fine Profit margin but the declining nature makes its lesser attractive. It lies between 
19.78(97-98) and 15.44(2004-05) with an average of 16.93 which is far better than the 
overall average of 12.35 for the same study period. The declining trend of the net 
profit margin ratio can be of serious concerns. 
Dr. Reddy’s Laboratories Ltd. is showing a tremendous fluctuating trend in the study 
period. The margins were stable in the initial years of the study period and improved 
in the middle part but declined and declined drastically 77% in the last year of the 
study period. It lies in between 29.53(2001-02) and 3.9 (2004-05) with an average of 
16.31 which is better than overall average of 12.35 for the same study period. The 
sudden decrease in the net profit margin in the last year can be attributed to the decline 
in sales by 7% and increase in expenses like interest expenses increased by 200%, 
miscellaneous expenses increased by 80%, selling and administration expenses 
increased by 14% and interestingly raw material cost decreased by 5%. 
IPCA is showing a mixed trend of fluctuation and increasing trend of net profit margin 
in the study period. It lies between 12.27 (2003-04) and 5.33(2000-01) with an 
average of 8.74 which is very low compared to the overall average 12.35 for the same 
study period. There has been a positive increasing trend observed from the period 
2001-02 to 2003-04 but the last year showed a decline which ended the positive trend. 
If company can work out properly and continue its positive trend it can definitely 
improve its margins in the coming times. 
Matrix Laboratories is showing a very high fluctuating trend in the net profit margin 
ratio with a loss in one of the year in the study period. It lies between 22.6(2003-04) 
and          -19.01(1999-2000) with an average of 6.76 which is almost 50% lesser than 
the overall average of 12.35 for the same period. 
Nicholas Piramal has shown a clear positive trend except in two years 2001-02 and 
2004-05 where it declined. It lies between 14.62(2002-03) and 7.22(2004-05) with an 
average of 10.70 which is lower than overall average of 12.35 for the same period. 
There is a 50% decline observed in the net profit margin in the last year making it 
more un-stable in the study period. 
Sun Pharmaceuticals has shown a positive trend in the study period except in two year 
1998-99 and 2003-04. It lies between 26.43(2002-03) and 16.5(98-99) with an average 
of 21.59 which is very high compared to the overall average of 12.35 for the same 
study period. The company has very fine consistency in the net profit margin 
compared to other companies in the study period which shows that it has fairly good 
control over its cost and given no major fluctuations in the prices it can maintain its 
profit margin pretty consistently. 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of net profit to sales ratio among different 
pharmaceutical companies under study during the study period and for establishing 
relationship in the ratio of net profit to sales ratio among different years for each 
(individual) company, F-Test ANOVA is used. The statements of hypothesis for the 
comparison among different companies and for comparison among different years for 
individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of net profit to sales between different 
companies under study during the study period is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of net profit to sales between different 
companies under study during the study period is not 
same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of net profit to sales between different years 
during the study period in each company under study is 
same.” 
Alternate Hypothesis (H1):-  “The ratio of net profit to sales between different years 
during the study period in each company under study is 
not same.” 
 In the following Table 5.3(a) the calculation of F Test (ANOVA) is shown of Net 
Profit to Sales ratio for the Pharmaceutical Companies under study, during the study 
period. 
 
Table :  5.3(a)                
Table showing calculation of F-Test (ANOVA)  
 
S V d f S.  S. M. S. S. F cal 
Between 
companies 7 1570.006219 224.2866027 6.920023522 
Between 
Years 7 423.5678938 60.50969911 1.866935145 
Error 49 1588.151181 32.4112486   
Total 63 3581.725294     
 
The above Table 5.3(a) shows the F value of 6.92 at 5% level of significance and at 
(7,49) degree of freedom for different pharmaceutical companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of Net 
Profit to Sales. 
 F value of 1.86 at 5% level of significance and at (7,49) degree of freedom is lower 
than the Table value of 2.16 hence null hypothesis is accepted and alternate hypothesis 
is rejected, which means that there is no significant difference between different 
years’ ratios for all the individual companies. 
 
Hence it can be concluded that the net profit to sales ratio among different companies 
under study is not same but the net profit to sales ratio between different years of each 
company is same. 
 
 
5. Conclusion of Statistical Analysis 
 
From the above calculation of profit to sales ratio there can be some general 
conclusions drawn from the statistical analysis. From the study of three individual 
profits to sales ratio and their comparison among companies for the study period and 
individual companies comparison for different years, following conclusions can be 
drawn: 
 
 The gross profit to sales ratio among companies is not same and the gross profit to 
sales ratio between different years of each individual company under study for the 
study period is also not showing any common trend. 
 
 The operating profit to sales ratio among companies is not same but the operating 
profit to sales ratio between different years of each individual company under study 
for the study period is showing the similar trend. 
 
 The net profit to sales ratio among companies is not same but the net profit to sales 
ratio between different years of each individual company under study for the study 
period is showing the similar trend. 
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1. Introduction 
Profit has always remained the topic of the business discussions because of its major 
utility as an effective measure of efficiency of managers and the measure of effective 
utilization of resources. The latter refers to the use of assets employed in the business 
for the business and the rate of conversion of investment into income. 
In the preceding chapter, i.e. chapter 5 we have discussed the utility and importance of 
Return on Investment as a tool to measure the profitability. ROI consists of two 
factors  (i) the profit margin and (ii) the assets turnover. In the preceding chapter we 
have already discussed the profit margin and its effects on profitability, in this chapter 
we will discuss the second part i.e. the assets turnover and its impact on profitability. 
 
2. Asset Turnover 
Asset Turnover is the percentage of sales to capital employed, in other words Asset 
turnover refer to the percentage of investment got converted to sales. ROI is the factor 
of Profit margin and the Asset Turnover. Profit margin shows the operational 
efficiency while the Asset turnover represents productivity. By productivity we mean 
the conversion of input into output, here it means conversion of assets into sales. As 
success of any business unit can be measured by increase in profit and profit can only 
increase if the sales volume increases hence calculation of productivity is an important 
part of calculating the profitability of any company.  
Whenever there is a change in the ROI of any company it may be attributable to either 
volumes or margins. Either the profitability is increased or decreased due to increased 
or decreased margins or due to increased or decreased volumes. Different types of 
profit margin and their calculation we have studied in the chapter of profit margin. In 
this chapter we would like to emphasize on the second part i.e. Volumes. 
The response of volume of sale to the capital employed is basically what we mean as 
Asset turnover ratio.  
 
 Asset Turnover =    
    
Hence the second part of ROI is the asset turnover or in other words we can say that 
apart from the operating profit margin whatever factor which affects the ROI refers 
the asset turnover, i.e. Productivity. Turnover ratios which are also referred as activity 
ratios, shows the relationship between sales and the assets and judges the effective 
utilization of asset.  In an analysis of profitability to reason the decreased productivity 
various further ratios can be calculated.  
3. Assets Turnover Ratios 
Assets turnover is calculated by dividing sales by capital employed. Now further 
analysis of assets turnover can be done by classifying the assets into different other 
categories. Total assets are made up of two types of assets on the basis of its nature, 
i.e. fixed assets and current assets. Once again current assets consists items like 
Debtors, Cash, Inventory, etc. Another major classification can be done of the total 
assets from the view point of its type, i.e. operating assets and non-operating assets. 
We shall discuss each of the above turnover ratios and calculate the same for all the 
selected companies under study. 
 
            Sales 
Capital Employed  
 4. Calculation of Total Assets Turnover Ratio of 
sample  units 
This ratio indicates the amount of sales generated from the use of total assets 
employed in the business. This ratio shows the overall picture of productivity in terms 
of revenue. Any profitability analysis would not be complete without making a total 
assets turnover ratio analysis. A high asset turnover ratio indicates efficient 
management and thus higher the ratio more efficient is the operation in the terms of 
conversion of total assets into sales or income. One more important area of importance 
here is the proportion of fixed as well as the non-fixed asset in the total assets. As such 
this ratio tries to evaluate the amount of sales with reference to the total assets, in 
order to make a detailed analysis of the exact impact of asset on revenue generation; 
we need to study the fixed asset turnover ratio as well as the current asset turnover 
ratio. Total Assets Turnover ratio can be calculated as under: 
 
 
Total Assets Turnover =  
 
 
 
 
 
 
 
 
 
 
 
 
  Net Sales 
Total Assets 
Table : 6.1:  
Table Showing Total Assets Turnover Ratio in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05  
[All amounts = Rs. in Crores] 
Company 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
AurobindoSales 295.31 550.03 739.9 972.52 1007.96 1180.33 1334.83 1153.43 
Total Assets 140.91 235.69 360.62 502.32 708.63 1058.86 1374.77 1617.71 
Turnover(times) 2.10 2.33 2.05 1.94 1.42 1.11 0.97 0.71 
  
        
Cadila - Sales 303.58 358.4 475.7 502.3 581.7 1005.2 1116 1125.3 
Total Assets 145.85 228.3 737.44 596.7 818.4 904.1 945.2 985.9 
Turnover(times) 2.08 1.57 0.65 0.84 0.71 1.11 1.18 1.14 
  
        
Cipla - Sales 514.43 617.16 759.75 1047.51 1385.84 1549.79 1974.63 2327.63 
Total Assets 382.92 496.02 595.09 748.69 924.03 1164.86 1474.63 1748.67 
Turnover(times) 1.34 1.24 1.28 1.40 1.50 1.33 1.34 1.33 
  
        
DrReddy- Sales 331.62 425.86 493.02 984.11 1557.78 1598.32 1740.2 1625.08 
Total Assets 401.74 494.86 609.82 928.63 1471.81 1835.68 2105.24 2347.32 
Turnover(times) 0.83 0.86 0.81 1.06 1.06 0.87 0.83 0.69 
  
        
IPCA - Sales 282.74 335.66 363.31 385.38 444.18 506.51 649.32 721.74 
Total Assets 228.11 252.61 272.25 334.63 301.61 342.09 430.33 558.33 
Turnover(times) 1.24 1.33 1.33 1.15 1.47 1.48 1.51 1.29 
  
        
Matrix - Sales 27.51 40.73 45.19 60.78 102.18 416.93 556.86 671.69 
Total Assets 21.53 29.61 22.77 27.07 40.49 232.24 385.69 669.42 
Turnover(times) 1.28 1.38 1.98 2.25 2.52 1.80 1.44 1.00 
  
        
N.Piram.-Sales 534.64 429.99 486.48 566.76 946.48 1136.13 1434.66 1384.68 
Total Assets 673.6 425.16 480.04 517.06 621.47 663.13 781.3 899.78 
Turnover(times) 0.79 1.01 1.01 1.10 1.52 1.71 1.84 1.54 
  
        
Sun - Sales 279.77 358.11 478.35 613.78 753.1 864.65 998.16 1263.86 
Total Assets 263.12 383.38 412.86 501.04 535.79 705.46 1171.82 2920.1 
Turnover(times) 1.06 0.93 1.16 1.23 1.41 1.23 0.85 0.43 
  
                
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
Table 6.1 provides information about Total Assets Turnover Ratio(TATR). This ratio 
implies the amount of sales generated by the use of total assets. In other words, how 
much sales revenue company could generate by using total assets. The ratio has been 
calculated for the study period from 1997-98 to 2004-05. 
 TATR of Aurobindo Pharma shows a continuous downward trend. The TATR varies 
from 2.33 (in the year 1998-99) to 0.71 (in the year 2004-05) with an average of 1.58. 
The overall average of TATR for all the companies under study for the same study 
period is worked out at 1.30. Hence although a continuous down trend but the average 
TATR of Aurobindo Pharma is better than the industry average for the same period. 
Sales of Aurobindo Pharma during the study period has shown a steady increasing 
trend , but the investment was much more than the increase in sales, hence the 
increase in sales has been offset by higher increase in investment which resulted 
ultimately in declining TATR. Even sales shown a decline in the last year of the study 
hence the TATR came to the 8 year low value. 
 
TATR of Cadila Healthcare shows a mixed trend in the ratio. There is no specific 
movement in this company. TATR varies from 2.08 (1997-98) to 0.65(1999-2000) 
with an average of 1.16. It is interesting to note that its average for the study period 
i.e. 1.16 is closer to the least value 0.65 (1999-2000). The highest value is much 
higher in the base year if it is compared with all the other years of the study period. 
The highest TATR of the base year is not able to uplift overall average of the 
company for the study period and ultimately average TATR of Cadila is 1.16 which is 
lower than the average TATR of the selected eight companies which is 1.30. 
 
 
Cipla Ltd. is showing quiet an impressive trend for the TATR as although there is no 
particular trend of this ratio in the study period but the ratio is quiet consistent. This 
shows the equal weightage of increase in investments along with increase in sales. The 
value of TATR for all the years is very close to the average of 1.35. Although it varies 
from 1.50 (2001-02) to 1.24 (1998-99) but the variation is quiet normal looking to the 
time period of eight years. This is an indicator of highest level of efficiency of the 
company to maintain the same rate of revenue even at increased investments. The 
shareholders can be rest assured for the returns as the company has the habit of 
earning uniform rate of revenues on its total investments. 
 
Dr. Reddy’s Laboratories Ltd. is also fairly consistent on TATR. Except the extra fall 
in the ratio in the last year of period (2004-05) the ratio is around and above the 
average 0.88. TATR varies from 1.06 in (2000-01, 2001-02) to 0.69 in the last year. 
Although the average for the study period 0.88 is quite lower than the overall average 
of 1.30 but there is not doubt in the consistent performance of the company as far as 
generating revenues are concerned. It is interesting to note that the sales almost 
doubled in the year 2000-01 compared to its previous year and that made the TATR to 
reach to its eight year high of 1.06 , the company maintained the ratio for the next year 
but could not cope up to increase the sales with the increase in assets and TATR 
showed a significant decline in the year 2002-03 to 0.87. Since then it has shown a 
declining trend. 
 
IPCA Laboratories Ltd. has shown a positive growth in the study period in TATR. 
Fairly consistent in the first three years of the study period but could not continue the 
momentum in the year 2000-01 and showed a eight year low TATR of 1.15 due to 
increased investment in that year. After that year the company has toiled hard to 
improve the figures of TATR with constant positive growth story again by reaching at 
eight year high of 1.51 but the last year 2004-05 was not that good for IPCA as well. 
TATR of IPCA varies from 1.51 (2003-04) to 1.15 (2000-01) with an average of 1.35 
which is very close to the overall average of 1.30. 
 
Matrix Laboratories had all the great going for the first five years with a continuous 
increase in TATR but the smooth ride was not continued due to some short fall of 
revenues compared to huge investments in the year 2002-03. The heavy investments 
did not turn out to be very profitable for the company as after that year of huge 
investments the company has shown a constant downfall in the TATR, which shows 
that company could not meet its own expectations. Its like the entire study period can 
be divided into two parts: One before huge investments with a continuous increasing 
trend of TATR and second of from the year of heavy investments which showed a 
constant decline in the TATR. The TATR of Matrix Laboratories varies from 2.52 
(2001-02) to 1.00 (2004-05). Again the lowest TATR is recorded in the last year of 
the study period. The average TATR of this company 1.71 is higher than that of the 
overall average of 1.30 but seems to go down in the couple of years if proper steps are 
not taken! 
Nicholas Piramal has got a very clear increasing trend of TATR from the start of the 
study period until the year 2003-04 but like some of the other companies of the study 
it could not continue this increasing trend in the last year of the period and showed a 
little decline in the last year i.e. 2004-05. TATR for Nicholas Piramal varies from 1.84 
(2003-04) to 0.79 (1997-98) with an average of 1.32 which is very close to the overall 
average of 1.30. 
Sun Pharmaceutical Ltd has got a story which is almost similar to that of Matrix 
Laboratories. Starting from the first year of the study period it has shown a relatively 
increasing trend of TATR but in the year 2002-03 it could not increase its revenue in 
response to the increased investments. Although the investments were not too huge 
like that of Matrix and hence the fall is also lesser but has happened in the same time 
period. And once again Sun has joined the club of least in the last year, as the least 
TATR is observed in the last year 2004-05. The TATR varies from 1.41 (2001-02) to 
0.43 (2004-05) with an average of 1.04 which is lower than 1.30 overall averages. 
 
Out of eight companies four companies has more or less similar trend of positive 
growth from 1997-98 to 2001-02 and then sudden start of downtrend of TATR from 
2002-03 and therefore it is reflected in the overall TATR of all the selected 
companies. The increasing trend ended at the eight year high of 1.45 (2001-02) and 
the decreasing trend brought the ratio to the bottom i.e. 1.02 in the last year of the 
study. The overall average is 1.30 which is lower than average of five companies and 
higher than three companies under study.   
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Total Assets Turnover among different 
Pharmaceutical companies under study during the study period and for establishing 
relationship in the ratio of Total Assets Turnover among different years for each 
(individual) company, F-Test ANOVA is used. The statements of hypothesis for the 
comparison among different companies and for comparison among different years for 
individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Total Assets Turnover between different 
companies under study during the study period is same.” 
 Alternate Hypothesis (H1):-  “The ratio of Total Assets Turnover between different 
companies under study during the study period is not 
same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Total Assets Turnover between different 
years during the study period in each company under 
study is same.” 
Alternate Hypothesis (H1):-  “The ratio of Total Assets Turnover between different 
years during the study period in each company under 
study is not same.” 
 
In the following Table 6.1(a) the calculation of F Test (ANOVA) is shown of Total 
Assets Turnover ratio for the Pharmaceutical Companies under study, during the study 
period. 
 
Table :  6.1(a)                
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 4.136569811 0.590938544 4.108889818 
Between 
Years 7 0.912766224 0.130395175 0.906658419 
Error 49 7.047156279 0.143819516   
Total 63 12.09649231     
 
The above Table 6.1(a) shows the F value of 4.10 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of Total 
Assets Turnover . F value of 0.9 at 5% level of significance and at (7,49) degree of 
freedom is lower than the Table value of 2.16 hence null hypothesis is accepted and 
alternate hypothesis is rejected, which means that different years’ ratios for all the 
individual companies are same. 
 
Hence it can be concluded that the Total Assets Turnover Ratio among different 
companies under study are not same but the Total Assets Turnover ratio between 
different years of each company is same. 
5. Calculation of Fixed Assets Turnover Ratio of 
sample units 
 
The earlier ratio was a total ratio which measures the sales generated compared to the 
total investment made in fixed as well as non-fixed assets. While Fixed Assets 
Turnover ratio compares the sales with only the fixed assets. This ratio is much 
important in the sense that the major portion of investment is normally in the fixed 
part of the assets. And from Fixed Assets Turnover ratio only we can identify the 
effect of fixed assets on the total income. As such earlier ratio failed to quantify the 
positive or negative effect of fixed assets on the sales, this ratio clearly makes a 
distinction between the fixed assets and non-fixed assets in terms of their contribution 
towards income. More specific relationship can be established between the investment 
and return from this ratio with regard to the fixed assets. Fixed assets turnover ratio 
can be calculated as under: 
 
Fixed Assets Turnover =  
 
 
One important consideration in this regard is the stage of asset in the books of the 
company or the age of assets with the company. Here while calculating the ratio the 
fixed assets are taken after deducting depreciation and hence if the firm has more of 
old assets a the firm will have a higher fixed assets turnover ratio compared to the firm 
having comparatively newer assets and thus less depreciated. Hence this ratio cannot 
be blindly used for making the comparison between the two firms, but should be 
carefully analysed. 
Along with the Net Block, Capital Work-in-progress is also added to make the total 
fixed assets. Hence in the present study total fixed assets are taken as the sum of these 
two items. A high fixed assets turnover ratio reflects a positive situation wherein the 
fixed assets are efficiently utilized to generate revenue. In the situation of expansion 
of business this ratio can be quite effective as well as in the situation of decreasing 
revenue this ratio can provide a useful guideline for making effective decision 
 
 
 
 
 
 
 
         Sales  
    Fixed Assets 
Table: 6.2:  
Table Showing Fixed Assets Turnover Ratio in Pharmaceutical Companies under 
                                       Study Period: 1997-98 to 2004-05        [All amounts = Rs. in 
Crores] 
Company 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
Aurobindo-Sales 295.31 550.03 739.9 972.52 1007.96 1180.33 1334.83 1153.43 
Fixed Assets 54.68 90.7 133.9 171.46 226.03 413.77 584.6 771.28 
Turnover(times) 5.40 6.06 5.53 5.67 4.46 2.85 2.28 1.50 
  
        
Cadila - Sales 303.58 358.4 475.7 502.3 581.7 1005.2 1116 1125.3 
Fixed Assets 61.79 142.08 254.75 263.27 382.6 682.9 689.2 718.4 
Turnover(times) 4.91 2.52 1.87 1.91 1.52 1.47 1.62 1.57 
  
        
Cipla - Sales 514.43 617.16 759.75 1047.51 1385.84 1549.79 1974.63 2327.63 
Fixed Assets 122.49 144.89 161.75 188.12 299.43 399.88 603.57 844.87 
Turnover(times) 4.20 4.26 4.70 5.57 4.63 3.88 3.27 2.76 
  
        
DrReddy- Sales 331.62 425.86 493.02 984.11 1557.78 1598.32 1740.2 1625.08 
Fixed Assets 116.5 179.77 191.31 331.01 395.96 447.17 563.35 622.67 
Turnover(times) 2.85 2.37 2.58 2.97 3.93 3.57 3.09 2.61 
  
        
IPCA - Sales 282.74 335.66 363.31 385.38 444.18 506.51 649.32 721.74 
Fixed Assets 104.12 117.81 135.14 154.85 143.27 149.88 195.91 322.46 
Turnover(times) 2.72 2.85 2.69 2.49 3.10 3.38 3.31 2.24 
  
        
Matrix - Sales 27.51 40.73 45.19 60.78 102.18 416.93 556.86 671.69 
Fixed Assets 7.49 12.18 12.16 12.16 28.37 151.06 266.99 371.11 
Turnover(times) 3.67 3.34 3.72 5.00 3.60 2.76 2.09 1.81 
  
        
N.Piram.-Sales 534.64 429.99 486.48 566.76 946.48 1136.13 1434.66 1384.68 
Fixed Assets 475.09 164.81 213.85 227.61 296.53 315.39 530.06 687.93 
Turnover(times) 1.13 2.61 2.27 2.49 3.19 3.60 2.71 2.01 
  
        
Sun - Sales 279.77 358.11 478.35 613.78 753.1 864.65 998.16 1263.86 
Fixed Assets 110.5 164.73 182.91 205.46 249 301.71 393.26 487.09 
Turnover(times) 2.53 2.17 2.62 2.99 3.02 2.87 2.54 2.59 
Aurobindo Pharmaceuticals has shown a positive trend for its Fixed assets turnover 
ratio (FATR) in the initial years but declined quite sharply in the latter stage of the 
period. As in the year 2002-03 there was inclusion of new fixed assets of 200 crore 
rupees but it could not be utilized for generating sales and sales increased by mere 180 
Crores thus could not continue with the ratio of 4 and above and hence it went down 
to 2.85. After this year it went on to decrease more and ended at the eight year low in 
the last year at 1.50 raising questions on the efficiency of the company with regard to 
utilization of its main assets – fixed assets. FATR lies between 6.06(98-99) and 
1.50(2004-05) with an average of 4.22 which is interestingly higher than the overall 
average of 3.10 which indicates that the initial higher FATR for the company helped 
the company to have a higher average.  
 
After showing a reasonable performance in the earlier stage of study period the FATR 
of Cadila Healthcare declined. The FATR for the company lies in between 4.91 
(1997-98) and 1.47(2002-03) with an average of 2.17 which is lower than the overall 
average of 3.10. There is no particular trend visible for the study period in this 
company. It can be termed as a mixed trend with many ups and downs. But overall 
cannot be termed as very efficient as far as utilization of fixed assets is concerned. 
One relative fine performance is observed in the year 2002-03 wherein company 
increased its fixed assets by 300 crores and managed to maintain its earlier ratio of 
1.5, but there is ample scope available for the company to improve its fixed capacity 
utilization. 
 
Cipla Ltd. is showing two trends in the entire study period. In the initial four years 
there is clear increasing trend and last four years are showing continuous declining 
trend. This trend is observed in other ratios as well for the same company. The highest 
FATR 5.57 
is observed in 2000-01 after that there is constant decline till the last year which is 
having the lowest FATR of 2.76. The average is 4.16 which is still much better than 
overall average of 3.10. This decline can cause a serious damage to the company if it 
is not rectified; even there are chances to decline further. 
There are no particular trends visible in the FATR of Dr. Reddy’s Laboratories Ltd. 
for the study period. The FATR lies between 3.93(2001-02) and 2.37(98-99) with an 
average of 3.00 which is close to overall average of 3.10. There is a constant 
increasing trend in the investment in the fixed assets and similar trend is observed in 
the sales trend except in the last year in spite of increase in the fixed assets the sales 
could not increase and decreased by 6.5%. And the year 2001-02 show a sharp 
increase in the sales by as high as 58% responding to mere 19% increase in the fixed 
assets. That was the year wherein the FATR was highest for the company in the study 
period. 
 
There is an almost increasing trend observed in the FATR for the IPCA Labs for the 
study period. The FATR lies between 3.38(2002-03) and 2.24(2004-05) with an 
average of 2.85 which is lower than the overall average of 3.10 for the study period. 
There is a constant increasing trend observed in the fixed assets as well as sales 
figures of the company for the study period. For the year 2001-02 the company’s 
efficiency was highest when the decrease in fixed assets was also not able to stop the 
growth the increase in sales of the company. And the next year also showed a sharp 
increase in the sales with a slight increase in fixed assets. 
Matrix Labs is also showing two trends for FATR in the study period. For the first 
four years it showed a positive trend which ended with a eight hear high at 5.00 but 
after that there was a constant negative trend observed which ended at the eight year 
low at 1.81. The negative trend started with the additional heavy investments done in 
the year 2002-03 of Rs. 125 crores more, this sudden major investment was not 
utilized and it resulted in negative trend implying company could not tackle the 
increased capacity and increased scale of business. The average FATR for the 
company is 3.25 which is slightly higher than the overall average 3.10. 
Nicholas Piramal is showing a mixed trend of FATR for the study period as there are 
no particular trends observed but a relatively increasing trend in the initial period and 
decreasing trend is observed in the latter stage of the study period. The FATR for the 
company lies between 3.19(2001-02) and 1.13(97-98) with an average of 2.50 which 
is quite low than the overall average of 3.10. The fixed assets were decreased in the 
second year after that there is a constant increase in the fixed assets with 
corresponding increase in sales. 
 
Sun Pharmaceuticals Ltd. is showing a mixed trend in the FATR for the study period. 
There is no particular trend observed for the FATR. It lies in between 3.02(2001-02) 
and 2.17(98-99) with an average of 2.67 which is lower compared to the overall 
average of 3.10. There is a constant increase in the trend of fixed assets as well as 
sales observed in the study period with no major fluctuations. The company can be 
considered as consistent in utilizing its fixed assets with a fairly uniform rate. 
Overall FATR for all the selected pharmaceutical companies under study has shown a 
pretty consistent trend with the highest 3.64 in the year 2000-01 and lowest 2.14 in the 
year 2004-05 with the average of 3.10. The overall performance can be considered as 
normal with Aurobindo and Cipla emerging out as better utilizers of Fixed Assets and 
Cadila not much efficient in the same. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Fixed Assets Turnover among different 
Pharmaceutical companies under study during the study period and for establishing 
relationship in the ratio of Fixed Assets Turnover among different years for each 
(individual) company, F-Test ANOVA is used. The statements of hypothesis for the 
comparison among different companies and for comparison among different years for 
individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Fixed Assets Turnover between different 
companies under study during the study period is same.” 
Alternate Hypothesis (H1):-  “The ratio of Fixed Assets Turnover between different 
companies under study during the study period is not 
same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Fixed Assets Turnover between different 
years during the study period in each company under 
study is same.” 
Alternate Hypothesis (H1):-  “The ratio of Fixed Assets Turnover between different 
years during the study period in each company under 
study is not same.” 
 
In the following Table 6.2(a) the calculation of F Test (ANOVA) is shown of Fixed 
Assets Turnover ratio for the Pharmaceutical Companies under study, during the study 
period. 
 
 
Table :  6.2(a)                
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 30.96604764 4.423721091 5.788066272 
Between 
Years 7 13.80046692 1.971495275 2.579535435 
Error 49 37.44987069 0.764283075   
Total 63 82.21638525     
 
 
The above Table 6.2(a) shows the F value of 5.79 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that the ratio of fixed 
assets turnover among different companies under the study is not same. F value of 
2.58 at 5% level of significance and at (7,49) degree of freedom is greater than the 
Table value of 2.16 hence null hypothesis is rejected and alternate hypothesis is 
accepted, which means that different years’ ratios for all the individual companies are 
not same. 
 
Hence it can be concluded that there is a the Fixed Assets Turnover Ratio among 
different companies under study is not same and the Fixed Assets Turnover ratio 
between different years of each company is also not same. 
 
 
 
 
6. Calculation of Current Assets Turnover Ratio of 
sample units 
Any study of figures mainly tries to find out the relationship between two related 
variables. Similarly here also our effort is to establish a relationship between two 
variables in order to establish some relationship between the two variables. Current 
assets turnover ratio is the ratio of sales to current assets, in other words how much 
sales has been generated compared to the current assets or the non-fixed assets. 
Current Assets refers to those assets which can be converted into cash within an 
accounting year and include Cash Balance, Bank Balance, Loans and Advances, 
Sundry Debtors (accounts receivables or book debts), Bills Receivables and Inventory. 
 
If there are situation of increased sales or the times of decreased sales and the 
financial analyst tries to locate the reasons for the same in the investment pattern and 
the changes in it, in that case this ratio would be very useful. As such this ratio gives a 
specific idea regarding the impact of current assets on sales or the amount of sales that 
could have been generated by employing the amount of current assets. This ratio is the 
indicator of utilization of current assets; higher the ratio better is the utilization done 
of the current assets of the firm. 
 
Current Assets Turnover =  
 
 
 
 
 
 
           Sales 
   Current Assets 
Table : 6.3:  
Table Showing Current Assets Turnover Ratio in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05  
[All amounts = Rs. in 
Crores]  
Company 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
  
                
AurobindoSales 295.31 550.03 739.9 972.52 1007.96 1180.33 1334.83 1153.43 
Current Assets 140.55 252.84 312.23 444.01 585.9 756.89 903.72 992.28 
Turnover(times) 2.10 2.18 2.37 2.19 1.72 1.56 1.48 1.16 
  
        
Cadila - Sales 303.58 358.4 475.7 502.3 581.7 1005.2 1116 1125.3 
CurrentAssets 126.44 135.28 570.8 252.19 396.8 404 433.5 466.3 
Turnover(times) 2.40 2.65 0.83 1.99 1.47 2.49 2.57 2.41 
  
        
Cipla - Sales 514.43 617.16 759.75 1047.51 1385.84 1549.79 1974.63 2327.63 
CurrentAssets 352.89 389.74 473.61 633.96 970.55 1291.1 1436.23 1752.89 
Turnover(times) 1.46 1.58 1.60 1.65 1.43 1.20 1.37 1.33 
  
        
DrReddy- Sales 331.62 425.86 493.02 984.11 1557.78 1598.32 1740.2 1625.08 
CurrentAssets 248.54 291.68 291.44 561.83 1256.04 1547.78 1321.63 1828.37 
Turnover(times) 1.33 1.46 1.69 1.75 1.24 1.03 1.32 0.89 
  
        
IPCA - Sales 282.74 335.66 363.31 385.38 444.18 506.51 649.32 721.74 
CurrentAssets 159.66 175.42 178.28 223.86 248.6 275.76 348.57 365.01 
Turnover(times) 1.77 1.91 2.04 1.72 1.79 1.84 1.86 1.98 
  
        
Matrix - Sales 27.51 40.73 45.19 60.78 102.18 416.93 556.86 671.69 
CurrentAssets 16.24 24.84 21.96 27.12 39.36 169.88 281.58 442.59 
Turnover(times) 1.69 1.64 2.06 2.24 2.60 2.45 1.98 1.52 
  
        
N.Piram.-Sales 534.64 429.99 486.48 566.76 946.48 1136.13 1434.66 1384.68 
CurrentAssets 304.72 255.48 268.94 336.63 443.42 535.45 530.06 550.09 
Turnover(times) 1.75 1.68 1.81 1.68 2.13 2.12 2.71 2.52 
  
        
Sun - Sales 279.77 358.11 478.35 613.78 753.1 864.65 998.16 1263.86 
CurrentAssets 154.91 225.26 248.19 324.02 325.88 486.92 480.63 1754.53 
Turnover(times) 1.81 1.59 1.93 1.89 2.31 1.78 2.08 0.72 
  
                
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
 
Aurobindo Pharma is showing two trends in its Current Assets Turnover Ratio 
(CATR) for the study period. In the first three years it is showing an increasing trend 
and clear decreasing trend in the last five years. The increasing trend is ending at the 
highest value of 2.37(1999-2000) and the last year of the study period (2004-05) has 
the lowest value of 1.16. The average of the study period for this company is 1.84 
which is almost same as the overall average of 1.81. There are no major fluctuations 
observed in the employment of current assets and sales hence it can be concluded that 
the down trend and its continuity can be a result of some sort of in-efficiency which is 
clearly visible from the year 2000-01 and onwards. 
 
Cadila Healthcare has high fluctuating ratios for the study period. There is no 
particular trend observed for the CATR for this company. It lies between 2.65(98-99) 
and 0.83(99-2000), with an average of 2.10 which is better than the overall average of 
1.81. There is a sudden decrease observed in the CATR for the year 99-2000 due to 
increase in the current assets in the form of term deposits with the bank which is 
making the CATR look dull, otherwise there is a normal movement observed in the 
ratio for the entire study period. 
 
Cipla Ltd. like in other ratios is very consistent in CATR for the study period. It lies 
between 1.65(2000-01) to 1.20(2002-03) with an average of 1.45 which is slightly low 
than the overall average of 1.81. The CATR for Cipla Ltd. can be considered as the 
most normal, almost without any sort of fluctuation in the ratios or current assets or 
sales. It has continued to employ the current assets as per requirement and got the 
sales with almost same percentage of current assets. 
 
Dr. Reddy’s Laboratories Ltd. is showing a clear increasing trend in the initial four 
years but then it declined a bit for the remaining four years. The CATR of the 
company for the study period lies in between 1.75(2000-01) and 0.89(2004-05) with 
an average of 1.34 which is slightly lower than the overall average of 1.81. There is an 
abnormal increase in the current assets observed in the year 2001-02 due to increase in 
term deposits with bank and debtors to those sales responded positively but could not 
respond to the required level and then the downfall started in the next years. 
 
There are not particular trends observed in the CATR of IPCA Labs for the study 
period. Initially for three years there was a positive trend but then there was no 
definite trend observed. The CATR lies between 2.04(1999-2000) and 1.72(2000-01) 
with the average of 1.86 which is close to the overall average 1.81 for the study 
period. There are no major fluctuations observed in the current assets and sales figures 
of the company for the study period. 
 
Matrix Labs is showing two trends in the CATR for the study period. It is showing a 
clear increasing trend in the initial five years and then there is a mixed decreasing 
trend observed. The CATR of the company for the study period lies between 
2.60(2001-02) and 1.52(2004-05) with an average of 2.02 which is higher than the 
overall average of 1.81 for the same study period. A major investment in current 
assets is observed in the year 2002-03 which was nicely responded by sales but then 
later on the momentum was not maintained and ultimately declining trend was 
observed for the last three years. 
 
 
Nicholas Piramal is showing a fluctuating trend in the CATR for the study period. It 
lies in between 2.71(2003-04) 1.68(98-99) with an average of 2.05 which is higher 
than overall average 1.81 for the same study period. There are some fluctuations 
observed in the employment of current assets and as expected the sales has responded 
to such fluctuations in the same manner. 
 
Sun Pharmaceuticals is having no particular trend in its CATR as it lies between 2.31 
(2001-02) and 0.72(2004-05) with an average of 1.76 which is almost near to the 
overall average 1.81 for the study period. There is a clear increasing trend observed in 
the employment of current assets for the study period and sales has responded in the 
similar manner by increasing continuously in the study period. 
 
The overall trend for all the eight companies for the study period is showing a steady 
and constant trend with a slightly increasing effect. It lies between 1.92(2003-04) and 
1.57 (2004-05) with an overall average of 1.81. It can be generally observed that 
majority of companies are showing some positive trend in the initial period of the 
study and then there are some downtrend observed in the last part of the study period. 
 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Current Asset Turnover Ratio among 
different Pharmaceutical companies under study during the study period and for 
establishing relationship in the ratio of Current Asset Turnover Ratio among different 
years for each (individual) company, F-Test ANOVA is used. The statements of 
hypothesis for the comparison among different companies and for comparison among 
different years for individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Current Asset Turnover between different 
companies under study during the study period is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of Current Asset Turnover between different 
companies under study during the study period is not 
same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Current Asset Turnover between different 
years during the study period in each company under 
study is same.” 
Alternate Hypothesis (H1):-  “The ratio of Current Asset Turnover between different 
years during the study period in each company under 
study is not same.” 
In the following Table 6.3(a) the calculation of F Test (ANOVA) is shown of Current 
Asset Turnover ratio for the Pharmaceutical Companies under study, during the study 
period. 
Table : 6.3(a)                
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 4.344781153 0.620683022 3.761600195 
Between 
Years 7 0.643634331 0.091947762 0.557242111 
Error 49 8.085247367 0.165005048   
Total 63 13.07366285     
 
The above Table 6.3(a) shows the F value of 3.76 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that the ratio of 
Current Asset Turnover among different companies is not same. F value of 0.56 at 5% 
level of significance and at (7,49) degree of freedom is lower than the Table value of 
2.16 hence null hypothesis is accepted and alternate hypothesis is rejected, which 
means that different years’ ratios for all the individual companies. 
 
Hence it can be concluded that in the Current Asset Turnover Ratio among different 
companies there are no similarities under study but the Current Asset Turnover ratio 
between different years of each company are same. 
 
 
 
7. Calculation of Working Capital Turnover Ratio of 
 sample units 
 
Earlier calculation was based on short term assets or current assets but like short term 
assets there are short term liabilities also, which are referred as current liabilities. 
Current liabilities are those claims of outsiders which are expected to mature for 
payment within an accounting year and include Creditors (accounts payable), Bills 
Payables, and Outstanding Expenses. If the Current Liabilities are deducted from 
Current Assets the resultant can be termed as Working Capital.  
 
Working capital has got a very interesting relationship with profit. Sufficient working 
capital is required for smooth sales and smooth sales will result in maintenance and 
increase in sales which will ultimately result in increased and sustained profits for the 
firm. Working capital can be both positive as well as negative. When the current 
assets are more than current liabilities, working capital will be positive and if the 
current liabilities are more than current assets, working capital will be negative. In this 
ratio we are trying to establish relationship between working capital and sales. If 
working capital is the factor affecting sales, then sales can be increased by increasing 
working capital. In other words we are trying to observe the relationship between 
working capital and sales and find out the degree of effect of increasing working 
capital on sales. 
Working Capital Turnover =   
 
 
In the table 6.4 Working Capital turnover ratios are calculated for the study period 
fore pharmaceutical companies under study: 
 
 
 
 
 
 
 
 
 
 
 
         Sales 
Working Capital 
Table : 6.4:  
Table Showing Working Capital Turnover Ratio in Pharmaceutical Companies under  
Study Period: 1997-98 to 2004-05 [All amounts = Rs. in Crores]  
 
Particulars 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
Aurobindo-Sale 295.31 550.03 739.9 972.52 1007.96 1180.33 1334.83 1153.43 
WorkingCapital 84.55 142.83 224.31 307.1 430.33 528.73 693.38 751.14 
Turnover(times) 3.49 3.85 3.30 3.17 2.34 2.23 1.93 1.54 
  
        
Cadila - Sales 303.58 358.4 475.7 502.3 581.7 1005.2 1116 1125.3 
WorkingCapital 79.45 74.82 457.54 155.63 286.5 200.7 200.5 224.4 
Turnover(times) 3.82 4.79 1.04 3.23 2.03 5.01 5.57 5.01 
  
        
Cipla - Sales 514.43 617.16 759.75 1047.51 1385.84 1549.79 1974.63 2327.63 
WorkingCapital 187.18 210.36 238.05 338.35 520.46 694.49 756.64 974.45 
Turnover(times) 2.75 2.93 3.19 3.10 2.66 2.23 2.61 2.39 
  
        
DrReddy- Sales 331.62 425.86 493.02 984.11 1557.78 1598.32 1740.2 1625.08 
WorkingCapital 195.29 211.54 223.4 424.08 1055.41 1274.21 972.1 1387.35 
Turnover(times) 1.70 2.01 2.21 2.32 1.48 1.25 1.79 1.17 
  
        
IPCA - Sales 282.74 335.66 363.31 385.38 444.18 506.51 649.32 721.74 
WorkingCapital 117.09 128.52 135.01 177.67 179.95 210.11 248.27 268.52 
Turnover(times) 2.41 2.61 2.69 2.17 2.47 2.41 2.62 2.69 
  
        
Matrix - Sales 27.51 40.73 45.19 60.78 102.18 416.93 556.86 671.69 
WorkingCapital 12.36 15.78 9.01 13.27 13.78 91.77 143.61 156.34 
Turnover(times) 2.23 2.58 5.02 4.58 7.42 4.54 3.88 4.30 
  
        
N.Piram.-Sales 534.64 429.99 486.48 566.76 946.48 1136.13 1434.66 1384.68 
WorkingCapital 167.16 168.77 168 187.13 242.5 327.86 263.27 244.55 
Turnover(times) 3.20 2.55 2.90 3.03 3.90 3.47 5.45 5.66 
  
        
Sun - Sales 279.77 358.11 478.35 613.78 753.1 864.65 998.16 1263.86 
WorkingCapital 102.29 155.62 179.83 238.39 230.55 349.87 293.69 1533.07 
Turnover(times) 2.74 2.30 2.66 2.57 3.27 2.47 3.40 0.82 
  
        
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
The above table number 6.4shows the calculation of working capital turnover 
ratio(WCTR). This is another ratio calculating the efficiency of a company with 
regard to use of its resources and converting them into revenues. The ratio is an 
indicator of how much sales is generated on an amount of working capital.  
 
The WCTR of Aurobindo Pharma lies between 3.85 (1998-99) and 1.54 (2004-05). 
Except in the second year there is continuously declining trend in the WCTR of this 
company. This can be an indicator of decreasing efficiency of working capital to 
generate sales. The average WCTR of this company for the study period is 2.73 which 
is lower than 3.02 overall average of all the companies for the entire study period. 
Although the decline is normal in all the years, there is a sharp fall in the year 2001-02 
as it was 2.34 in the year 2001-02 compared to 3.17 in the earlier year 2000-01. 
 
Cadila Healthcare shows a fluctuating trend for its WCTR for the study period. There 
are no particular trends observed for the company, the ratio lies between 5.57 (2003-
04) and 1.04 (1999-2000). The average ratio for the company for the study period is 
3.81 which is higher than the overall average 3.02 of all the companies for the study 
period. There is no consistency observed in the ratio which shows the un-predictable 
ability of company to use its resources.  
 
Cipla Ltd. shows a mixed trend of WCTR for the study period. For the initial period of 
3 years the company has shown an increasing trend of ratio while there is negative 
trend observed for the next three years. Hence although its not too fluctuating but it’s 
a mixed trend. The WCTR of the company lies in between 3.19(1999-2000) and 
2.23(2002-03) with an average of 2.73 which is quite low than the overall average 
3.02 of all the companies under study. Although there are no high ratios in this 
company but it is fairly consistent and reliable as there is not much difference in the 
highest and lowest value of WCTR for the study period.  
 
Dr. Reddy’s Laboratories Ltd. is showing two clear trend of WCTR for the study 
period. It is a clear increasing trend for the first four years and decreasing trend for the 
last four years. The ratio varies between 2.32(2000-01) and 1.17 (2004-05). The 
company has to remain vigilant in the coming years if the ratio declines in the similar 
patter, especially its eight year high is not much impressive. The average ratio for the 
company is 1.74 which is very low compared to the overall average of  3.02 hence as 
far as WCTR is concerned it is respectfully submitted that this company is not able to 
utilize its resources in efficient way. 
 
IPCA has partly consistent trend for the WCTR in the study period. The ratio varies 
from 2.69 to 2.41, but the most interesting part is in the latter stage of the study period 
it has shown a positive trend which is quite opposite to what is observed in other 
companies in the study. Also the ratio has never been lower than 2.41 and this value is 
too close to 2.69 the highest value is suggesting the consistency of the company. 
Hence to a certain extent we can observe the part consistent trend for the company. 
The average ratio is 2.51 which is lower than overall average 3.02 but seems to be 
very promising in the coming years as there is a consistent increasing trend observed. 
Matrix Laboratories is showing a fairly fluctuating trend for the study period in the 
calculation of WCTR, as its high is as high as 7.42 (2001-02) and low is very low 2.23 
(1997-98). The high ratio can be due to a huge 70% increase in sales in the year 2001-
02 without much increase in working capital; this cannot be considered as a true 
picture of efficient utilization of working capital. There could be several other reasons 
which might have influenced a sudden increase in sales. Except that abnormal 
increase company has made reasonable progress in its utilization of working capital to 
generate revenues. Its average is 4.32 which is much higher than overall average of 
3.02 but this high average is due to the abnormal increase in the ratio in the year 2001-
02. 
 
Nicholas Piramal is the only company among all the companies under study which is 
showing a clear positive trend in the entire study period. It has its eight year low in 
second year 2.55 (1998-99) and eight year high in the last year 5.66 (2004-05) this 
shows that in the winds of downtrend of other companies this company is standing tall 
and continuing its increasing trend in the WCTR. Expectedly its average 3.77 is 
higher than the overall average of 3.02. But the analysis would be incomplete if we 
are not observing the figures of sales and working capital. There is a downtrend in the 
sales of initial two year after base year and then there is a constant increasing trend 
with a decrease in sales in the last year [Table 4.7], and even working capital as 
decreased in the last year. It is interesting findings that decrease in working capital led 
to decrease in sales but the ratio has managed to remain constant. This could be 
leading us to believe that there is a high degree of relationship between working 
capital and sales revenues. 
 
The WCTR for the Sun Pharmaceuticals is the most fluctuating one as it increases in 
one year and decreases in the second year and continues to move in the same manner 
in the study period. The ratio decreased for four times in the entire study period and 
increased for three times in the study period which depicts that there is a high amount 
of fluctuation. The ratio lies between 3.27 (2001-02) and 0.82 (2004-05) and the 
amount of fluctuation is also visible in the difference between the highest value and 
the lowest value. Its average 2.53 is lower than the overall average of 3.02. If we try to 
analyze this fluctuating nature of WCTR then we can observe that sales trends have no 
fluctuations as there is a clear increasing trend observed in the sale of Sun 
Pharmaceuticals in the study period [Table 4.7] but there is a huge amount of 
fluctuation seen in the working capital for the study period. Working capital decreased 
for the first time in the year 2001-02 which resulted in the highest WCTR and 
working capital abnormally increased by 450% which is abnormal by any means 
which lead to a sudden decline in the WCTR to its eight year low of 0.82. The 
abnormal increase of 450% of working capital is due to increase in loans given to 
others and term deposits with bank. Hence huge fluctuations are more present in the 
ratio of this company. 
 
A small increasing trend is observed in the overall WCTR for the selected companies 
and the minimum is at the beginning 2.79 (97-98) and highest is at the end 3.40 (2003-
04) which consolidates the positive trend of WCTR in the selected pharmaceutical 
companies under study for the eight year study period. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Working Capital Turnover Ratio 
among different Pharmaceutical companies under study during the study period and 
for establishing relationship in the ratio of Working Capital Turnover Ratio among 
different years for each (individual) company, F-Test ANOVA is used. The statements 
of hypothesis for the comparison among different companies and for comparison 
among different years for individual companies during the study period are as under: 
 Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Working Capital Turnover between 
different companies under study during the study period 
is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of Working Capital Turnover between 
different companies under study during the study period 
is same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Working Capital Turnover between 
different years during the study period in each company 
under study is same.” 
Alternate Hypothesis (H1):-  “The ratio of Working Capital Turnover between 
different years during the study period in each company 
under study is not same.” 
 
In the following Table 6.4(a) the calculation of F Test (ANOVA) is shown of 
Working Capital Turnover ratio for the Pharmaceutical Companies under study, 
during the study period. 
 
 
 
 
Table : 6.4(a)                
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 41.39264519 5.913235028 5.28481192 
Between 
Years 7 2.124981094 0.303568728 0.271307266 
Error 49 54.82664676 1.118911158   
Total 63 98.34427305     
 
The above Table 6.4(a) shows the F value of 5.28 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there is a 
significant difference among the different companies under study in the ratio of 
Working Capital Turnover. F value of 0.27 at 5% level of significance and at (7,49) 
degree of freedom is lower than the Table value of 2.16 hence null hypothesis is 
accepted and alternate hypothesis is rejected, which means that there is no significant 
difference between different years’ ratios for all the individual companies. 
 
Hence it can be concluded that there is a significant difference in the Working Capital 
Turnover Ratio among different companies under study but there is no significant 
difference in the Working Capital Turnover ratio between different years of each 
company. 
 
 
 
 
8. Calculation of Inventory Turnover Ratio of sample 
 units 
 
The Inventory turnover ratio measures the speed with which inventory is converted 
into sales for the firm. It reflects the efficiency of the firm’s inventory management. 
Inventory refers to stock of goods with the company; it includes Raw Material, Work-
in-progress, Finished Goods, Stores, Spares, Packing Materials, Good-in-transit, Other 
Inventory, etc.   
 
Inventory Turnover ratio refers to number of times that inventory has been sold during 
the year. Generally a high inventory turnover is an indicator of good inventory 
management, which means that the funds are not un-necessarily blocked in inventory 
but the inventory got quickly converted to sales and hence efficiently managed. For 
maintaining proper levels of inventory it is required to estimate the exact requirement 
of inventory as well as the speed with which it will be utilized and the time required 
for receiving the fresh inventory. Efficient management of inventory also requires a 
good skill set from the manager as such he has to maintain a balance between the 
minimum requirement of stock and maximum stock which can be stocked. Higher 
levels of inventory leads to blockage of funds and thus less profitability while lower 
levels of inventory helps maintain the profitability but there is always a risk of stock 
out situation. For smooth sales enough inventory levels are like compulsion. A high 
inventory turnover ratio can also mean there is a shortage of inventory. A low 
turnover may indicate overstocking or obsolete inventory.  
Inventory Turnover =  
 
 
   Cost of Goods Sold 
          Inventory 
Table : 6.5:  
Table showing Inventory Turnover Ratio in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05 [All amounts = Rs. in Crores]  
Company 97-98 98-99 99-00 2000-01 2001-02 2002-03 2003-04 2004-05 
AurobindoCOGS 256.16 508.56 614.1 952.92 874.9 1059.18 1167.29 1039.68 
Inventory 47.23 81.23 99.92 172.99 125.46 203.52 259.64 323.58 
ITR 5.42 6.26 6.15 5.51 6.97 5.20 4.50 3.21 
          
Cadila-COGS 242.91 319.5 386.44 433.8 510.28 848.15 913.5 985.2 
Inventory 47.68 62.6 70.7 83.74 105.7 175.6 160.3 193.9 
ITR 5.09 5.10 5.47 5.18 4.83 4.83 5.70 5.08 
          
Cipla-COGS 429.1 459.65 660.66 895.07 1248.19 1395.89 1569.38 1997.54 
Inventory 147.9 158.42 212.2 275.36 396.28 589.23 568.94 745.68 
ITR 2.90 2.90 3.11 3.25 3.15 2.37 2.76 2.68 
          
Dr.Reddy-COGS 240.13 343.69 376.93 767.46 991.51 1153.38 1384.64 1476.68 
Inventory 55.7 73.98 69.83 157.61 189.81 240.11 258.01 303.81 
ITR 4.31 4.65 5.40 4.87 5.22 4.80 5.37 4.86 
          
IPCA-COGS 265.67 297.09 329.54 368.55 386.54 415.7 578.89 645.48 
Inventory 73.71 81.65 70.13 90.2 96.31 102.72 150.22 173.87 
ITR 3.60 3.64 4.70 4.09 4.01 4.05 3.85 3.71 
          
Matrix-COGS 26.1 39.31 51.34 65.34 105.94 277.92 470.53 514.42 
Inventory 8.15 15.85 16.47 15.27 25.16 70.07 125.11 171.01 
ITR 3.20 2.48 3.12 4.28 4.21 3.97 3.76 3.01 
          
Npirmala-COGS 417.51 345.62 422.18 468.25 728.75 965.01 1193.15 1317.61 
Inventory 89.48 66.99 86.75 100.06 147.47 170.23 195.59 274.67 
ITR 4.67 5.16 4.87 4.68 4.94 5.67 6.10 4.80 
          
Sun-COGS 203.29 284.07 366.28 529.44 505.6 605.25 713.2 900.29 
Inventory 50.99 50.1 72.38 147.97 131.05 155.62 161.45 186.62 
ITR 3.99 5.67 5.06 3.58 3.86 3.89 4.42 4.82 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
The Inventory Turnover Ratio (ITR) for the Aurobindo Pharma is showing a mixed 
trend for the study period. It lies between 6.97 (2001-02) and 3.21 (2004-05) with an 
average of 5.40 which is quite higher than the overall average 4.45 of all the 
companies under study for the study period. There is positive trend of inventory in the 
entire study period but in the year 2001-02 there was a 28% decrease in inventory 
which was accompanied by 8% decrease in Cost of goods sold which ultimately 
resulted in improvement of the ITR while as in the last year 2004-05 the 24% increase 
in inventory was accompanied by 12% decrease in cost of goods sold which led to 
tremendous decrease in ITR.  
 
The ITR of Cadila Healthcare shows an average consistent trend with decrease in just 
two years in the study period. It lies between 5.70 (2003-04) and 4.83(2001-02 and 
2002-03) with an average of 5.16 which is quiet higher than the overall average of 
4.45. Hence this company is performing better and consistently. Although the increase 
in inventory in the year 2001-02 was responded by equal increase in Cost of goods 
sold but the increase was not enough to maintain the ratio. There is constant positive 
trend observed in both inventory levels and the Cost of goods sold for the entire study 
period which is the reason for the consistent ITR for the study period of Cadila 
Healthcare Ltd. 
 
Cipla Ltd is once again consistent performer although its ratio declined in the latter 
years but on the average it stands as a semi consistent performer as far as ITR is 
concerned. ITR lies between 3.25(2000-01) and 2.37 (2002-03) with an average of 
2.89 which is very low compared to the overall average of 4.45 for the study period. 
Except for the year 2003-04 in all the years the inventory levels have shown a steady 
increasing trend and there is a constant increasing trend in the cost of goods sold for 
the company in the study period. This has lead to a semi consistent performance by 
the company. By the standards of other companies in the study, Cipla is under-
performer in this criteria which is hampering its liquidity as well. It is taking more 
time compared to other companies in converting its inventories to sales.  
 
Dr. Reddy’s Laboratories Ltd. shows a relatively mixed trend but quite higher ITR. It 
lies between 5.40 (1999-2000) and 4.31(1997-98), although there is a significant 
difference between the highest and lowest value but comparatively both show an 
impressive performance of the company with regard to the turnover of inventory. The 
average for the company is 4.93 for the study period which is near to the overall 
average of all the companies 4.45 for the study period. There is a constant positive 
trend visible in the inventory levels for the company for the study period and similar 
positive increasing trend is observed for the Cost of goods sold figures. 
 
IPCA Laboratories a normal trend of ITR in the study period, except one major 
fluctuation in the year 1999-2000 which was due to decrease in inventory and increase 
in sales, which showed the positive picture. ITR for the study period lies in between 
4.70 (1999-2000) and 3.60(1997-98) and the average of ITR of IPCA for the study 
period works out to be 3.96 which is quite lower than the overall average of all the 
companies for the study period. 
 
 
Matrix shows a huge amount of fluctuation in the ITR calculation for the study period 
which is visible from the difference between it’s high and low ratio in the study 
period. ITR lies between 4.28(2000-01) and 2.48 (98-99) and the average of the ITR 
for the company is 3.50 which is quite low than the overall average of 4.45. There has 
been a significant increase in scale of production in the year 2003-04 as we can 
observe a 80% increase in inventory levels and 70% increase in sales, it is interesting 
to conclude that in spite of such a huge increase in both the items the company has 
managed to maintain the relationship between them, which is a good sign for the 
inventory management. 
  
Nicholas Piramal has shown a very fine performance as far as inventory turnover ratio 
is concerned and it is pretty consistent also. There are no particular trends visible in 
the ITR of the company for the study period but it has managed to maintain the rate 
close to 5.00 which can be considered as an achievement as the overall average is 
below 4.50 for the study period. Its eight year high is 6.10 (2003-04) and eight year 
low is 4.67 (1997-98) this shows that in the recent times company is doing well and 
expected to do well in the coming times as well. Its average is 5.11 which is well 
above overall average of 4.45 for the study period. 
 
Sun Pharmaceuticals seems to be trying hard to improve its ITR and has remained 
successful on couple of occasions where it managed to move above 5.00 but could not 
consistently perform which brought its average 4.41 which is although very close to 
the overall average of 4.45 for the study period. It lies in between 5.67(98-99) and 
3.58 (00-01) and shows increasing trend in inventory levels and cost of goods sold. 
No major fluctuations are observed in the group figures for the all eight years of study 
period as the ITR lies in between 4.73(99-2000) and 4.02 (2004-05) and the overall 
average is 4.45 which is very good representative of all the companies. 
 
 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Inventory Turnover Ratio among 
different Pharmaceutical companies under study during the study period and for 
establishing relationship in the ratio of Inventory Turnover Ratio among different 
years for each (individual) company, F-Test ANOVA is used. The statements of 
hypothesis for the comparison among different companies and for comparison among 
different years for individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Inventory Turnover between different 
companies under study during the study period is same.” 
Alternate Hypothesis (H1):-  “The ratio of Inventory Turnover between different 
companies under study during the study period is not 
same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Inventory Turnover between different 
years during the study period in each company under 
study is same.” 
Alternate Hypothesis (H1):-  “The ratio of Inventory Turnover between different 
years during the study period in each company under 
study is not same.” 
 
In the following Table 6.5(a) the calculation of F Test (ANOVA) is shown of 
Inventory Turnover ratio for the Pharmaceutical Companies under study, during the 
study period. 
Table : 6.5(a)                
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 53.55958191 7.651368844 13.73177913 
Between 
Years 7 3.795525884 0.542217983 0.973109223 
Error 49 27.30287676 0.557201567   
Total 63 84.65798456     
 
The above Table 6.5(a) shows the F value of 13.73 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is greater than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that among the 
different companies under study in the ratio of Inventory Turnover is not same. F 
value of 0.97 at 5% level of significance and at (7,49) degree of freedom is lower than 
the Table value of 2.16 hence null hypothesis is accepted and alternate hypothesis is 
rejected, which means that different years’ ratios for all the individual companies are 
same. 
 
Hence it can be concluded that the Inventory Turnover Ratio among different 
companies under study are not same but the Inventory Turnover ratio between 
different years of each company are same. 
 
 
9. Calculation of Debtors Turnover Ratio of sample 
units 
 
A company’s liquidity position affects the financial position to a great extent. In fact 
liquidity and profitability are the two extremes between which a financial manager has 
to make a balance. With reference to debtors, in order to increase sales for earning 
more profits, customers are offered credit; but by granting credit to customers the 
funds are blocked for the credit period. Now, it is very much essential for the firm to 
realize the debtors on time other wise it would hamper its liquidity position. Hence the 
firm needs to strengthen its collection policy.  
 
Debtor turnover ratio shows the number of times each year a company’s debtor turn 
into cash. The payment made by debtors largely depends upon the relationship the 
company maintains with the debtors and the type of customers to who company is 
granting credit. It also highlights the company’s efficiency with regard to collecting 
the dues. The ratio provides some indication of the quality of both the debtors and the 
company’s collection efforts.1 
 
Debtors Turnover =  
 
 
 
 
 
 
 
  Sales 
Debtors 
Table : 6.6:  
Table Showing Debtors Turnover Ratio in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05  
[All amounts = Rs. in 
Crores]  
Particulars 97-98 98-99 99-00 00-01 2001-02 2002-03 2003-04 2004-05 
                  
Aurobindo-Sales 295.31 550.03 739.9 972.52 1007.96 1180.33 1334.83 1153.43 
Debtors 60.35 115.11 142.75 201.3 337.57 407.65 456.85 441.38 
DTRatio 4.89 4.78 5.18 4.83 2.99 2.90 2.92 2.61 
  
        
Cadila-Sales 303.58 358.4 475.7 502.3 581.7 1005.2 1116 1125.3 
Debtors 51.8 46.01 59.13 51.61 66.9 136.8 165.9 108.8 
DTRatio 5.86 7.79 8.04 9.73 8.70 7.35 6.73 10.34 
  
        
Cipla-Sales 514.43 617.16 759.75 1047.51 1385.84 1549.79 1974.63 2327.63 
Debtors 53.5 59.23 80.85 149.52 254.71 355.57 498.23 587.32 
DTRatio 9.62 10.42 9.40 7.01 5.44 4.36 3.96 3.96 
  
        
Dr.Reddy-Sales 331.62 425.86 493.02 984.11 1557.78 1598.32 1740.2 1625.08 
Debtors 117.86 142.08 128.14 284.97 444.95 432.45 444.05 417.64 
DTRatio 2.81 3.00 3.85 3.45 3.50 3.70 3.92 3.89 
  
        
IPCA-Sales 282.74 335.66 363.31 385.38 444.18 506.51 649.32 721.74 
Debtors 57.89 62.52 74.61 78.27 98.98 120.18 139.04 157.16 
DTRatio 4.88 5.37 4.87 4.92 4.49 4.21 4.67 4.59 
  
        
Matrix-Sales 27.51 40.73 45.19 60.78 102.18 416.93 556.86 671.69 
Debtors 5.47 5.62 2.6 6.11 7.1 56.17 94.15 136.75 
DTRatio 5.03 7.25 17.38 9.95 14.39 7.42 5.91 4.91 
  
        
NicholasP-Sales 534.64 429.99 486.48 566.76 946.48 1136.13 1434.66 1384.68 
Debtors 127.32 72.51 84.61 90.16 120.06 171.33 172.85 140.9 
DTRatio 4.20 5.93 5.75 6.29 7.88 6.63 8.30 9.83 
  
        
Sun-Sales 279.77 358.11 478.35 613.78 753.1 864.65 998.16 1263.86 
Debtors 40.34 82.37 70.89 93.99 107.76 197.16 128.37 234.97 
DTRatio 6.94 4.35 6.75 6.53 6.99 4.39 7.78 5.38 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
 
Debtor’s Turnover Ratio calculated in Table 6.6 shows the number of times each year 
a company’s debtors turn into cash. A high debtor turnover ratio indicates that debtors 
were converted frequently into cash and the quality of the company’s portfolio of 
debtors can be considered good. 
 
For Aurobindo Pharma a positive trend of Debtors’ Turnover Ratio (DTR) is observed 
which indicates that company is very vigilant with regard to its collection policies and 
has maintained a strict collection policy. But from the year 2001-02 there is a serious 
downfall in the DTR, which has remained stable till the last year of the study period. 
DTR of the company lies between 5.18 (99-2000) and 2.61 (2004-05) with an average 
of 3.89 which is very low compared to the overall average of 6.13. Although strong 
DTR in the initial period, it is no longer satisfactory in the second part of the period. 
This shows the weak collection efforts and it hampers the overall liquidity position of 
the company. 
 
Cadila Healthcare has shown impressing DTR for the study period. It lies between 
10.34 (2004-05) and 5.86 (1997-98) and has an average of 8.07 which is far better 
than the overall average of 6.13. The most fascinating thing about DTR for Cadila is it 
has a constant positive trend throughout the period of study, except in the year 2003-
04 it has shown a continuous increasing trend which is very impressive. This shows 
that company is very conscious regarding its liquidity position and is working very 
hard on its collection policy. 
 
 
Cipla Ltd. is showing a declining trend of DTR for the study period. The DTR was as 
high as 10.42(98-99) but could not continue its strict measures and gradually ended up 
with a very low DTR of 3.96 (2004-05). There is constant increasing trend observed in 
the sales figures and debtors figures also but the funds has remained tied up for long 
as the years have progressed. 
 
Dr. Reddy’s Laboratories a stable but slightly increasing trend of DTR. Although a 
low DTR throughout the study period but the company is successful in maintaining 
that low ratio and improved in the latter part of the period. The company is consistent 
and if it works on its collection policies it can improve its DTR. It lies between 3.92 
(2003-04) and 2.81 (97-98) and has an average of 3.52 which is very low compared to 
the overall average of 6.13. 
 
There is a fluctuating trend observed in the DTR of IPCA Labs but luckily the 
fluctuations are not too big to make them very in-effective. DTR lies between 5.37 
(98-99) and 4.21 (2002-03) with an average of 4.75 which is lesser compared to the 
overall average of 6.13. There is continuous positive trend observed in both sales and 
debtors figures but the company has done medium efforts for maintaining its liquidity 
position but has remained quite consistent. 
 
Matrix Laboratories is showing a mixed trend of DTR with ending at a low ratio. It 
lies between 17.38(1999-2000) and 4.91(2004-05) with an average of 9.03 which is 
very high compared to the overall average of 6.13. The company is very vigilant in its 
collection efforts and its DTR shows it has faster debtors’ turnover cycles. But there is 
constant decline in this ratio in the last four years which might go still lower in the 
coming years which is a matter to look on for the company. 
 
Nicholas Piramal has shown a constant increasing trend in the DTR for the study 
period which is exceptionally remarkable. Its clear increasing trend is visible in its 
eight year high and eight year low. The lowest value 4.20 is observed in the very first 
year 1997-98 and the highest value is found in the last year 2004-05 which makes us 
believe in the tremendous collection policies of the company. There are very 
minimum funds tied up with debtors in this company. It has a very fine average of 
6.85 which is as expected higher than the overall average of 6.13 for the study period.  
 
Sun Pharmaceuticals is pretty consistent barring two years in which it could not 
manage to maintain its DTR. It lies between 7.78 (2003-04) and 4.35 (1998-99) with 
an average of 6.14 which is exactly same to the overall average of 6.13, hence 
implying that the company has very fine collection efforts and no much funds are tied 
up with the debtors. 
 
The overall trend for the study period is showing a continuous increasing trend which 
is a very positive sign for the liquidity position for all the companies. Barring one year 
2002-03 which is having its eight year low of 5.12 all the years have shown a positive 
upward movement in the DTR. It lies between 7.65 (1999-2000) and 5.12(2002-03) 
3with an overall average of 6.13. The companies like Aurobindo, Dr.Reddy’s Lab. 
and  IPCA have been under performer as far as DTR is concerned otherwise all the 
other companies have shown a very fine performance in terms of collection period and 
ultimately maintaining a better liquidity position. 
 
 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Debtors Turnover Ratio among 
different Pharmaceutical companies under study during the study period and for 
establishing relationship in the ratio of Debtors Turnover Ratio among different years 
for each (individual) company, F-Test ANOVA is used. The statements of hypothesis 
for the comparison among different companies and for comparison among different 
years for individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Debtors Turnover between different 
companies under study during the study period is same.” 
Alternate Hypothesis (H1):-  “The ratio of Debtors Turnover between different 
companies under study during the study period is not 
same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Debtors Turnover between different years 
during the study period in each company under study is 
not same.” 
Alternate Hypothesis (H1):-  “The ratio of Debtors Turnover between different years 
during the study period in each company under study is 
not same.” 
 
In the following Table 6.6(a) the calculation of F Test (ANOVA) is shown of Debtors 
Turnover ratio for the Pharmaceutical Companies under study, during the study 
period. 
Table : 6.6(a) 
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 167.5743143 23.93918775 0.930522207 
Between 
Years 7 134.9844259 19.28348941 0.74955405 
Error 49 1260.604197 25.72661627   
Total 63 1563.162937     
  
The above Table 6.6(a) shows the F value of 0.93 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is lower than the table value of 2.16 hence the null hypothesis 
is accepted and the alternate hypothesis is rejected, which means that among the 
different companies under study in the ratio of Debtors Turnover is same. F value of 
0.75 at 5% level of significance and at (7,49) degree of freedom is lower than the 
Table value of 2.16 hence null hypothesis is accepted and alternate hypothesis is 
rejected, which means that between different years’ ratios for all the individual 
companies is same. 
 
Hence it can be concluded that the Debtors Turnover Ratio among different 
companies under study is same and the Debtors Turnover ratio between different years 
of each company is same. 
 
 
10. Calculation of Cash Turnover Ratio of sample units 
 
Cash is considered to be the life blood for any business organization, without which 
we cannot even imagine any financial activity. Mere availability of cash does not end 
the story; efficient management of cash holds the key. Cash management assumes 
more importance than other current assets because cash is the most significant and the 
least productive asset that a firm holds.2 As discussed in debtor turnover ratio, 
profitability and liquidity are the two opposite sides between which a financial manger 
has to maintain balance. If excessive cash balance is maintained it will serve the 
purpose of liquidity and there will be no risk of stoppage of activities owing to 
shortage of cash, but the funds blocked in form of cash balance or bank balance has 
got its own cost. And, inadequate cash balance may lead to disastrous situation for the 
company as it would affect liquidity negatively.  
 
It takes some time for the cash or bank balance to once again get converted into its 
own form after they are used for several purposes. The important thing here is how 
much time does this cycle takes i.e. from cash to once again cash. Higher cash 
turnover ratio (Smaller cash cycle) better the liquidity position, but too much of funds 
should not be kept for the sake of liquidity which is at the cost of profitability. 
 
Cash Turnover =   
 
 
 
 
 
Sales 
Cash 
Table: 6.7:  
Table Showing Cash Turnover Ratio in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05  
[All amounts = Rs. in 
Crores]  
Particulars 97-98 98-99 99-00 00-01 01-02 02-03 03-04 2004-05 
  
                
Aurobindo Sales 295.31 550.03 739.9 972.52 1007.96 1180.33 1334.83 1153.43 
Cash &Bank 10.23 15.11 14.02 4.55 22.41 33.15 37.41 13.8 
Turnover Ratio 28.87 36.40 52.77 213.74 44.98 35.61 35.68 83.58 
  
        
Cadila-Sales 303.58 358.4 475.7 502.3 581.7 1005.2 1116 1125.3 
Cash & Bank 4.06 6.84 378.66 41.87 5.7 9 37.2 26.4 
Turnover Ratio 74.77 52.40 1.26 12.00 102.05 111.69 30.00 42.63 
  
        
Cipla-Sales 514.43 617.16 759.75 1047.51 1385.84 1549.79 1974.63 2327.63 
Cash & Bank 3.02 3.54 4.27 5.8 15.57 13.12 6.24 15.38 
Turnover Ratio 170.34 174.34 177.93 180.61 89.01 118.12 316.45 151.34 
  
        
Dr.Reddy Sale 331.62 425.86 493.02 984.11 1557.78 1598.32 1740.2 1625.08 
Cash & Bank 14.35 18.88 21.91 19.43 488.56 688.4 408.08 891.72 
Turnover Ratio 23.11 22.56 22.50 50.65 3.19 2.32 4.26 1.82 
  
        
IPCA-Sales 282.74 335.66 363.31 385.38 444.18 506.51 649.32 721.74 
Cash & Bank 3.41 2.79 4.31 4.96 3.14 2.44 4.77 4.17 
Turnover Ratio 82.91 120.31 84.29 77.70 141.46 207.59 136.13 173.08 
  
        
Matrix-Sales 27.51 40.73 45.19 60.78 102.18 416.93 556.86 671.69 
Cash & Bank 0.11 0.19 0.07 2 2.21 8.72 3.61 8.76 
Turnover Ratio 250.09 214.37 645.57 30.39 46.24 47.81 154.25 76.68 
  
        
Npiramal-Sale 534.64 429.99 486.48 566.76 946.48 1136.13 1434.66 1384.68 
Cash & Bank 3.54 31.52 49.76 33.94 23.04 15.99 15.47 7.49 
Turnover Ratio 151.03 13.64 9.78 16.70 41.08 71.05 92.74 184.87 
  
        
Sun-Sales 279.77 358.11 478.35 613.78 753.1 864.65 998.16 1263.86 
Cash & Bank 6.37 8.5 4.35 10.56 24.78 78.68 75.75 890.03 
Turnover Ratio 43.92 42.13 109.97 58.12 30.39 10.99 13.18 1.42 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
 
 
Aurobindo Pharma shows a mixed trend for the Cash Turnover Ratio(CTR) for the 
study period. It lies between 213.74(2000-01) and 28.87 (97-98) with an average of 
66.45 which is lower than overall average of 91.36 for the same study period. There 
are two instances where the cash and bank balances have been reduced to very low 
levels which have resulted in higher CTR, viz. in the year 2000-010 and 2004-05. 
Otherwise there are no major fluctuations observed. 
 
Cadila Healthcare is high fluctuating trend of CTR as there have been huge 
differences in the cash and bank balance with the company in the study period. It lies 
between111.69(2002-03) and 1.26 (99-2000) with an average of 53.35 which is very 
low compared to overall average of 91.36 for the same study period. There are 
abnormal changes observed in the cash and bank balance which has resulted in such a 
big differences in the CTR for the company for the study period. 
 
Cipla Ltd has a consistent increasing trend in the first four year and then there are no 
particular trend observed in the CTR for the study period. It lies between 316.45(03-
04) and 89.01 (01-02) with the average of 172.27 which is very high compared to the 
overall average of 91.36. This shows that compared to other companies there are no 
times where in the company has either maintained abnormally high or abnormally low 
cash and bank balances. 
 
There is a constant increasing trend observed in the CTR of Dr. Reddy’s Laboratories 
Ltd. for the initial four years and then there are fluctuations observed in the CTR for 
the next four years. It lies in between 50.65(00-01) and 2.32(02-03) with an average of 
16.30 which is very low compared to the overall average of 91.36 for the same study 
period. This sort of heavy fluctuations shows the lesser reliability of this ratio as a 
measure to compare the effect on sales. 
 
IPCA is showing a fluctuating trend of CATR for the study period. It lies between 
207.59(02-03) and 82.91 (97-98) with an average of 127.93 which is higher than the 
overall average of 91.36 for the same study period. It is interesting to note that there 
are no major fluctuations observed in the cash and bank balances of this company and 
constant increasing trend of sales can be observed for the study period.  
 
Matrix Laboratories is showing no particular trend for the CTR for the study period. It 
lies between 645.57(99-2000) and 30.39(2000-01) with an average of 183.18 which is 
almost double of the overall average of 91.36 for the same study period. Sales is 
observed as increasing constantly for the study period and some fluctuations are 
observed in the cash and bank balance. 
 
Nicholas Piramal is showing not major trends for the CTR in the study period, it lies 
in between 184.87(2004-05) and 9.78(99-2000) with an average of 72.61 which is 
lower than the overall average of 91.36. There are some fluctuations observed in the 
cash and bank balance of the company while sales have remained more or less steady 
but have increased sharply in the year2001-02 and onwards.  
 
Sun Pharmaceuticals is also showing no particular trends in the CTR for the study 
period. The CTR of the company for the study period lies in between 109.97(99-2000) 
and 1.42(2004-05) with an average of 38.76 which is very low compared to the overall 
average of 91.36. Cash and Bank is showing an increasing trend and sales is also 
showing a clear increasing trend which proves the utility of cash and bank balance in 
increasing the sales volume of the company. 
 
Overall there are no major trends identified for all the companies under study which 
reflects the fluctuating feature of CTR. Almost all the companies have shown the 
same fluctuation nature of this ratio. CTR lies in between 138 in the year 1999-2000 
and 62 in 2001-2002 for the study period. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Cash Turnover Ratio among different 
Pharmaceutical companies under study during the study period and for establishing 
relationship in the ratio of Cash Turnover Ratio among different years for each 
(individual) company, F-Test ANOVA is used. The statements of hypothesis for the 
comparison among different companies and for comparison among different years for 
individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Cash Turnover between different 
companies under study during the study period is same.” 
Alternate Hypothesis (H1):-  “The ratio of Cash Turnover between different 
companies under study during the study period is not 
same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Cash Turnover between different years 
during the study period in each company under study is 
same.” 
Alternate Hypothesis (H1):-  “The ratio of Cash Turnover between different years 
during the study period in each company under study is 
not same.” 
 
In the following Table 6.7(a) the calculation of F Test (ANOVA) is shown of Cash 
Turnover ratio for the Pharmaceutical Companies under study, during the study 
period. 
 
Table : 6.7(a) 
Table showing calculation of F-Test (ANOVA) 
S V d f S.  S. M. S. S. F cal 
Between 
Companies 7 217041.5632 31005.9376 3.911141157 
Between 
Years 7 29023.00707 4146.143867 0.523001566 
Error 49 388452.0864 7927.5936   
Total 63 634516.6567     
 
The above Table 6.7(a) shows the F value of 3.91 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is higher than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that among the 
different companies under study the ratio of Cash Turnover is not same. F value of 
0.52 at 5% level of significance and at (7,49) degree of freedom is lower than the 
Table value of 2.16 hence null hypothesis is accepted and alternate hypothesis is 
rejected, which means that between different years’ ratios for all the individual 
companies is same. 
 
Hence it can be concluded that the Cash Turnover Ratio among different companies 
under study is not same and the Cash Turnover ratio between different years of each 
company is same. 
 
 
11. Conclusion  
From the above calculation of Turnover ratios there can be some general conclusions 
drawn from the statistical analysis. From the study of seven individual Turnover ratio 
and their comparison among companies for the study period and individual companies 
comparison for different years, following conclusions can be drawn: 
 
 The Total Assets Turnover ratio among companies is not same and the Total Assets 
Turnover ratio between different years of each individual company under study for 
the study period is same.  
 The Fixed Assets Turnover ratio among companies is not same and the Fixed 
Assets Turnover ratio between different years of each individual company under 
study for the study period is also not same. 
 The Current Assets Turnover ratio among companies is not same and the Current 
Assets Turnover ratio between different years of each individual company under 
study for the study period is same.  
 The Working Capital Turnover ratio among companies is not same and the Working 
Capital Turnover ratio between different years of each individual company under 
study for the study period is same.  
 The Inventory Turnover ratio among companies is not same and the Inventory 
Turnover ratio between different years of each individual company under study for 
the study period is same.  
 The Debtors Turnover ratio among companies is same and the Debtors Turnover 
ratio between different years of each individual company under study for the study 
period is same.  
 The Cash Turnover ratio among companies is not same and the Cash Turnover ratio 
between different years of each individual company under study for the study 
period is same.  
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1. Concept 
Be it a business or non-business activity, the efforts are put in the expectation of some 
reward, the expectation of reward may be of different size or variety but there is 
always a calculation of the reward or return of efforts put in. When we talk with 
reference to purely business activity the efforts that are put in are of different forms, 
which include employing different factors of production. Entrepreneur puts his money 
as well as the borrowed money along with his labour and the paid labour for the 
business activity and thus it is quiet natural for him to measure the return he is earning 
for the risk he has taken in the form of the labour he has done and the money he has 
expended. The discovery of return on investment is necessary irrespective of the fact 
that the business activity is with or without the profit objective, as such even the non-
profit organizations would also want to be efficient in utilizing their resources. 
 
Return on the investment made in the business gives an idea regarding the utilization 
of the resources employed. This also measures the efficiency of management along 
with the quality of resources and the marketability of the business. As a prime 
calculator of profitability the utility of Return on Investment Ratio has already been 
discussed in chapter 5th – “Analysis of Profit Margin”. This chapter is totally designed 
and prepared for emphasizing and proving the importance of this measure and also for 
deriving some genuine findings and making serious observations for the present study. 
As a measure of profitability it can be considered as a superior most ratio as it is made 
up of two important ratios of profit margin and productivity. Return on Investment is a 
mixture of profit margin ratio and the asset turnover ratio, the former one is the ratio 
of profit percentage in sales while the later is a measure of productivity. Hence ROI 
can be considered as a complete ratio for analyzing the profitability of any firm.  
 As the present study is entirely devoted to the analysis of profitability of companies of 
Indian Pharmaceutical Industry, this ratio can be considered as the theme ratio which 
will be primarily used for the pure analysis of the profitability. Now going into the 
details of the calculation of the ratio, we find basically two things, i.e. profit and 
investment, which are essential for this ratio. Profit and Profit margin we have already 
discussed in the chapter- 5th – “Analysis of Profit Margin”, now let us concentrate on 
the investments part. When the overall profitability is to be compared with the 
investment, it will not be just one amount that we can take into consideration. Let us 
discuss the various forms of investment. 
 
 
 
 
 
2. Capital Employed / Investment 
 
(a) Gross Capital Employed: Total assets comprises two parts, fixed assets and                      
current assets. When we refer to Gross Capital Employed we refer to the sum 
of both the fixed assets as well as the current assets. 
(b) Net Capital Employed: This is an extension of the earlier concept of capital 
employed. If the current liabilities are deducted from the gross capital 
employed, the resultant amount is referred as the Net Capital Employed. In 
other words from the sum of current assets and fixed assets if we deduct the 
current liabilities we get Net Capital Employed. 
(c) Proprietor’s Net Capital Employed: This is an extension of the earlier concept 
of net capital employed. If long term liabilities are also deducted from net 
capital employed, the resultant amount is referred to as Proprietor’s Net 
Capital Employed. In other words if total liabilities are deducted from total 
assets the resultant amount is referred to as Proprietor’s Net Capital 
Employed. 
 
Following items are to be excluded while calculating capital employed: 
I. Idle asset: The assets which are not used and are idle should be excluded from 
the calculation of capital employed. Idle assets can also be like Capital Work-
in-progress which is an asset under construction, for example a new 
manufacturing facility is under construction. As this is under-construction it is 
non-usable for the purpose of production and hence should not be counted 
with other investments used to earn profits. The non-use may also be due to 
obsoleteness of the asset or some abnormal situation of strike, lock-out, or 
other such abnormalities. Eg: Obsolete assets, etc. 
II. Fictitious Assets: Capital employed will not include the group of fictitious 
assets; as such they are basically long term expenses rather than any property 
for the firm. Hence fictitious assets like preliminary expenses, advertisement 
account, discount on debentures, etc will be excluded while calculating capital 
employed. 
III. Intangible Assets: The assets which are not real, or which cannot be seen or 
touched are all referred as intangible assets like patents, copyrights, etc will 
not be included in calculating capital employed. 
IV. Outside Investment (Non-Business): The amount invested outside the business 
which has no relation with the business activity is referred as outside 
investment. This happens when the company has some excess funds with it 
which it invests outside the business which do not have any connection with 
the business activity. 
 
 
3. Calculation of Return on Investment  
For the present study as discussed earlier we have chosen Return on Investment 
measure as a prime measure of profitability. For the calculation of Return on 
Investment for the present study of selected Indian Pharmaceutical companies under 
study, the operating profits before interest and taxes are used and the gross capital 
employed in the business as per the previous discussion in this chapter. The 
importance and utility of operating profits has already been discussed in the Chapter-
5th “Analysis of Profit Margin”.  
ROI is the percentage of profit to capital employed and is the product of two ratios: (i) 
Percentage of profit to sales and (ii) sales to capital employed, i.e. the rate of asset 
turnover. Thus 
ROI =  
 
         Profit   
Capital Employed 
Profit 
Sales 
         Sales 
Capital Employed = X 
Hence ROI is a product of profit margin ratio and asset turnover ratio; we have 
already discussed the profit margin in depth in Chapter-5th “Analysis of Profit 
Margin” and the asset turnover ratio has been discussed in detail in Chapter-6th “Asset 
Turnover”, hence now we shall move to the detail analysis of Return on Investment 
Analysis. 
In the present study for the calculation of Return on Investment (ROI) the operating 
profits before interest and taxes are taken as profits and the capital employed is taken 
as per the earlier discussion about the capital employed in this chapter. Hence the ratio 
is as under: 
 
 
ROI =  
 
Table : 7.1:  
Table Showing Return on Investment in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05 
                                                                                             [All amounts = Rs. in 
Crores] 
 
Co. 97-98 98-99 99-00 00-01 01-02 02-03 03-04 04-05 
Aurobindo 22.59 24.3 25.29 18.16 13.09 17.52 17.29 8.33 
Cadila 26.7 23.8 10.79 16.5 13.1 17.13 16.55 16.55 
Cipla 27.32 28.65 26.55 27.79 24.28 18.56 18.35 18.61 
Dr.Reddy 22.91 22.11 24.96 31.88 37.16 25.33 18.3 7.74 
IPCA 11.32 12.99 14.49 10.77 17.21 20.29 20.53 18.5 
Matrix 8.81 9.84 -11.46 0.81 16.58 43.59 35.11 23.29 
N.Piramal 14.73 21.92 18.43 20.1 22.38 24.67 26.01 17.32 
Sun 21.58 19.02 25.33 29.18 33.94 33.87 37.59 16.53 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
Operating Profit before Interest & Taxes 
            Gross Capital Employed 
Aurobindo Pharma is showing an increasing trend in the initial part of the period but 
then there is fluctuating trend observed in the Return on Investments of the company 
for the study period. It lies in between 25.29(1999-2000) and 8.33(2004-05) with an 
average of 18.32 which is lesser than the overall average of 20.37 for the same study 
period. 
 
There is a constant fluctuation observed in the return on investment figures for Cadila 
for the study period. The ration lies between 26.7(97-98) and 10.79(1999-2000) with 
an average of 17.64 which is lower than the overall average 20.37 for the selected 
companies for the same period. 
There is a mixed trend observed in the figures of Cipla Ltd. for the study period. It lies 
in between 28.65(98-99) and 18.35(2003-04) with an average of 23.76 which is higher 
than overall average of 20.37 for the same period. 
Dr. Reddy’s Laboratories is showing an increasing trend in the initial five years but 
there is a severe downtrend observed in the last three years of the study period. The 
ratio lies in between 37.16(2001-02) and 7.74(2004-05) for the study period. The 
average is 23.80 which is higher than the overall average of 20.37 for the same period. 
IPCA is showing a mixed trend of increasing trend in the initial three years and there 
is a constant trend observed and the ratio declines in the last year. It lies between 
20.53(2003-04) and 10.77(2000-01) with an average of 15.76 which is quite low 
compared to the overall average 20.37 for the same study period.  
Matrix Laboratories is showing a tremendous fluctuating trend in the return on 
investment ratios as it includes very low as well as very high values. It lies between 
43.59(2002-03) and -11.46(1999-2000) with an average of 15.82 which is very low 
compared to the overall average of 20.37 for the same study period. 
Nicholas Piramal is showing a mixed trend in the return on investment ratios. It lies 
between 26.01(2003-04) and 14.73(97-98) with an average of 20.70 which is similar 
to the overall average of 20.37 for the same study period. The ratio seems to be more 
consistent for the study period compared to other companies in the study. 
Sun Pharmaceuticals is showing a mixed trend but has very impressive figures for the 
return on investments. It lies between 37.59(2003-04) and 16.53(2004-05) with an 
average of 27.13 which is far more than the overall average 20.37 for the same study 
period. 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Return on Investment among different 
Pharmaceutical companies under study during the study period and for establishing 
relationship in the ratio of Return on Investment among different years for each 
(individual) company, F-Test ANOVA is used. The statements of hypothesis for the 
comparison among different companies and for comparison among different years for 
individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Return on Investment between different 
companies under study during the study period is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of Return on Investment between different 
companies under study during the study period is not 
same.” 
 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Return on Investment between different 
years during the study period in each company under 
study is same.” 
Alternate Hypothesis (H1):-  “The ratio of Return on Investment between different 
years during the study period in each company under 
study is not same.” 
 
 
 
In the following Table 7.1(a) the calculation of F Test (ANOVA) is shown of Return 
on Investment ratio for the Pharmaceutical Companies under study, during the study 
period. 
 
Table Number:  7.1(a) 
Table Showing calculation of F-Test (ANOVA) 
 
S V d f S.  S. M. S. S. F cal 
 
Between 
Companies 
7 981.1796437 140.1685205 2.014599519 
 
Between Years 7 575.9826938 82.28324196 1.182632013 
 
Error 49 3409.242106 69.57636952   
 
Total 63 4966.404444   
  
  
The above Table 7.1(a) shows the F value of 2.01 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is lower than the table value of 2.16 hence the null hypothesis 
is accepted and the alternate hypothesis is rejected, which means Return on 
Investment among the different companies is same. F value of 1.18 at 5% level of 
significance and at (7,49) degree of freedom is also lower than the Table value of 2.16  
hence null hypothesis is accepted and alternate hypothesis is rejected, which means 
that different years’ ratios for all the individual companies are same. 
 
Hence it can be concluded that the Return on Investment ratio among different 
companies under study and the Return on Investment ratio between different years of 
each company are both same. 
 
4. Calculation of Return on Gross Capital Employed  
Gross Capital employed refers to the investment in total assets which includes the 
fixed assets and the current assets. When gross capital is compared with the operating 
profits before interest and taxes it gives a clear indication of the return on the total 
assets invested. We have already discussed the operating margin in the Chapter-5th 
“Analysis of Profit Margin” and we have also discussed the details of Gross Capital 
Employed earlier in this same chapter. Now here an attempt has been made to 
calculate the Return on Gross capital employed for the selected companies. This ratio 
will measure the returns received on overall investment in the individual companies 
and will also reveal the overall efficiency which will be shown by the return received 
on the total investment. The ratio is as under: 
 
 
ROGCE=   
 
 
Profit before Interest & Taxes 
   Gross Capital Employed 
Table: 7.2:  
Table Showing Return on Gross Capital Employed in Pharmaceutical Companies 
under 
Study Period: 1997-98 to 2004-05 
                                                                      [All amounts = Rs. in Crores] 
Co. 97-98 98-99 99-
2000 
2000-
01 
2001-
02 
2002-
03 
2003-
04 
2004-
05 
Aurobindo 20.44 22.25 24.79 19.58 16.16 15.6 13.76 4.7 
Cadila 18.46 15.73 7.96 14.26 10.26 13.16 16.29 14.13 
Cipla 29.2 29.74 27.61 29.22 24.67 18.75 20 20.26 
Dr.Reddy 17.46 15.4 17.23 24.52 29.35 21.92 14.28 2.07 
IPCA 12.38 13.07 13.67 10.09 14.23 20.21 21.1 16.91 
Matrix 6.62 6.97 -16.79 15.89 14.33 38.3 30.51 20.71 
Npiramal 7.08 20.17 18.09 18.17 17.12 19.34 20.85 18.71 
Sun 21.92 16.35 20.93 26.95 29.04 29.05 34.05 15.91 
Aurobindo Pharma. is showing no particular trend in the ratio of return on gross 
capital employed. In the initial period there was an increasing trend observed for the 
first three years but afterwards there was no trend observed. The Return on gross 
capital employed lies in between 24.79(1999-2000) and 4.7(2004-05) with an average 
of 17.16 which is lower than the overall average 18.15 for the same study period. 
Cadila is also showing a mixed trend of Return on Gross Capital Employed for the 
study period as there is no particular trend observed in the entire study period. It lies 
between 18.46(97-98) and 7.96(99-2000) with an average of 13.78 which is very low 
as compared to overall average 18.15 for the same study period. 
Cipla Ltd. is showing a constant consistent rate of return on gross capital employed. 
There are no major or minor fluctuations observed in the rate for the company in the 
study period. It lies between 29.74(98-99) and 18.75(2002-03) with an average of 
24.93 which is a very good average compared to the overall average of 18.15 for the 
same study period. 
Dr. Reddy’s Laboratories is showing a fluctuating trend of Return on Gross Capital 
Employed for the study period. It ranges between 29.35(2001-02) and 2.07(2004-05) 
with an average of 17.78 which is slightly lesser than overall average of 18.15 for the 
same study period. 
 
IPCA is showing an overall positive trend of return on gross capital employed for the 
study period. It ranges in between 21.1(2003-04) and 10.09(2000-01) with an average 
of 15.21 which is lower than the overall average of 18.15 for the same study period. 
 
Matrix Labs is showing fluctuating trend in the initial years of the study period, but in 
the latter stage of the study period it has shown a very fine performance. It ranges 
from 38.3(2002-03) and -16.79(1999-2000) with an average of 14.57 which is lower 
than overall average of 18.15 for the same study period. 
 
Nicholas Piramal is a fairly consistent performance for its return on gross capital 
employed ratio for the study period. Apart from the very first year in all the years the 
company has managed to receive a consistent return on its gross capital. It ranges 
between 20.85(2003-04) and 7.08(97-98) with an average of 17.44 which is slightly 
lower than overall average of 18.15 for the same study period. 
Sun Pharmaceuticals is showing a fairly consistent trend apart from the first year and 
last year the return on gross capital is showing positive increasing trend. It ranges 
between 34.05(2003-04) and 15.91(2004-05) with an average of 24.28 which is far 
better than the overall average of 18.15 for the same study period.  
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Return on Gross Capital Employed 
among different Pharmaceutical companies under study during the study period and 
for establishing relationship in the ratio of Return on Gross Capital Employed among 
different years for each (individual) company, F-Test ANOVA is used. The statements 
of hypothesis for the comparison among different companies and for comparison 
among different years for individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Return on Gross Capital Employed 
between different companies under study during the 
study period is same.” 
 
Alternate Hypothesis (H1):-  “The ratio of Return on Gross Capital Employed 
between different companies under study during the 
study period is not same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Return on Gross Capital Employed 
between different years during the study period in each 
company under study is same” 
Alternate Hypothesis (H1):-  “The ratio of Return on Gross Capital Employed 
between different years during the study period in each 
company under study is not same.” 
 
In the following Table 7.2(a) the calculation of F Test (ANOVA) is shown of Return 
on Gross Capital Employed ratio for the Pharmaceutical Companies under study, 
during the study period. 
 
Table :  7.2(a) 
Table Showing calculation of F-Test (ANOVA) 
 
S V d f S.  S. M. S. S. F cal 
 
Column 7 1005.595244 143.6564634 2.387894301 
 
Row 7 511.2620188 73.03743125 1.214046773 
 
Error 49 2947.855231 60.16031084   
 
Total 63 4464.712494   
 
  
  
 
The above Table 7.2(a) shows the F value of 2.39 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is higher than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that the ratio of 
Return on Gross Capital Employed among different companies is not same. F value of 
1.21 at 5% level of significance and at (7,49) degree of freedom is lower than the 
Table value of 2.16 hence null hypothesis is accepted and alternate hypothesis is 
rejected, which means that different years’ ratios for all the individual companies are 
showing similar trend or are same. 
Hence it can be concluded that there are no similarities in the Return on Gross Capital 
Employed ratio among different companies under study and there are similarities in 
the Return on Gross Capital Employed ratio between different years of each company. 
 
5. Calculation of Return on Net Capital Employed  
Net capital employed refers to the total assets less the current liabilities, in other 
words net capital employed refers to the fixed assets plus current assets minus current 
liabilities. This ratio can be described as one of the significant measure of profitability 
as the current liabilities are deducted with a logic that the part of total assets which 
would be utilized to pay to current liabilities will not be permanently invested in the 
business. Hence the amount of total assets equaling to current liabilities is deducted 
from the gross capital employed and thus remaining part of total assets or gross capital 
employed is the amount which is referred as net capital employed. The concept of net 
capital employed has been discussed in depth earlier in this chapter and the profit 
margin used here i.e. the operating profits before interest and taxes has also been 
discussed in the Chapter-5th “Analysis of Profit Margin”.  The ratio is as under: 
 
RONCE =  
Table : 7.3: 
Table Showing Return on Net Capital Employed in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05 
                                                                                                [All amounts = Rs. in 
Crores] 
Co. 97-98 98-99 99-
2000 
2000-
01 
2001-
02 
2002-
03 
2003-
04 
2004-
05 
Aurobindo 27.56 31.28 30.38 24.48 19.63 18.98 15.77 5.41 
Cadila 23.5 19.6 8.97 16.25 11.35 15.51 19.27 16.6 
Cipla 33.43 33.59 33.17 36.66 30.63 23.8 24.51 25.02 
Dr.Reddy 19.78 18.05 19.5 28.11 32.78 24.61 16.51 2.39 
IPCA 14.48 15.29 15.64 11.4 16.59 23.01 24.66 19.29 
Matrix 7.91 9.23 -27.07 24.54 22.03 47.56 37.97 27.67 
Npiramal 8.17 24.02 21.54 23.04 22 23.71 25.32 22.89 
Sun 25.39 18.7 24 30.15 32.6 32.14 39.14 16.94 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
Profit before Interest & Taxes 
Net Capital Employed 
From the table showing calculation of Return on Net Capital Employed Aurobindo 
Pharma. is showing a positive trend for the first three years but afterwards for the rest 
of eight years it has shown a declining trend. It ranges between 31.28(98-99) and 
5.41(2004-05) with an average of 21.69 which is almost equal to the overall average 
of 21.67 for the same study period of all the selected pharmaceutical companies. 
Cadila is showing a fluctuating trend for the return on net capital employed for the 
study period. It ranges between 23.5(97-98) and 8.97(1999-2000) with an average of 
16.38 which is quite lower than the overall average of 21.67 for the same study period 
of all the selected pharmaceutical companies. 
Cipla Ltd. is showing a very consistent trend of its Return on net capital employed 
with a very small decline observed in the last three years of the study period. It ranges 
between 36.66(2000-01) and 23.8(2002-03) with an impressive average of 30.10 
which narrates the story of high and consistent performance of Cipla Ltd. in the study 
period. The average of the company is very high compared to the overall average of 
eight companies 21.67 for the same study period. 
Dr. Reddy’s Laboratories is showing a fluctuating trend for its return on net capital 
employed for the period under study. It ranges between 32.78(2001-02) and 
2.39(2004-05) with an average of 20.22 which is although close to overall average of 
21.67 but has lot of fluctuations making it an unstable performer. 
Some fluctuations are observed in the Return on net capital employed ratio of IPCA 
for the study period. It ranges between 24.66(2003-04) and 11.4(2000-01) with an 
average of 17.55 which is lower than the overall average of 21.67 for the same study 
period. 
Matrix Laboratories is showing some very high fluctuations in the initial three years 
but after wards the rate has improved in the last five years. It ranges between 
47.56(2002-03) and -27.07(1999-2000) with an average of 18.73 which is lower than 
overall average of 21.67 for the same study period. 
Nicholas Piramal is a fairly consistent and better performer barring its performance in 
the first year for the return on net capital employed. It ranges from 25.32(2003-04) 
and 8.17(97-98) with an average of 21.34 which is very close to the overall average of 
21.67 for the same study period. This company has shown a very fine performance in 
this ratio making it a reliable and stable company. 
Sun Pharmaceuticals has shown a very fine and increasing trend in the return on net 
capital employed barring two years when its performance was slightly weak. It ranges 
between 39.14(2003-04) and 16.94(2004-05) with an average of 27.38 which is better 
than the overall average of 21.67 for the same study period. The company can be 
given all the credit for being the first company in the study for having a positive 
increasing trend of return on net capital employed and its fine performance is visible 
even in its average. If these efforts are continued the company can show wonderful 
results in the coming times.  
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Return on Net Capital Employed 
among different Pharmaceutical companies under study during the study period and 
for establishing relationship in the ratio of Return on Net Capital Employed among 
different years for each (individual) company, F-Test ANOVA is used. The statements 
of hypothesis for the comparison among different companies and for comparison 
among different years for individual companies during the study period are as under: 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Return on Net Capital Employed between 
different companies under study during the study period 
is same.” 
Alternate Hypothesis (H1):-  “The ratio of Return on Net Capital Employed between 
different companies under study during the study period 
is not same.” 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Return on Net Capital Employed between 
different years during the study period in each company 
under study is same.” 
Alternate Hypothesis (H1):-  “The ratio of Return on Net Capital Employed between 
different years during the study period in each company 
under study is not same.” 
In the following Table 7.3(a) the calculation of F Test (ANOVA) is shown of Return 
on Net Capital Employed ratio for the Pharmaceutical Companies under study, during 
the study period. 
Table Number:  7.3(a)                
Table Showing calculation of F-Test (ANOVA) 
 
S V d f S.  S. M. S. S. F cal 
 
Column 7 1276.589861 182.3699801 1.799259459 
 
Row 7 829.0566609 118.4366658 1.16849435 
 
Error 49 4966.559427 101.3583556   
 
Total 63 7072.205948   
  
  
The above Table 7.3(a) shows the F value of 1.79 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is lower than the table value of 2.16 hence the null hypothesis 
is accepted and the alternate hypothesis is rejected, which means that there are 
similarities among the different companies under study in the ratio of Return on Net 
Capital Employed . F value of 1.17 at 5% level of significance and at (7,49) degree of 
freedom is lower than the Table value of 2.16 hence null hypothesis is accepted and 
alternate hypothesis is rejected, which means that there are similarities between 
different years’ ratios for all the individual companies. 
 
Hence it can be concluded that there are similarities in the Return on Net Capital 
Employed ratio among different companies under study and there are similarities in 
the Return on Net Capital Employed ratio between different years of each company. 
6. Calculation of Return on Proprietor’s Net Capital 
Employed 
This ratio is also referred as return on net worth. This is another profitability 
measuring ratio which would compare the profit with the amount of investment. Here 
investment refers only ownership capital. For the objective of profitability in relation 
to investment, this is another ratio which is used. Every company has a mixture of 
ownership capital and borrowed capital in their capital structure, but in general the 
higher the share of proprietors in the total capital of the company (either in the form of 
share capital or retained earnings), less is the likelihood of insolvency in future.1 This 
ratio carries importance especially for the current and prospective investors; as the 
shareholders are the real owners and it is quite important to find out how much they 
are earning in relation to their investment. 
This ratio has also got specific utility with reference to calculation and analysis of 
“Trading on Equity”, as such the management intends to pass on the benefit of the risk 
of borrowed capital to the shareholders, especially the equity shareholders by paying 
more dividends to them. The ratio is as under: 
 
ROPNW =    
Table: 7.4:  
Table Showing Return on Proprietor’s Net Capital Employed in Pharmaceutical 
Companies under Study Period: 1997-98 to 2004-05 
                                                                      [All amounts = Rs. in Crores] 
Co. 97-98 98-99 99-
2000 
2000-
01 
2001-
02 
2002-
03 
2003-
04 
2004-
05 
  
                
Aurobindo 34.1 40.22 33.91 24.89 16.86 17.54 16.82 4.45 
Cadila 25.55 35.57 7.45 11.91 12.27 18.36 27.95 22.97 
Cipla 27.92 24.73 22.9 24.07 25.73 22.38 24.56 23.14 
Dr.Reddy 16.18 13.54 13.9 26.25 31.71 21.7 14.12 3.06 
IPCA 14.17 16.39 16.08 11.7 22.11 29.22 28.91 23.07 
Matrix 1.05 2.54 -108.05 34.15 20.83 74.74 70.69 20.95 
Npiramal 15.85 13.73 14.1 16.62 26.72 43.78 46.61 17.81 
Sun 25.06 18.09 21.51 28.2 32.29 32.77 27.11 27.12 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
This ratio has got a lot many similarities with the earlier ratio hence it would be very 
interesting to observe how the two ratio show similarity in their results for the study 
period. Aurobindo Pharma is showing a fluctuating trend in the return on shareholders 
funds for the study period. It ranges between 40.22(98-99) and 4.45(2004-05) for the 
study period with the average of 23.60 which is better than the overall average of 
21.45. The decreasing trend in the latter part of the study period and a huge decrease 
in the last year makes the company a bit fluctuating other wise it has good 
performance to boast off in the first three years of the study period. 
Cadila has shown a big downfall in the ratio in the third year of the study period 
which is as big as 80%. But after that a steady increase is observed for the next four 
    Net Profit after Tax 
P. Net Capital Employed 
years. It ranges between 35.57(98-99) and 7.45(1999-2000) with an average of 20.25 
which slightly lower than the overall average of 21.45 for the same study period. 
Cipla Ltd. is once again perfectly consistent with its performance making it most 
reliable and stable company among all the selected pharmaceutical companies of the 
present study. It ranges between 27.92 (1997-98) and 22.38(2002-03) with an average 
of 24.43 which is even better than the overall average of 21.45 for same study period. 
The thing which is peculiar about this company is it earns a very fine return on its 
investment and icing on the cake is it does it always! Thus making this company a 
very stable company. 
Dr. Reddy has shown a mixed trend in the study period but a severe decline of 70% 
(app.) on return on shareholders fund makes it a very un-stable company in the study. 
This sudden decline can be attributed to decline in Operating profit margin as well as 
Net Profit margin. The sudden decrease in the net profit margin in the last year can be 
attributed to the decline in sales by 7% and increase in expenses like interest expenses 
increased by 200%, miscellaneous expenses increased by 80%, selling and 
administration expenses increased by 14% and interestingly raw material cost 
decreased by 5%. It ranges between 31.71(2001-02) and 3.06(2004-05) with an 
average of 17.56 which is lower than overall average of 21.45 for the same study 
period. The decreasing trend observed in the last three years can turnout to be a very 
dangerous situation for the company if immediate actions are not taken by the 
company. 
IPCA is showing a mixed trend of increasing and decreasing trend of return on 
shareholders fund for the study period. It ranges between 29.22(2002-03) and 
11.7(2000-01) with an average of 20.21 which is slightly lower than the overall 
average of 21.45 for the same study period. 
Matrix Laboratories Ltd. is showing a very huge fluctuation in the return on 
shareholders funds for the study period.  It ranges between 74.74(2002-03) and -
108.05(1999-2000) with an average of 14.16 which is lower than the overall average 
of 21.45 for the same study period. 
Nicholas Piramal is showing a very fine increasing trend for five years in between the 
study period but the decline in the second and last year makes the overall performance 
bit dull. It ranges between 46.61(2003-04) and 13.73(98-99) with an average of 24.40 
which is better than overall average of 21.45 for the same period. If proper steps are 
taken the company can reach some very fine heights in the future. 
Sun Pharmaceuticals is showing a mixed trend on return on shareholders funds but has 
been able to maintain a certain level of consistency. It ranges between 32.77(2002-03) 
and 18.09(98-99) with an average of 26.52 which is higher than overall average of 
21.45 for the same study period. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Return on Proprietor’s Net Capital 
Employed among different Pharmaceutical companies under study during the study 
period and for establishing relationship in the ratio of Return on Proprietor’s Net 
Capital Employed among different years for each (individual) company, F-Test 
ANOVA is used. The statements of hypothesis for the comparison among different 
companies and for comparison among different years for individual companies during 
the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio of Return on Proprietor’s Net Capital 
Employed between different companies under study 
during the study period is same.” 
Alternate Hypothesis (H1):-  “The ratio of Return on Proprietor’s Net Capital 
Employed between different companies under study 
during the study period is not same.” 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Return on Proprietor’s Net Capital 
Employed between different years during the study 
period in each company under study is same.” 
Alternate Hypothesis (H1):-  “The ratio of Return on Proprietor’s Net Capital 
Employed between different years during the study 
period in each company under study is not same.” 
 
 
In the following Table 7.4(a) the calculation of F Test (ANOVA) is shown of Return 
on Proprietor’s Net Capital Employed ratio for the Pharmaceutical Companies under 
study, during the study period. 
 
Table:  7.4(a)                
Table Showing calculation of F-Test (ANOVA) 
  
S V d f S.  S. M. S. S. F cal 
 
Column 7 902.2431609 128.8918801 0.291438063 
 
Row 7 4868.275411 695.4679158 1.572525921 
 
Error 49 21670.82108 442.2616546   
 
Total 63 27441.33965   
The above Table 7.4(a) shows the F value of 0.29 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is lower than the table value of 2.16 hence the null hypothesis 
is accepted and the alternate hypothesis is rejected, which means that there are 
similarities among the different companies under study in the ratio of Return on 
Proprietor’s Net Capital Employed . F value of 1.57 at 5% level of significance and at 
(7,49) degree of freedom is lower than the Table value of 2.16 hence null hypothesis 
is accepted and alternate hypothesis is rejected, which means that there is are 
similarities between different years’ ratios for all the individual companies. 
 
Hence it can be concluded that there are similarities in the Return on Proprietor’s Net 
Capital Employed ratio among different companies under study and there are 
similarities in the Return on Proprietor’s Net Capital Employed ratio between 
different years of each company. 
 
7. Calculation of Earnings per Share  
As the name suggests this ratio refers to the earnings or the profit per share. This is 
another important measure of profitability; this ratio is different from other ratios in 
the way that this ratio measures the profitability on the per share basis. This is the 
ultimate ratio for the investors as well as the prospective investors who are planning to 
invest with the company. This ratio is calculated by dividing the amount available for 
equity shareholders by the outstanding number of equity shares. The amount available 
for equity shareholders refers to Net profits after tax and after paying dividend to 
preference shareholders (if any). In other words the profit which is remaining after 
paying to all the liabilities as well as to the preference shareholders. The ratio is 
calculated as under: 
 
EPS=  
 
Table : 7.5:  
Table Showing Earnings Per Share in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05 
                                                                      [All amounts = Rs. in Crores] 
Co. 97-98 98-99 99-
2000 
2000-
01 
2001-
02 
2002-
03 
2003-
04 
04-05 
  
                
Aurobindo 49.85 52.22 72.86 33.74 33.14 43.92 24.73 6.84 
Cadila 11.13 13.49 6.03 10.66 11.24 12.38 21.99 20.08 
Cipla 50.46 56.68 21.86 29.4 39.2 40.03 49.22 13.16 
Dr.Reddy 18.14 19.24 22.36 45.32 59.56 50.6 36.37 7.85 
IPCA 15.06 16.61 20.29 15.46 25.62 48.34 62 31.54 
Matrix 0.37 1.28 0 10.55 6.23 76.4 99.72 42.65 
Npiramal 8.74 15.26 12.88 18.36 12.69 29.67 47.06 8.33 
Sun 35.94 36.08 49.36 27.33 36.3 24.18 24.99 15.94 
Aurobindo Pharma is showing a positive trend in the EPS for the first three years of 
the study period after that there is fluctuation observed in the EPS of the company for 
the remaining years. It ranges between 72.86(1999-2000) and 6.84(2004-05) with an 
average of 39.66 which is very high as compared to the overall average of 29.05 for 
the same study period. 
 
Cadila Healthcare has improved over the years as far EPS is concerned. There is a 
clear positive increasing trend observed from the year 2000-01 till the end i.e. 2003-
04. EPS for the entire period ranges in between 21.99(2003-04) and 6.03(1999-2000) 
with an average of 13.38 which is although very low as compared to the overall 
average of 29.05 for the same period, but if company continues on its positive trend it 
can improve its EPS figures in the coming times. 
Amount available for Equity Shareholder 
  Outstanding number of equity shares 
Cipla Ltd. is showing some wonderful figures in the initial years but then could not 
continue the momentum and has some fluctuations in its EPS during the study period. 
It ranges between 56.68(98-99) and 13.16(2004-05) with an average of 37.50 which is 
even then better than the overall average of 29.05 for the same period. 
 
Dr. Reddy’s Laboratories is showing a constant increasing trend in the initial five-six 
years but it has decline a lot in the last two years. It ranges in between 59.56(2001-02) 
and 7.85(2004-05) with an average of 32.43 which is better than the overall average 
29.05 for the same period. 
 
IPCA Labs is showing an increasing trend for the study period with decline in two 
years. Excepting these two years there is a steady growth observed in the EPS of the 
company for the study period. It ranges in between 62(2003-04) and 15.06(97-98) 
with an average of 29.37 which almost equal to the overall average of 29.05 for the 
same period. 
 
Matrix Laboratories is showing tremendous fluctuation in the ratio as it has shown 
fluctuation of over 99% over a period of five years. It ranges between 99.72(2003-04) 
and 0(1999-2000) with an average of 29.65 which is almost same as the overall 
average of 29.05 but the high level of fluctuation makes the company more unreliable 
and un-stable. 
 
Nicholas Piramal is showing an overall trend of increasing excepting two years where 
it has registered declining EPS. It ranges in between 47.06(2003-04) and 8.33(2004-
05) with an average of 19.12 which is very low as compared to the overall average of 
29.05 for the same period. 
Sun Pharmaceuticals has shown a constant increasing trend through out the study 
period except decline in two or three occasions. But then also this company has 
managed to maintain it’s EPS with some degree of consistency. It ranges from 
49.36(1999-2000) to 15.94(2004-05) with an average of 31.27 which is higher than 
the overall average of 29.05 and no major fluctuations Sun Pharma is nicely poised to 
improve its performances in the coming times. 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the ratio of Earnings Per Share among different 
Pharmaceutical companies under study during the study period and for establishing 
relationship in the ratio of Earnings Per Share among different years for each 
(individual) company, F-Test ANOVA is used. The statements of hypothesis for the 
comparison among different companies and for comparison among different years for 
individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The ratio Earnings Per Share between different 
companies under study during the study period is same.” 
Alternate Hypothesis (H1):-  “The ratio of Earnings Per Share between different 
companies under study during the study period is not 
same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The ratio of Earnings Per Share between different years 
during the study period in each company under study is 
same.”  
Alternate Hypothesis (H1):-  “The ratio of Earnings Per Share between different years 
during the study period in each company under study is 
not same.” 
In the following Table 7.5(a) the calculation of F Test (ANOVA) is shown of 
Earnings Per Share for the Pharmaceutical Companies under study, during the study 
period. 
 
Table :  7.5(a)                
Table Showing calculation of F-Test (ANOVA) 
 
S V d f S.  S. M. S. S. F cal 
 
Column 7 4360.596819 622.9424027 1.819082973 
 
Row 7 4842.924619 691.8463741 2.020292652 
 
Error 49 16779.98101 342.448592   
 
Total 63 25983.50244   
  
  
 
The above Table 7.5(a) shows the F value of 1.82 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is lower than the table value of 2.16 hence the null hypothesis 
is accepted and the alternate hypothesis is rejected, which means that there are 
similarities among the different companies under study in the ratio of Earnings Per 
Share. F value of 2.02 at 5% level of significance and at (7,49) degree of freedom is 
lower than the Table value of 2.16 hence null hypothesis is accepted and alternate 
hypothesis is rejected, which means that there are similarities between different years’ 
ratios for all the individual companies. 
 
Hence it can be concluded that there are similarities in the Earnings Per Share ratio 
among different companies under study and there are similarities in the Earnings Per 
Share ratio between different years of each company. 
 
8.Calculation of Dividend Pay Out Ratio & its 
Statistical Analysis 
A company would be interested in the profit earned and its profitability situation, and 
this indicates the expectation of return on its investment of resources. After making 
investment in the form of financial and non-financial resources the company would be 
definitely interested in knowing and receiving and measuring the returns received. 
This refers to the profitability analysis and we have been discussing about the same in 
the current chapter. Now similar logic applies for the owners of the company. We can 
definitely make the independent analysis of the company as well as its investors as 
company is having its own identity which is distinct from its owners. 
 
Dividend analysis for the owner (investor) is having the similar significance as the 
profitability analysis is for the company. The success or the otherwise of their 
investment and their future relation with the company depends on the dividends 
received by them; hence dividend policy or dividend decision carries a tremendous 
importance for the company.  
 
Dividend decision is among the top three core areas of decision to be made by any 
business enterprise as far as its financial management is concerned. In the eyes of 
shareholders the real success of company is when they (shareholders) receive hefty 
amount of dividends, whatever intelligent or aware an investor may be his final view 
for the company’s profitability is the amount of dividend received. It is in this regard 
that the company makes very calculative decision of paying dividends, because 
regular payments of dividend would make fewer amounts available for ploughing 
back of profit. And the company has to make a right balance between the payment of 
dividends and retaining profits with the company. Ultimately the fact that “how often” 
a company has declared the dividend and “how much” is counted by the market.  
 
Dividend Payout ratio is the ratio of dividend declared to the amount available for 
equity shareholders. In other words this ratio measures the proportion of amount 
declared as dividend out of the total amount available to equity shareholders. As the 
amount left is ploughed back into the business or reinvested the remaining amount is 
referred as the retained earnings. If the Dividend Payout ratio is deducted from 100, 
the ratio of retained earnings is derived. Dividend payout ratio gives a clear indication 
of the dividend decision made by the financial manager of the company. This ratio is 
not a dedicated profitability ratio but definitely gives a fine view of profitability 
situation of the company. Unless the company is having some specific plans for the 
profits it would like to distribute the profits to the shareholders and earn the increased 
market price of the shares, along with the investors’ confidence. Let us examine this 
statement by making calculation of the dividend pay out ratio. The ratio is as under: 
 
Dividend pay out ratio=  
 
 
 
Table:  7.6:  
Table Showing Dividend Payout Ratio in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05 
                                                                      [All amounts = Rs. in Crores] 
Co. 97-98 98-99 99-
2000 
2000-
01 
2001-
02 
2002-
03 
2003-
04 
2004-
05 
Aurobindio 9.88 6.32 6.55 8.81 9.95 8.49 8.98 7.23 
Cadila 22.08 28.44 36.47 27.54 30.71 25.98 25 26.72 
Cipla 10.8 13.11 13.49 15.47 18.33 25.04 28.97 29.2 
Dr.Reddy 14.41 15.29 13.13 8.7 12.41 9.76 13.24 60.34 
IPCA 32.18 25.28 26.17 30.4 19.79 18.18 17.25 17.66 
Matrix 220 0 0 0 16.07 12.83 12.01 13.76 
Npiramal 60.66 35.93 36.38 35.81 42.48 24.06 27.53 58.65 
Sun 16.39 21.57 19.69 17.82 13.52 20.39 25.87 23.21 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
   Dividend paid to equity shareholders 
Amount available to equity shareholders 
Aurobindo Pharma seems to be fairly consistent in paying to its shareholders in the 
study period. This shows a concern for the shareholders and also the efficiency of the 
company to manage funds for its expansion and developmental activities. Dividend 
Payout Ratio (DPR) ranges between 9.95(2001-02) to 6.32(98-99) with an average 
rate of 8.28 which is although very low compared to the overall ratio of 23.95 for the 
same period, but the consistency of the company in providing for the dividend is 
impressive. 
Cadila Healthcare is showing a mixed trend of increase and decrease but with no 
major fluctuations which is good sign for any company. DPR of the company for the 
study period ranges between 36.47(1999-2000) and 22.08(97-98) with an average of 
27.87 which is better than the overall average of 23.95 for the same period.  
Cipla Ltd. is showing a very impressive and unique continuously increasing trend in 
the DPR for the study period. This makes the company the most favorite for the 
investors. This also proves that with the increasing margins the company is increasing 
the DPR which in real sense is passing on the profit due to efficiency to the investors 
who are the real owners of the company. The DPR of the company for the study 
period ranges in between 29.2(2004-05) and 10.8(97-98) with an average of 19.30 
which is although lesser compared to the overall average of 23.95 but the average has 
got no fluctuations whatever hence it’s the real average with which company is paying 
to its shareholders from the profits which are available to them. 
Dr. Reddy’s Laboratories is showing some mixed trends and with some amount of 
fluctuations. It ranges from 60.34(2004-05) to 8.7(2000-01) with an average of 18.41 
which is lower than the overall average of 23.95 for the same period. There is a 
significant increase in the dividend payout ratio of the last year of the study period 
(2004-05) compared to other previous years.  
IPCA is showing better ratio in terms of their values in the initial four years of the 
study period with no major fluctuations. But from the fifth year (2001-02) there is a 
decline observed in the dividend payout ratio of the company. It ranges between 32.18 
(97-98) to 17.25 (2003-04) with an average of 23.36 which is almost equal to the 
overall average 23.95 for the same period.  
Matrix Laboratories has not declared dividend for three consecutive years i.e. from 
98-99 to 2000-01 but is quite consistent for declaring dividends after that period. It 
ranges between 220(97-98) to 12.01(2003-04) with an average of 34.33 which is 
although higher than the overall average 23.95 but the amount of fluctuations which 
are involved in the ratios of the company makes it get counted as unstable as far as 
dividend declaration is concerned.  
Nicholas Piramal is showing a stable and consistent trend of the dividend payout ratio 
for the study period except in couple of years in between. A very high rate of DPR is 
observed in the first year of study period. After that a constant positive trend is 
observed for the four years and then the downfall for the two years but ultimately 
ended with a positive note in the year 2004-05. It ranges between 60.66(97-98) and 
24.06(2002-03) with an average of 40.19 which is far more better than the overall 
average 23.95 and more importantly the average is much more reliable. 
Sun Pharmaceuticals is showing a mixed trend but cannot be termed as a fluctuating 
ratio. It ranges between 25.87(2003-04) and 13.52(2001-02) with an average of 19.81 
which is lower than the overall average of 23.95 but the DPR seems to be promising 
for the company in the coming years. 
 
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the Dividend Payout Ratio among different 
Pharmaceutical companies under study during the study period and for establishing 
relationship in the Dividend Payout Ratio among different years for each (individual) 
company, F-Test ANOVA is used. The statements of hypothesis for the comparison 
among different companies and for comparison among different years for individual 
companies during the study period are as under: 
 
 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “The Dividend Payout Ratio between different 
companies under study during the study period is same.” 
 
Alternate Hypothesis (H1):-  “The Dividend Payout Ratio between different 
companies under study during the study period is not 
same.” 
 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The Dividend Payout Ratio between different years 
during the study period in each company under study is 
same.”  
Alternate Hypothesis (H1):-  “The Dividend Payout Ratio between different years 
during the study period in each company under study is 
not same.” 
 
In the following Table 7.6(a) the calculation of F Test (ANOVA) is shown of 
Dividend Payout Ratio for the Pharmaceutical Companies under study, during the 
study period. 
Table:  7.6(a)                
Table Showing calculation of F-Test (ANOVA) 
 
S V d f S.  S. M. S. S. F cal 
 
Column 7 5618.384344 802.6263348 1.04464823 
 
Row 7 6242.009794 891.7156848 1.160601355 
 
Error 49 37647.78351 768.3221124   
 
Total 63 49508.17764   
  
  
 
The above Table 7.6(a) shows the F value of 1.04 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is lower than the table value of 2.16 hence the null hypothesis 
is accepted and the alternate hypothesis is rejected, which means that there are 
similarities among the different companies under study in the Dividend Payout Ratio. 
F value of 1.16 at 5% level of significance and at (7,49) degree of freedom is 
lower than the Table value of 2.16 hence null hypothesis is accepted and alternate 
hypothesis is rejected, which means that there are similarities between different years’ 
ratios for all the individual companies. 
 
Hence it can be concluded that there are similarities in the Dividend Payout Ratio 
among different companies under study and there are similarities in the Dividend 
Payout Ratio between different years of each company. 
 
9.Calculation of Fixed Charges Cover Ratio  
Coverage ratios try to measure the amount available to pay the fixed expenses. Interest 
coverage ratio tries to find out the ratio of amount available to the interest payable. It 
can be considered as a margin of safety for the investors, as higher the ratio higher is 
the safety net for the investors. The ratio should be high, which shows the company’s 
ability to earn on the borrowed capital and also to pass on the additional benefits to the 
shareholders of the company. But too much of high ratio shows an opportunity 
missed, as it shows that although the company has enough capacity to pay higher 
amounts of interest but it did not took the calculated risk of borrowing more funds and 
earn a better revenues for the shareholders. 
 
Hence it can be said that higher ratio shows a safety for shareholders but too much 
high ratio shows the company is not able to take the advantage of “Trading on 
Equity”. And the lower ratio can be an alarm for the company towards the risks 
associated with the use of borrowed funds. 
The interest coverage ratio is used to test the firm’s debt-servicing capacity.1 The 
interest coverage ratio measures the number of times the interest is covered by funds 
that are available for their payment. 
 
The above ratio is good enough but it has a serious limitation of not considering the 
principal amount, in only considers the interest as the liability and tries to find the 
amount available to pay the interest and the ratio. Therefore a better ratio to interest 
coverage ratio is fixed charges coverage ratio, which tries to establish a relationship 
between the actual liability of interest and principal amount with the amount available 
to pay the liability. 
 
 
Fixed Charge Coverage Ratio  =  ------------------------------------------ 
 
 
 
 
 
 
 
 
Table: 7.7:  
Table Showing Fixed Charges Coverage Ratio in Pharmaceutical Companies under 
Study Period: 1997-98 to 2004-05 
                                                                      [All amounts = Rs. in Crores] 
Co. 97-98 98-99 99-
2000 
2000-
01 
2001-
02 
2002-
03 
2003-
04 
2004-
05 
Aurobindo 2.82 3.62 3.78 3 3.1 4.29 6.35 2.07 
Cadila 2.41 5.24 3.13 5.99 5.31 3.38 6.71 7.04 
Cipla 35.97 34.8 64.01 90.65 79.32 70.6 30.28 45.13 
Dr.Reddy 6.14 5.65 5.09 5.05 34.27 72.27 72.71 4.48 
IPCA 2.38 2.31 2.66 2.33 3.48 12.1 15.65 9.61 
Matrix 1.12 1.22 -2.16 3.32 4.5 4.32 8.26 20.63 
Npiramal 2.37 2.4 2.63 3.51 2.34 4.09 5.77 9.07 
Sun 6.16 6.1 9.67 19.91 52.88 269.97 82.22 10.77 
 
 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
Aurobindo Pharma is showing an almost increasing trend in the FCCR for the study 
period. A very high ratio of 6.35 in the year 2003-04 shows that there was a scope for 
“Trading on Equity” but in the next year itself the ratio declines to 2.07 which shows 
Earnings before Interest & Tax 
Interest 
that the company needs to take care of its earnings or it has to restrict use of borrowed 
funds. The sudden decline in the ratio can be attributed to decreased profits owing to 
decreased sales and increased costs. The ratio ranges between 6.35 (2003-04) and 
2.07(2004-05) with an average of 3.63 which is fairly lower than the overall average 
of 20.41 for the same study period. 
 
Cadila Healthcare is showing a mixed trend of FCCR. There is no particular trend 
observed in the ratio for the study period. It lies in between 7.04(2004-05) and 
2.41(97-98) with an average of 4.90 which is very low compared to the overall 
average of 20.41 for the study period. The ratio shows that company has got a fine 
balance between the interests and the profits. 
A very high ratio for Cipla Ltd. shows the lesser amount of borrowed funds with the 
company. Company is in a very sound position to pay interests as it is earning very 
high as compared to its fixed commitment. The ratio is in between 90.65(2000-01) 
and 30.28(2003-04) with an average of 56.35 which is very high as compared to the 
overall average of 20.41. One inference can be drawn from the ratio for the company 
that company is earning very high as compared to its fixed commitment, which means 
that the company is risk averse ; but has got a lot scope of trading on equity in real 
sense. 
 Dr. Reddy’s Laboratories is showing an interesting story as far as FCCR is concerned 
as for the first four years of the study period it is around 5 and suddenly in the year 
2001-02 the ratio has climbed to 34.27 and in the next year once again it increased to 
72.27. It lies between 72.27(2002-03) and 4.48(2004-05) with an average of 25.71 
which is better than the overall average of 20.41. 
IPCA Labs is showing a fairly consistent ratio in the first five years of the study 
period, but showed an increase in the last three years. It lies in between 15.65(2003-
04) and 2.31(98-99) with an average of 6.32 which is very low as compared to the 
overall average of 20.41. Company has to be very conscious with regard to its profit 
margins as it is too close to the fixed commitment. 
 
Matrix Laboratories is showing a steady increasing trend in the FCCR which can be 
an indication of its better profits and lesser borrowed funds. It lies in between 
20.63(2004-05) and -2.16(1999-2000) with an average of 5.15 which is very low as 
compared to the overall average of 20.41. There is a negative ratio in the figures for 
the study period which shows the weak financial state of the company. 
 
Nicholas Piramal is a steady increasing trend in the FCCR for the study period. It 
ranges in between 9.07(2004-05) and 2.34(2001-02) with an average of 4.02 which is 
very low as compared to the overall average of 20.41. 
 
Sun Pharmaceuticals is showing a clear increasing trend in the initial five years of the 
study period which is an indication of its increasing profits and lesser reliance on fixed 
cost funds. But later on the company has used some fixed cost funds and the ratio has 
declined. It lies in between 269.97(2002-03) and 6.1(98-99) with an average of 57.21 
which is higher as compared to the overall average of  20.41.  
 
F – Test (ANOVA) Analysis 
In order to establish relationship in the Fixed Charges Cover Ratio among different 
Pharmaceutical companies under study during the study period and for establishing 
relationship in the Fixed Charges Cover Ratio among different years for each 
(individual) company, F-Test ANOVA is used. The statements of hypothesis for the 
comparison among different companies and for comparison among different years for 
individual companies during the study period are as under: 
 
Hypothesis for comparison between different companies:- 
Null Hypothesis (H0):-  “Fixed Charges Cover Ratio between different 
companies under study during the study period is same.” 
 
Alternate Hypothesis (H1):-  “Fixed Charges Cover Ratio between different 
companies under study during the study period is not 
same.” 
 
Hypothesis for comparison between different years:- 
 Null Hypothesis (H0):-  “The Fixed Charges Cover Ratio between different 
years during the study period in each company under 
study is same.” 
Alternate Hypothesis (H1):-  “The Fixed Charges Cover Ratio between different 
years during the study period in each company under 
study is not same.” 
 
 
In the following Table 7.7(a) the calculation of F Test (ANOVA) is shown of Fixed 
Charges Cover Ratio for the Pharmaceutical Companies under study, during the study 
period. 
Table:  7.7(a)                
Table Showing calculation of F-Test (ANOVA) 
 
S V d f S.  S. M. S. S. F cal 
 
Column 7 31166.46434 4452.352048 4.063395222 
 
Row 7 14047.06704 2006.723862 1.831416758 
 
Error 49 53690.38413 1095.722125   
 
Total 63 98903.9155   
  
  
 
 
 
The above Table 7.7(a) shows the F value of 4.06 at 5% level of significance and at 
(7,49) degree of freedom for different Pharmaceutical Companies under study during 
the study period which is higher than the table value of 2.16 hence the null hypothesis 
is rejected and the alternate hypothesis is accepted, which means that there are no 
similarities among the different companies under study in the Fixed Charges Cover 
Ratio. F value of 1.83 at 5% level of significance and at (7,49) degree of freedom is 
lower than the Table value of 2.16 hence null hypothesis is accepted and alternate 
hypothesis is rejected, which means that there are similarities between different years’ 
ratios for all the individual companies. 
 
Hence it can be concluded that there are no similarities in the Fixed Charges Cover 
Ratio among different companies under study and there are similarities in the Fixed 
Charges Cover Ratio between different years of each company. 
 
 
 
10. Conclusion  
 
From the above calculation of ratios there can be some general conclusions drawn 
from the statistical analysis. From the study of seven individual ratio and their 
comparison among companies for the study period and individual companies 
comparison for different years, following conclusions can be drawn: 
 
 There is no significant difference in the Return on Investment ratio among different 
companies under study and there is no significant difference in the Return on 
Investment ratio between different years of each company. 
 
 There are no similarities in the Return on Gross Capital Employed ratio among 
different companies under study and there are similarities in the Return on Gross 
Capital Employed ratio between different years of each company. 
 
 There are similarities in the Return on Net Capital Employed ratio among different 
companies under study and there are similarities in the Return on Net Capital 
Employed ratio between different years of each company 
 
 There are similarities in the Return on Proprietor’s Net Capital Employed ratio 
among different companies under study and there are similarities in the Return on 
Proprietor’s Net Capital Employed ratio between different years of each company. 
 
 There are similarities in the Earnings Per Share ratio among different companies 
under study and there are similarities in the Earnings Per Share ratio between 
different years of each company. 
 There are similarities in the Dividend Payout Ratio among different companies 
under study and there are similarities in the Dividend Payout Ratio between 
different years of each company. 
 There are no similarities in the Fixed Charges Cover Ratio among different 
companies under study and there are similarities in the Fixed Charges Cover Ratio 
between different years of each company. 
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1. Concept of Common Size Income Statement  
The real test of ability or efficiency of any activity is done when it is compared with 
something similar to it. In this research work it has been an effort to look into the 
details of the profit and profitability of the various selected companies.  This chapter 
is an addition to the exercise of making an analysis of profitability of pharmaceutical 
companies of India. Any assessment is not complete till it is compared with some 
base; similarly, in this research work also we are now trying to compare the different 
years’ income statements of the companies under study. 
 
In order to carry out some real genuine comparison it needs to convert the different 
statements into a common measure. Like income of Rs. 1,00,000 cannot be compared 
with income of 1,00,000 $ , as both the figures are in different currencies, similarly 
the statements of different years cannot be compared directly, they need to have 
something in common to compare, hence here the comparison is made by preparing a 
special purpose statement termed as “Common Size Income Statement”. As every 
year the scale of operation can be different of the same company and so the scale of 
amount expended and the income received would be definitely different, in this 
situation the income statement of different years cannot be compared directly, it can 
turn out to be meaningless. Financial statements when read with absolute figures are 
not easily understandable, sometimes they are even misleading.1 Hence it is required 
to convert the figures of income statement into some common base.  
This type of analysis is also referred as “Vertical Analysis”. In profit and loss account 
or income statement sales figure is assumed to be equal to 100 and all other figures are 
expressed as percentage of sales. 
 
 2. Steps for preparing the Common size Income 
 Statement 
(a) Net sales are taken as base for every year, for whatever number of years’ 
common size income statement is to be prepared. 
 
(b) The ratio of each item and each account category is found out by dividing the 
respective amounts by the base figure and multiplying by 100. 
 
(c) The common size income statement has been prepared for each selected 
Pharmaceutical company separately. 
 
 
3. Advantages of Common Size Income Statements 
The following are the benefits or the advantages of common size income statements 
and thus they have been used as a tool of analysis for the present study. 
(a) A precise and perfect comparison of yearly performance of the company can 
be done. 
(b) Profitability situation of individual years and of all years can be done. 
 
(c) The effects of some small, medium or large scale decision on profit can be 
identified. 
 
(d) Any abnormalities in any year however meager can be highlighted. 
 
(e) The effect of any deliberate change made by the management in any area can 
be traced, if any. 
 
(f) The progress or otherwise in cost cutting and improved revenue generation 
exercise can be identified. 
 
 
4. Limitations of Common Size Income Statements 
 
Although a very method but still it suffers from limitations, which are described as 
under: 
 
(a) As per the concept of GIGO (Garbage In Garbage Out) the quality of the  
            common size statement depends totally on the quality of data that are used for  
            preparing the statements.      
 
(b) A small calculative error could destroy the objective of preparing the      
            statements and will be totally misleading. 
 
(c) If one or more years are abnormal in terms of some events then the different               
            statements can never be compared.         
 
(d) This tool cannot be used as an end tool, as such in order to make some  
            generalizations or some findings it is essential to analyze the statements,   
            hence an expert and informed analyst is what required even after preparing  
            this statement. 
 
 
 
 
 
 
5. Common Size Income Statements of sample units 
 
9. AUROBINDO PHARMACEUTICALS LTD. 
 
Table: 8.1:  
 
 
The following page has the Table Showing the Common Size Income Statement for 
Aurobindo Pharmaceuticals for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 Table 8.1 
        
           
Table Showing the Common Size 
the period of 8 (Eight) Years from 1997
           
 
          
 
          
  97-98 98-99 99-2000 2000-01 2001-02 
Particulars Amt. % Amt. % Amt. % Amt. % Amt. % 
Sales 295.31 100.00 550.03 100.00 739.9 100.00 972.52 100.00 1007.96 100.00
Less:COGS 253.48 85.84 468 85.09 626.78 84.71 858.44 88.27 909 90.18
Operating Profit 41.83 14.16 82.03 14.91 113.12 15.29 114.08 11.73 98.96 9.82
Add:Non-op. 
Income 1.48 0.50 2.79 0.51 9.29 1.26 35.23 3.62 54.44 5.40
Total 43.31 14.67 84.82 15.42 122.41 16.54 149.31 15.35 153.4 15.22
Less:Non-op. Exp. 3.41 1.15 8.39 1.53 11.22 1.52 24.2 2.49 22.17 2.20
Profit before 
Tax&Int. 39.9 13.51 76.43 13.90 111.19 15.03 125.11 12.86 131.23 13.02
Less: Interest 14.13 4.78 21.1 3.84 29.4 3.97 41.68 4.29 42.39 4.21
Profit before Tax 25.77 8.73 55.33 10.06 81.79 11.05 83.43 8.58 88.84 8.81
Less: Tax 1.98 0.67 5.19 0.94 7.19 0.97 15.12 1.55 20.33 2.02
Net Profit  23.79 8.06 50.14 9.12 74.6 10.08 68.31 7.02 68.51 6.80
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
From table 8.1 showing the common size profit and loss account it is evident that cost 
of goods sold has remained steady over a period of four years from 1997-98 to 2000-
01 to around 85% but increased in the fifth year of study period to 90.18% but again it 
became normal for the last three years of the study period.  
 
Operating profit has remained steady for initial four years of the study period but 
showed decrease in the fifth owing to increased Cost of goods sold. Operating profit 
have again shown increasing trend in the sixth and seventh year but a decline in the 
last year i.e. in the year 2004-05.  
 
The non-operating income has shown an increasing trend in the initial five years but a 
declining trend in the last three years.  
 
The profit before interest and tax is showing an increasing trend for continuous seven 
years in the study period with a sudden decline in the profit in the last year to almost 
50% lesser than the previous year. Even the Profit as percentage of sales has declined 
from average 15% to 7% in the   last year.  
 
Net profit figure lies between Rs. 23.79 crores in the first year and Rs. 127.03 crores 
in the year 2003-04. There is a clear increasing trend found in the net profit for the 
company in the initial three years, afterwards both absolute and percentage to sales 
has shown a fluctuating trend. There is huge fluctuation observed in the last year as 
the net profit has decreased 70% absolutely and 60% decrease has been observed in 
the rate of net profit to sales. Costs including non-operating expenses have increased 
and income has declined which has resulted in decreased profits in the last year.  
Hence we can conclude that performance of the company is mixed one! As such there 
are a good number of ups and downs observed in the absolute and percentage profit to 
sales during the entire study period and some of the fluctuations are pretty abnormal 
too. 
 
 
 
10. CADILA HEALTHCARE LTD. 
 
Table: 8.2:  
 
The following page has the Table Showing the Common Size Income Statement for 
Cadila Healthcare Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 8.2 
        
           
Table Showing the Common Si
the period of 8 (Eight) Years from 1997
           
           
  97-98 98-99 99-2000 2000-01 2001-02 
Particulars Amt. % Amt. % Amt. % Amt. % Amt. % 
Sales 303.58 100.00 358.4 100.00 475.7 100.00 502.3 100.00 581.7 100.00
Less:COGS 256.43 84.47 296.18 82.64 388.28 81.62 408.04 81.23 472.28 81.19
Operating Profit 47.15 15.53 62.22 17.36 87.42 18.38 94.26 18.77 109.42 18.81
Add:Non-op. 
Income 4.37 1.44 7.45 2.08 10.65 2.24 32.69 6.51 27.3 4.69 
Total 51.52 16.97 69.67 19.44 98.07 20.62 126.95 25.27 136.72 23.50
Less:Non-op. Exp. 16.58 5.46 24.87 6.94 31.57 6.64 41.95 8.35 46.42 7.98 
Profit before 
Tax&Int. 34.94 11.51 44.8 12.50 66.5 13.98 85 16.92 90.3 15.52
Less: Interest 14.49 4.77 8.55 2.39 21.27 4.47 14.18 2.82 17 2.92 
Profit before Tax 20.45 6.74 36.25 10.11 45.23 9.51 70.82 14.10 73.3 12.60
Less: Tax 3.5 1.15 5 1.40 7.54 1.59 5.25 1.05 6.2 1.07 
Net Profit  16.95 5.58 31.25 8.72 37.69 7.92 65.57 13.05 67.1 11.54
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From table 8.2 showing the common size profit and loss account it is evident that 
Sales have increased over the entire study period and there is a constant increase in the 
sales in every year. The company has shown a disciplined performance in the cost of 
goods sold as its proportion to sales has almost remained steady in the study period. 
The cost of goods sold in the first year was 84.47% of sales which was the highest and 
the lowest ratio to sales of 81.19% was observed in the fifth year, but it can be easily 
said that more or less there is not much fluctuation observed in the ratio of cost of 
goods sold to sales for Cadila Healthcare limited. 
 
There is a constant increase observed in the non-operating income but a un-usual 
increase was observed in the seventh year (2003-04) which was more than double of 
the sixth (previous) year.  
 
Profit before interest and tax has shown a constant increase for the study period with a 
slight fluctuating trend in the last four years. In the first year the rate of profit was 
11.51% and the maximum rate of 17.20% was attained in the year 2003-04. Although 
there is some fluctuating trend observed in the profit in the last four years but absolute 
profit has decreased for the first time in the last year.  
 
There is a fluctuating trend observed in the payment of interest every year in the study 
period which shows the in-consistent use of borrowed funds. 
 
There is a clear increasing trend observed in the figures of Net Profit in the initial five 
years of the study period with a fluctuating trend in the last three years. Where as the 
rate of net profit to sales has remained more or less fluctuating in the entire study 
period. The amount of net profit lies between Rs. 16.95 crores in the first year i.e. 
1997-98 and  
Rs. 142.9 crores in the seventh year i.e. 2003-04. 
 
Hence we can conclude that performance of the company is fairly good as much effort 
is done behind maintaining the increasing trend of net profit, which is successful also 
to a certain extent but even then there is an amount of fluctuation in the rate of net 
profit to sales during the entire study period although not very high. 
 
 
 
11. CIPLA  LTD. 
 
Table: 8.3:  
 
 
The following page has the Table Showing the Common Size Income Statement for 
Cipla Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 
 
 
 
 
 Table 8.3 
        
           
Table Showing the Comm
the period of 8 (Eight) Years from 1997
           
           
           
  97-98 98-99 99-2000 2000-01 2001-02
Particulars Amt. % Amt. % Amt. % Amt. % Amt. %
Sales 514.43 100.00 617.16 100.00 759.75 100.00 1047.51 100.00 1385.84 100.00
Less:COGS 385.94 75.02 464.75 75.30 592.02 77.92 819.89 78.27 1078.01 77.79
Operating Profit 128.49 24.98 152.41 24.70 167.73 22.08 227.62 21.73 307.83 22.21
Add:Non-op. 
Income 26.59 5.17 27.99 4.54 31.64 4.16 38.1 3.64 43.03 3.10
Total 155.08 30.15 180.4 29.23 199.37 26.24 265.72 25.37 350.86 25.32
Less:Non-op. Exp. 16.25 3.16 21.38 3.46 23.97 3.15 25.5 2.43 37.55 2.71
Profit before 
Tax&Int. 138.83 26.99 159.02 25.77 175.4 23.09 240.22 22.93 313.31 22.61
Less: Interest 3.86 0.75 4.57 0.74 2.74 0.36 2.65 0.25 3.95 0.29
Profit before Tax 134.97 26.24 154.45 25.03 172.66 22.73 237.57 22.68 309.36 22.32
Less: Tax 33 6.41 39.5 6.40 39.6 5.21 58.5 5.58 74.25 5.36
Net Profit  101.97 19.82 114.95 18.63 133.06 17.51 179.07 17.09 235.11 16.97
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From table 8.3 showing the common size profit and loss account it is evident that the 
sales is increasing every year in the entire period of study with Rs. 514.43 Crores in 
the first year and Rs. 2327.63 Crores in the last year. 
Cost of goods sold which is a collection of several cost is steady in the initial two 
years after that it is also increasing as a percentage of sales. It was 75.02% of sales in 
the first year which is lowest in the entire study period and it was highest 81.56% in 
the seventh year (2003-04). 
 
Operating Profit margin ratio was steady in the initial two years afterwards it has 
shown a constant decline, albeit decline is very less.  
 
Profit before interest and taxes have increased constantly in the entire study period. 
The ratio of profit to sales after remaining steady in the initial years have shown slight 
decline in the middle years and trying to stabilize in the last three years.  
 
Interest expenses have also shown over the study period which shows that company is 
increasing debt in its capital structure. 
 
Finally net profit has increased in the entire study period for the company, but with 
decreased rates. The ratio of net profit to sales has declined over the study period with 
trying to stabilize in the last year. The ratio lies in between 19.82% in the first year to 
15.53% in the seventh year i.e. 2003-04 which shows that there is a clear declining 
trend of net profit to sales ratio for this company. 
 
Finally it can be concluded that the rate of profit to sales is much higher in this 
company compared to other companies, it is almost double than other companies, but 
even this company is not successful in maintaining its rate of profit to sales. And there 
is a clear decreasing trend observed in this ratio in this company. 
 
 
 
12. DR. REDDY’S LABORATORIES LTD. 
 
Table: 8.4:  
 
 
The following page has the Table Showing the Common Size Income Statement for  
Dr. Reddy’s Laboratories Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-
05 
 
 
 
 
 
 
 
 
 
Table 8.4 
        
           
Table Showing the Common Size Income Statemen
the period of 8 (Eight) Years from 1997
           
           
           
  97-98 98-99 99-2000 2000-01 2001-02
Particulars Amt. % Amt. % Amt. % Amt. % Amt. %
Sales 331.62 100.00 425.86 100.00 493.02 100.00 984.11 100.00 1557.78 100.00
Less:COGS 249.65 75.28 326.27 76.61 377.43 76.55 710.48 72.20 969.47 62.23
Operating Profit 81.97 24.72 99.59 23.39 115.59 23.45 273.63 27.80 588.31 37.77
Add:Non-op. Income 3.57 1.08 5.68 1.33 4.87 0.99 17.49 1.78 85.89 5.51
Total 85.54 25.79 105.27 24.72 120.46 24.43 291.12 29.58 674.2 43.28
Less:Non-op. Exp. 21.82 6.58 32.67 7.67 37.29 7.56 72.19 7.34 197.24 12.66
Profit before 
Tax&Int. 63.72 19.21 72.6 17.05 83.17 16.87 218.93 22.25 476.96 30.62
Less: Interest 10.38 3.13 12.84 3.02 16.35 3.32 43.38 4.41 14.15 0.91
Profit before Tax 53.34 16.08 59.76 14.03 66.82 13.55 175.55 17.84 462.81 29.71
Less: Tax 4.5 1.36 8 1.88 6.5 1.32 31.08 3.16 11.12 0.71
Net Profit for the 
Year 48.84 14.73 51.76 12.15 60.32 12.23 144.47 14.68 451.69 29.00
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From table 8.4 showing the common size profit and loss account it is evident that the 
sales is increasing every year in the entire period of study with Rs. 331.62 Crores in 
the first year and Rs. 1625.08 Crores in the last year. 
 
Cost of goods sold which is a collection of several cost is steady in the initial three 
years after that it is decreasing as a percentage of sales. It was 75.28% of sales in the 
first year and 87.22% in the last year of the study period. COGS showed a very fine 
performance in three year from 2000-01 to 2002-03 wherein it touched the lowest 
62.23%. But last two years showed an increasing trend in the Cost of Goods sold 
including a eight year high(87.22%)  in the last year. 
 
Operating Profit margin ratio is closely related to the Cost of Goods sold and hence 
the operating margin ratio was maximum when the cost of goods sold ratio was 
minimum. Operating profit margin ratio is maximum 37.77% in the year 2001-02 and 
minimum 12.78% in the last year when cost of goods sold was maximum. 
 
Normally it is found that Profit before interest and taxes increases constantly. But in 
the case of this company the absolute amount of profit before interest and taxes is 
showing decline from 2002-03 and ended at the eight year low in the last year of the 
study period. Even as a ratio profit before interest and taxes is showing a clear 
declining trend from the year 2002-03 and the ratio is least in the last year of the study 
period. 
 
Interest expenses have also shown over the study period which shows that company is 
increasing debt in its capital structure. 
Finally net profit has increased in the initial five years but with the decline from sixth 
year the profit has been declining till end. The ratio of net profit to sales has remained 
quite fluctuating over the study period. The ratio lies in between 29% in the fifth year 
to 3.92% in the eighth year i.e. 2004-05 which shows that there was a clear increasing 
trend in the performance in the initial five years and then the decline has started in the 
last three years taking to minimum in the last year. 
 
Finally it can be concluded that the expenses were in control in the initial period of 
five years and then they have shown an increasing trend, which makes it clear that the 
company has failed to control its costs. The revenues have increased but at a declining 
rate and the last year has been miserable for the company in more than one ways. 
From the sixth year 2002-03 the margins are declining and hits bottom in the last year 
of the study period. This gives an alarming signal to the financial performance of the 
company and it needs to improve on several fronts to get things back on track. 
 
  
 
13. IPCA LABORATORIES LTD. 
 
 
Table: 8.5:  
The following page has the Table Showing the Common Size Income Statement for  
IPCA Laboratories Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
Table 8.5 
        
           
Table Showing the Common Size
the period of 8 (Eight) Years from 1997
           
           
           
  97-98 98-99 99-2000 2000-01 2001-02 
Particulars Amt. % Amt. % Amt. % Amt. % Amt. % 
Sales 282.74 100.00 335.66 100.00 363.31 100.00 385.38 100.00 444.18 100.00
Less:COGS 252.59 89.34 297.35 88.59 319.12 87.84 345.21 89.58 376.7 84.81
Operating Profit 30.15 10.66 38.31 11.41 44.19 12.16 40.17 10.42 67.48 15.19
Add:Non-op. Income 11.03 3.90 10.36 3.09 10.1 2.78 11.4 2.96 13.27 2.99
Total 41.18 14.56 48.67 14.50 54.29 14.94 51.57 13.38 80.75 18.18
Less:Non-op. Exp. 7.77 2.75 9.56 2.85 11.16 3.07 13.13 3.41 24.71 5.56
Profit before 
Tax&Int. 33.41 11.82 39.11 11.65 43.13 11.87 38.44 9.97 56.04 12.62
Less: Interest 14.01 4.96 16.94 5.05 16.21 4.46 16.47 4.27 16.12 3.63
Profit before Tax 19.4 6.86 22.17 6.60 26.92 7.41 21.97 5.70 39.92 8.99
Less: Tax -0.05 -0.02 0.75 0.22 0.8 0.22 1.5 0.39 7.9 1.78
Net Profit for the 
Year 19.45 6.88 21.42 6.38 26.12 7.19 20.47 5.31 32.02 7.21
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From table 8.5 showing the common size profit and loss account of IPCA Labs it is 
evident that the sales is increasing every year in the entire period of study with Rs. 
282.74 Crores in the first year and Rs. 721.74 Crores in the last year. 
 
Percentage of Cost of goods sold to sales can be considered as a strong area for the 
company. It was 89.34% of sales in the first year and 83.05% in the last year of the 
study period. COGS showed a very fine performance in the entire study period which 
is evident as it has decreased as a ratio over the period of study 
 
Operating Profit margin ratio is closely related to the Cost of Goods sold and hence 
the operating margin ratio is also showing a positive trend in the entire study period. 
The ratio of operating margin to sales was 10.66% in the first year of the study period 
and it was 16.95% in the last year of the study period which shows that there is an 
increasing trend found in the operating profit margin ratio. 
 
Profit before interest and taxes amount is increasing constantly and along with it the 
ratio of profit to sales is also more or less increasing found in the study period. 
Although the ratio is not too consistent but there are no major fluctuations observed in 
this ratio for the study period. 
 
Net profit has shown an increasing trend in the entire study period, with just one year 
2000-01 as exception. As cost of goods sold have also increased as a ratio to sales in 
that year and hence the percentage of net profit to sales has also decreased in that year. 
Although there is no clear increasing trend observed in the ratio of net profit to sales 
but even then the company is fairly consistent. The net profit margin ratio lies 
between 5.31 in the year 2000-01 and 12.21 in 2003-04. 
 
Finally it can be concluded that the major expenses were in control in the entire period 
of study. The revenues have shown increase but the company is not able to maintain a 
consistent increasing rate of profit margin. Except couple of deviations the company 
has shown a reasonably good performance during the study period. 
 
 
 
14. MATRIX LABORATORIES LTD. 
 
Table: 8.6:  
 
 
The following page has the Table Showing the Common Size Income Statement for  
Matrix Laboratories Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 
 
 
 
 
 
 Table 8.6 
        
           
Table Showing the Common Size In
the period of 8 (Eight) Years from 1997
           
           
           
  97-98 98-99 99-2000 2000-01 2001-02 
Particulars Amt. % Amt. % Amt. % Amt. % Amt. % 
Sales 27.51 100.00 40.73 100.00 45.19 100.00 60.78 100.00 102.18 100.00 
Less:COGS 25.42 92.40 37.27 91.51 49.1 108.65 60.46 99.47 91.06 89.12 
Operating Profit 2.09 7.60 3.46 8.49 -3.91 -8.65 0.32 0.53 11.12 10.88 
Add:Non-op. 
Income 0.14 0.51 0.01 0.02 0.01 0.02 7.12 11.71 1.89 1.85 
Total 2.23 8.11 3.47 8.52 -3.9 -8.63 7.44 12.24 13.01 12.73 
Less:Non-op. Exp. 0.66 2.40 0.89 2.19 1.83 4.05 1.2 1.97 3.19 3.12 
Profit before 
Tax&Int. 1.57 5.71 2.58 6.33 -5.73 -12.68 6.24 10.27 9.82 9.61 
Less: Interest 1.4 5.09 2.11 5.18 2.65 5.86 1.88 3.09 2.18 2.13 
Profit before Tax 0.17 0.62 0.47 1.15 -8.38 -18.54 4.36 7.17 7.64 7.48 
Less: Tax 0.02 0.07 0.05 0.12 0.21 0.46 0.16 0.26 3.16 3.09 
Net Profit for the 
Year 0.15 0.55 0.42 1.03 -8.59 -19.01 4.2 6.91 4.48 4.38 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
  
 
 
 
 
 
 
 
 
 
 
 
 
From table 8.6 showing the common size profit and loss account of Matrix Labs it is 
evident that the sales is increasing every year in the entire period of study with Rs. 
27.51 Crores in the first year and Rs. 671.69 Crores in the last year of the study 
period. 
 
A fluctuating trend is visible in the cost of goods sold for the company in the 
beginning of the study period and it is trying to stabilize in the end of the period. In 
the year 1999-2000 the cost is more than revenues which caused a situation of loss, 
but after that year the cost of goods sold as a percentage to sales is continuously 
declining. This is an indicator of how the company has made a come-back and that too 
very effective. 
  
Except two years i.e. 1999-2000 and the next year 2000-2001 operating profit margin 
have been showing an increasing trend. The ratio of operating margin to sales was 
2.09 in the first year 1997-98 and it was 26.87 in the last year 2004-05. This shows the 
company has made noteworthy progress in its net profit margin. 
 
There is a huge amount fluctuation observed in the profit before interest and taxes. 
Profit has increased by more than 10 times in the year 2002-03 compared to its 
previous year 2001-02. Afterwards it has shown a constant trend. There is a 
significant increase observed in the profit before interest and taxes, as it was 1.57 
crore in the first year 1997-98 and it was 168.47 in the last year of the study period. 
 
 
 
Net profit has shown an increasing trend in the entire study period, with those two 
years  as exception. As cost of goods sold have also increased as a ratio to sales in that 
year and hence the percentage of net profit to sales has also decreased in that year. 
After the year in which company recovered from the loss it has made significant 
progress in the profits. The net profit for the company was just 15 lakhs in the first 
year of the study period and in the last year of the study period the profit was 129.54 
crores which shows the speedy and strong recovery of the company from the financial 
difficulty. 
 
Finally it can be concluded that although there are some big fluctuations observed in 
the profit during the study period but in the last three years company has recovered 
very well and is able to compete with the big giants of the industry. The ability to 
come out so quickly and strongly from the losses can be a strong ability for the 
company. 
 
 
 
15. NICHOLAS PIRAMAL INDIA LTD. 
 
Table: 8.7:  
 
 
The following page has the Table Showing the Common Size Income Statement for  
Nicholas Piramal Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 Table 8.7 
        
           
Table Showing the Common Si
the period of 8 (Eight) Years from 1997
           
           
           
  97-98 98-99 99-2000 2000-01 2001-02 
Particulars Amt. % Amt. % Amt. % Amt. % Amt. % 
Sales 534.64 100.00 429.99 100.00 486.48 100.00 566.76 100.00 946.48 100.00
Less:COGS 424.33 79.37 339.38 78.93 398.68 81.95 456.83 80.60 781.85 82.61
Operating Profit 110.31 20.63 90.61 21.07 87.8 18.05 109.93 19.40 164.63 17.39
Add:Non-op. Income 14.89 2.79 39.73 9.24 40.6 8.35 34.03 6.00 60.14 6.35
Total 125.2 23.42 130.34 30.31 128.4 26.39 143.96 25.40 224.77 23.75
Less:Non-op. Exp. 70 13.09 45.55 10.59 41.04 8.44 41.41 7.31 98.11 10.37
Profit before 
Tax&Int. 55.2 10.32 84.79 19.72 87.36 17.96 102.55 18.09 126.66 13.38
Less: Interest 23.3 4.36 35.38 8.23 33.22 6.83 29.22 5.16 54.07 5.71
Profit before Tax 31.9 5.97 49.41 11.49 54.14 11.13 73.33 12.94 72.59 7.67
Less: Tax 4.9 0.92 5.44 1.27 7.16 1.47 6.87 1.21 24.36 2.57
Net Profit for the 
Year 27 5.05 43.97 10.23 46.98 9.66 66.46 11.73 48.23 5.10
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the common size statement of Nicholas Piramal it can be observed that the sales 
figures are not stable in the initial three years, after that it has shown a steady increase. 
As far as cost of goods sold is concerned it is also showing an increasing trend as a 
percentage of sales. It was 79.37% of sales in the first year of the study period and it 
was 85.83% of sales in the last year of the study period, which shows that costs have 
increased and company is not much successful in controlling the costs. Although the 
increase is of 5% but it does matter when it is already around 80%, as this would 
affect the overall profitability. 
 
Operating profit as a percentage of sales has also decreased a bit due to increase in 
cost of goods sold. It was 20.63% in the first year and 21.07% of sales in the second 
year but it is found as low as 18.44% and 14.17% in the last years of the study period.  
 
There is one positive point observed, which is the decrease in the percentage of non-
operating expenses ratio to sale. It was 13.09% in the first year which is found 
reduced to 7.41% in the last year of the study period, which shows that company has 
controlled its other costs. 
 
There is also an increase observed in the figures of Profit before interests and taxes. It 
was 10.32% in the first year of the study period and 16.73% in the last year of the 
study period, which shows that margins have improved over the period. 
 
There is also significant improvement observed in the ratio of net profit to sales, 
which can be considered as a major and important indicator of profitability of the 
company. It was mere 5.05% in the first year (1997-98) of the study period which has 
improved to 12.25% in the last year (2004-05) of the study period. 
 
Hence it can be concluded that although the company has not been able to control its 
main costs but it has successfully control and reduced its non-operating costs and also 
increased its revenues which has led to improvement in the overall profit margin of 
the company over the period of time. 
 
 
 
16. SUN PHARMACEUTICALS INDUSTRIES LTD. 
 
 
Table: 8.8:  
 
 
The following page has the Table Showing the Common Size Income Statement for  
Sun Pharmaceuticals Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 
 
 
 
 
Table Number 8.8 
       
           
Table Showing the Common Size Income Statemen
the period of 8 (Eight) Years from 1997
           
           
           
 
Table 8.8 
        
           
Table Showing the Common Size Incom
the period of 8 (Eight) Years from 1997
           
           
           
  97-98 98-99 99-2000 2000-01 2001-02 
Particulars Amt. % Amt. % Amt. % Amt. % Amt. % 
Sales 279.77 100.00 358.11 100.00 478.35 100.00 613.78 100.00 753.1 100.00
Less:COGS 214.75 76.76 275.73 77.00 359.78 75.21 451.58 73.57 542.48 72.03
Operating Profit 65.02 23.24 82.38 23.00 118.57 24.79 162.2 26.43 210.62 27.97
Add:Non-op. 
Income 14.7 5.25 8.58 2.40 12.23 2.56 7.33 1.19 5.88 0.78 
Total 79.72 28.49 90.96 25.40 130.8 27.34 169.53 27.62 216.5 28.75
Less:Non-op. Exp. 11.53 4.12 18.02 5.03 30.09 6.29 17.25 2.81 25.61 3.40 
Profit before 
Tax&Int. 68.19 24.37 72.94 20.37 100.71 21.05 152.28 24.81 190.89 25.35
Less: Interest 11.07 3.96 11.95 3.34 10.41 2.18 7.65 1.25 3.61 0.48 
Profit before Tax 57.12 20.42 60.99 17.03 90.3 18.88 144.63 23.56 187.28 24.87
Less: Tax 1 0.36 1.95 0.54 6.64 1.39 9.45 1.54 16 2.12 
Net Profit  56.12 20.06 59.04 16.49 83.66 17.49 135.18 22.02 171.28 22.74
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
  
 
 
 
 
 
 
 
 
 
There is a noteworthy increase observed in the sales of the Sun Pharmaceuticals Ltd. 
for  the period of study. The sales was Rs. 279.77 Crores in the first year (1997-98) of 
the study period which went on to increase to Rs. 1263.86 Crores in the last year of 
the study period (2004-05). 
 
The company has made significant improvement in its percentage of cost of goods 
sold to sales margin. It was as high as 76.76% in the first year which went as low as 
68.07% in 2003-04, this shows that company has made serious efforts in controlling 
its cost and successfully brought down its costs over the period of time. 
 
Ratio of operating margin to sales has also shown considerable improvement. It was 
23.24% in the first year which went on to increase to 31.93%, although a decrease was 
observed in the last year of the study period, overall the ratio has shown improvement 
in the entire study period which is a healthy sign for the company. 
 
Profit before interest and taxes has also shown improvement as it lies in between 
21.05 (99-2000) and 29.82 (2003-04) during the period of study. A minor decrease is 
observed in the last year but as it’s a last year no trend can be observed from the 
movement of the ratio in the last year. As far as amounts are concerned it was 
Rs.68.19 crores in the first year and Rs. 356.6 crores in the last year of the study 
period. 
 
The final indicator of the overall profitability is Net Profit in the common size 
statement. The ratio of net profit to sales has improved over the period of time from 
20.06% (1997-98) to 24.19% (2004-05). This improvement is due to controlling the 
costs and improvement in the revenues. Even company has reduced the use of fixed 
charged funds which helped them to reduce their costs too and hence overall profits 
have shown much improvement. 
 
Hence it can be concluded that overall profitability and financial performance of the 
company has improved. Although the improvement is not very significant but it 
indeed is eye-catching. If revenues can be increased and costs can be controlled like in 
the past then the company can still do better in the coming times. 
 
The non-operating income is showing a fluctuating trend with highest Rs. 53.36 in the 
last year of study period while lowest of Rs. 5.88 in the year 2001-02. Profit before 
interest and tax is showing a clear increasing trend with highest in the last year of 
study period which narrates a positive growth story of the company.  Even the rate of 
profit before interest and tax is increasing at although lesser rate, but it is steadily 
increasing. Finally net profit is also having increasing trend with the increasing rate. 
 
 
6. Conclusion 
Aurobindo Pharmaceuticals has shown a mixed performance. As such there are a good 
number of ups and downs observed in the absolute and percentage profit to sales 
during the entire study period and some of the fluctuations are pretty abnormal too. 
 
Performance of Cadila Healthcare is fairly good as much effort is done behind 
maintaining the increasing trend of net profit, which is successful also to a certain 
extent but even then there is an amount of fluctuation in the rate of net profit to sales 
during the entire study period although not very high. 
 
For Cipla Ltd. it can be concluded that the rate of profit to sales is much higher in this 
company compared to other companies, it is almost double than other companies, but 
even this company is not successful in maintaining its rate of profit to sales. And there 
is a clear decreasing trend observed in this ratio in this company. 
 
As per final analysis of Dr. Reddy’s Laboratories it can be concluded that the 
expenses were in control in the initial period of five years and then they have shown 
an increasing trend, which makes it clear that the company has failed to control its 
costs. The revenues have increased but at a declining rate and the last year has been 
miserable for the company in more than one ways. From the sixth year 2002-03 the 
margins are declining and hits bottom in the last year of the study period. This gives 
an alarming signal to the financial performance of the company and it needs to 
improve on several fronts to get things back on track. 
 
For IPCA Labs it can be concluded that the major expenses were in control in the 
entire period of study. The revenues have shown increase but the company is not able 
to maintain a consistent increasing rate of profit margin. Except couple of deviations 
the company has shown a reasonably good performance during the study period. 
 
As far as Matrix Laboratories is concerned it can be concluded that although there are 
some big fluctuations observed in the profit during the study period but in the last 
three years company has recovered very well and is able to compete with the big 
giants of the industry. The ability to come out so quickly and strongly from the losses 
can be a strong ability for the company. 
 
For Nicholas Piramal it can be concluded that although the company has not been able 
to control its main costs but it has successfully control and reduced its non-operating 
costs and also increased its revenues which has led to improvement in the overall 
profit margin of the company over the period of time. 
 
For Sun Pharmaceuticals overall profitability and financial performance has improved. 
Although the improvement is not very significant but it indeed is eye-catching. If 
revenues can be increased and costs can be controlled like in the past then the 
company can still do better in the coming times. 
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1. Development of Value Added  Concept 
 
 
In order to gauge the efficiency or performance of the pharmaceutical companies 
under study, we have used several profit and profitability measures. Value Added 
Statement is a relatively newer concept in the field of accounting. Value added 
concept is based on the theory of value addition to the input to become output. When 
the various resources are utilized for the production of goods or services and till it 
becomes the final product, there are several resources utilized in it. The resources are 
of different types and varieties and are utilized to convert input into output; hence the 
effort put in by management, employees and by capital in adding the value to the input 
refers to value addition.  
 
Value added statement has in recent times occupied a very prominent position in 
modern corporate reporting. The preparation of this statement can be termed as an 
innovation in the field of corporate reporting. Economists are using the concept since 
long but for the accounting it’s not long that the concept has been into use. The 
concept is said to be originated in U.S.A. Treasury in 18th Century, but it has been 
used with greater frequency in Europe and more particularly in U.K. The discussion 
paper “Corporate Report” published in 1975 by the then Accounting Standard 
Steering Committee (now Accounting Standard Board) of the U.K. advocated the 
publication of value added statement along with the conventional annual report. The 
Department of Trade, U.K. published in 1977, “The Future of Company Reports” 
which stated to all the leading companies of U.K to include the Value added statement 
in their annual reports. 
 
2. Concept of Gross Value Added and Net Value Added 
Value Added Concept is the emerging accounting concept which has been discussed 
since long, but applied in practice in the recent past. Very few Indian companies are 
showing the value addition compared to some foreign companies. Value addition is 
show by way of preparing a Value Added Statement. 
 
Value Added Concept is as the name suggests, regarding what value has been added 
to the goods which are purchased and sold. Value added is the wealth an entity has 
been able to create through the utilization of land, labour, capital and management. In 
the words of Ravi M. Kishore, “The ‘Value Added’ is a basic and broad standard of 
judging the performance of an enterprise.” 
 
First the goods and services are purchased from the market, than some changes are 
made to these purchases, that is to say their form is changed and they are sold at some 
other place, which is nothing but changing the availability location of the goods. 
Hence these alterations made to the goods and services purchased are known as value 
addition or value generation, which is nothing but the extra price realized by selling 
these (altered) goods and services in the market. 
 
The excess of turnover plus income from services over the cost of bought in materials 
and cost of services is termed as ‘Gross Value Added’. The annual charge of 
depreciation is deducted from the gross value added and the remainder is known as 
‘Net Value Added’.  
 
 
Here is the Performa of a Value Added Statement: 
 
XYZ LTD. 
Value Added Statement for the year ended 31st March 20xx 
Particulars       Rs.  Rs. 
 
CREATION OF ADDED VALUE: 
a. Sales (including Excise Duty and Sales Tax)  xxx  xxx 
 Less: Rebate      xxx  xxx 
           Returns      xxx  xxx 
           Commission     xxx  xxx 
           Discounts     xxx  xxx 
           Goods used for self consumption  xxx 
 xxxx   
                  xxx 
 
b. Income from Services      
   
 Royalty      xxx 
 Dividends and Interest    xxx 
 Rent Received      xxx 
 Other miscellaneous Income    xxx 
        xxx 
 Less: Scrap Realized     xxx 
           Increase in stock of finished goods and WIP xxx 
 xxxx 
                 xxxx 
 
 
 
 
 
 
 
 
 
 
 
 
Particulars       Rs.  Rs. 
 c. Cost of bough-in materials and services:         
  Add: Cost of bought-in materials:            xxxx 
   Opening stock of raw materials   xxx 
 Add: Purchases                xxx 
        xxx 
 Less: Closing Stock                xxx 
 Raw Material Consumed    xxx 
 
 Other materials: 
 Consumables      xxx 
 Packing      xxx 
 Stationery      xxx 
 Fuel & Oil      xxx 
 Electricity      xxx 
 Repairs to plant and building                          xxx 
 xxxx  
 
           
      
d. Cost of Services       
  Audit fees      xxx 
 Insurance      xxx 
 Rent, Rates, etc     xxx 
 Travelling Expenses     xxx  
  Advertisement      xxx 
 Postage and telegram     xxx 
 Printing      xxx 
 Subscriptions      xxx 
 Carriage Outwards     xxx 
 Other Expenses                                    xxx 
 xxxx 
  Added Value Created (a + b – c – d)   
 xxxx 
 
 
 
 
 
 
 
 
 
Particulars       Rs.  Rs. 
 
DISTRIBUTION OF ADDED VALUE  
a. To Employees:       
  Wages and Salaries     xxx 
  MD’s Remuneration     xxx 
  Directors Sitting fees etc    xxx 
  Contribution to PF, ESI and other benefits  xxx 
  Staff welfare etc.                                    xxx 
         xxxx  
   
b. To Government:       
  Customs Duty      xxx 
  Excise Duty      xxx 
  Sales Tax      xxx 
  Income Tax      xxx 
  Wealth Tax      xxx 
  Rates and taxes etc                xxx 
          xxx
  Less: Subsidizing on exports etc.              xxx 
         xxxx  
 
c. To Providers of Capital:      
  Interest on bank borrowings    xxx 
  Interest on term loans     xxx 
  Interest on debentures     xxx 
  Other interest      xxx 
  Dividends                 xxx 
         xxxx 
 
d. Retained in Business:      
  Depreciation      xxx 
  Retained Profit                xxx 
         xxxx  
Disposal of Total Added Value (a+b+c+d)    xxxx  
----------------------------------------------------------------------------- 
 
 
 
 
 
 
3. Generation of Value Added 
 
 
Value added is an excess of turnover plus income from services over the cost of 
bought-in-materials and services. Turnover includes all sales including sales of 
manufactured goods and sales of traded goods. Income from services includes number 
of items like: Export Incentives, Dividend Income, Interest Income, Interest on 
Application money, Rent Received, Lease Rent and hire charges, Compensation and 
Reimbursement income, Refunds or claims received, Income from subsidiaries, Fees 
income, Income from guarantee commission, income from underwriting commission, 
Other commission income, Income from leasing operations, Income from hire 
purchase operations, Income from merchant banking operation, etc. 
 
Hence income from sales and income from services are added up and they make up 
the total income. From the total income cost of Materials and Services are to be 
deducted. Cost of materials includes purchases of raw materials, purchases of trading 
goods, direct expenses on purchases, etc. Cost of Services includes power and fuel 
cost, electricity expenses, water charges, freights and transportation charges, packing 
charges, job work and other contract charges, etc. Finally adjustment from closing 
stock is done. 
 
After deducting cost of materials and services from the total income we derive 
GROSS VALUE ADDED. From this GVA Depreciation is deducted and finally we 
get NET VALUE ADDED. 
 
 
4. Application of Value Added 
 
 
The total value added is distributed among four major parties, they are Employees, 
Government, Providers of Capital and the fourth part is retained in business. 
 
The value distributed to Employees includes Directors Remuneration, Salaries, 
Wages, Bonus, Contribution to funds, Staff Welfare Expenses, VRS Compensation, 
Gratuity Paid, and other employees cost. 
 
The value distributed to Government includes Excise Duty, Wealth Tax, Cess, Sales 
Tax, Income tax, etc 
 
The value distributed to Providers of capital includes: Interest on bank borrowings, 
Interest on term loans, Interest on debentures, Other interests and Dividends. 
 
Finally the balance is retained in the business for expansion and any other contingency 
requirements of the business. This is also value which belongs to the shareholders but 
is not distributed to them. 
 
  
 
 
 
 
 
 
 
5. Advantages of Value Added Statement 
 
 
1. Value added statement is an innovative and proficient tool to measure the 
performance or efficiency of any organization. A study of value added by an 
organization over the number of years can give a very useful insight into the 
direction in which the company is moving towards. 
 
 
2. When any information however unbiased is kept secret, arouses doubts in the 
minds of related parties. Hence as the value added statement reveals all the 
information of value creation and distribution, this creates a positive attitude of 
employees and other related parties towards a company and its operations. 
 
 
3. Value added statement of a company is directly related to the total national 
income of any country.  Hence the information of company’s contribution to 
national income is provided in value added statement. 
 
4. For comparative analysis of various expenses and income to value added, this 
statement becomes quite a useful tool. For example what is the percentage of 
taxes to value added, what is ratio of value added to sales or what amount of 
value added is distributed to employees or how much value added is 
transferred to the share holders? 
5. Value added statement provides a useful guide with regard to the ultimate 
objective of any company – “Wealth Maximization of its shareholders”. 
 6. Value added statement can be utilized as an internal evaluation statement. For 
the decision making, as well as for the evaluation and analysis of past 
performance and making predictions about future, the value added statement 
can be very useful. 
 
 
 
 
6. Limitations of Value Added Statement 
 
1. Not a very popular mode for measuring the performance or profitability, hence 
not much acceptable method. 
 
2. Value creation talk about profitability; but in different language, but not the 
other way. Value creation can be there without increase in profitability 
situation. 
 
3. Other than the concept there is nothing new in the value added statement, just 
the same items with the same figures from the financial statements are utilized. 
 
4. There is no standard way of preparing the value added statement; hence it has 
lot of subjectivity involved. 
 
5. As there is no compulsion from any legal front; it is still in its primary stage of 
development. There is time for the statement to become the most accepted 
document. 
 
 
 
 
7. Generation and Application of Value Added of 
sample  units 
 
10. AUROBINDO PHARMACEUTICALS LTD. 
 
 
Table: 9.1:  
 
 
The following page has the table showing the Value Added Statement for  
Aurobindo Pharmaceuticals Ltd. for the period of 8 (Eight) years from 1997-98 to 
2004-05 
 
 
 
 
 
         
 
Table 9.1 
      
         
Table Showing the Valu
the period of 8 (Eight) Years from 1997
         
         
         
         
GENERATION OF VALUE 
ADDED 
                
Particulars 97-98 98-99 99-00 00-01 
  Amt % Amt % Amt % Amt % 
Sales 295.31 99.51 550.03 99.50 739.9 98.774 972.52 96.78
Add:Service Income 1.46 0.49 2.76 0.50 9.18 1.2255 32.33 3.22 
Total: A 296.77 100.00 552.79 100.00 749.08 100 1004.9 100.00
Cost of M&S : B 215.34 72.56 404.73 73.22 554.84 74.07 772.4 76.86
Gross  (A-B) 81.43 27.44 148.06 26.78 194.24 25.93 232.45 23.13
Less:Depreciation 2.22 0.75 6.29 1.14 9.52 1.2709 14.78 1.47 
Net Value Added 79.21 26.69 141.77 25.65 184.72 24.66 217.67 21.66
                  
APPLICATION OF VALUE 
ADDED 
                
Particulars 97-98 98-99 99-00 00-01 
  Amt % Amt % Amt % Amt % 
To Employees 6.44 8.13 10.34 7.29 15.68 8.49 21.63 9.94 
To Government 30.85 38.95 52.77 37.22 57.94 31.37 71.62 32.90
To Prov of cap 16.49 20.82 24.27 17.12 34.28 18.56 47.74 21.93
Retained in Busines 25.43 32.10 54.39 38.36 76.82 41.59 76.68 35.23
N.Value Distributed 79.21 100.00 141.77 100.00 184.72 100.00 217.67 100.00
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
         
         
 
        
 
        
         
         
         
         
 
        
         
 
        
         
         
         
         
         
         
 
 
From the table it is evident that Sale of goods consists of major share in the overall 
income of the company as it ranges from 99.51% (1997-98) to 98.25% (2004-05). The 
income from service comprises of a very meager share in the total income of the 
company for the study period. The share of income from services in total income is in 
between 0.49% (1997-98) and 3.47% (2001-02) which shows that company has 
confined its activities to product selling only and not ventured much into the sale of 
services. 
 
There is an increasing trend in the percentage of cost of material and services to total 
income. The increase in observed in a constant manner in the first five years of the 
study period. It was 72.56% in the first year and it went up to 77.17% in the fifth year 
but after that some decline in this ratio was observed as in the sixth year it went 
down to 71% and in the seventh year it further went down to 68% which shows that 
there is a considerable amount of cost reduction compared to sales in these years. 
 
The trend of ratio of percentage of cost of materials and services to sales is visible in 
the Net value added too. Hence the net value added is showing decreasing trend in the 
first five years. And from sixth year the net value added is showing an increasing 
trend as a percentage of sales. However in the declining trend of the first five years the 
absolute figures show increase howsoever. The net value added in the first year was 
Rs. 26.69 Crore in the first year and it was highest Rs. 29.18 Crores in the year 2003-
04 and least Rs. 21.31 in the year 2001-02. 
 
In the application of value added shows the distribution of value added during the 
year. The first part describes the value distributed to employees of the companies. 
There is a significant increase observed in the proportion of employees in the total 
value added. It was 8.13% in the first year of the study period which increased to 
22.12% in the last year of the study period. Hence over the period of year there is a 
significant increase in the employees participation in the value addition. And this 
shows a very fine positive trend as employees are to a great extent in the value 
creation in any business and their participation in the earnings as partners is a 
welcome changes which is observed in Indian scenario and our value added statement 
is a fine example of that.  
 
The second party to whom the value is distributed is Government in form of various 
taxes. There are no major fluctuations or trends observed in this ratio but this ratio is 
very high in the entire study period. It lies in between 38.95% (1997-98) and 28.53% 
(2004-05) during the period of the study. 
The providers of capital are provided with some portion of the value added. It lies in 
between 21.93% (2000-01) and 11.05% (2003-04) during the study period. There are 
no particular trends observed in this ratio. 
For retained earnings in the business there is a positive trend observed in the initial 
three years of the study period. Afterwards there are some minor fluctuations observed 
in the ratio of retained earnings to total value added during the year. It lies in between 
41.59% (1999-2000) and 28.14% (2001-02). 
Hence it can be observed that there is an increasing trend in the share of employees in 
the value added in this company. And there is overall improvement observed in the 
retained earnings ratio to total value. Apart from these there are no major trends 
observed in the other places. 
 
11. CADILA HEALTHCARE LTD. 
 
 
Table: 9.2:  
 
 
The following page has the Table Showing the Value Added Statement for  
Cadila Healthcare Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
           
 
Table 9.2 
        
           
Table Showing the Value Added Statement for Cadila Healthcare Ltd. for 
the period of 8 (Eight) Years from 1997
           
           
GENERATION OF VALUE 
ADDED 
                    
Particulars 97-98 98-99 99-2000 2000-01 2001-02
  Amt. % Amt. % Amt. % Amt. % Amt. % 
Sales 303.58 98.73 358.4 97.99 475.7 98.11 502.3 94.90 581.7 95.88
Add: Service Income 3.91 1.27 7.37 2.01 9.18 1.89 26.99 5.10 25 4.12
Total: A 307.49 100.00 365.77 100.00 484.88 100.00 529.29 100.00 606.7 100.00
Cost of M&S: B 204.02 66.35 230.86 63.12 315.97 65.16 297.38 56.18 351.38 57.92
Gross VA (A-B) 103.47 33.65 134.91 36.88 168.91 34.84 231.91 43.82 255.32 42.08
Less:Depreciation 3.68 1.20 4.4 1.20 9.86 2.03 14.33 2.71 18.8 3.10
Net Value Added 99.79 32.45 130.51 35.68 159.05 32.80 217.58 41.11 236.52 38.98
                      
APPLICATION OF VALUE 
ADDED 
                    
Particulars 97-98 98-99 99-00 00-01 2001-02
  Amt % Amt % Amt % Amt % Amt % 
To Employees 27.91 27.97 35.58 27.26 39.63 24.92 50.25 23.09 55.3 23.38
To Government 23.24 23.29 27.09 20.76 38.22 24.03 62.41 28.68 68.2 28.83
To Prov of cap 18.21 18.25 17.48 13.39 35.06 22.04 32.04 14.73 37.8 15.98
Retained in Busines 30.43 30.49 50.36 38.59 46.14 29.01 72.88 33.50 75.22 31.80
Net Value Distributed 99.79 100.00 130.51 100.00 159.05 100.00 217.58 100.00 236.52 100.00
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
   
 
 
 
 
 
 
 
 
 
 
The sales figures reveal that with the passage of time there is a minor improvement in 
the income from services. The sales percentage in the overall incomes were 98.73% in 
the first year 1997-98 whereas it was 93.35% in the last year 2004-05 of the study 
period, this reveals that the company is earning income from other than sales sources 
as well. 
 
The ratio of cost of materials and services to total income has gradually shown a 
declining trend during the period of study. This is an indicator of the cost 
effectiveness of the company and the measures the company must be taking to reduce 
its costs to improve the profitability. It was 66.35% in the first year 1997-98 and 
56.18% in the year 2000-01, this shows that the costs have reduced by 10% in just 4 
years time period, although it again showed increase and it was 59.60% in the last 
year of the study period. 
 
There are no clear trends observed in the trend of the Net Value added during the 
study period for the company. But a considerable improvement in the ratio is observed 
over the period of time. It was 32.45% in the first year and it reached as high as 
41.11% in the year 2000-01 which shows that due to reduction in cost there is a direct 
advantage available by way of improved Net Value Added and hence to the related 
parties. 
 
For the distribution of value added the first party is employees. There is slight 
improvement in the ratio of distribution of added wealth to the employees. It was 
27.97% in the first year (1997-98) and 31.15% in the last year (2004-05) of the study 
period. Hence it shows that there is quiet improvement in the ratio of wealth 
distributed to employees. 
 The second party to whom the value is distributed is Government in form of various 
taxes. There are no major fluctuations or trends observed in this ratio. It lies in 
between 23.29% (1997-98) and 20.30% (2004-05) during the period of the study. It 
did touch the high of 31.99% in the year 2002-03, but then again it came down to the 
normal levels. 
 
There are also no major fluctuations observed in the distribution of wealth to the 
providers of capital. It lies between 18.25% (1997-98) to 14.54% (2004-05) during the 
study period. The lowest ratio was 13.39 in the year 1998-99. The highest ratio 
22.04% was observed in the year 1999-2000. 
 
A considerable amount of wealth created has been retained in the business for most of 
the year during the study period. This is a big achievement for the company as this is a 
provision for development and contingencies hence more the retained earnings more 
sound the financial situation of any company. It lies between 22.98% (2002-03) and  
38.59% (1998-99). 
 
Hence there is a positive trend observed in the retained earnings over the period of 
study. Even the cost of material and services has declined which has led to 
improvement in the ratio of net value added during the period of the study for the 
company.   
 
 
 
12. CIPLA LTD. 
Table: 9.3:  
The following page has the Table Showing the Value Added Statement for  
Cipla Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
Table 9.3 
          
            
Table Showing the Value Added Statement for Cipla Ltd. for 
the period of 8 (Eight) Years from 1997-98 to 2004
            
            
GENERATION OF VALUE 
                        
97-98 98-99 99-2000 2000-01 2001-02 2002-03 
Amt. % Amt. % Amt. % Amt. % Amt. % Amt. % 
514.43 95.19 617.16 95.95 759.75 96.20 1047.5 97.04 1385.8 97.56 1549.79 97.73 
25.99 4.81 26.06 4.05 30.01 3.80 31.96 2.96 34.72 2.44 36.07 2.27 
540.42 100.00 643.22 100.00 789.76 100.00 1079.5 100.00 1420.6 100.00 1585.86 100.00 
306.25 56.67 351.98 54.72 447.32 56.64 619.36 57.38 792.43 55.78 934.26 58.91 
234.17 43.33 291.24 45.28 342.44 43.36 460.11 42.62 628.13 44.22 651.6 41.09 
8.69 1.61 13.5 2.10 13.34 1.69 15.63 1.45 21.28 1.50 28.36 1.79 
225.48 41.72 277.74 43.18 329.1 41.67 444.48 41.18 606.85 42.72 623.24 39.30 
                        
APPLICATION OF VALUE 
                        
97-98 98-99 99-00 00-01 2001-02 2002-03 
Amt % Amt % Amt % Amt % Amt % Amt % 
22.48 9.97 29.12 10.48 34.96 10.62 49.93 11.23 63.28 10.43 73.49 11.79 
69.03 30.61 77.74 27.99 95.76 29.10 172.12 38.72 215.22 35.47 207.2 33.25 
14.85 6.59 19.56 7.04 20.52 6.24 29.64 6.67 45.93 7.57 64.46 10.34 
119.12 52.83 151.32 54.48 177.86 54.04 192.79 43.37 282.42 46.54 278.09 44.62 
Net Value Distributed 225.48 100.00 277.74 100.00 329.1 100.00 444.48 100.00 606.85 100.00 623.24 100.00 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
     
 
 
 
 
 
 
 
 
 
 
 
 
The total income of company comprises majority of sales income which lies in 
between 95.06% (2003-04) to 97.73% (2002-03). There are no major fluctuations 
observed in the percentage of sales to total income, it has more or less remained stable 
over the period of time during the period of study. There is more of income of sales in 
the total income in the years as the years move ahead.  
 
There are no clear trends visible in the ratio of cost of material and services to total 
sales income. It lies between 59.97% (2003-04) and 54.72 (1998-99).  The percentage 
share of cost of materials and services to sales does not show major fluctuations 
during the period of study. It was 56.67% in the first year of the study period and it 
was 59.12% in the last year of the study period. This shows that over the period of 
time there is an increase observed in the ratio but not of a big amount.  
 
With the increase in the percentage of cost of materials and services there is a decline 
observed in the ratio of net value added to the total income. It was 41.72% in the first 
year which increased to 43.18% in the second year of the study but it was 38.61% in 
the last year which shows a small but declining trend in the percentage of Net Value 
Added to sales. Value wise there is an increase observed to the extent of, it was Rs. 
225.48 crores in the first year and Rs. 934.21 crores in the last year of the study 
period. 
 
 
Similarly there are no clear directions seen in the trend of the Net Value Added for the 
company during the study period. It lies between 43.18% in the year 1998-99 and  
38.09 % in the year 2003-04. 
After the generation of net value added, the second part of value added statement 
shows the distribution of net value added. The first distribution is shown to 
Employees. Interestingly enough there is an increasing trend observed in the ratio of 
employees cost to net value added. Hence every year the ratio of value distributed to 
employees to total net value added is increasing. Employees are backbone of any 
organization and they can be rewarded best by increasing their share in the profits. 
This type of trend is visible from the value added statement of the company for the 
study period. There is a clear increasing trend observed in the percentage of 
employees cost to net value added during the period of study. It was 9.97% in the first 
year (1997-98) of the study period and it was 12.48% in the last year (2004-05) of the 
study period. This shows that employees are getting increased shares in the net value 
added in the company.  
 
Another distribution of net value added is to the Government in form of various taxes 
etc. The percentage of value distributed to government to total net value added is not 
showing any particular trend. It was 30.61% in the first year and the highest ratio 
observed was 38.72% in the year 2000-01 and it was least in the last year 27.62%. 
 
The percentage of value contributed to providers of capital to the total net value added 
is also showing some increasing trend which reflects that there is an increase in the  
payments of dividends along with the use of fixed charges funds must also have 
increased which is responsible for the increasing trend. It was 6.59% in the first year 
and it was 12.48% in the last year of the study period.  
 
The last portion of the distribution is the distribution as retained in the business which 
is also popularly known as Ploughing Back of Profit. It can easily be inferred from the 
value added statement that majority of the value added during the year is retained in 
the business. This is always important as there can always be bigger plans and 
strategies for the implementation of which you need to have sufficient funds. 
Although there is a slight decrease observed in this ratio over the period of time but it 
is already a significant ratio. It was 52.83% in the first year and it increased to 54.48% 
in the second year which was highest during the entire study period. And it was 
recorded at 47.41% in the last year of the study period. 
 
Hence it can be observed that the employees share is increasing and company has the 
policy to retain maximum of its retained earnings. This also shows that company is 
not a too liberal dividend distributor. But as the ratio of distribution to providers of 
capital is also positive in a way it shows that company is passing on the benefits to the 
employees as well as the providers of capital and thereafter also managing to keep 
reserves for business. This shows a very bright picture of the company during the 
study period. 
 
 
13. DR. REDDY’S LABORATORIES LTD. 
 
Table: 9.4:  
The following page has the Table Showing the Value Added Statement for  
Dr. Reddy’s Laboratories Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-
05 
 
          
 
Table 9.4 
       
          
Table Showing the Value Added Sta
the period of 8 (Eight) Years from 1997
          
          
GENERATION OF VALUE 
ADDED 
                  
Particulars 97-98 98-99 99-2000 2000-01 2001
  Amt. % Amt. % Amt. % Amt. % Amt. 
Sales 331.62 98.93 425.86 98.68 493.02 99.02 984.11 98.69 1557.8 
Add: Service Income 3.57 1.07 5.68 1.32 4.87 0.98 13.1 1.31 62.31 
Total: A 335.19 100.00 431.54 100.00 497.89 100.00 997.21 100.00 1620.1 
Cost of M&S: B 188.78 56.32 237.21 54.97 237.71 47.74 550.71 55.23 761.26 
Gross Value Added (A-B) 146.41 43.68 194.33 45.03 260.18 52.26 446.5 44.77 858.83 
Less:Depreciation 6.55 1.95 10.16 2.35 13.07 2.63 42.5 4.26 47.42 
Net Value Added 139.86 41.73 184.17 42.68 247.11 49.63 404 40.51 811.41 
                    
APPLICATION OF VALUE 
ADDED 
                  
Particulars 97-98 98-99 99-00 00-01 2001
  Amt % Amt % Amt % Amt % Amt 
To Employees 24.9 17.80 31.82 17.28 39.07 15.81 83.09 20.57 121.07 
To Government 39.24 28.06 57.83 31.40 65.02 26.31 107.76 26.67 98.26 
To Prov of cap 18.33 13.11 20.79 11.29 24.29 9.83 56.02 13.87 71.54 
Retained in Busines 57.39 41.03 73.73 40.03 118.73 48.05 157.13 38.89 520.54 
Net Value Distributed 139.86 100.00 184.17 100.00 247.11 100.00 404 100.00 811.41 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
  
Sales occupy a major source of income for the company which is visible from the 
ratio of sale to total income. But in the later part of the years it is showing a very small 
decrease. It was 98.93% in the first year (1997-98) and it went on to increase to 
99.02% in the year 1999-2000 and declined to 96.46% in the last year (2004-05) of 
the study period. 
 
There is no particular trend visible for Dr. Reddy’s Laboratories Ltd. regarding its cost 
of materials and services. The ratio of this cost to total income is varying at different 
years. It was observed as 56.32% in the first year (1997-98) of the study period which 
decreased for two year and went to as low as 47.74% (1999-2000). The least ratio 
observed is 46.99% (2001-02) and the highest ratio is 68.56% in the last year of the 
study period. 
 
Net value added is reflecting the trend of the cost of materials and services and hence 
there is an increasing trend observed in the initial three years of the study period 
wherein the net value added increased. It was 41.73% in the first year and it increased 
to 49.63% in the third year and went on to increase 50.08% in the year 2001-02 and it 
was least 25.95% in the last year (2004-05) of the study period.  
 
After the value creation now it is the turn of distribution of value added. For the first 
case where the value is distributed to employees there is no clear particular trend 
visible.  It was 17.80% in the first year and least 14.92% in the year 2001-02. It was 
highest 40.88% in the last year of the study period. 
 
There is a sudden downfall observed in the ratio of value distributed to government. It 
was 28.06% in the first year and it increased to 31.40% in the second year itself, but 
afterwards it went on decreasing and drastically to 12.11% in the year 2001-02 and it 
was 14.31% in the last year of the study period. 
 
There is a decline observed in the ratio of value distributed to providers of capital. It 
was 13.11% in the first year which went on to decrease to 9.83% in the third year 
(1999-2000) after some more fluctuations it was showing 11.67% in the last year of 
the study period. Hence there are lot amount of fluctuations observed in this part of 
distribution of value added to providers of capital. This also shows that company does 
not have a steady dividend policy and it is also not using the debt on an uniform basis. 
 The last distribution of value added is retained in the business. There is no particular 
trend observed in this but quite an amount of fluctuations observed. It was 41.03% in 
the first year and the highest was 64.15% (2001-02) and 33.15% in the last year 
(2004-05) of the study period. 
 
The first three years showed a positive trend with regard to creation of value but after 
that there are no particular trend identifiable in the value addition and even in the 
distribution of value added. 
 
 
14. IPCA LABORATORIES LTD. 
Table: 9.5:  
The following page has the Table Showing the Value Added Statement for  
IPCA Laboratories Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 
 
 
 
 
 
 
         
 
Table 9.5 
      
         
Table Showing the Value Added Stat
the period of 8 (Eight) Years from 1997
         
         
GENERATION OF VALUE 
ADDED 
                
Particulars 97-98 98-99 99-2000 2000-01 
  Amt. % Amt. % Amt. % Amt. % 
Sales 282.74 96.29 335.66 97.03 363.31 97.33 385.38 97.14
Add: Service Income 10.9 3.71 10.28 2.97 9.98 2.67 11.36 2.86 
Total: A 293.64 100.00 345.94 100.00 373.29 100.00 396.74 100.00
Cost of M&S : B 204.86 69.77 231.17 66.82 247.78 66.38 262.78 66.23
Gross Value Added (A-B) 88.78 30.23 114.77 33.18 125.51 33.62 133.96 33.77
Less:Depreciation 6.1 2.08 7.03 2.03 8.18 2.19 10.18 2.57 
Net Value Added 82.68 28.16 107.74 31.14 117.33 31.43 123.78 31.20
                  
APPLICATION OF VALUE 
ADDED 
                
Particulars 97-98 98-99 99-00 00-01 
  Amt % Amt % Amt % Amt % 
To Employees 25.48 30.82 32.99 30.62 34.27 29.21 39.99 32.31
To Government 22.2 26.85 33.94 31.50 37.87 32.28 43.94 35.50
To Prov of cap 20.26 24.50 23.19 21.52 23.08 19.67 22.72 18.36
Retained in Busines 14.74 17.83 17.62 16.35 22.11 18.84 17.13 13.84
Net Value Distributed 82.68 100.00 107.74 100.00 117.33 100.00 123.78 100.00
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
In the entire study period the contribution of sales to total income has remained almost 
uniform. It was 96.29% in the first year (1997-98) and it was 97-92% in the last year 
(2004-05) of the study period. There are no major fluctuation observed in this ratio for 
the period of study. 
 
Cost of Materials and Services have shown a continuous decline for first six 
consecutive years in the study period. This shows a very positive result in the margin 
of costs to total income and icing of the cake is the fact that there is a constant decline 
in this ratio. Even in the last year this downfall in the cost to income ratio is declining. 
It was 69.77% in the first year (1997-98) of the study period which declined 
continuously and it was 62.66% in the last year (2004-05) of the study period. This 
can be regarded as excellent by any standards. With the ever increasing sales if the 
costs are reduced as a percentage of income then it would definitely help a lot in 
creating value. 
 
The incredible efforts of reducing costs every year has shown its results in the creation 
of Net Value Added. There is a constant increase observed in the creation of value 
added throughout the study period. It was 28.16% in the first year and it was 34.76% 
in the last year of the study period. During all these eight years there is a constant 
increasing trend observed. This also makes one point clear that the decrease of costs 
lead directly to value creation, so any steps taken to decrease the costs helps directly. 
 
For the distribution of value added the first party is the Employees. During the period 
of study there is no particular trend identifiable in the distribution of value added to 
the employees. It lies in between 30.82% in the first year and 33.35% in the last year 
of the study period. 
 
The distribution of value added to government is showing a mixed trend of increasing 
in the initial phase and then constant. It lies in between 26.85% in the first year 
29.62% in the last year of the study period. 
 
There is a constant decreasing trend observed in the ratio of distribution of value to 
providers of capital to total value added. It was 24.50% in the first year of the study 
period and it was mere 9.55% in the seventh year (2003-04) of the study period. This 
could be an indicator of the company’s policy to reduce debt from its capital structure 
gradually and hence it is showing up in the value added statement. 
 
For the last portion of retained earnings, there is an overall increasing trend observed 
but not on a continuous basis, as there are some fluctuating ratios in between during 
the period. It lies in between 17.83% in the first year of the study period and 26.93% 
in the last year of the study period. 
 
 
Hence it can be concluded that the company has controlled its cost throughout the 
study period and improved on its value addition and finally increased its retained 
earnings throughout the study period. Even the expenses on interests have declined 
along with decline in the dividend distribution. 
 
15. MATRIX LABORATORIES LTD. 
 
 
Table: 9.6:  
 
 
The following page has the Table Showing the Value Added Statement for  
Matrix Laboratories Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 
 
 
 
 
           
 
Table 9.6 
        
           
Table Showing the Value Added Statement for Matrix Laboratories Ltd. for 
the period of 8 (Eight) Years from 1997
           
           
GENERATION OF VALUE 
ADDED 
                    
Particulars 97-98 98-99 99-2000 2000-01 2001-02 
  Amt. % Amt. % Amt. % Amt. % Amt. % 
Sales 27.51 99.49 40.73 99.98 45.19 99.98 60.78 89.51 102.18 98.18
Add: Service Income 0.14 0.51 0.01 0.02 0.01 0.02 7.12 10.49 1.89 1.82 
Total : A 27.65 100.00 40.74 100.00 45.2 100.00 67.9 100.00 104.07 100.00
Cost of M&S : B 24.51 88.64 31 76.09 41.26 91.28 50.09 73.77 72.1 69.28
Gross Value Added (A-B) 3.14 11.36 9.74 23.91 3.94 8.72 17.81 26.23 31.97 30.72
Less:Depreciation 0.3 1.08 0.59 1.45 0.73 1.62 0.86 1.27 1.53 1.47 
Net Value Added 2.84 10.27 9.15 22.46 3.21 7.10 16.95 24.96 30.44 29.25
                      
APPLICATION OF VALUE 
ADDED 
                    
Particulars 97-98 98-99 99-00 00-01 2001-02 
  Amt % Amt % Amt % Amt % Amt % 
To Employees 0.42 14.79 1.02 11.15 1.02 31.78 1.76 10.38 5.14 16.89
To Government 0.51 17.96 5.12 55.96 6.7 208.72 8.36 49.32 16.49 54.17
To Prov of cap 1.73 60.92 2.11 23.06 2.65 82.55 1.88 11.09 2.9 9.53 
Retained in Busines 0.18 6.34 0.9 9.84 -7.16 
-
223.05 4.95 29.20 5.91 19.42
Net Value Distributed 2.84 100.00 9.15 100.00 3.21 100.00 16.95 100.00 30.44 100.00
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
   
 
 
 
 
 
 
 
 
 
Income from sales occupies a predominant position in the total income of the 
company which is visible from the value added statement of Matrix Laboratories for 
the period under study. It was 99.49% in the first year of the study and 97.85% in the 
last year of the study period. And there were no major fluctuations observed in these 
figures during the study. 
 
There is a fluctuating observed in the cost of materials and services. It is 88.64% in 
the first year and it was 91.28% in the third year of the study period. Afterwards it has 
declined for continuous four year and at the end increased by a small margin. The 
least ratio was 57.37% (2003-04) which shows the amount of fluctuations observed in 
the company during the period of study. But as the fluctuation is showing positive 
trends it is always acceptable. 
 
The amount of fluctuation experienced in the cost of materials and services, same is 
observed in the net value added. It was 10.27% in the first year which went down to 
7.10% in the third year of the study period, afterwards it started showing an upward 
movement and till the end of the period. It was highest 40.58% in the seventh (2003-
04) year of the study period. 
 
For the distribution of value created the first party is employee. It includes payment of 
salaries, bonuses, and all other payments to the work force. It is showing a complete 
fluctuating picture throughout the study period from which no inference can be made 
and no trends can be established. It lies in between 31.78% (1999-2000) and 9.23% 
(2002-03)  
For payment to government also there is no particular trend visible, neither any sort of 
stability is observed from the figures in the value added statement. But in the last three 
years it has stabilized with decreased ratios. It lies between 17.96% (1997-98) and 
26.21% (2004-05) during the period of study. 
 
For payment to the providers of capital also there is no particular trend visible, neither 
any sort of stability is observed from the figures in the value added statement. But in 
the last three years it is showing some declining trend. It lies between 60.92% (1997-
98) and 10.32% (2004-05) during the period of study. 
 
As far as retained earnings are concerned there is no particular trend visible, neither 
any sort of stability is observed from the figures in the value added statement. But in 
the last three years it is showing some stability. It lies between 6.34% (1997-98) and 
47.32% (2004-05) during the period of study. 
 
Hence we can conclude that although there are huge fluctuations in the figures of the 
company but they are all leading to the positive financial situation of the company. 
After those uncertain fluctuating and negative trend years the company has made 
noteworthy progress in the last five years during the study period of eight years. 
 
16. NICHOLAS PIRAMAL INDIA LTD. 
Table: 9.7:  
The following page has the Table Showing the Value Added Statement for  
Nicholas Piramal India Ltd. for the period of 8 (Eight) Years from 1997-98 to 2004-05 
 
 
 Table 9.7 
       
          
Table Showing the Value Added 
the period of 8 (Eight) Y
          
          
GENERATION OF VALUE 
ADDED 
                  
Particulars 97-98 98-99 99-2000 2000-01 2001
  Amt. % Amt. % Amt. % Amt. % Amt. 
Sales 534.64 97.44 429.99 92.02 486.48 92.82 566.76 94.34 946.48 
Add: Service Income 14.02 2.56 37.27 7.98 37.63 7.18 34.03 5.66 56.86 
Total: A 548.66 100.00 467.26 100.00 524.11 100.00 600.79 100.00 1003.3 
Cost of M&S : B 266.28 48.53 219.86 47.05 260.26 49.66 305.54 50.86 547.64 
Gross Value Added (A-B) 282.38 51.47 247.4 52.95 263.85 50.34 295.25 49.14 455.7 
Less:Depreciation 18.46 3.36 8.92 1.91 10.58 2.02 13.9 2.31 16.89 
Net Value Added 263.92 48.10 238.48 51.04 253.27 48.32 281.35 46.83 438.81 
                    
APPLICATION OF VALUE 
ADDED 
                  
Particulars 97-98 98-99 99-00 00-01 2001
  Amt % Amt % Amt % Amt % Amt 
To Employees 70.5 26.71 49.63 20.81 56.81 22.43 55.74 19.81 82.47 
To Government 92.45 35.03 75.33 31.59 88.77 35.05 102.42 36.40 176.1 
To Prov of cap 51.01 19.33 50.62 21.23 52.23 20.62 53.62 19.06 86.37 
Retained in Busines 49.96 18.93 62.9 26.38 55.46 21.90 69.57 24.73 93.87 
Net Value Distributed 263.92 100.00 238.48 100.00 253.27 100.00 281.35 100.00 438.81 
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
  
Apart from sales there are other incomes also which are adding up to the total income. 
The ratio of sales to total income is showing that other incomes are having their share 
in the total income during the period of study. The ratio of sales to total income is 
97.44% in the first year and it was 91.21% in the last year of the study period.  
 
The ratio of cost to total income is shown by cost of Material and services ratio. It is 
48.53% in the first year and 57.12% in the last year of the study period. This ratio 
shows that how much portion of income is eaten up by the cost of materials and 
services. In this case this ratio is showing an increasing trend during the period of 
study which is a negative sign for the company.  
 
The negative trend of cost of material and services is directly showing its effect on the 
ratio of net value added to total income. As the cost of material and services are 
increasing as a percentage of total income it is very obvious that the percentage of net 
value added to total income is would be declining. This means that over the period of 
study the company’s performance is deteriorated as per this Value Added Statement. 
The ratio in the first year was 48.10% and in the last year it was 39.76%.  
 
After the calculation of net value added in the value added statement the value added 
would be distributed. The first party to whom the value would be distributed would be 
the employees. There is considerable amount (26.71% in 97-98) of value distributed to 
the employees of the companies in the initial period of study, but gradually this ratio is 
showing decline and at the end it is showing some improvement as it is 23.86% in the 
year 2004-05. There is no particular trend observed in this distribution. 
After distribution to employees the net value added is distributed to government. The 
ratio of value distributed to government has remained constant almost throughout the 
period of study. It was 35.03% in the first year (1997-98) and it was 35.46% in the last 
year (2004-05) of the study period.  
 
After distributing to government the value is distributed to the providers of capital. 
There are no major fluctuations observed in this ratio over the period of study and the 
ratio is showing some declining trend in the last years of the study period. It was 
19.33% in the first year of the period and 13.68% in the last year of the period. This 
shows that over the years the payments to government have reduced. 
 
Finally the value created is retained in the business. It was 18.93% in the first year and 
27.01% in the last year. The amount of value created which is retained in the business 
is very less and it is showing some increase during the period of study is really a 
matter of fine value for the company. 
 
During the period of study year by year the ratio of cost to total income has increased 
which means the share of cost to income has increased. This reflects that either the 
company has not made serious efforts to control costs or it shows that whatever efforts 
are made were un-successful and that leaded to decrease in the rate of net value added 
from the income, during the study period. The improvement in the retained earnings 
over the period of years as a percentage of total value created is a positive sign for the 
financial health of the company. 
 
17. SUN PHARMACEUTICALS INDUSTRIES LTD. 
 
 
Table: 9.8:  
 
 
The following page has the Table Showing the Value Added Statement for  
Sun Pharmaceuticals Industries Ltd. for the period of 8 (Eight) Years from 1997-98 to 
2004-05 
 
 
 
 
         
 
Table 9.8 
      
         
Table Showing the Value A
the period of 8 (Eight) Years from 1997
         
         
GENERATION OF VALUE 
ADDED 
                
Particulars 97-98 98-99 99-2000 2000-01 
  Amt. % Amt. % Amt. % Amt. % 
Sales 279.77 95.14 358.11 97.66 478.35 97.55 613.78 98.98
Add: Service Income 14.28 4.86 8.58 2.34 12.03 2.45 6.31 1.02 
Total: A 294.05 100.00 366.69 100.00 490.38 100.00 620.09 100.00
Cost of M&S :B 157.39 53.52 211.72 57.74 274.02 55.88 332.01 53.54
Gross Value Added (A-B) 136.66 46.48 154.97 42.26 216.36 44.12 288.08 46.46
Less:Depreciation 5.98 2.03 8.67 2.36 12.94 2.64 16.21 2.61 
Net Value Added 130.68 44.44 146.3 39.90 203.42 41.48 271.87 43.84
                  
APPLICATION OF VALUE 
ADDED 
                
Particulars 97-98 98-99 99-00 00-01 
  Amt % Amt % Amt % Amt % 
To Employees 21.61 16.54 27.12 18.54 29.14 14.33 37.15 13.66
To Government 34.87 26.68 36.9 25.22 56.39 27.72 81.54 29.99
To Prov of cap 20.2 15.46 24.29 16.60 25.83 12.70 31.03 11.41
Retained in Busines 54 41.32 57.99 39.64 92.06 45.26 122.15 44.93
Net Value Distributed 130.68 100.00 146.3 100.00 203.42 100.00 271.87 100.00
(Source: Annual Reports of Companies from the year 1997-98 to 2004-05) 
 
 
 
 
 
 
 
 
 
 
 
Income from sales occupies a predominant position in the total income of the 
company which is visible from the value added statement of Sun Pharmaceuticals 
Industries Ltd. for the period under study. It was 95.14% in the first year of the study 
and 96.90% in the last year of the study period. And there were no major fluctuations 
observed in these figures during the study. 
 
 
Cost of Materials and Services have not shown any particular trend during the period 
of study. It was 53.52% in the first year then it increased to 57.74% in the second year 
and then it showed decrease for the next two years, afterwards it was stabilized at 
around 50% and in the last year it was 54.69%. This shows that there are small 
fluctuations in this ratio but overall it has neither shown any increase nor any decrease 
in the ratio of cost of material and services to total income. 
 
The trend of ratio of percentage of cost of materials and services to sales is visible in 
the Net value added too. Hence the net value added is also not showing any particular 
trend throughout the study period for the ratio of net value added to total income in the 
value added statement for Sun Pharmaceutical Industries Ltd. It was 44.44% in the 
first year and 42.80% in the last year of the study period. 
 
After the calculation of net value added in the value added statement the value added 
would be distributed. The first party to whom the value would be distributed would be 
the employees. There is a small decline visible in the value distributed to employees 
over the period of time. It was 16.54% in the first year, although it showed increase in 
the second year but afterwards there is a decreasing trend observed in the ratio of 
employees cost to net value added. In the last year the ratio is 14.83%. It should be the 
matter of concern for the company if this ratio declines, on the other hand more use of 
machinery may also lead to such a situation if manpower is reduced in business 
operations. 
 
After distribution to employees the net value added is distributed to government. 
There are no major fluctuations observed in this ratio. It was 26.68% in the first year 
and it was 29.99% in the year 2000-01. It is showing an increase but the increase is 
not much higher.   
 
After distributing to government the value is distributed to the providers of capital. 
There are no major fluctuations observed in this ratio over the period of study and the 
ratio is showing some declining trend in the middle of the study period. It was 15.46% 
in the first year of the period and 18.40% in the last year of the period. This shows that 
over the years the payments to government have increased.  
 
Finally the value created is retained in the business. It was 41.32% in the first year and 
47.17% in the last year. The amount of value created which is retained in the business 
is significant and it is showing some increase during the period of study is really a 
matter of fine value for the company. In the year 2001-02 the amount of value added 
retained was 49.72% which is an example that company believes in retaining the 
earnings rather than distributing as dividends.  
 
Hence it can be concluded that there are no major positive or negative movements 
observed in the entire vale added statement for Sun Pharmaceuticals Industries Ltd. 
Only significant item is regarding a considerable big amount (nearly 50%) is retained 
by the company in almost all the years during the period of the study. The company 
has not been very successful in controlling the cost and has not been rewarded with 
improved value creation. Even employees are not getting any improved share from the 
value created, in fact over the years the share of employees in the net value added has 
reduced. Hence it shows an overall mix picture for the company from the Value 
Added Statement. 
 
 
8. Conclusion 
In Aurobindo Pharmaceuticals Ltd. it can be observed that there is an increasing trend 
in the share of employees in the value added in this company. And there is overall 
improvement observed in the retained earnings ratio to total value. Apart from these 
there are no major trends observed in the other places. 
 
For the company Cadila Healthcare Ltd. there is a positive trend observed in the 
retained earnings over the period of study. Even the cost of material and services has 
declined which has led to improvement in the ratio of net value added during the 
period of the study for the company.   
 
For Cipla Ltd. it can be observed that the employees share is increasing and company 
has the policy to retain maximum of its retained earnings. This also shows that 
company is not a too liberal dividend distributor. But as the ratio of distribution to 
providers of capital is also positive in a way it shows that company is passing on the 
benefits to the employees as well as the providers of capital and thereafter also 
managing to keep reserves for business. This shows a very bright picture of the 
company during the study period. 
 
In Dr. Reddy’s Laboratories the first three years showed a positive trend with regard 
to creation of value but after that there is no particular trend identifiable in the value 
addition and even in the distribution of value added. 
 
For IPCA Laboratories Ltd. it can be concluded that the company has controlled its 
cost throughout the study period and improved on its value addition and finally 
increased its retained earnings throughout the study period. Even the expenses on 
interests have declined along with decline in the dividend distribution. 
 
For Matrix Laboratories Ltd. we can conclude that although there are huge 
fluctuations in the figures of the company but they are all leading to the positive 
financial situation of the company. After those uncertain fluctuating and negative 
trend years the company has made noteworthy progress in the last five years during 
the study period of eight years. 
 
For Nicholas Piramal India Ltd. during the period of study year by year the ratio of 
cost to total income has increased which means the share of cost to income has 
increased. This reflects that either the company has not made serious efforts to control 
costs or it shows that whatever efforts are made were un-successful and that leaded to 
decrease in the rate of net value added from the income, during the study period. The 
improvement in the retained earnings over the period of years as a percentage of total 
value created is a positive sign for the financial health of the company. 
 For Sun Pharmaceutical Industries Ltd. it can be concluded that there are no major 
positive or negative movements observed in the entire vale added statement for Sun 
Pharmaceuticals Industries Ltd. Only significant item is regarding a considerable big 
amount (nearly 50%) is retained by the company in almost all the years during the 
period of the study. The company has not been very successful in controlling the cost 
and has not been rewarded with improved value creation. Even employees are not 
getting any improved share from the value created, in fact over the years the share of 
employees in the net value added has reduced. Hence it shows an overall mix picture 
for the company from the Value Added Statement. 
 
 
 
References 
 
1. S.N.Maheshwari, Advanced Accountancy:, Sultan Chand & Sons, Volume II, 6th Edi 
2. R. N. Anthony / G. A. Walsh : Management Accounting 
3. M. Y. Khan. K. P. Jain : Management Accounting 
4. I. M. Pandy : Management Accounting 
5. J. Betty : Management Accounting 
6. Sr. K. Paul : Management Accounting 
7. Dr. Jawharlal : Management Accounting 
8. Manmohan Goyal : Management Accounting 
9. S. N. Maheshwari : Principles of Management Accounting 
10. Ravi M. Kishore : Financial Management (Taxmann,New Delhi) 
11. R. K. Sharma and Shashi K. Gupta : Management Accounting 
12. Richard M. Lynech and Robert Williamson : Accounting for Management Planning and 
 Control 
13. Dr. Mahesh Kulkarni : Management Accounting Career Publications, Nasik 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Chapter 10 
 
SUMMARY, FINDINGS & 
SUGGESTIONS 
 
 
 
 
 
 
 
  
 
Contents 
                                                                       Page Number 
 
1. Prelude of the Study........................................10.3 
2. Findings............................................................10.4 
3. Suggestions......................................................10.18 
 
 
 
 
 
 
 
 
 
 
1. Prelude of the Study 
 
A highest academic degree and the biggest formal research project; this is what a 
Ph.D. means in a very concise form. If I try to define Philosophy in my words it also 
refers to some unique and fresh knowledge which is brought into world for the very 
first time. Interestingly this is not out-of-the-blue thoughts, but are the results of some 
concrete work in a particular direction using some appropriate way or method. 
 
The following research, which is although a post-mortem of things happened with 
selected units, but the new flow of conclusions that are derived from this work are 
showing a way ahead and hence can be futuristic. 
 
The operationalization of the new patent regime in 2005 is likely to bring about 
fundamental changes in the composition of the pharmaceutical industry for the 
coming times especially the next decade. The reintroduction of product patent would 
mean that companies would not be able to copy drugs patented after 1995. In other 
words, most Indian companies may face an acute decline in market opportunities after 
2005. It is also pointed out that a shift to a product patent regime would demand that 
basic capabilities of indigenous research be developed. Big companies have started 
preparing themselves for improving their R&D standard as well as R&D budget and 
also making tie-ups with the leaders for the R&D, but the real test is for the small 
units because they not only lack financial resources but also lack trained manpower 
and accessible testing facilities.  
In the light of the above status of Pharmaceutical Industry of India with reference to 
the Patent regime, the present research is objected to study and observe that:  
“How the Industry is poised to face this change in the Patent laws” And for that 
purpose it was essential to study the working of the industry before the patent law 
comes into force, i.e. 1st April 2005. 
 
In order to study the status of industry, sample units were selected on some criteria 
which nearly reflected the population. The sample is a good representation of the 
population and the period for which study is undertake is as big as 8 [Eight] Years. 
 
After making a detailed analysis of the research work this chapter brings the gist or 
essence of the entire work. Even a humble endeavor has been done to present some 
suggestions to the companies under study to improve the present state of affairs and 
financial performance. 
 
 
2. Findings 
 
CHAPTER 1:  CONCEPT AND MEASUREMENT OF PROFITABILITY 
 
In order to arrive at exact conclusions and observations and for finding out something 
new from a given set of things, one needs to go into the details of the things. Going 
into detail does not only mean intensive study but also extensive study.  
 
Similarly, for going into the detail of the financial performance of the selected 
pharmaceutical companies of India it was required to work intensively and extensively 
on the profits and profitability of these companies.  
Several relational dimensions of profit margin, several dimensions of sales volume 
and finally several dimensions of profitability needs to be used to do an in-depth study 
of profit and profit earning capacity of the companies. 
 
Finally using all the above described ways an effort has been made to measure the 
profitability of the selected companies under study for a specified period. 
 
 
CHAPTER 2: A STUDY OF PHARMACEUTICAL INDUSTRY 
1. Self sufficient to meet domestic demand. 
2. Huge Size 
3. Huge Volume of Production 
4. Low Prices 
5. Growth in Exports 
6. Drug Price Control Order 
The Drug Price Control Order (DPCO) was established in 1985, enabling the 
government to dictate drug prices for 143 basic drugs, with the purpose of ensuring 
the availability of medicines at low prices.  Price controls  disrupted free-market 
forces further because there was no control over the  price of any raw materials needed 
for manufacturing drugs. 
 
7. Patents and Patents Act 
Patent refers to an official document giving the holder the sole right to make, use or 
sell an invention and preventing others from copying it 
 
8. Research and Development 
The major shortcomings of the Indian pharmaceutical industry are in the fields of 
Research and Development and new drug discovery. Research and development has 
always taken the back seat amongst  Indian pharmaceutical companies.  
 
9. TRIPS 
The IPR regime, as it is often referred to in the literature, is a mega proposition on 
comprehensively enforcing and regulating, on a global scale, protections for patents, 
copyrights, designs and the entire system of intellectual property.   
 
10. Dichotomous Structure of Industry 
A small number of large enterprises and MNC subsidiaries have come   to 
coexist with a very large number of small units. 
 
11. Growing Industry 
The Indian pharmaceutical industry is highly fragmented, but has grown rapidly due 
to the friendly patent regime and low cost manufacturing structure. Intense 
competition, high volumes and low prices characterize the Indian domestic market. 
 
CHAPTER 3: RESEARCH METHODOLOGY 
For genuine decision making genuine informational base is essential. Same applies to 
research oriented projects wherein the major objective is to find out some sort of new 
identity of things which have happened in past. 
 In this research work an effort has been made to check the dual relationship 
establishing profit and profitability base among selected pharmaceutical companies 
for the study period. First aspect was to find out the relation between several 
companies during the period of study on the front of their performance, taking several 
performance measurement criteria. Second aspect was to find out the relationship or 
trend between several years of study of the same company on the front of their 
performance, taking several performance measurement criteria. 
 
In the best of the knowledge of the researcher and the informational knowledge 
collected from various sources, it was believed that F-Test should be used to check the 
dual relationship establishing profit and profitability base among selected 
pharmaceutical companies for the study period. 
 
Eight companies are selected for the purpose of research and their eight years’ data are 
collected, analyzed and applied statistical tools on those data. And finally from the 
statistical analysis some conclusions can be drawn for the profit and profitability of 
the selected companies for the study period. 
 
 
CHAPTER 4:  COST AND SALES TREND ANALYSIS 
 
From the calculation of individual cost to total cost ratio there can be some general 
conclusions drawn from the statistical analysis. From the study of six individual cost 
to total cost ratio and their comparison among companies for the study period and 
individual companies comparison for different years, following conclusions can be 
drawn: 
 
 There is a significant difference in the Percentage of raw material cost to total cost 
ratio among companies and there is also a significant difference in the Percentage of 
raw material cost to total cost between different years of each individual company 
under study for the study period. 
 There is a significant difference in the Percentage of Employee cost to total cost 
ratio among companies and there is also a significant difference in the Percentage of 
Employee cost to total cost between different years of each individual company 
under study for the study period. 
 There is a significant difference in the Percentage of Excise to total cost ratio 
among companies and there is also a significant difference in the Percentage of 
Excise to total cost between different years of each individual company under study 
for the study period. 
 There is a significant difference in the Percentage of Factory Overheads to total cost 
ratio among companies and there is also a significant difference in the Percentage of 
Factory Overheads to total cost between different years of each individual company 
under study for the study period. 
 There is a significant difference in the Percentage of Administrative Overheads to 
total cost ratio among companies and there is also a significant difference in the 
Percentage of Administrative Overheads to total cost between different years of 
each individual company under study for the study period. 
 There is a significant difference in the Percentage of Selling & Distribution cost to 
total cost ratio among companies but there is no significant difference in the 
Percentage of Selling & Distribution cost to total cost between different years of 
each individual company under study for the study period. 
 
Hence all the null hypotheses are rejected and alternate hypotheses are accepted that 
that there is a significant difference found in the individual cost to total cost ratio for 
all the companies under study for the study period. 
 
Even for each company the null hypothesis is rejected and alternate hypothesis is 
accepted that there is a significant difference found in each company among several 
years in the ratio of individual cost to total cost. 
 
 
CHAPTER 5: ANALYSIS OF PROFIT MARGIN 
 
From the calculation of Profit to Sales ratio there can be some general conclusions 
drawn from the statistical analysis. From the study of three individual Profit to Sales 
ratio and their comparison among companies for the study period and individual 
companies comparison for different years, following conclusions can be drawn: 
 
 There is a significant difference in the Gross Profit to Sales ratio among  companies 
and there is also a significant difference in the Gross Profit to Sales  ratio 
between different years of each individual company under study for the study 
 period. 
 There is a significant difference in the Operating Profit to Sales ratio among 
 companies but there is no significant difference in the Operating Profit to Sales 
 ratio between different years of each individual company under study for the study 
 period. 
 There is a significant difference in the Net Profit to Sales ratio among companies 
but there is no significant difference in the Net Profit to Sales ratio between 
different years of each individual company under study for the study period. 
 
 
CHAPTER 6: ASSETS TURNOVER 
From the calculation of Turnover ratios there can be some general conclusions drawn 
from the statistical analysis. From the study of seven individual Turnover ratio and 
their comparison among companies for the study period and individual companies 
comparison for different years, following conclusions can be drawn: 
 There is a significant difference in the Total Assets Turnover ratio among 
companies and there is no significant difference in the Total Assets Turnover ratio 
between different years of each individual company under study for the study 
period.  
 There is a significant difference in the Fixed Assets Turnover ratio among 
companies and there is a significant difference in the Fixed Assets Turnover ratio 
between different years of each individual company under study for the study 
period. 
 There is a significant difference in the Current Assets Turnover ratio among 
companies and there is no significant difference in the Current Assets Turnover 
ratio between different years of each individual company under study for the study 
period.  
 There is a significant difference in the Working Capital Turnover ratio among 
companies and there is no significant difference in the Working Capital Turnover 
ratio between different years of each individual company under study for the study 
period.  
 There is a significant difference in the Inventory Turnover ratio among companies 
and there is no significant difference in the Inventory Turnover ratio between 
different years of each individual company under study for the study period.  
 There is no significant difference in the Debtors Turnover ratio among companies 
and there is no significant difference in the Debtors Turnover ratio between 
different years of each individual company under study for the study period.  
 There is a significant difference in the Cash Turnover ratio among companies and 
there is no significant difference in the Cash Turnover ratio between different years 
of each individual company under study for the study period.  
 
CHAPTER 7: ANALYSIS OF RETURN ON INVESTMENT 
From the calculation of ratios there can be some general conclusions drawn from the 
statistical analysis. From the study of seven individual ratio and their comparison 
among companies for the study period and individual companies comparison for 
different years, following conclusions can be drawn: 
 There is no significant difference in the Return on Investment ratio among different 
companies under study and there is no significant difference in the Return on 
Investment ratio between different years of each company. 
 
 There is a significant difference in the Return on Gross Capital Employed ratio 
among different companies under study and there is no significant difference in the 
Return on Gross Capital Employed ratio between different years of each company. 
 
 There is no significant difference in the Return on Net Capital Employed ratio 
among different companies under study and there is no significant difference in the 
Return on Net Capital Employed ratio between different years of each company 
 
 There is no significant difference in the Return on Proprietor’s Net Capital 
Employed ratio among different companies under study and there is no significant 
difference in the Return on Proprietor’s Net Capital Employed ratio between 
different years of each company. 
 
 There is no significant difference in the Earnings Per Share ratio among different 
companies under study and there is no significant difference in the Earnings Per 
Share ratio between different years of each company. 
 
 There is no significant difference in the Dividend Payout Ratio among different 
companies under study and there is no significant difference in the Dividend 
Payout Ratio between different years of each company. 
 
 There is a significant difference in the Fixed Charges Cover Ratio among different 
companies under study and there is no significant difference in the Fixed Charges 
Cover Ratio between different years of each company. 
 
CHAPTER 8: ANALYSIS OF COMMON SIZE INCOME STATEMENT 
Common size statement presents a clear picture of a company’s profit and its 
comparison with the sales and other expenses. This common size statement prepared 
for all the eight companies for all the eight years has enabled researcher to understand 
the details of the profit and its relationship with sales over a period of time for the 
selected companies under study. 
 
 Aurobindo Pharmaceuticals has shown a mixed performance. As such there are a 
good number of ups and downs observed in the absolute and percentage profit to 
sales during the entire study period and some of the fluctuations are pretty abnormal 
too. 
 
 Performance of Cadila Healthcare is fairly good as much effort is done behind 
maintaining the increasing trend of net profit, which is successful also to a certain 
extent but even then there is an amount of fluctuation in the rate of net profit to 
sales during the entire study period although not very high. 
 
 For Cipla Ltd. it can be concluded that the rate of profit to sales is much higher in 
this company compared to other companies, it is almost double than other 
companies, but even this company is not successful in maintaining its rate of profit 
to sales. And there is a clear decreasing trend observed in this ratio in this company. 
 
 As per final analysis of Dr. Reddy’s Laboratories it can be concluded that the 
expenses were in control in the initial period of five years and then they have shown 
an increasing trend, which makes it clear that the company has failed to control its 
costs. The revenue has increased but at a declining rate and the last year has been 
miserable for the company in more than one ways. From the sixth year 2002-03 the 
margins are declining and hits bottom in the last year of the study period. This gives 
an alarming signal to the financial performance of the company and it needs to 
improve on several fronts to get things back on track. 
 
 For IPCA Labs it can be concluded that the major expenses were in control in the 
entire period of study. The revenues have shown increase but the company is not 
able to maintain a consistent increasing rate of profit margin. Except couple of 
deviations the company has shown a reasonably good performance during the study 
period. 
 
 As far as Matrix Laboratories is concerned it can be concluded that although there 
are some big fluctuations observed in the profit during the study period but in the 
last three years company has recovered very well and is able to compete with the 
big giants of the industry. The ability to come out so quickly and strongly from the 
losses can be a strong ability for the company. 
 
 For Nicholas Piramal it can be concluded that although the company has not been 
able to control its main costs but it has successfully control and reduced its non-
operating costs and also increased its revenues which has led to improvement in the 
overall profit margin of the company over the period of time. 
 
 For Sun Pharmaceuticals overall profitability and financial performance has 
improved. Although the improvement is not very significant but it indeed is eye-
catching. If revenues can be increased and costs can be controlled like in the past 
then the company can still do better in the coming times. 
 
 
 
CHAPTER 9: VALUE ADDED STATEMENT 
 
Value added statement is a useful measure to find out the value added by the 
organizational activities. It is a special tool which tries to measure the additions called 
the “Value” added and its relationship with the revenues over the period of time. 
 
 In Aurobindo Pharmaceuticals Ltd. it can be observed that there is an increasing 
trend in the share of employees in the value added in this company. And there is 
overall improvement observed in the retained earnings ratio to total value. Apart 
from these there are no major trends observed in the other places. 
 
 For the company Cadila Healthcare Ltd. there is a positive trend observed in the 
retained earnings over the period of study. Even the cost of material and services 
has declined which has led to improvement in the ratio of net value added during 
the period of the study for the company.   
 For Cipla Ltd. it can be observed that the employees share is increasing and 
company has the policy to retain maximum of its retained earnings. This also shows 
that company is not a too liberal dividend distributor. But as the ratio of distribution 
to providers of capital is also positive in a way it shows that company is passing on 
the benefits to the employees as well as the providers of capital and thereafter also 
managing to keep reserves for business. This shows a very bright picture of the 
company during the study period. 
 
 In Dr. Reddy’s Laboratories the first three years showed a positive trend with regard 
to creation of value but after that there is no particular trend identifiable in the value 
addition and even in the distribution of value added. 
 
 For IPCA Laboratories Ltd. it can be concluded that the company has controlled its 
cost throughout the study period and improved on its value addition and finally 
increased its retained earnings throughout the study period. Even the expenses on 
interests have declined along with decline in the dividend distribution. 
 
 For Matrix Laboratories Ltd. we can conclude that although there are huge 
fluctuations in the figures of the company but they are all leading to the positive 
financial situation of the company. After those uncertain fluctuating and negative 
trend years the company has made noteworthy progress in the last five years during 
the study period of eight years. 
 
 For Nicholas Piramal India Ltd. during the period of study year by year the ratio of 
cost to total income has increased which means the share of cost to income has 
increased. This reflects that either the company has not made serious efforts to 
control costs or it shows that whatever efforts are made were un-successful and that 
leaded to decrease in the rate of net value added from the income, during the study 
period. The improvement in the retained earnings over the period of years as a 
percentage of total value created is a positive sign for the financial health of the 
company. 
 
 For Sun Pharmaceutical Industries Ltd. it can be concluded that there are no major 
positive or negative movements observed in the entire vale added statement for Sun 
Pharmaceuticals Industries Ltd. Only significant item is regarding a considerable 
big amount (nearly 50%) is retained by the company in almost all the years during 
the period of the study. The company has not been very successful in controlling the 
cost and has not been rewarded with improved value creation. Even employees are 
not getting any improved share from the value created, in fact over the years the 
share of employees in the net value added has reduced. Hence it shows an overall 
mix picture for the company from the Value Added Statement. 
 
 
3. Suggestions 
 There are no trends identified in the ratio of individual cost to total cost which 
states that company is not consistent in its procuring prices of materials and the use of 
materials. As such either of them are fluctuating and hence they are having not having 
any standard proportion to total costs. All the companies can have standardization in 
the type of material, prices at which they are available and also other expenses which 
are incurred needs to make standardized. 
    Despite being an essential commodity, excise duty for the pharma sector 
remains at 16%. The industry was expecting a reduction in excise duty to 8%, 
especially now that the excise duty is MRP based. Hence excise duty need to be 
reduced to less than 10%. 
   Extension of deduction of 150% of R&D expenses. This would encourage 
more and more companies to invest in R&D. 
 
  An academic –industrial relationship need to be further explored, like the 
U.S., where the universities innovate and the industry commercialize the product. The 
universities are permitted to own the Intellectual Property Rights (IPR) and get a share 
of the profits. Academic institutions will then become the engines of entrepreneurship. 
This also requires setting up of greater number of centers of academic excellence 
throughout India in different states, so that people from across the country can avail of 
such education and make their contributions without feeling the need to look beyond 
India for achieving academic excellence.1 
 
  Income tax exemptions should be given on clinical trials and contract research 
done outside the company and abroad. This is because India is seen as emerging as 
a major center for outsourcing of clinical trials for the Pharmaceutical MNCs.2 
 
 The government should encourage setting up of USFDA-compliant plants by 
providing tax holidays for a specified period (as given in regions like Baddi), so 
that the Indian companies can exploit the opportunity arising out of patented drugs 
and take up marketing of generics in the developed countries like USA.3 
 Raw materials consists the major portion of total cost for all the companies, which 
means that this cost should be checked to improve margins. Even backward 
integration of value chain can be a good idea if it is a feasible one. 
 
 There have been a number of instances of mergers and acquisition in 
Pharmaceutical Industry in India in recent times. For decreasing the input cost and 
for better marketing and other advantages, the companies can strengthen itself by 
acquiring strategic pharma units. 
 
 If government can be instrumental in providing the raw materials at subsidized rates 
to the companies, the companies can reduce their prices of drugs which can provide 
relief to the general public and would increase the competitiveness of Indian firms 
in global markets. 
 
 Proper equilibrium must be maintained between the pays and performances of 
work-force, this would provide twin benefit. Firstly would check the increasing 
salary and wages cost and secondly it would improve the qualitative work from the 
workers. 
 
 Promotional activity must be carried out with the objective of disease awareness 
and disease prevention messages in association with NGOs.  
 
 Government can boost the exports by giving extra benefits to the export oriented 
units. 
 Extra incentives can be awarded to the companies working for the social causes in 
rural area. Government can procure drugs in bulk for its various medical 
programmes in rural areas. 
 
 Sales promotion activity can be carried out by the sample units in rural areas where 
maximum population of the country resides. This can also be clubbed with the 
efforts done by government and the social responsibility activities of the companies. 
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